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Abstract
The synthesis of ligand systems and complexes thereof suitable for use as positron
emission tomography (PET) agents is studied herein. The ligands 6,6’-(1,4-diazepane-
1,4-diyl)bis(3-aminobenzoate) (HPR), 6,6’-(piperazine-1,4-diyl)bis(3-aminobenzoate) (PipR.2HCl),
6,6’,6”-(1,4,7-triazonane-1,4,7-triyl)tris(3-aminobenzoate) (TACNR), 1,4-bis(2-amino-4-tolyl)-
1,4-diazepane (HPTol), 1,4-bis(2-amino-4-trifluoromethylphenyl)-1,4-diazepane (HPCF3),
di-tert-butyl 4,4’-(1,4-diazepane-1,4-diyl)bis(3-aminobenzoate) (HP
tButyl), 1,3-bis(2-amino-
4-tolyl)-1,3-diazacyclohexane (PipTol), 1,4,7-tris(2-amino-4-trifluoromethylphenyl)-1,4,7-
triazacyclononane (TACNCF3), have been studied. Ni(II), Cu(II), and Zn(II) complexes
of these ligands have been synthesised, DFT calculations have elucidated structural con-
figuration, whilst x-ray crystal structures of NiHP
tButyl, and CuTACNCF3 have been de-
termined. EPR measurements of CuHPR have been taken.
A series of triazine core compounds have been prepared for use as model com-
pounds for targeting molecules. The compound Tz(EtGly)(BocGuan)Cl has been syn-
thesised with the required arms to selectively bind to the integrin αvβ3. DO3A moieties
have been added to these ligands, and mass spectra analysis of the coordination prod-
ucts with a series of metals has been determined.
NO2A derived compounds 2,2’-(7-tosyl-1,4,7-triazonane-1,4-diyl)diaceticacid (TsTACNA2)
and 2,2’-(7-(4-nitrophenyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NPhTACNA2) have
been studied, with the x-ray crystallography of the copper complexes completed. Positron
emmision tomography (PET) studies of the complexes have also been undertaken and
show high levels of complexation at ng scales, with moderate stability in human serum.
Glutaric acid functionalised compounds (2S,2’S)-2,2’-(1,4-diazepane-1,4-diyl)dipentanedioic
acid (HPGlut), 2,2’,2”-(1,4,7-triazonane-1,4,7-triyl)tripentanedioicacid (TACNGlut), and
2,2’-(4,11-dimethyl-1,4,8,11-tetraazacyclotetradecane-1,8-diyl)dipentanedioic acid (DM-
iii
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CGlut) have been synthesised, with the copper complex of DMCGlut affording struc-
tural determination. The Mn(II) and Gd(III) complexes of the DMCGlut ligand system
have been studied by xylenol orange UV titration for their metal-ligand binding ratio,
with the Mn(II) system showing a 1:1 binding ratio, whilst the Gd(III) complex showed
no binding at all.
Synthesis of the trispyrazylborate analogue, tris(4-methyl-2-(2-pyridine)pyrazyl)borate
(MeTpPy), was unsuccessful, however, the bis- (MeDpPy) and tetra- (MeQpPy) substi-
tuted analogues were successfully synthesised.
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Chapter 1
Introduction
1.1 Macrocycles
1.1.1 Introduction To Macrocycles
Macrocyclic chemistry is a vast, varied, and extremely active area of research even
though it originates from the early 1960s. A macrocycle is defined by IUPAC as a cyclic
macromolecule or a macromolecular cyclic portion of a molecule, and is more generally
associated with rings of greater than 9 atoms, and in the context of ligands for metals, a
minimum of 3 donor atoms. Synthetic chemists usually restrict this definition further so
as it includes only cyclic molecules with three or greater hetero atoms. Macrocycles have
found use in many areas of medical research such as contrast agents, biological tracers,
anti AIDS/HIV drugs, tumour therapy, enzymemodelling, and protein labelling, which
may account for their presence naturally in biological systems. Macrocycles have also
been used in surfactant chemistry, metal extraction/recognition, and more recently in
liquid crystals.
Naturally occurring macrocycles include porphyrin rings (1) found in hemoglobin,
chlorin (2) rings found in chlorophyll, and corrin (3) rings in vitamin B12. More syn-
thetic examples of macrocycles include, crown ethers (4), cryptands (5), calixarenes (6),
polyamines (7), phthalocyanines (8), and mixed donor macrocycles (9) (fig. 1.1). Macro-
cycles have found an extended use in systems such as catenanes, rotaxanes, and molec-
1
CHAPTER 1. INTRODUCTION 2
NH N
HNN
NH N
HNN
N N
NNH
(1) (2) (3)
O
O
O
OO
O
N
O
N
O O
O O
OHOH HOOH
(4) (5) (6)
NH
NH
HN
HN NH
N
N
N
HN
N
N
N
As As
SAs
(7) (8) (9)
Figure 1.1: Examples of macrocycles
ular knots (knotanes) that involve interlocked macrocyclic molecules.
1.1.2 Azamacrocycles
Polyazamacrocycles are an extremely important area of modern medical research,
with derivatives of 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) find-
ing use in many areas including cancer treatment and diagnosis. The ability to func-
tionalise the amine moieties of these macrocycles allows easy access to ’tuned’ lig-
ands suitable for binding most metal ions. Polyazamacrocycles come in many sizes,
however, most research is currently based on 1,4,9-triazacyclononane (TACN), 1,4,7,10-
tetraazacyclododecane (cyclen), and 1,4,8,11-tetrazatetradecane (cyclam) (fig. 1.2).
NH
H
N
HN
NH
NHHN
HN NH
NH
HN
HN
TACN Cyclen Cyclam
Figure 1.2: Polyazamacrocycles
The concentration on these macrocycles in particular is due to the size of the cavity
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hole created by the amines being the correct size to comfortably bind metals of medi-
cal interest. Complexes of TACN usually form with the TACN occupying one face of
the coordination sphere, leading to ’piano-stool’ like complexes, whilst complexes of
cyclam usually occur with the metal ion in the centre of the macrocycle (fig. 1.3).
M
NH
CO
HN NH
COOC NH
NH
HN
HN
Ni2+
Figure 1.3: TACN piano stool, and cyclam complex
M = Mo, W
1.1.3 Chelate and Macrocyclic Effect
Chelate Effect
The chelate effect is defined as the greater stability of chelated complexes compared
with their non-chelated analogues. An example of the chelate effect can be seen in the
stability constants of the complexes [Cd(MeNH2)4]2+ and [Cd(en)2]2+. [1]
−RT lnK = △Gº = △Hº− T△Sº (1.1)
Equilibrium log β ΔG ΔH -TΔS
Cd2+ + 4 MeNH2 [Cd(MeNH2)4]2+ 6.55 -37.4 -57.3 19.9
Cd2+ + 2 en [Cd(en)2]2+ 10.62 -60.67 -56.48 -4.19
R = gas constant, T = temperature (kelvin), K = equilibrium constant, Gº = Gibb’s free
energy, Hº = standard enthalpy, Sº = standard entropy
The free energy is related to the equilibrium constant K through equation 1.1, with
a larger equilibrium constant meaning a more stable complex. As would be expected,
the enthalpy of the complexes is very similar due to the bond formation being very
similar for both complexes – both are Cd-NH bonds. The largest difference between
the two complexes is a result of a greater entropy of the chelated system. This in its
simplest form is due to the fact that in the chelate complex three molecules join to form
one, whilst in the monodentate complex five molecules become one, so there is less
loss of disorder in the chelate system. This is further compounded when the molecules
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of solvation are accounted for, with four solvation molecules replacing two chelating
molecules, increasing entropy further.
NH3 NH2H2N
NH2H2N
NH HN
NH2NH2NH3NH3
NH3 NH NH2
NH3NH2
Figure 1.4: Increasing stability of chelate complexes
Another factor involved in the chelate effect is well described by Schwarzenbach.[2]
If the chelate and its monodentate analogue are in competition with each other, both
have an equal chance of coordination the first time. After that, the pendant arm of
the chelate is more likely to coordinate in another position due to the fact that it is
in much closer proximity to the metal centre. The proximity argument also helps to
explain the greater stability of large chelates over multiple smaller ones, such as two
ethylenediamine molecules are less stable than one triethylenetetraamine ligand (fig.
1.4).
Macrocyclic Effect
The macrocyclic effect is an expansion of the chelate effect and describes the in-
creased stability of macrocyclic complexes over their open chain analogues when there
are no steric influences on the complex. The cause of increased stability is two-fold in the
macrocyclic effect, there are favourable enthalpic and entropic effects upon coordination
of a macrocycle. The entropic effects are similar to those in the chelate effect, with the
addition macrocycles have a lower rotational freedom than linear chelates and so upon
coordination less rotational freedom is lost from the macrocycle than the chelate. The
larger effect comes from enthalpy. If the macrocycle has the correct cavity size for the
metal ion it is coordinating the metal-donor bonds will be significantly stronger than
those that are strained. This is best shown in the stability constants of Ni(cyclam) and
Cu(cyclen) complexes (fig. 1.5).
The increase in stability (log β) of Ni(cyclam) over its acyclic analogue is 6.9, whilst
the increase for Cu(cyclen) over its acyclic analogue is only 3.7. The cavity size of the
cyclam macrocycle is the correct size for the Ni2+ ion, where it sits in the plane of the
macrocycle, whilst the cavity in cyclen is too small for the Cu2+ ion and it sits above
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Figure 1.5: Macrocyclic effect
the ring, causing the macrocycle to twist so the nitrogen lone pairs point up toward
the metal ion. Not only has the cavity hole been shown to affect the macrocyclic effect,
but also a number of other factors such as pH, and solvation of the macrocycle. It is
therefore hard to define exactly and must be taken as a sum of all these factors.
1.1.4 Jahn-Teller Distortion
The Jahn-Teller distortion is an electronic effect describing the distortion of non-
linear electronic states in molecules .[3] The effect is most noticeable in d9 octahedral
copper complexes, due to the unequal occupancy of a degenerate molecular orbital, but
is also easily seen in complexes where a doubly degenerate orbital (eg. eg) is unequally
occupied (low spin d7, and high spin d4) (fig. 1.6).
high spin d4 low spin d7 d9
eg
t2g
Oh
Figure 1.6: Unequally occupied eg orbitals
The effect is most noticed in eg orbitals as they are orientated toward the ligands and
so distortion results in large changes in the relative energies, where as t2g orbitals are
orientated between the ligands and so any distortion results in smaller energy changes.
The same is true of tetrahedral complexes where the distortion is less obvious as the
orbitals do not align with the ligands. The Jahn-Teller distortion can manifest itself as
either a lengthening or shortening of bonds, however, longer bonds are most common.
CHAPTER 1. INTRODUCTION 6
The effect is easily seen when viewing the crystal structure of Cu(H2O)62+. The axial
Cu-O bonds are found to be ~ 2.38 Å, whilst the equatorial bonds are ~ 1.95 Å (fig. 1.7).
Figure 1.7: Crystal structure of [Cu(H2O)6]2+
1.2 Positron Emission Tomography
1.2.1 Positron Emission Tomography
Positron emission tomography (PET) is currently the fastest growing area of research
in nuclear medicine. This is due to the ability of PET to be used in both diagnostic and
therapeutic medicine as well as study of metabolic pathways through the use of [18F]-
fluorodeoxyglucose (FDG). PET is currently used extensively in the US by oncological
specialists who have found PET results have altered the management of patients in up
to 30 % of cases (based on study of 5,062 patients).[4] An example of these alterations is
the case of a patient with known lung cancer but no other symptoms. After an FDG-PET
examination it was found the patient had extensivemetastatic disease in their brain, and
so a different treatment was administered. (fig. 1.8) This was only possible due to the
metabolic nature of the FDG probe, and would most likely have been missed by older
techniques. PET is not only useful in oncology, but also cardiology and neuropsychia-
try. The ability of PET imaging to alter treatment in such large ways it can no longer be
thought of as optional, and should be considered a key diagnostic tool even in health
care systems at the lower end of gross national product investment (i.e. the NHS), and
to this end must be an area of chemical and biological research to expand rapidly. This
expansion has already started in engineering terms, with more and more sensitive de-
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tectors being designed and implemented almost daily, allowing patients to be scanned
with a higher resolution and at a higher turn over. Modern PET scanners are combining
imaging modalities to allow fusion of different imaging techniques, such as MRI/PET
and CT/PET. This allows the spatial resolution of PET overlaying a more general image
of the body offered by the other modalities.
Figure 1.8: PET scan of patient with lung and brain cancer
Currently there are three main areas in which PET imaging is used; Cancer diagnosis
and treatment, cardiac surgery, and neurology. The oncological use of PET has beenwell
established in the USA for a decade with the first approval of PET imaging in diagnos-
tic tests coming as early as 01.01.1998.(Medicaid/Medicare)Oncological PET is used for
a wide variety of reasons including; diagnosis of scarring versus active tumours, how
aggressive a tumour is (based on degree of FDG uptake), how widespread the cancer is
(staging), measuring the response to therapy, and identification of the cancer site itself.
Use of PET in cardiac surgery is mainly aimed at measuring myocardial perfusion (how
the heart functions currently through blood flow studies) using 13N-ammonia, and my-
ocardial viability (whether the heart can recover from dysfunctions, or can be used in a
transplant) using FDG. In neurology PET is used for management of brain tumours (es-
pecially those causing para-neoplastic symptoms), and has been shown to give earlier
diagnosis and determination of dementia than current methods.
One of the main criticisms (unfairly) aimed at PET imaging is its cost. PET imaging
requires use of a cyclotron and specialised laboratory facilities that are expensive to
set up. However, the use of PET to change treatments and diagnose problems reduces
the overall cost of the treatment of a patient. Cost effectiveness studies by Bailey et al.
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show that PET imaging is ’cost-neutral’ in most cases and some times ’cost-saving’ over
non PET techniques (table 1.1).[5] They argue that the long term effects cannot yet be
evaluated as the technique is still relatively young, but the early results suggest that
we should not wait another 10 years before using PET widely as its short term benefits
(unnecessary surgery avoided, necessary surgery sped up etc.) massively out-way the
negatives.
Procedure Cost/Year saved ($)
Liver Transplant 43,000 - 250,000
Renal Dialysis 116,000
Chemotherapy (breast) 46,200
Cardiac Transplant 27,200
Table 1.1: Money per life-year saved through differential treatment after PET scan
1.2.2 The Science of PET
Positron Emission Tomography is based on the ability of a positron to annihilate an
electron with the resulting emission of two equal energy photons in opposite directions.
The positron (same mass but opposite charge to an electron) was first postulated by
Dirac in 1928, but wasn’t observed until 1932 during cosmic ray research by Anderson,
and both were awarded the Nobel Prize in physics for the discovery.
In PET the emission of a positron from the radionuclide results in an annihilation
event with a nearby electron. This emission is the result of radioactive decay, whereby
the radioactive nucleus is trying to lower its energy and reach a stable nuclear con-
figuration. Radiation can by classified into two general forms; electromagnetic, and
particulate. Electromagnetic radiation results in the production of pure energy in the
form of x-ray and γ-ray photons. Positrons are particulate radiation. Particulate radi-
ation includes α-decay, β−-decay, and β+-decay.1 Positrons are produced in two ways:
pair production, and nuclear transmutation. Nuclear transmutation is when an element
spontaneously converts into another through long term radioactive decay. Pair produc-
tion results in the production of a positron and neutrino as by-products of the decay of a
proton into a neutron. This process requires a proton rich nucleus, and after conversion
1
a-decay is the loss of 42He
2+, b−-decay is the loss of an electron and antineutrino (¯u), b+-decay is the loss
of a positron and neutrino (n).
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into a neutron, the remaining charge is released as a positron. The resultant neutrino
production is the result of a need to conserve energy, and was postulated by Pauli in
1931. As the resultant nucleus has a charge of one less than the starting element, an
electron is also released, which leaves the resultant nucleus and a neutral species. The
general equation for positron decay is given below. (eq. 1.2)
A
ZX →
A
Z−1 Y +
0
1 β
+ + υ +Q+ β− (1.2)
After decay, the positron emitted can have any energy up to a given maximum.
This energy is then reduced through collision and scattering interactions with the sur-
rounding environment. When the positron has reached a low enough energy (energy
of positron and electron must be similar) a collision with an electron will lead to the
formation of a new particle called a positronium. Positronium is a metastable element
and has a half life of around 10−7s . In human tissue the probability of formation of a
positronium is much lower, and direct annihilation is much more likely. The distance
the positron travels after emission is given the value Z and is a major contributor to the
maximum theoretical resolution possible. Higher energy positrons will have a highers
Z value than low energy positrons, and results in differing resolutions depending on
the positron emitive element used. (table 1.2) If Z can be lowered, then the resolution of
PET can be greatly increased.
Nuclide Emax (MeV) Zmean (mm) (in water)
11C 0.959 1.1
13N 1.197 1.5
15O 1.738 2.5
18F 0.633 0.6
68Ga 1.898 2.9
82Rb 3.400 5.9
Table 1.2: Different Z values (in water) shown as function of initial positron energy
When the positron and electron finally annihilate, the resulting energy is released
in the form of photons (usually two, but three is possibly - <1% probability). If there
is no momentum of the positron at the point of annihilation, the resultant photons are
released at exactly 180° to each other, however if there is not zero-energy momentum at
the point of annihilation, then the photons are released within ±0.5° of this value. This
also adds to the error in resolution by up to 1.5 mm depending on the distance of the
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detectors from the annihilation site. The photons emitted have an energy of 511 KeV,
which can be easily calculated using Einstein’s energy-mass equivalence. (eq. 1.3)
E = mc2
= (9.11x10−31Kg).(3x108ms−1)2
= 8.2x10−14 J
=
8.2x10−14 J
1.6x10−19 JeV−1
(1.3)
= 511KeV
1.2.3 PET Detectors
The type of detectors used in PET imaging are scintillation detectors, and consist
of an inorganic crystal layer, which upon interaction with an external photon releases
visible light photons via excitation and relaxation of an electron to the conduction band,
which are then themselves detected by a photo-detector. The photo-detector measures
the number of photons that interact with it, and this value is proportional to the original
energy of the external photon. Scintillation detectors also have a very good stopping
efficiency for the PET photons due to their composition (heavy inorganic elements, and
high density).
The sensitivity of the detector is dependent on a number of factors; the stopping
power of PET photons, signal decay time, light output, and intrinsic energy resolution.
The stopping power is measured by the attenuation length of a photon in the scintillator.
A low attenuation value signifies a highly efficient stopping power of the crystal, and is
dependent on its density and effective atomic number. A short decay time is important
as it allows each pulse to be processed independently and at a faster rate. Good light
output is vital as it helps achieve good spatial and energy resolutions. Good energy
resolution is needed to process the difference between a legitimate PET photon signal,
and one which has been Compton scattered2 in the subject. Intrinsic energy resolution
also affects the energy resolution of the system, and arises from inhomogeneities in the
2Compton scattering occurs when the photon interacts with electrons in atoms in the tissue and causes a
deflection of the photon and drop in the energy.
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crystal, which can lead to non-uniform light output.
Common crystals used in scintillators include; NaI(Tl), BGO (bismuth germanate -
Bi4Ge3O12), LSO (lutetium oxyorthosilicate doped with cerium - Lu2SiO5:Ce), YSO (Yt-
trium oxyorthosilicate doped with cerium - Y2SiO5:Ce), GSO (Gadolinium oxyorthosil-
icate doped with cerium - Gd2SiO5:Ce), BaF2. (fig. 1.9) Each crystal system has advan-
tages and disadvantages, but most current whole body scanners use BGO due to their
excellent stopping power and high sensitivity of photon detection, the major drawback
being a low light emission that requires the addition of photo-multipliers to achieve a
good spatial resolution. This increases the cost and complexitiy of the machine some-
what. LSO looks like a possible candidate to replace the BGO systems, as it has very
good light output and a high stopping power. Its major drawback is the presence of
naturally occurring 176Lu (2.6 % abundance, τ1/2= 3.8x1010 yrs) which is a β− emitter
and therefore releases γ-rays in the energy range 88-400KeV. This intrinsic radiation
means it is not suitable for low energy application.
Figure 1.9: Scintillator crystals exposed to X-rays: NaI(Tl), BGO, and BaF2 (left to right)
Due to the difference in distance a photon needs to travel, and slight differences in
the scanner surfaces, an uncertainty in coincidence will occur. It is therefore necessary
for the detector to take this possibility into account when dismissing random coinci-
dences. After detection of photon one, the detector sends a signal. If another signal is
detected within 2τ of the first, then it is counted as a potential signal. If it is outside
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of this time, then the signals are ignored. In this case 2τ is any time, but must be more
than the time taken for a photon to travel from one side of the scanner to the other, as
not all events occur in the centre. For a 1m wide scanner this means 2τ must be more
than 3.3 ns. Ultra-fast scintillators such as BaF2 require little more than 3.3 ns to accept
coincidence, whereas slower detectors such as NaI(Tl) would require a slightly longer
time. The problem with having a coincidence window is the occurrence of random
coincidences, and the larger the window the larger the opportunity for random coin-
cidences to occur. This increases the noise in the measurement, as well as flagging up
potentially false positives. The level of random coincidences increases proportionally
with the square of the activity, whilst the true coincidences only increase linearly. This
means that at high activity levels, random coincidence can overtake true levels. There is
no really successful method for removal of these random levels so the best way to lower
the random noise is to have a small timing window, and hence an ultra-fast scintillator.
Good timing resolution is not only good for reducing the noise levels in data, but
is key to working out where the annihilation reaction took place. The difference in
arrival time between two photons can be used to work out the exact space in which the
annihilation took place. This calculation requires an ultra-fast scintillator for a decent
resolution (~ 6 mm), currently the only scintillator quick enough is BaF2.
As with the timing of the detection, the energy of detection must also be within a
predefined window. This prevents Compton scattered pairs registering on the detector
and giving false data on the position of the annihilation events. As in a scintillator the
energy is detected as a function of light, a good light emitting source is required for
accurate definition of the photon energies. Even the best (of the common crystals) de-
tection systems have a low end energy value of 450 KeV. This means that a deviation
of up to 30° from the true response line will be detected as a hit. This requires addi-
tional layers of computer software to estimate the distribution of scattered photons and
remove them from the signal, hence improving the image contrast.
The sensitivity of a scanner is dependent on two main properties; the shape of the
scanner, and the stopping efficiency of the scintillator. The ideal geometry of a scanner
is a thin ring in which the patient lies. (fig. 1.10) This allows complete 360° detection
of annihilation events, whilst keeping longitudinal scattering coincidences low. The
high stopping efficiency, as mentioned earlier, allows for more coincident events to be
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Figure 1.10: A Siemens TruePoint PET-CT multimodal scanner
recorded in a set time, which in turn reduces the signal to noise ratio and gives better
resolution images. A high stopping power also reduces the parallax error in images.
The parallax error is caused by a lack of adjustment for the depth the photon travels in
the detector before being detected. (fig. 1.11) This can cause some blurring of images,
but can be avoided by having thinner films of crystals, with higher stopping powers.
Figure 1.11: Representation of parallax error
Dotted line = Actual photon path
Solid line = Interpreted path
1.2.4 Synthesis of PET isotopes
The nuclear reactions involved in synthesising the PET isotopes are of major im-
portance. It must be possible to successfully separate the desired PET element from its
starting material, and so has been a source of heavy research. There are many different
methods for synthesising PET isotopes, but the major methods for the synthesis of 60Cu,
64Cu, 68Ga, 86Y, and 89Zr are described.
60Cu Production
60Cu (τ1/2= 24min., β+ 93 %) is prepared using a targeting system in which the reac-
tion 60Ni(p,n)60Cu takes place and 60Cu is isolated via ion exchange chromatography.[6]
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A 60Ni enriched target is sometimes used, but increases the cost.
64Cu Production
64Cu (τ1/2= 12.7 hrs, β+ 19 %) is prepared using a similar method to 60Cu, through
either 64Ni(p,n)64Cu or 64Ni(d,2n)64Cu reactions.[6] Both use enriched 64Ni targets that
must be irradiated before use to increase production of 64Cu.[7] The difficulty in recov-
ering the 64Ni has led to recent developments including the use of 64NiO.
68Ga Production
68Ga (τ1/2= 68 min., β+ 89 %) is produced naturally by the electron capture decay
of 68Ge (τ1/2= 271 days). 68Ga is isolated by elution with 0.1M HCl forming the salt
68GaCl3. Complications arise due to the presence of some impurities (Ti4+, Fe3+, Zn2+
from the initial Ge source), high volumes of eluate, and high concentrations of HCl. This
has led to recent work into chromatographic methods of purification.[8]
86Y Production
86Y (τ1/2= 14.7hrs , β+ 34%) is produced through the bombardment of Sr targetswith
high energy protons, although reaction of Ge targets with heavy ion particles (16O6+)
has also been used. Isolation of the 86Y has been achieved through many methods, but
ion exchange chromatography is the most common.[9]
89Zr Production
89Zr (τ1/2= 78hrs, β+ 23%) is prepared via a 89Y(p,n)89Zr reaction, and purified using
a double extraction protocol, followed by anion exchange, resulting in 99.999% purity.
Other methods have recently been published, but have major problems particularly in
the production of YCl3 by-products. [10]
1.3 Potential Ligands in Copper and Gallium PET Agents
Whilst the use of metal ions in PET agents is still a relatively new area of interest,
there are a number of popular motifs that allow facile coordination of a metal to a func-
tionalisable generic core. The ligands used in copper PET chemistry tend to have coordi-
nation number between 4 and 6, with those tetradentate ligands using copper(II)’s pref-
erence for square planar geometry over tetrahedral (see the Jahn-Teller distortion). Cur-
rent tetradentate copper ligands commonly contain two neutral nitrogen donors (amino
or imino) and two charged species such as amido, oxo, or thiolato moieties to neutralise
CHAPTER 1. INTRODUCTION 15
the complex. Due to the added stability gained by filling the coordination sphere of
the copper ion, hexadentate ligands have become the focus of much research. These
hexadentate ligands are generally based on polyazamacrocyclic cores such as TACN,
cyclen, and cyclam. Methods of functionalisation of the macrocycles by addition of
pendant arms to the amine nitrogens and the carbon backbone have been developed.
Commonly anionic groups are added to these macrocycles so as neutral complexes are
formed. Gallium chelators generally include hard donors such as anoinic oxygens, and
thiolates, due to the hard acidic nature of the Ga3+ ion. There are therefore some ligands
that can be used for both Cu(II) and Ga(III) chemistry.
1.3.1 Acyclic ligands
Themost researched acyclic copper ligands are based around the bis(thiosemicarbazonato)
motif (fig. 1.12). These ligands have a rigid planar structure, forcing the copper centre
into its favoured square planar geometry. The terminal sulphur moieties deprotonate
upon coordination forming neutral complexes. The square planar geometry has been
proven by a series of x-ray crystal structures, and it has been found that alkylation of
the carbon backbone caused a lengthening of the C-C bond, and hence a bigger cavity
hole in which the copper can sit.[11] These molecules have been investigated for hy-
poxia imaging, as reduction of the copper centre from Cu(II) to Cu(I) causes the metal
to become uncoordinated, and stay in the hypoxic tissue.
NN
NN
SHH2N HS NH2
Figure 1.12: Bis(thiosemicarbazonato) ligand system
Many generic chelators have also been tested and derivatised for use in PET. Cu-
EDTA complexes form a distorted N2O4 octahedron, whilst CuDTPA forms an N3O3
complex (fig. 1.13).[12] 1,3,5-triaminocyclohexanewith threeN-substitutedmethylpyridines
has been testedwith radio copper, and the crystal structure shows a distorted octahedral
environment (fig. 1.14).[13]
Ligands designed for gallium chemistry include derivatives of o-hydroxybenzyl imin-
odiacetic acid, forming an NO3 coordination geometry, where it was found that sub-
stituents in the para positions had a substantial effect on the stability constants of the
complexes (fig. 1.15).[14] The more electron withdrawing the para group the lower the
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Figure 1.13: X-ray crystal structures of CuEDTA and CuDTPA [12]
HN
NHN
H
N N
N
Figure 1.14: Substituted 1,3,5-triaminocyclohexane [13]
stability, due to the presence of lower electron density on the hydroxyl oxygen.
R
OH N
CO2HHO2C
R = OMe, NO2
Figure 1.15: o-hydroxybenzyl iminodiacetic acid [14]
Another tetradentate gallium chelate is a tripodal tris(2-mercaptobenzyl)amine,which
forms a stable tetrahedral NS3 Ga(III) complex, whereas the indium analogue requires
additional solvent coordination.[15] The EDTAderived ligandN,N’-bis(2-hydroxybenzyl)-
ethylenediamine-N,N’-diacetic acid (HBED) has been shown to have an exceptionally
high stability constant (37.7) in the Ga(III) complex, and derivatives (HBED-CC) have
been synthesised that allow coupling to antibody fragments (diabodies).[16] Whilst
EDTA and DTPA complexes of Ga(III) are known, these ligands favour In(III) coordina-
tion (fig. 1.16).[17]
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N
HS
SH SH
N N
CO2HHO2C
HO OH
Figure 1.16: Tripodal tris(2-mercaptobenzyl)amine (left) and HBED (right) ligands [15,
16]
1.3.2 Macrocyclic ligands
TACN derived NO2A and NOTA are TACNmacrocycles with 2 or 3 carboxymethyl
pendant arms respectively. They have been shown to have a good affinity to copper,
and take square-pyramidal and octahedral geometries respectively (fig. 1.17).[18, 19]
The stability of NO2A is not significantly less than for NOTA complexes, and as such
allows access to further functionalisation through the unsubstituted third amine nitro-
gen. Oddly, the crystal structure of CuNO2A shows that only one acetate is coordinating
to copper, with both oxygen atoms bound to separate copper atoms. The remaining ac-
etate arm remains protonated, and is involved in hydrogen bonding to the perchlorate
counter ion. Ga complexes of NOTA have been shown to have a very high tolerance to
acid decomplexation, with a sample reportedly surviving 6 months in 5 M HNO3.[20]
The stability of the GaNOTA complex is attributed to the full encapsulation of the Ga(III)
ion within the macrocyclic cavity. Nucleophilic attack is also negated in this complex
due to the acetate arms, hence increasing its stability both in vitro and in vivo. The
tris(2-mercaptoethyl) substituted ligand, TACN-TM, was found to form a distorted oc-
tahedron, with similarly impressive stability (fig. 1.17).[21]
Figure 1.17: X-ray crystal structures of CuNO2A (left), CuNOTA (centre), andGaTACN-
TM (right) [18, 19, 20]
DO3A and DOTA – the cyclen analogues of NO2A and NOTA – have been synthe-
CHAPTER 1. INTRODUCTION 18
sised and their copper binding investigated.[22, 23] Both DO3A and DOTA form octahe-
dral copper complexes, with N4O2 donor groups (fig. 1.18). The coordinated carboxyl
moieties are found to be trans each other and coordinate on the same face.
Figure 1.18: X-ray crystal structures of CuDOTA (left), and GaDOTA (right) [22, 24]
A cross bridged DO2A complex was developed to envelop the copper ion into its
centre (Cu-CB-DO2A).[25] X-ray data showed that the copper ion sat out of the plane
of the cyclen ring in a severely distorted octahedral geometry, believed to be due to
a shrunken cavity hole (fig. 1.19). Ga complexes of DOTA has been studied, as the
potentially octadentate ligand can successfully fill the required six coordination sites
of octahederal gallium complexes. Simple complexes of Ga and DOTA show a similar
structure to those afford by the copper complex, with two binding acetate arms, and
two free (fig. 1.18).[24]
Figure 1.19: X-ray crystal structure of Cu-CB-DO2A [25]
These free acetate arms are advantageous and can be used for conjugation to tar-
geting molecules, and indeed many such molecules have been described. Ga-DOTA-
D-PheNH2 forms an octahedral complex with one free acetate arm and one free amide
arm, and has been used to explain the better kidney clearance of the octapeptide la-
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belled Ga-DOTA-TOC when compared with the Y3+ analogue (fig. 1.20).[26] The Y3+
complex is likely to make use of the full octadentate potential of the ligand, although no
structural evidence exists to defend the assumption. However, DOTA and its deriva-
tives are not ideal chelators of Ga(III) as the cavity size of the macrocycle is much too
large for the metal and so stabilities of the complexes are significantly lower than those
of the NOTA analogues (GaNOTA log K = 31.0, whilst GaDOTA log K = 21.3).[27, 28]
Figure 1.20: Ga-DOTA-D-PheNH2 [26]
Copper cyclam complexes have been studied due to the larger cavity size of the
macrocycle. This cavity is larger than that of cyclen, and therefore accommodates the
copper(II) ion better. Ligands involving at least one pendant acetate arm have been
studied, with the hexamethyl mono carboxyl arm (CuMe6TE1A) forming the expected
square pyramidal complexes (fig. 1.21).[29]
Figure 1.21: X-ray structure of CuMe6TE1A [29]
Addition of two arms leads to two possible situations, the arms adjacent or opposite
each other. In both cases the acetate arms assume the axial positions above and below
the copper centre that sits in the plane of the cyclam ring (fig. 1.22).
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Figure 1.22: X-ray strucutres of both CuTE2A complexes - cis (left) and trans (right)
X-ray structures of the tetrasubstituted Cu-TETA complexes show the possibility of
distortion along either the acetate axial, or across two of the cyclam nitrogens.[30] Func-
tionalisation of the carbon backbone of a TETA complex with a p-nitrobenzyl moiety,
shows the formation of the expected octahedral complex (fig. 1.23).[31] As would be
expected, given the larger cavity size than found in cyclen derivative, no structural data
has been obtained for GaTETA complexes, and it should also be noted that the stability
of these complexes is still lower with log K = 19.7.[28]
Figure 1.23: X-ray structure of C-functionalised CuTETA complex [31]
Bridged cyclam complexes of copper(II) have also been investigated, with the syn-
thesis of a diacetate ligand (CB-TE2A) and a monoacetate-monoacetamide ligand (CB-
TEAMA) accessed for investigation into their in vivo behaviour (fig. 1.24).[32] It was
found that while both complexes formed the expected enveloped octahedral complexes,
the Cu-Oamide bondwasweaker than that of the Cu-Oacetate bond. More interestingly, the
Cu-CB-TE2A complex is shown to have remarkable stability toward acid decomplexa-
tion, with a half-life of a week in 5 M HCl at 90°C.[33] The ligand has since been further
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C-functionalised with a p-isothiocyanatobenzyl group, which was subsequently cou-
pled to biotin.[34] Adjacently bridged cyclam complexes have also been synthesised,
and are found to form square planar complexes, with any pendant arm coordination
occurring axially forming square based pyramidal complexes.[30] Ga-CB-TE2A com-
plexes also show inertness toward demetallation, with a sample reportedly more than
80 % intact after 6 months in 5 M DCl (fig. 1.24).[35]
Figure 1.24: X-ray structures of Cu-CB-TE2A (left), Cu-CB-TEAMA (centre), and Ga-
CB-TE2A (right) [32, 35]
Cryptand ligands have been researched for their ability to act as ligands for 64Cu due
to the well-known strong binding and inertness of sarcophagine complexes DIAMSAR
and SARAR have both received recent attention (fig. 1.25).[36, 37, 38] Doubly proto-
nated DIAMSAR is found to have a coordination geometry between octahedral and
trigonal prismatic, with elongation of two trans Cu-N bonds. A glutaric acid derived
DIAMSAR ligand has recently been synthesised, forming distorted octahedral copper
complexes, with the ability to conjugate peptides to the glutaric arms.[39]
Figure 1.25: DIAMSAR (left), SARAR (centre), and x-ray structure of CuDIAMSAR
(right)
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1.4 Aims
In this thesis we aim to develop novel PET imaging agents that have the ability to
target specific anatomical or biological functions. The suitability of these ligands for
PET will also be tested.
Development of previouswork in the Fallis group on homopiperazine based ligands
with a view to use in PETwill also be undertaken, whilst also assessing the coordination
chemistry of these ligands.
Chapter 2
Rigid Arm Polyazamacrocycles
2.1 Introduction
Functionalisation of macrocycles has been extensively researched in the last decade.
The ability to selectively tune the metal-ligand interaction by the addition of different
pendant arms has become both academically and commercially important, for instance
in the formation of exceptionally stable biologically active metal complexes. Nitrogen
containing azamacrocycles are amongst the most commonly studied, and are the focus
of our work. The amine in these macrocycles has the advantage of being a relatively
hard donor, and therefore suitable for complexation to PET active metals, such as cop-
per, yttrium, and gallium. Azamacrocycles can be functionalised in one of two general
ways; first, through derivatisation of the carbon backbone, and secondly through func-
tionalisation of the nitrogen atoms. The major disadvantage of derivatisation of the
carbon backbone is that each variation requires total synthesis of the molecule, whereas
functionalisation of the nitrogen atom has a standard carbon backbone and addition
of separate specialised pendant arms for each variation. Large scale synthesis of the
main framework is therefore possible and reduces the amount of steps needed to make
each derivative. The drawback of functionalisation of the nitrogen ring only, is that the
number of substituents possible is dictated by the number of nitrogen atoms in the ring
(small) compared to the number of carbons in the framework (large). Addition of func-
tionality to a C2 carbon backbone can most easily be added through use of an amino
acid derivative, as exemplified by the synthesis of the TACN and cyclen derivatives
23
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from (2S)-lysine by Parker et al. and from p-nitrophenylalanine by Meares, Moi, and
DeNardo (fig. 2.1).[40, 41] It is interesting to note that in the formation of the TACN
derivative, the diethylenetriamine nitrogens are protected by coordination to copper
before protection of the terminal amine, and then deprotected with H2S and cyclised in
the normal manner. In all the complexes detosylation was best achieved through cleav-
age with conc. H2SO4, although other methods such as reductive cleavage in Li/NH3(l)
were attempted.
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Figure 2.1: C-Functionalised macrocycles
(1) Lysine functionalised ethylenediamine
(2) C-functionalised TACN from lysine
(3) C-functionalised cyclen from lysine
(4) C-functionalised cyclen from nitrophenylalanine
i) BH3.THF ii) CuCO3, Benzoyl chloride, H2S iii) TsCl iv) Ethyleneglycol ditosylate
When there is a C3 backbone, e.g. cyclam and 12N3, use of a β-amino acid could take
the place of the amino-acids as described above, however an alternative is to perform
a condensation reaction of a diamine with a C-substituted malonate to form an amide,
followed by reduction with BH3.THF as shown by Parker (fig. 2.2).[42]
Our focus, however, was on functionalisation of the nitrogen. Substitution of the
nitrogen has been well documented, and has included (but are not limited to) ani-
lines (1), phenols (2), thiophenols (3), phosphonates (4), amides (5), carboxylic acids
(6), alcohols (7), amines (8), thiols (9), alkyl (10), vinyl (11), and alkynyl (12) groups (fig.
2.3).[43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53]
Previous work in the Fallis group has shown that synthesis of a more rigid arm
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Figure 2.2: Malonate synthesis of c-functionalised macrocycles
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Figure 2.3: TACN with pendant donors
macrocycle increases the metal-ligand interaction, compared to the 6 member chelate
analogue (L1).[54] Synthesis of the rigid arm macrocycle was through an SNAr type re-
action of 2-fluoronitrobenzene with TACN in acetonitrile, giving the desired product in
good yield (72 %). Hydrogenation of the nitro group to an aniline by hydrogen gas over
Pd/C gave the free oxygen sensitive 1,4,7-tris(2-aminophenyl)-1,4,7-triazacyclononane
(L33) ligand. Complete hydrogenation was indicated by a colour change from orange to
colourless due to the conversion of the nitro group to an aniline. Coordination of L33 to
a series of first-row transition metals (Fe – Zn) was completed by addition of the ligand
in ethanol to the metal perchlorate (fig. 2.4). X-ray crystal structure data showed av-
erage metal-nitrogen bond lengths were considerably shorter than previously reported
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hexaaza-metal complexes, and EPR studies indicated that there was a much greater tor-
sional strain upon these complexes than their L1 equivalents.
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Figure 2.4: L33 and L1
This work was expanded upon, by Fallis and Tatchell, with further functionalisation
of the benzene rings.[55] Addition of difluoronitrobenzenes resulted in the formation of
ligands with a free fluorine upon the benzene ring which could potentially be further
substituted in a similar reaction to that of the initial reaction (fig. 2.5). Mis-insertion
products could be removed by recrystallisation, yielding the desired symmetrically sub-
stituted products. These compounds were then hydrogenated as before to yield the free
oxygen-sensitive ligands. Coordination to a wide range of metals was possible (Mn –
Zn, Cd, Hg, and Pb) and x-ray structure analysis for most of the complexes obtained. It
was found that the average bond length for all of the complexes was comparable with
other common MN6 complexes, and that therefore functionalisation of the benzene ring
had little effect on the strength of the metal-ligand bond. It was also noted that 19F NMR
shifts could be used as an indication of coordination and successful hydrogenation of
the nitro moiety in some cases, with a shift from c. -100 ppm to c. -125 ppm upon hy-
drogenation, then to c. -110 ppm upon Zn coordination, in the case of the para-fluoro
ligand.
It was shown that sequentially substituted TACN rings were accessable by control-
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Figure 2.5: Mis-insertion product
ling the number of equivalents of pendant arm added (fig. 2.6). Addition of 1 equivalent
led to the formation of the mono-substituted compound. Addition of a second equiva-
lent of a different pendant arm lead to the asymmetrically substituted compound, and
addition of a third equivalent of a further pendant arm yielded the triply substituted
compound. The order of pendant arm addition was said to be important in minimising
the chances of mis-insertion products, but this would only be the case in the addition of
fluoro derivatives.
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Figure 2.6: Mixed fluoro TACN synthesis
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Homopiperazine can be thought of as a pseudo-macrocycle, in that its chemistry
is similar to TACN – it can be functionalised through the carbon backbone and the
nitrogens in the ring – although it only forms chelates, rather than capping a metal
centre as TACN would. Little chemistry has been done on the formation of rigid arm
homopiperazine complexes, with unpublished work from the Fallis group being the
only compounds we are aware of.[55, 56] Synthesis of homopiperazine analogues of the
fluoro-functionalised L33 has been reported by Fallis and Tatchell (fig. 2.7). Coordina-
tion of metal species was achieved by addition of the metal perchlorate to an ethanolic
solution of the ligand under anaerobic conditions, with x-ray crystal structure data of
the Ni complex obtained. The bond lengths for the fluoro-functionalised complexes
were found to be slightly different from that of the parent compound, with an increase
of 0.012 Å in the Ni-Nring distance and a shortening of the Ni-Naniline distance by 0.013
Å. It is suggested that this is due to the electron withdrawing effect of the fluorine on
the para ring amine, causing a lengthening of the bond distance. Functionalisation of
the aniline was also investigated with the addition of tosyl chloride to form a sulfon-
amide, with the aim of forming charge neutral square planar complexes (fig. 2.7). After
reduction of the nitro moiety to an aniline, tosyl chloride in basic conditions was added,
forming the sulfonamides. Reaction with various metal salts was attempted, but only
the nickel complex was obtained, although fortunately yielding crystals of x-ray qual-
ity. X-ray data showed the presence of a neutral nickel complex, with no coordinating
solvent. The nickel was in a square planar environment, with a slight distortion of 11°,
which was suggested to be caused by the tight bite angle due to the small ring system.
N N
H2
N
H2
N
M
F F
N N
HN HN
M
S SOO O O
Figure 2.7: Homopiperazine analogues, and tosylated L22
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2.2 Anilino ligand synthesis
Given that previous evidence supported the fact that functionalisation of the ben-
zene ring had little effect on the strength of the metal-ligand bond, we believed that
functionalisation of these rings could lead to potential peptide binding sites, and thus
a method of using these chelates in PET studies. In order to understand further how
the functionalisation of the benzene pendant arm would affect the metal-ligand bond
strength a series of 5-functionalised-2-fluoronitrobeneznes with electron withdrawing
and electron donating groups were chosen for use as the pendant arms. Synthesis of the
homopiperazine compounds was analogous to that described previously for L22, with
2 equivalents of the fluoronitrobenzene added to a solution of homopiperazine and 2
equivalents of potassium carbonate in acetonitrile under an inert atmosphere. The com-
pounds were formed in moderate to high yields (47 - 99 %), as yellow to dark red solids
(table 2.1).
Synthesis of the more complicated amide (HPAmide−NO2) (fig. 2.8) was achieved
through the reaction of 4-fluoro-3-nitrobenzoic acid with oxalyl chloride to give the
acid chloride, followed by addition of the desired amine, this was then reacted with
homopiperazine under the aforementioned conditions.
F
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CO2H
F
NO2
COCl
F
NO2
OHN
H2N(COCl)2
DMF
N N
O2NNO2
N
H
O
N
H
O
Figure 2.8: Synthesis of HPAmide
Both the racemic and chiral compounds were synthesised. The 1H NMR of the
racemic compound showed only one set of signals, so it was hypothesised that there
was some kind of intermolecular influence between the pendant arms, resulting in only
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Ligand Yield (%) Colour λmax (nm) (ε (mol−1cm−1))
N N
NO2 O2N 90 Bright orange 384 (2706)
L22−NO2
N N
NO2 O2N 97 Dull orange 422 (4506)
HPTol−NO2
N N
NO2 O2N
F3C CF3
47 Orange 404 (4651)
HPCF3−NO2
N N
NO2 O2N
O2N NO2
49 Yellow 369 (27549)
HPSang−NO21
N N
NO2 O2N
O
O
O
O
90 Yellow 407 (4992)
HP
tButyl−NO2
N N
NO2 O2N
H2N NH2
91 Red-Brown 458 (2937)
HPNH2−NO2
N
NO2
NH
O
N
O2N
HN
O
76 Yellow 417 (5632)
HPAmide−NO2
Table 2.1: Homopiperazine ligands
one stereoisomer being formed. The hypothesis was tested by performing a ’doped’
experiment, in which 20 % of the pendant arm addedwas known to be pure (R-), whilst
the remaining 80 % was racemic. This should have resulted in a larger proportion of
the (R, R-) compound being formed and so the difference in shift would have been ob-
servable in the 1H NMR, however, only one set of signal was observed, meaning that
the racemic and chiral molecules were not distinguishable by 1H NMR. As in the pre-
vious examples we then attempted to reduce the nitro group to an aniline. Successful
reduction is indicated by a colour change from orange to colourless, associated with
the conversion of the nitro group to an aniline. 2 different methods were deployed for
the functional group interconversion, both being successful. Reduction of the nitro-
compounds to their aniline counterparts with tin chloride in acidic ethanol under nitro-
gen gave the desired colour change, however, attempts to isolate the aniline based inter-
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mediates were unsuccessful due to the highly oxygen sensitive nature of these ligands.
Instead the interconversion was completed using the previously described hydrogena-
tion method, involving Pd/C and methanolic solutions. It was found that pre-washing
the Pd/C catalyst media with methanol gave faster reaction times, which has been at-
tributed to impurities being present in the commercially purchased compounds. The
hydrogenation was usually complete overnight, and as before was indicated by a colour
change from orange to colourless. After completion the ligand was isolated by filtration
under nitrogen and the solvent removed under reduced pressure yielding the desired
product as a white/off-white solid. The free aniline ligands were found to be oxygen
sensitive and went off irreversibly within a few hours in the presence of air, indicated
by a browning of the solid, and so were stored under a nitrogen atmosphere. Due to
the oxygen sensitive nature of these ligands they were used without further purifica-
tion or characterisation. However, during attempts to grow crystals of complexes of the
HPCF3 ligands, crystals of the free ligand were obtained, of which the structure is given
in appendix A.
Synthesis of the TACN analogue of HPCF3−NO2 was also successful, using the same
general conditions as for the homopiperazine compound, whilst the piperazine ana-
logue of HPTol−NO2 was also synthesised again yielding the desired compound. Hy-
drogenation of the piperazine compound gave the desired colour change from orange
to colourless; however attempts to form complexes did not give the desired mass al-
though colour changes were noted. Attempts to grow crystals of the copper complex
yielded the free ligand, and the structure is given in appendix A. It is thought that the
complexes exist in equilibrium in solution due to the large strain that would be exerted
in the structure, however it was decided not follow up on this. The TACNCF3−NO2 was
also hydrogenated as before, giving the colour change of orange to colourless.
We hypothesise that the use of diazacyclooctane (DACO) in the place of piperazine
or homopiperazine would afford more stable complexes. This is due to the larger ring
size lowering the ring stain in the complexes. This has not been tested in this thesis, but
would be interesting to follow up in future.
A comparison of the UV-Vis data for the ligands shows the influence the para group
has on the electronics of the system (fig. 2.9). Using the parent compound L22−NO2 as
a comparison, it would be expected that there would be a shift to lower wavelengths
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Figure 2.9: UV-Vis comparison of ligands
Artifacts at 382 nm are a machine error during bulb changeover
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of those compounds with electron withdrawing groups in the para position, whilst an
increase in wavelength for those compounds with electron donating groups would be
expected. The Hammett parameters give a numerical value to the electronic effect of
the substituent in both para- and ortho- positions (see table 2.2), with positive numbers
meaning electron withdrawing, and negative numbers being electron donating. The
Hammett parameter (σvP) is the summation of the relative inductive and resonance ef-
fects of the group. It is important to remember that these effects are in addition to
Group σvp
H 0.00
Me -0.17
CF3 0.54
CO2Me 0.45
NO2 0.78
NH2 -0.66
CO2NH2 0.36
Table 2.2: Hammett Parameters
that of the ortho nitro group, which is exerting an effect on the electronics of this sys-
tem, therefore the order of electron withdrawing strength should be considered to be
HPSang−NO2 > L22−NO2 > HPCF3−NO2 > HPtButyl−NO2 > HPAmide−NO2 > HPTol−NO2 >
HPAmine−NO2. This order is found to be present in the lambda max values of these com-
pounds. The other striking difference in these values is the extinction coefficients (ε). By
far the largest value is that of the HPSang−NO2 compound (ε = 27549 M−1cm−1), which
is due to the chromophoric nature of the nitro groups. The parent compound has the
lowest extinction coefficient due to it being the least conjugated, and an increase in ex-
tinction coefficient is noted for the HPAmide−NO2 compound which contains additional
chromophores in the presence of phenyl rings.
2.3 Metal complexes of HPTol
Metal complexes of theHPTol ligandwere preparedby addition of a degassed ethano-
lic solution of the desired metal perchlorate to solid ligand under an inert atmosphere.
Gentle heat was applied for 2-3 minutes with stirring, and then the solution allowed to
cool, and stirred at room temperature for at least one hour. Addition of diethyl ether to
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the solution resulted in the precipitation of the metal complexes, which were found to
be air stable.
2.3.1 Nickel(II) complex
The nickel complex was found to be a cream solid. UV-Vis spectroscopy, run in
acetone, shows the presence of 3 distinct absorptions at 435 (ε = 75.7 mol−1cm−1), 583
(ε = 7.2 mol−1cm−1), and 630 (ε = 1.9 mol−1cm−1) nm, indicating a mixture of square
planar and octahedral species in solution.1HNMR, also in acetone, show a slight broad-
ening of all signals, with the sharpest being that of the methyl group on the ring, which
would be explained by its distance through space from the paramagnetic centre. This
paramagnetism could be attributed to coordination of acetone to the metal centre, even
though acetone is generally regarded is a weakly coordinating solvent. The IR spectrum
shows a signal at 3226 cm−1 and 3186 cm−1 assigned as the symmetrical and asymmet-
rical stretches of a coordinated aniline. The mass spectra showed the required isotope
pattern for this complex.
Attempts to grow crystals of x-ray quality was unsuccessful, so DFT calculations
were undertaken to gain more insight into the likely structure and bonding found in
the molecule (fig. 2.10).2 The calculations assumed square planar geometry, without the
presence of coordinating solvent. The nickel atom sits in the middle of the amine and
aniline atoms, in a slightly distorted square with angles found to be 86.3° and 93.7°. The
Nring-Ni bond lengths are found to be 1.899 Å, whilst the Naniline-Ni bond lengths are
calculated as 1.931Å, these values are comparable to those found by Perkins for the par-
ent L22 ligand (Nring-Ni 1.898 Å and Naniline-Ni 1.911 Å), indicating the methyl groups
has little effect on the electronics of the delocalised system.[56] The average Ni-N bond
length of 1.915 Å is almost exactly that of a strain free NiN4 square planar complex (1.91
Å), however the large difference between the two nitrogen environments indicate that
there is significant strain on the molecule.[57] The benzene rings are bent slightly from
linearity, which can be attributed to the unsymmetrical nature of the homopiperazine
ring, causing this molecule to lose a high degree of symmetry and join the CS point
group, only having a mirror plane.
2B3LYP / 6-31G (B3LYP / 6-31G(d,p) for metal atom and bound atoms) - input and output files on attached
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Figure 2.10: DFT calculated structure of NiHPTol
Selected Bond Lengths: Ni-N(34) 1.931 Å, Ni-N(37) 1.898 Å, Ni-N(38) 1.899 Å, Ni-N(39) 1.931 Å
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2.3.2 Copper(II) complex
The copper complex was synthesised in an analogous method to that of the Ni com-
plex. UV-Vis data shows a peak at 565 nm (ε = 292.2 mol−1cm−1) in acetone, assigned to
the 2T2g← 2Eg transition. The IR data shows signals at 3522 and 3243 cm−1, which have
been assigned as the symmetrical and asymmetrical stretching frequencies of a coordi-
nated aniline. The mass spectra showed the required isotope pattern for this complex.
Figure 2.11: EPR of CuHPTol in DMF/MeCN
An EPR spectrum of the compound was collected by members of Dr. D. Murphy’s
group from a frozen glass MeCN-toluene solution of the sample (fig. 2.11). The spec-
trum shows the presense of 4 distinct peaks as would be expected from a d9 copper(II)
complex with four coordinated nitrogens. Hyperfine coupling constants of Aq = 200 G
are noted, with gq = 2.195 and g⊥ = 2.041. Compounds with gq < 2.3 are considered to
be covalent in nature, whilst gq ≥ 2.3 are ionic, therefore the complex CuHPTol is to be
considered highly covalent in nature.[58] The values for gq and Aq are also close to those
reported for other CuN4 complexes such as [Cu(AMH)2](OH)2 - gq = 2.171 and Aq = 210
G.[58]
Again, growth of suitable crystals was unsuccessful, so DFT calculations were used
to probe the structure of the complex in a square planar geometry (fig. 2.12). As in the Ni
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Figure 2.12: DFT calculate structure of CuHPTol
Selected Bond Lengths: Cu-N(34) 2.014 Å, Cu-N(37) 1.987 Å, Cu-N(38) 1.987 Å, Cu-N(39) 2.013 Å
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complex the Cu atom sits slightly above the centre (2.4°) of a distorted square formed by
the amine and aniline nitrogen atoms, where the angles are found to average 84.5° and
95.5°. The Nring-Cu bond lengths are found to be 1.987 Å, whilst the Naniline-Cu bond
lengths are calculated as 2.013 Å, which is comparable to those found by Perkins in L22
( Nring-Cu 1.992 Å and Naniline-Ni 2.008 Å). As in the nickel complex, the benzene rings
are bent out of linearity, which is caused by the lack of flexibility in the homopiperazine
ring. The molecule has only a mirror plane and no other symmetry operators and thus
is also part of the CS point group.
2.4 Metal complexes of HPCF3
Metal complexes of theHPCF3 ligandwere preparedby addition of a degassed ethano-
lic solution of the desired metal perchlorate to solid ligand under an inert atmosphere.
Gentle heat was applied for 2-3 minutes with stirring, and then the solution allowed
to cool, and stirred at room temperature for at least one hour. Addition of ether to the
solution resulted in the precipitation of the metal complexes, which were found to be
air stable.
2.4.1 Nickel(II) complex
UV data for the nickel complex shows 3 peaks as found for the HPTol complex, 391
(ε = 40.2 mol−1cm−1), 507 (ε = 19.8 mol−1cm−1), and 803 (ε = 11.2 mol−1cm−1) nm, this
again indicates a mixture of square planar and octahedral species in solution. This was
also shown in the 1HNMR spectra, where the peaks were very broad, and therefore not
analysed or reported. Peaks in the IR spectra at 3419 and 3344 cm−1 are assigned to the
symmetrical and asymmetrical stretches of aniline coordination, and the sharp peak at
1332 cm−1 is asigned to the C-F bond.
DFT calculations show that the nickel atom sits very slightly above the plane (0.8°)
in a distorted square planar arrangement, with angles of 86.2° and 93.8°, similar to that
calculated for the NiHPTol complex (fig. 2.13). The Nring-Ni bond lengths are found to
be 1.898 Å, whilst the Naniline-Ni bond lengths are 1.934 Å. The Nring-Ni bond length
is the same as that of the parent L22 ligand, the Naniline-Ni bond is slightly longer. The
CF3 group is sufficiently electron withdrawing (c.f. Hammett parameters 2.2) that one
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Figure 2.13: DFT calculated structure of NiHPCF3
Selected Bond Lengths: Ni-N(34) 1.934 Å, Ni-N(37) 1.898 Å, Ni-N(38) 1.898 Å, Ni-N(39) 1.934 Å
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would assume therefore, that there would be a lengthening of the Nring-Ni bond length
as opposed to the Naniline-Ni bond length as that is para to the CF3 group. This is proba-
bly just an anomaly in the calculation method, and real data would be needed to assess
this properly. The large difference in the Nring-Ni and Naniline-Ni bond lengths shows
significant strain in the system, as in the analogous HPTol complex. Once again, the ben-
zene rings are bent from linearity, giving the molecule CS symmetry, with the presence
of only a single mirror plane.
2.4.2 Copper(II) complex
The purple copper complex gave a single peak in the UV spectrum at 572 (ε = 142.8
mol−1cm−1) nm, which is assigned the 2T2g ← 2Eg transition, although is a very long
tail starting from beyond 1100 nm that may be hiding other peaks. As with the nickel
complex there were peaks at 3519 and 3433 cm−1 in the IR spectrum accosiated with the
symmetrical and asymmetrical stretches of the coordinated aniline, and a peak at 1332
cm−1due to the C-F bond.
Like the Ni complex, DFT studies show that the copper atom sits very slightly out
of the plane (0.8°) in a distorted square planar geometry, with angles of 84.3° and 95.7°
(fig. 2.14). The larger distortion than in the nickel complex is due to the larger size of the
copper ion than its nickel partner. At 1.987 Å, the Nring-Cu bond lengths are the same
as the CuHPTol complex, whilst the Naniline-Cu bond lengths are also similar at 2.017
Å. As in the nickel complex, it is slightly surprising that the Nring-Cu bond lengths are
not slightly longer, but again these lengths are from an idealised gas calculation and
may not be exactly as found in reality. Again, there is a large strain in the molecule as
evidenced by the fact there is a large discrepancy between the Nring-Cu and Naniline-Cu
bond lengths. The molecule is in the CS point group, due to the presence of only one
mirror plane.
2.4.3 Zinc(II) complex
The zinc complex was analysed using IR spectoscopy, a peak at 3287 cm−1 is asigned
to the aniline, whilst the presense of a peak at 1334 cm−1 is indicative of the C-F bond.
DFT calculations of the Zn complex show the molecule is highly distorted, with the
Zn atom trying to force a tetrahedral geometry and causing a large twist in the molecule
(fig. 2.15). This is understandable as Zn has no preference for its geometry and tends
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Figure 2.14: DFT calculated structure of CuHPCF3
Selected Bond Lengths: Cu-N(34) 2.017 Å, Cu-N(37) 1.987 Å, Cu-N(38) 1.987 Å, Cu-N(39) 2.017 Å
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Figure 2.15: DFT calculated structure of ZnHPCF3
Selected Bond Lengths: Zn-N(34) 2.056 Å, Zn-N(37) 2.052 Å, Zn-N(38) 2.069 Å, Zn-N(39) 2.044 Å
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to form tetrahedral complexes over square planar ones due to the lower energy of the
system. If a plane is drawn through the line of the ring nitrogens and the Zn centre,
there is a twist of 57.8°, and 71.5° from the plane to the Naniline atoms (fig. 2.16).
Figure 2.16: Plane in the Zn structure
The N-Zn bond distances are all different, with the two Naniline-Zn bond lengths
being 2.044 Å and 2.056 Å, whilst the two Nring-Zn lengths are 2.052 Å and 2.069 Å. It is
interesting to note that the longest and shortest bonds are both on the same side of the
molecule, (fig. 2.15(left) left hand side). There are currently no pure ZnN4 complexes
reported in the Cambridge Crystal Database, all complexes involve at least one more
coordinating ligand. It is therefore unwise to compare these bond lengths to any other
reported distance. This indicates that the likely structure obtained, if crystals of this
complex ever come to light, would have at least coordinating solvent, and may not be
as strained as this structure is.
2.5 Metal complexes of TACNCF3
Metal coordination was attempted by addition of metal perchlorate in degassed
ethanol to the free ligand under an inert atmosphere. Gentle heat was applied, and
the solution stirred at room temperature over night. After filtration the solvent was
removed in vacuo, and the complex found to be stable to air.
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2.5.1 Copper(II) complex
Crystals suitable for x-ray diffraction of the copper complex were grown by vapour
diffusion of diethyl ether into acetonitrile. The acquired structure was not as expected,
but showed the loss of one pendant arm, and the formation of a 5 coordinate MN5
species. It is believed that this structure is of a small impurity in the sample and not
reflective of the bulk species. The crystals were sent off for analysis before any further
data was accumulated. We were unable to repeat the synthesis so no further data has
been recorded.
2.6 Metal complexes of HP
tButyl
Metal complexes of the HP
tButyl ligandwere prepared as for the HPTol complexes, by
addition of a degassed ethanolic solution of the desiredmetal perchlorate to solid ligand
under an inert atmosphere. Gentle heat was applied for 2-3 minutes with stirring, and
then the solution allowed to cool, and stirred at room temperature for at least one hour.
Addition of ether to the solution resulted in the precipitation of the metal complexes,
which were found to be air stable.
2.6.1 Nickel(II) complex
High resolution mass spectrometry revealed the correct m/z and isotopic pattern
for the formation of the complex, whilst also visable in the spectra was a signal for
the demetallated compound. IR spectra showed a broad signal at 3399 cm−1, which
indicates the presense of water in the sample. This peak has covered the area of the
spectrum where aniline stretches are usually visable, and so they are unassignable. The
sample had been dried under vacuum prior to the IR analysis, and therefore hints at the
presense of water in the solid structure. The peak at 1635 cm−1 has been assigned to the
ester function. This value is significantly lower than usually expected for an ester (~1740
cm−1) and this is due to the large amount of delocalisation throughout the molecule.
This has the result of greatly lowering the double bond nature of the C=O bond, and
in turn lowering the expected frequency of the moiety in the IR spectrum. The UV-Vis
spectrum was dominated by the chromophoric ligand, however, 2 shoulders relating to
d-d transisitions were visible, these lie at 487 and 623 nm, and indicate a square planar
geometry in the complex. The transitions are tentatively assigned the 2B1g ←1B2g and
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Figure 2.17: X-ray structure of CuTACNCF3 (left with perchlorate anions and solvent, right without)
Selected Bond Lengths: Cu-N(22) 1.995(3) Å, Cu-N(12) 2.008(3) Å, Cu-N(11) 2.039(3) Å, Cu-N(21) 2.060(3) Å, Cu-N(31) 2.188(3) Å
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2A1g ←1B2g transition respectively, although there maybe more signals hidden by the
large ligand signal as found for the other NiHPx complexes.
Crystals suitable for x-ray diffraction were able to be grown by vapour diffusion of
diethyl ether into acetonitrile (fig. 2.18). The colourless needle-like crystals were or-
thorhombic and occupied the Pbca space group.3 The nickel atom sits slightly above
the middle of a distorted square planar geometry (1.5°), with angles of 85.8°, 86.4°,
93.8°, 94.0° for the aniline nitrogens and ring nitrogens respectively. The Nring-Ni bond
lengths are found to be 1.905(5) Å, whilst the Naniline-Ni bond lengths are 1.905(4) Å and
1.916(4) Å. These lengths are very similar to those quoted for a strain free NiN4 complex
(see above), although the bond angles show that there is some steric strain on the sys-
tem. There is no difference in the bond lengths found in this complexes when compared
with those of the parent L22 complex, showing that (at least in the solid state) there is no
effect on the nitrogen-metal bond strengths with a change in the electron withdrawing
nature of the para substituent. As seen in the DFT calculated structures there is a bend
from linearity for the benzene rings, leading to a CS symmetrical molecule. There is also
a NiCl4 moiety in the crystal lattice to give the molecule overall charge neutrality.
2.6.2 Copper(II) complex
IR sprectra for the copper complex showed similar features to the Ni complex. A low
frequency C=O stretchwas observed at 1635 cm−1, with aniline stretches present at 3245
and 3382 cm−1. The low frequency of the C=O stretch is again believed to be caused by
the large delocalisation of charge throughout the molecule, lowering the double bond
character of the bond. UV-Vis sprectroscopy showed the presense of 3 distinct peaks
lying at 410, 612, and 813 cm−1. This indicates the presense of a number of coordination
geometries in solution. High resolution mass spectrometry shows the required mass
and isotope pattern for the formed complex, whilst the demetallated compound is also
visible in the low resolution spectrum.
Crystals suitable for x-ray analysis were not obtainable, and so DFT calculations
were undertaken to afford information on the structure of the molecule (fig. 2.19). Once
again the copper atom sits in the centre of a distorted square (0.5° out of the plane),
with angles of 84.5° and 95.5°. The Nring-Cu bond lengths of 1.988 Å are the same as for
the HPTol and HPCF3 complexes. The Naniline-Cu bond lengths are 2.010 Å and 2.012 Å,
3Full crystal data is available in Appendix X
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Figure 2.18: X-ray structure of NiHP
tButyl with NiCl4 counter ion
Selected Bond Lengths: Ni-N(1) 1.916(4) Å, Ni-N(2) 1.905(5) Å, Ni-N(3) 1.905(5) Å, Ni-N(4) 1.905(4) Å
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Figure 2.19: DFT Structure of CuHP
tButyl
Selected Bond Lengths: Cu-N(62) 2.012 Å, Cu-N(65) 1.988 Å, Cu-N(66) 1.987 Å, Cu-N(67) 2.010 Å
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which is the same as those in the HPCF3 complexes Again the molecule is displaying a
CS symmetry, having only one mirror plane and no axis of rotation.
2.6.3 Zinc(II) complex
The zinc complex was also synthesised, and was analysed using IR and mass spec-
trometry. A high resolution mass spectrum was not accessable for the complex, with
values outside the allowed range found. However, a low resolution spectrum gave a
signal at the desired mass. IR analysis showed the 2 signals for aniline coordination as
in other complexes, at 3466 and 3260 cm−1, with the C=O stretch at a higher frequency
than for the other HP
tButyl complexes at 1714 cm−1. DFT shows geometrical distortion
and therefore a loss of conjugation relative to the other metal complexes and this would
account for a higher frequency than seen before (although still lower than a typical ester
signal).
DFT calculations show that the zinc complex is, again, highly distorted, with the ani-
line nitrogens twisted by 58.6° and 71.9°, which is very similar to the ZnHPCF3 complex
(fig. 2.20 and 2.21).
Figure 2.21: Plane in Zn structure
The Nring-Zn bond lengths of 2.052 Å and 2.068 Å are very similar to the ZnHPCF3
complex, whilst the Naniline-Zn bond lengths of 2.048 Å and 2.038 Å are considerably
shorter. This is a continuation of the pattern noticed for the CuHP
tButyl complex. Again,
it can be assumed that there will be some form of coordinating ligand in experimentally
formed crystals, and so little conclusions should be drawn from these calculations.
It can be seen from the x-ray and DFT structures that substitution of the benzene
ring para- to the ring nitrogen has only a small effect on the metal bond strength. There-
fore functionalisation of these areas is an option when trying to synthesise a targeting
molecule. We have also shown that it is possible to form amide bonds at the para posi-
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Figure 2.20: DFT structure of ZnHP
tButyl
Selected Bond Lengths: Zn-N(62) 2.048 Å, Zn-N(65) 2.052 Å, Zn-N(66) 2.068 Å, Zn-N(67) 2.038 Å
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tion, and it is therefore a route to peptide conjugation.
2.7 Carboxy ligand synthesis
Having shown that functionalisation of the benzene para to the ring nitrogens had
little effect we became interested in synthesising neutral complexes. It is desirable clini-
cally to have neutral drugs, as this lowers the chance of patients suffering drug-induced
shock. As the ortho-nitro group activates the fluorine of the benzene ring towards nucle-
ophilic substitution we needed to find a suitably electron withdrawing group to match
its activating power. The carboxyl group was chosen, but due to the ability of this to
also react with an amine to form an amide, we needed to protect it in the form of an
ester.
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NO2
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NO2
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O F
NO2
OEt
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Br
O O
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Figure 2.22: Pendant arm synthesis
Synthesis of the benzyl, ethyl, and tbutyl esters was performed on both 2-halobenzoic
acid, and 2-halo-5-nitrobenzoic acid. Benzyl protection of the carboxylic acidwas achieved
through reaction of benzyl bromide with the acid in DMF in the presence of a phase
transfer catalyst yielding the desired ester as yellow/orange powders in moderate to
high yields (68 % - 92 %) (fig. 2.22). Both the fluoro- and chloro-nitrobenzoic acids
were used as we wished to see if the presence of two electron withdrawing groups was
enough to activate the chlorine towards substitution. Fluorobenzoic acid and iodoben-
zoic acid were chosen to see whether the ester was activating enough to activate the
fluorine towards substitution, with the option of a Buchwald-Hartig amination using
the iodide if the former was not possible.
The ethyl esters were synthesised from the acid in ethanol with sulfuric acid as the
CHAPTER 2. RIGID ARM POLYAZAMACROCYCLES 52
catalyst, whilst the tbutyl esters were formed by reaction of the acid with boc-anhydride
in the presence of DMAP4 (fig. 2.22). Addition of the carboxyl pendant arms 1-NO2, 2-
NO2, and 3-NO2 to homopiperazine proceeded as with the nitro compounds. It was
found there was no difference in reactivity between the fluoro- and chloro- derivatives,
and so the chloro- compound was used preferentially on economic grounds. Addition
of the non-nitro derivatives by this method failed, and Buchwald-Hartig amination was
not attempted due to problems found later in the complex synthesis.
HN NH
F
NO2
CO2R
N N
O2N
CO2R RO2C
NO2
+
CH3CN,
K2CO3
Figure 2.23: HPLX−NO2
In addition to homopiperazine compounds, we also produced piperazine, TACN,
and dimethylcyclen based ligands. This was to prove that the reaction conditions were
the same for similar macrocycles as well as giving a route to related complexes. Crystal
structures for the ligand precursors Pip3−NO2 , HP1−NO2 , HP3−NO2 , TACN1−NO2 and
DMC1−NO2 were obtained and are given in Appendix A.
4DMAP = N,N-dimethyl-4-aminopyridine
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Figure 2.24: Synthesis of free carboxyl ligands
(i) Pd/C, THF:MeOH, H2 (ii) Pd/C, THF, acetic acid, H2 (iii) SnCl2, EtOH (iv) Pd/C,
MeOH, H2 (v) HCl (2 M)
The free ligand was accessed through various means depending upon the protecting
group of the ester (fig. 2.24).
The TACN1−NO2 pro-ligand was deprotected in a one step protocol using Pd/C in
a THF:MeOH solution under an atmosphere of hydrogen (i). The hydrogenation of the
nitro group to an aniline and deprotection of the benzylic ester occur simultaneously.
Reduction of the nitro group to an aniline results in a colour change from orange to
colourless, however, this is not indicative of the benzylic ester cleavage, and so the
hydrogenation was performed over 2 days. It was also noted that the colour change in
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this compound occured much slower than the time taken for similar reductions for the
HPAnilino ligands described previously. This resulted in a highly air sensitive compound
that had to be stored under an inert atmosphere.
The sensitivity of the HP1−NO2 compounds to this method was found to be equally
as challenging, and the hydrogenation needed stronger conditions with the addition of
a drop of acetic acid to lead it to completion (ii).
We also attempted selective reduction of the nitro-group to an aniline, leaving the
ester function in place (iii). This was due to the possibility of a method of tagging a
protein or amino acid type group to the ligand through amide bond formation. To this
end reduction of HP1−NO2 by SnCl2 in ethanol was undertaken. After reflux for 18 hours
a colour change was noted, from bright orange to an off white-orange. After extraction
with chloroform and removal of solvents in vacuo, the product was found as a brown-
orange oil. 1H NMR data showed the presense of the compound, but also many other
signals, and mass spectra showed the desired m/z peak, as well as a plethora of other
values. It was therefore concluded that the sample was air sensitive in this form as well,
and no further work was attempted.
The HCl salt of the free ligand PipR was accessed from the pro-ligand Pip3−NO2 .
Hydrogentation of the pro-ligand gave the expected reduction of the nitro to an aniline,
as evidenced through loss of colour from orange to colourless (iv). To this was then
added degassed HCl (2 M) and stirred at room temperature under an inert atmosphere
for 18 hours (v). After removal of the solvent in vacuo a colourless white solid remained
that was very hygroscopic. 1H NMR whilst broad showed the loss of the ethyl group,
as well as a shift in aromatic protons as would be expected from reduction of the nitro-
group.
2.8 Metal complex of carboxyl ligands
Metal complexes of the free ligand were accessed through addition of an alcoholic
solution of the desired metal salt to a solution of free ligand. It was found that the
complexes had very limited solubility and so samples strong enough to give useful UV
data were unable to be accessed, resulting in analysis by MS, IR, and EPR only.
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2.8.1 Copper(II) Complexes
Complex of PipR
Neutralisation of the free ligand salt with triethylamine under inert conditions fol-
lowed by addition of copper(II) chloride in a degassed methanol solution resulted in a
colour change from colourless to deep blue. Removal of the solvents in vacuo follwed
by precipitation of a chloroform solution in hexane resulted in a blue solid. IR sprectra
of the solid showed the expected peaks for a free aniline 3446 and 3356 cm−1 as well
as an unexplained signal at 3221 cm−1. The later signal could identify the presense of a
protonated aniline species, either from the complex, or from triethylamine that has not
been successfully removed during work up. The coordinated carboxylate is seen with
stretches at 1597 and 1377 cm−1.
Complex of HPR
Addition of an ethanolic solution of copper acetate to a THF solution of the free
ligand afforded a colour change from colourless to blue then green. High resolution
mass spectrum of the resulting solid showed presense of the desired compound as the
Na+ salt. IR data show the desired 2 signals for the presense of an aniline at 3437 and
3217 cm−1, with bound carboxylate signals at 1596 and 1398 cm−1.
Figure 2.25: EPR spectra of CuHPR
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A samplewas handed in for EPR analysis as a blue frozen glass solution of DMSO:EtOH
(fig. 2.25). The spectrum shows the presense of only one species but others are poten-
tially hidden by the broadness of the peak. To identify if there are hidden species, fur-
ther analysis at a greater frequency would be required in order to pull the peaks apart.
A value of Aq = 110 G is found with gq = 2.250 and g⊥ = 2.083. The larger gq value found
here than for the CuHPTol complex shows the greater degree of ionic bonding between
the carboxylate and copper, than that of the aniline copper bond.
Figure 2.26: EPR spectra of CuHPR with excess DMSO
It was noted that when additional DMSO was added to the EPR sample there was
a colour change from blue to red. A further EPR spectra of the red solution was taken,
and a vast difference in output was seen (fig. 2.26). A complete loss of peak definition is
noted, and is believed to be caused by an overlap of both octahedral and square planar
complexes due to coordination of DMSO to the copper centre. Again, higher frequency
analysis of the sample may shed some light on this, but was not available at the time
these results were acquired.
Complex of TACNR
Addition of an ethanolic solution of copper(II) nitrate to a THF solution of the free
CHAPTER 2. RIGID ARM POLYAZAMACROCYCLES 57
ligand under inert conditions afforded a colour change from colourless to purple. After
work up, the product was isolated as a deep purple/black solid.
IR analysis showed the 2 expected peaks for the presense of an aniline group at
3353 and 3216 cm−1, with coordinated carboxyl signals at 1560 and 1374 cm−1. High
resolution mass spectrometry of the solid gave the required mass and isotope pattern
predicted for the complex.
Figure 2.27: EPR spectra of CuTACNR
Once again EPR studies were undertaken of the complex using a DMSO:MeOH
frozen glass. Two distinct patterns are observed in the EPR spectrum indicating the
presense of 2 species in the solution (fig. 2.27). Species 1 has Aq = 170 G with gq = 2.202
and g⊥ = 2.119. Species 2 has Aq = 143 G with gq = 2.156 and g⊥ = 2.041. The val-
ues for species 1 compare well with those reported for a bis-[9]aneN2O copper complex
Cu([9]aneN2O)2+2 , which contains a similar CuN4O2 ligand framework, at gz = 2.202
and Az = 193.5 G.[59]
It is also stated in Kavana’s paper that a minor signal is seen and is attributed to the
conformational isomers possible. This could explain the presense of 2 discrete signals
in the acquired sprectum for this complex, with the isomers being an octahedral and
triganol bipyramidal geomtery. Further EPR studies, and structural data - either X-ray
data, or computational - would be needed to add weight to this theory.
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Figure 2.28: Cu([9]aneN2O)2+2 [59]
2.8.2 Nickel(II) Complex
Complex of HPR
The nickel(II) complex of HPR was also synthesised in the same manner as the cop-
per complex. A high resolution mass spectrum was unobtainable due to values outside
of the allowed range, however, the low resolution spectra showed the desired m/z and
isotopic pattern for the complex, with an mono aqua adduct also seen. IR spectroscopy
revealed a broad peak at 3429 cm−1 assigned to a water molecule and indicates that wa-
ter is trapped in the solid lattice, which is therefore covering any signals that would be
seen for the anilines. The signals for the carboxylate occur slightly higher than for the
copper complex at 1634 and 1384 cm−1 indicating a slightly weaker bond to the metal
centre.
Chapter 3
Triazine Core Derived PET
Agents
3.1 Introduction
Cyanuric chloride (2,4,6-trichloro-1,3,5-triazine) and its fluorine analogue have long
been used as building blocks for polymers and herbicides, however more recently they
have been shown to exhibit biological functionality, specifically in tumour inhibition.[60,
61] Current chemotherapeutic agents that contain the 1,3,5-triazine moiety include hex-
amethylmelamine (HMM, Altretamine©), and 2-amino-4-morpholino-s-triazine both of
which are used to treat ovarian and breast cancers (fig. 3.1).
N N
NN N
N
N N
N NH2Cl
N
O
Figure 3.1: HMM (left) and 2-amino-4-morpholino-s-triazine (right)
The ability to progressively substitute the chlorine atoms of cyanuric chloride with
nucleophiles allows facile access to a vast library of compounds with the same core
structure, but also the ability to tune the substituents to fit a desired purpose, e.g. addi-
tion of hydrophilic side arms to increase water solubility.
Previous work has shown that imidazoyl moieties attached to the triazine core ex-
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hibit inhibition of aromatase of the human placental microsomes, which are expressed
excessively in breast cancers.[62] These compounds also include the presence of morpholino-
, and thiomorpholino- moieties, with themost inhibitory compound being the bis(thiomorpholino-
)imidazoyl-triazine, which has a 15x inihibitory affect when compared to the reference
compound CGS-16949A (Fadrozole hydrochloride) (fig. 3.2).
N N
N NN
N
N
S S
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.HCl
Figure 3.2: Bis(thiomorpholino)-imidazoyl-s-triazine (left), fadrazole hydrochloride
(right)
Sulphonamide inhibition of carbonic anhydrases (CAs) has been known for a long
time, with many different compounds currently being used clinically as antiglaucoma
agents, antiepileptics and diuretics. However, some CAs are found more regularly in
cancer cells than in normal cells, as they convert CO2 into bicarbonate and allow the
tumour cells to regulate their pH more effectively.[63] Acetazolamide (AAZ, Diamox©)
was primarily used to treat glaucoma and epilepsy, but its ability to interfere with the
mode of action of CAs (and hence reducing the pH) in tumour cells has allowed it to be
used alongside existing cytotoxic agents as part of anticancer therapies. Further stud-
ies showed that other effective antiglaucoma agents have significant anticancer prop-
erties, these include methazolamide (MZA, Neptazane), and ethoxzolamide (EZA) (fig.
3.3).[64]
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Figure 3.3: AAZ (left), MZA, EZA (right)
Work by Garaj has shown that triazines with attached sulphonamide show good in-
hibition of the tumour associated CAs I, II, and IX. Synthesis involved the 1:1 addition of
sulphanilamide to cyanuric chloride followed by further functionalisation by addition
of a series of amines, amides, and phenols, in a 1:2 ratio, affording the fully substituted
triazine (fig. 3.4).[65] Higher levels of inhibition were noted for those compounds with
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smaller moieties at the triazine core, whilst there was also high selectivity shown by
those with acidic moieties towards CA IX which could be used as a methodology to
target hypoxic tumours.
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Figure 3.4: Synthesis of Garaj’s most successful CA IX inhibitor
Dipyridamole (Persantine) has a similar core structure to that of cyanuric chloride,
with a tetrasubstituted pyrimidopyrimidine core. The drug (fig. 5), used as a treatment
for prevention of strokes, inhibits thrombus formation and is also a vasodilator, making
it an attractive target for a PET active tracer. We believe that a similarly substituted tri-
azine ring would be an interesting target as the interactive moieties would be the same,
but there would be position left on the ring that would allow further functionalisation
e.g. addition of a metal binding site.
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Figure 3.5: Dipyridamole (left), our target (right)
Integrins are hetreodimeric glycoproteins containing alpha and beta subunits, which
have, in mammals, been characterised into combinations of 18 alpha units, and 8 beta
units. Integrins are important in biological mechanisms for cell-cell and cell-matrix
interactions, and as such have been studied extensively. Tumour metastasis involves
many cell-cell and cell-matrix interactions, for example transfer from one site to an-
other through the blood or lymph systems and so inhibition of the protein is therefore
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important in the treatment and diagnosis of cancers, oestoporosis, renal failure, and
retinopathy.[66] The integrin αVβ3 is responsible for cells binding to proteins in the ex-
tracellular matrix (ECM), and has been found to be over expressed in many tumour
cells, including osteosarcomas, neuroblastomas, lung/breast/prostate/bladder carci-
nomas, and melanomas.[67, 68, 69, 70] It is also important to consider that many dis-
eases are caused by the misregulation of blood vessel growth for example rheumatoid
arthritis, and so could also be diagnosed or treated if the over expression of these pro-
teins could be traced.[71] The crystal structure of the integrin complexed with an arg-
gly-asp (RGD) ligand was first published in 2002 by Arnaout, Shang, et.al, and showed
inhibition of the molecule occurred through an RGD cyclic peptide.[72] The distance be-
tween the terminal ends of this cyclic peptide is around 14 Å, with one terminus being
a glycidic acid moiety and the other being the guanidnyl moiety of arginine (fig. 3.6).
Figure 3.6: Integrin-RGD crystal structure (above), cyclic RGD peptide distance (below)
The RGD sequence is known as the "universal cell recognition site" as it is frequently
found as the binding sequence for ligands to integrins (table 3.1), however there is a high
selectivity for differing proteins all containing the RGD sequence for each integrin.[73]
This selectivity is not fully understood yet, however the conformation of the peptide can
alter the receptor selectivity and affinity.[66] It has also been shown that small changes
to the sequence i.e. substitution of Asp with Glu, can result in a total loss of binding
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affinity.[74]
Integrin Ligand Binding Sequence
α2β1 Collagen DGEA/RGD
Laminin Unknown
α3β1 Laminin KQNCLSSRASFRGCVRNLRLSR
Collagen; Epiligrin Unknown
Fibronectin RGD
α4β1 Fibronectin IDAPS/LDV/REDV/X-D-Y
VCAM-1 Unknown
α5β1 Fibronectin RGD
αVβ1 Fibronectin, Vitronectin RGD
αLβ2 ICAM-1 KELLLPGNNRKV
ICAM-2, ICAM-3 Unknown
αMβ2 Fibrinogen GGAKQAGDV
Compliment 3bi Unknown
αXβ2 Fibrinogen GPRP
αI Ibβ3 Fibrinogen GGAKQAGDV/RGD
Fibronectin, Vitronectin, RGD
vWF, Thrombospondin
αVβ3 Vitronectin, Fibronectin, RGD
Fibrinogen, Collagen,
Thrombospondin, Thrombin,
Osteopontin, Bone Sialoprotein,
Tenascin
αLRIβ3 Entactin RGD
αVβ5 Vitronectin RGD
αVβ6 Fibronectin RGD
Table 3.1: Binding sites of selected integrins[73]
The distance between the active moieties (pharmacophors) of the RGD sequence
has been shown to be important in the activity and specificity in inhibition of the inte-
grin αI Ibβ3, and can therefore be assumed that this also an important factor when de-
signing integrin inhibitors.[75] Given that the distance between pharmacophors in the
crystallised αvβ3 structure is 12 Å, any nonpeptidic target molecule must also be of this
length.
3.2 Synthesis of Dipyridamole Analogues
As previously described, the use of cyanuric chloride as a model for the dipyri-
damole core affords the ability to add extra functionality to the molecule through substi-
tution at the 3rd chloride. Addition of a DO3Amoiety here allows facile access to metal
complexes and therefore adds potential as a Cu, Ga or Y PET agent. Before synthesising
the target compound, it was important to understand the conditions needed to add a
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DO3A moiety to a triazine ring. Synthesis of symmetrically and asymmetrically sub-
stituted aminochlorotriazines with morpholino-, piperidino-, and thiomorphilino- side
chains has been known for a long time and are simple one-pot reactions (fig. 3.7).[76]
The reaction proceeds as an SNAr type reaction with substitution of the chlorine atoms
by the chosen amine.
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Figure 3.7: General synthesis of mono, bis, and tri substituted s-triazines
We prepared a sequence of symmetrically and asymmetrically substituted triazines
to explore new reaction conditions (table 3.2). It was found that stirring at room temper-
ature was sufficient for substitution of the second chlorine in moderate yield, where as
in the previous literature, heating to around 40°C was required.[76] 1HNMR identifica-
tion of the products can be difficult due to the lack of aromatic protons for integration,
however, 13CNMRgives amuch better understanding of whether the reaction has given
the mono- or bis- substituted products. Relative integration of the triazinyl quaternary
carbons shows the carbon environment that is more populated, with the peak around
170 ppm representing the chlorocarbon and the lower peak being that of the substituted
carbon.
R R’ Yield (%)
Piperidine Cl 66
Morpholine Cl 61
Diethanolamine Cl 77
Thiomorpholine Cl 61
Piperidine Piperidine 64
Piperidine Diethanolamine 62
Piperidine Morpholine 57
Morpholine Morpholine 65
Diethanolamine Diethanolamine 90
Table 3.2: Symmetrically and asymmetrically substituted triazines and yields
2,4-Dimorpholino-s-triazine was reacted with DO3A.HBr in acetonitrile in an inert
atmosphere under reflux for 5 days to yield the trisubstituted s-triazine (TzMorph2DO3A).
A lack of unreacted DO3A was noted in the 1H NMR spectrum by a loss of a broad
resonance above 10 ppm characteristic of DO3A.HBr, which is the result of proton co-
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ordination to the DO3A core itself. Deprotection using TFA, followed by addition of
metal acetate gave the desired metal complex (fig. 3.8). The addition of metal salt and
its subsequent coordination was achieved in milligram scale, and complex formation
was shown by high resolution mass spectrometry. The extremely long reaction time in
comparison to that of mono- and bis- substituted triazines is believed to be due to a
combination of the much less activated 3rd chlorine substitution along with the lower
reactivity of the 4th amine in the macrocyclic ring.
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Figure 3.8: Synthesis of TzM2DO3A complexes
Attempts to grow crystals of these structures have so far failed. It was believed that
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Figure 3.9: X-Ray structure of crystals from EuTzM2DO3A coordination attempts
simplified to show the 2 Eu environments (left), full (right)
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crystals of a Eu complex had formed, however, the X-ray diffraction data shows the
formation of a large ordered structure of Eu and DO3A (fig. 3.9) with the asymmetric
fragment containing 5 Eu atoms in 2 environments (one environment being coordinated
by DO3As and the other being an aqua-acetate coordination sphere) and a large amount
of disordered water. This is believed to have formed by metal promoted cleavage of the
N-triazine bond due to the lewis acidity of the metal chosen. As the triazine core is very
electron deficient, addition of a lewis acidic metal to the DO3A moiety would make it
an excellent candidate to act as a leaving group, and this we believe is what is seen in
this crystal structure. A less lewis acidic metal such as lanthanum would most likely
not cause this cleavage, and would be an interesting avenue to follow up.
DFT studies of the Ni, Cu, and Zn complexes show an interesting bend in the molec-
ular structure, giving the molecules have a perceived boat formation (fig. 3.10). The
DO3A fragment is bent back toward the triazine core, so as the metal centre is level
with the triazine core. Bond lengths from the DFT have not been analysed, as with no
real data to compare it against for accuracy.
The zinc(II) complex is a 5 coordinate N3O2 donor set species, with N2O2 forming
a perfect square planar cavity (fig. 3.11). The amine furthest from the triazine ring
also coordinates to the metal centre, whilst its acetate arm does not due to the charge
neutrality of the complex. It is interesting to note that there is no bonding between the
metal and the amine attached to the triazine, which is most likely due to the lone pair
being withdrawn into the delocalised ring.
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Figure 3.10: DFT calculated structures of Ni (left), Cu, and Zn (right) complexes. Above: side on view. Below: showing metal coordination pocket
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Figure 3.11: DFT structure of Zn(II) complex
Selected Bond Lengths: Zn-N(19) 2.306 Å, Zn-N(25) 2.289 Å, Zn-O(36) 1.960 Å,
Zn-O(42) 1.962 Å
The nickel(II) complex is a 4 coordinate N2O2 donor set species, forming a slightly
distorted square planar structure, with no bonding of note between the amines attached
to and furthest from the triazine (fig. 3.12).
CHAPTER 3. TRIAZINE CORE DERIVED PET AGENTS 70
Figure 3.12: DFT structure of Ni(II) complex
Selected Bond Lengths: Ni-N(19) 2.016 Å, Ni-N(25) 1.995 Å, Ni-O(36) 1.845 Å, Ni-O(42)
1.853 Å
The copper(II) complex is a 5 coordinate N3O2 structure, with an elongated Cu-N
bond to the furthest amine of the DO3A ring. The middle amines and acetates are
arranged in a distorted squarer planar formation, with a much larger twist than the
computed nickel complex (fig. 3.13).
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Figure 3.13: DFT structure of Cu(II) complex
Selected Bond Lengths: Cu-N(19) 2.128 Å, Cu-N(25) 2.097 Å, Cu-O(36) 1.911 Å,
Cu-O(42) 1.923 Å
3.3 Dendrimeric Triazines
Following successful addition of DO3A to substituted triazines, we decided to probe
the success of addition of DO3A to unsubstituted triazines. Attempts to synthesise the
mono-, bis-, and tris- DO3A-triazineswere under taken, with successful addition of both
one and two DO3A moieties. Addition of the third DO3A was believed to be unlikely
due to the steric bulk of the DO3A moiety itself and the relatively small triazine core. It
was found that addition of 3 equivalents of DO3A.HBr to a triazine slurry followed by
reflux overnight afforded the bis-substituted product, and could be purified by recrys-
tallisation away from the excess DO3A. Addition of 1 or 2 equivalents of DO3A.HBr
gave the expected mono- (TzDO3ACl2) or bis- (TzDO3A2Cl) substituted triazines (fig.
3.14). The remaining chlorines could then be substituted with a smaller cyclic amine
such as morpholine, to give an asymmetrically substituted triazine.
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Figure 3.14: Mono- and bis- DO3A substituted s-triazine
We decided to use these DO3A-amino-chlorotriazines tomake some interesting dedrimeric
’snowflake’ compounds (fig. 3.17). Using a macrocyclic core – either TACN or cyclen
– we are able to add the substituted triazines through an SNAr reaction at the final
chlorine, forming large, potentially highly symmetrical ligands, capable of coordinating
multiple metal centres. The completely unsubstituted compound, TCl6, was accessed
through addition of TACN to excess cyanuric chloride in the presense of base. Reaction
of TACN with 3 equivalents of morpholino-dichlorotriazine (TzMorph2Cl) resulted in
the formation of a trisubstituted TACN ring with 3 triazines each with a morpholino
and chlorine moiety (TM3Cl3 - fig. 3.15).
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Figure 3.15: TM3Cl3
The 1HNMR shows a broadmultiplet with little defining character, which can be at-
tributed to the TACN andmorpholine protons all being in a similar environments and at
similar frequencies. The 13CNMR is more complicated with a number of signals around
a similar frequency, indicating the presence of rotamers, which would also contribute to
the broad peak of the 1HNMR. Characterisation of the molecule was therefore difficult,
and is based on the single species seen in the high resolution mass spectrumwith a m/z
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equal to that expected of the desired molecule (724.2245), and also a distinctive isotopic
pattern, which matched that predicted for the compound. It was therefore preferable
to have a totally symmetrical compound formed using the same conditions, so that the
NMRs would be clear. The presence of 3 ’free’ chlorines on this structure allows access
to further functionalisation of the molecule through substitution at these positions, and
any reaction of the sort would also prove the startingmaterial was as believed. The reac-
tion of DO3A.HBr with the molecule resulted in the formation of a symmetrical DO3A –
morpholine derivative (TD3M3). This was shown by distinct peaks in the 1HNMR, and
by the correct number of signals in the 13CNMR. Furthermore, the 13CNMR shows that
the 3 triazinyl carbons are all in different environments, which would also be expected
of this molecule. This therefore proves that the previous molecule was indeed as was
expected.
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Figure 3.16: Steric explanation for lack of rotamers
The loss of rotamers explains the low yield. Formation of the molecule is sterically
hindered when there are 2 DO3A moieties oriented in to the same space, meaning that
these molecules will form with either the loss of a DO3A molecule, or will not form at
all (fig. 3.16). It is believed that these possible reaction outcomes are removed during
the work up, leaving the singular trisubstitued isomer only.
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Figure 3.17: Morpholine dendrimers
Addition of bismorpholinochlorotriazine to TACN resulted in the expected trisub-
stituted TACN molecule, TM6 (fig. 3.17). 1H NMR showed 2 distinct signals, one at
3.79 ppm attributed to that of the TACN ring, and a broader resonance at 3.74 – 3.61
ppm assigned to the morpholine rings. 13CNMR shows the 5 signals expected of the C3
symmetrical molecule, with 2 distinct triazinyl environments and 3 allylic carbon envi-
ronments. High resolution mass spectrum shows the mass and isotope pattern expected
of this molecule.
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Figure 3.18: TD3Cl3 molecule
After success with the model compounds, synthesis of the DO3A analogues was
undertaken. DO3A-dichlorotriazine (TzDO3ACl2) was reacted with TACN to form the
trisubstituted TACN compound (TD3Cl3 - fig. 3.18). 1H NMR data showed the pres-
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ence of distinct environments for the DO3A ring protons, TACN ring protons, acetate
protons, and tbutyl protons, indicating no formation of rotamers. This was confirmed
with 13C NMR data which showed a number of signals that would be expected in a
C3 symmetrical molecule. The lack of rotamers is most likely due to the sterics of the
compound, with large bulky DO3A moieties trying not to interact and thus forming in
an ordered pattern.
3.4 Synthesis of RGD nonpeptidic mimic
In the RGD cyclic peptide the active pharmacophors are a guanidinyl and carboxylic
acid group. This functionality can be added to the triazine core through the use of func-
tionalised amines (vide supra). To this end, cyanuric chloride was reacted with 1 equiv-
alent of the hydrochloride salt of ethyl glycine using the general conditions described
previously, resulting in the mono-substituted triazine in moderate yields (66 %).
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Figure 3.19: First attempt at preparation of the RGD mimic
Addition of the guanidinyl moiety was initially attempted through a 2 step process;
first, addition of a mono-Boc-protected diamine, and subsequent deprotection, followed
by addition of a di-Boc-guanidinyl group to the terminal amine, which could then be
deprotected yielding the target molecule. Both mono-Boc-ethylene diamine (Boc-EDA),
and mono-Boc-propylene diamine (Boc-PDA) were synthesised by dropwise addition
of Boc-anhydride into a large excess (< x10) of the required diamine under an inert at-
mosphere at 0°C. Removal of solvent and excess diamine in vacuo, and an acid/base
work up, resulted in pale yellow oils of the required mono-protected diamines in rea-
sonable yields (~ 50 %). Addition of the mono-protected diamines to the triazine core
(TzEtGlyCl2) using standard conditions yielded the required disubstituted intermedi-
ate, TzEtGlyBoc-E(P)DACl. Before deprotection of the terminal amine, substitution of
the final chlorine at the triazine core was undertaken using DO3A.HBr, using the same
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conditions as upon addition to the bis-morpholino compound, TzMorph2Cl (vide supra).
Deprotection using TFA then afforded the compound with an unprotected DO3A coor-
dination core, as well as a free terminal amine. Addition of various d-block metals
gave the desired metal complexes of the compound as shown by high resolution mass
spectral analysis (fig. 3.19). Addition of the guanidinyl pharmacophor was explored
through reaction of the terminal amine with a bis-Boc-mono-triflate-guanindine moi-
ety previously reported by Feichtinger.[77] However the reaction did not proceed as
expected, and 1H NMR data suggested the isolated compounds did not include addi-
tional Boc moieties (incorrect integration of the peak at 1.5 ppm) and confusing signals
in the aliphatic region, which are as of yet unidentified.
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Figure 3.20: Synthesis of guanidine arm triazine
Conditions: i) Boc-anhydride, Dioxane, NaOH, 0°C ii) Triflic anhydride, Et3N, DCM,
-78°C iii) Diamime, Et3N, DCM, r.t. iv) TzGlyCl2, NaHCO3, acetone/water, 0°C
It was therefore decided to synthesise the complete protected guanidinyl amine arm
before addition to the triazine core. Synthesis of the protected guanidine using the
method described by Feichtinger, followed by dropwise addition into a large excess
of ethylene diamine in a manner similar to the mono-boc diamines, and purification by
column chromatography (EtOAc/MeOH/Et3N) yielded the desired monosubstituted
diamines as previously reported by Castagnolo.[77, 78] Attempts to scale the reaction
from that reported resulted in significantly lower yields, and thus was deemed unac-
ceptable. It should also be noted that this method is not appropriate when wishing
to use propylene diamine, as formation of a cyclic guanidine is favoured over the lin-
ear product.[78] However, if the compound were to be synthesised for PET purposes
then the low yield would not be a hindrance as the required volumes of the target
molecule are so small. Also if this reaction were to be automated the possibility of
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parallel experiments would facilitate higher output of this key intermediate. Addition
of the guanidinyl amine to the triazine core by the standard procedure was a success
(TzEtGlyBocGuanCl), although the yield was relatively low for this step as well (23 %)
(fig. 3.20). Due to the scarcity of the product and the difficulty in its synthesis, addition
of the DO3A macrocycle and subsequent deprotection has not been attempted.
Click Chemistry
Although the DO3A group allows incorporation of various metal ions into the struc-
ture, we were interested in ways of easily incorporating other functionalisable moiety
to the triazine core. "Click" chemistry was first described by Barry Sharpless, and is a
chemical philosophy based on the way nature forms chemical bonds that allows a vast
library of chemicals to be made from a few simple chemical reactions.[79] One of the
most commonly used click techniques involves a [2+3] cycloaddition to an azide moiety
forming the triazole, as the azides are generally stable to dimerisation and hydrolysis.
Addition of an azide moiety directly to cyanuric chloride has already been used experi-
mentally in the synthesis of more water soluble HMM based antitumour drugs, as well
as in the formation of stable energetic materials.[80, 81] In the case of Simmonds, syn-
thesis involved the addition of sodium azide to a solution of the disubstituted triazine
in boiling acetic acid, followed by addition of water and recrystallisation from ethanol.
Addition of an azide moiety to our disubstituted Boc-propylenediamine-ethylglycine
triazine was achieved by addition of sodium azide to the monochloro-triazine in ace-
tonitrile. Successful addition was shown by the addition of a band at 2137 cm−1 in the
IR spectrum, consistent with that of an aryl azide, as well as high resolution mass spec-
trometry. Due to the availability of 18F, we decided to ’click’ on a glycidic alkyne chain,
in order to perform a functional group conversion from an alcohol to a halide as the last
step (fig. 3.21).
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Figure 3.21: Click synthesis
Synthesis of the glycidic chain, AlkyGlycol, was achieved through addition of propar-
gyl bromide to a large excess of triethylene glycol in the presence of a strong base
(NaH). Extraction from water, followed by flash column purification yielded the tar-
get molecule as a yellow oil, shown in the 1H NMR by the addition of a alkyne signal
at 1.98 ppm. ’Clicking’ of the alkyne to the azide was attempted with catalytic copper
sulphate in the presence of ascorbic acid, yielding a mixture of products as show by the
1HNMR, including the desired product seen through the appearance of a triazole signal
at c.4.2 ppm. So far attempts at purification of this molecule have failed.
Chapter 4
Acetate Functionalised TACNs as
PET Agents
4.1 Introduction
Polyazamacrocycles have been found to exhibit exceptionally strong bonds to tran-
sition metals, which has made them ideal candidates for use in medical applications
were the need for low dissociation constants is great.
Tetraazamacrocycles have been employed as successful chelators of PET active met-
als. The unsymmetrically substituted triacetic acid derivative of cyclen (DO3A) has
found widespread use in molecular imaging as it was shown that the absence of one
acetate arm (compared to the parent DOTA compound) had only a small effect on the
metal dissociation constants.[82, 83] DO3A is best suited to large tripositive ions such as
the lanthanides, whilst its use with smaller tripositive metals is possible but not ideal,
due to the large cavity hole of the macrocycle. NO2A is a TACN analogue of DO3A,
with one secondary amine available for derivatisation, and is much better suited for the
PET metals considered in this work due to their smaller size (fig. 4.1).
NO2A as a bis-acid is most suited to chelation to a dipositive ion such as copper(II).
With this in mind recent attention has turned to the synthesis of Cu-PET agents bear-
ing a NO2A core. Synthesis of NO2A based compounds has so far centred on addition
of a bridging moiety to the unsubstituted nitrogen centre to allow further functionali-
sation through the addition of the desired peptide chain using standard methods.[84]
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Figure 4.1: NO2A and DO3A
Copper(II) chelation has been achieved through addition of a copper salt to the desired
chelating compound at neutral pH, followed by HPLC purification.
Recent work by McBride et al. has also shown the use of NOTA/NO2A derivatives
to coordinate to an Al3+ atom, which can then bind strongly with an 18F− ion, allowing
the complex to be used in PET imaging.[85] Studies have shown that this interaction be-
tween Al and F is much stronger than 60 other metals, whilst being selective for F over
the other halides. McBride et al. used the commercially available p-SCN-Bn-NOTA
starting material, to which they conjugated the desired peptide chain as previously
reported.[86] The first complexes were synthesised by addition of an Al-F solution to
the compounds, although later it was found that addition of the fluoride source could
occur after addition of the Al salt, allowing for quicker (in terms of F decay) synthesis.
Figure 4.2: NO2A-Al-F complex
Single crystal structure data of a model NO2A-Al-F complex was obtained by Shetty
et. al. (fig. ).[87] The complex was shown to form a series of 5 member chelate rings,
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with the compound showing coordination to all of the TACN nitrogens on one face, and
the acetic acid oxygen atoms on the other in a distorted octahedral geometry. Al-O bond
lengths were comparable with the parent NOTA complex (1.8856(16) and 1.8446(16) Å
vs 1.84Å), whilst it was found the averageAl-N bond lengths were slightly longer (2.083
Å) by 0.02 Å. The Al-F bond length of 1.709 (14) Å was comparable with the calculated
bond length in diatomic Al-F, indicating a strong Al-F bond.
There is a strong history of TACN coordination chemistry in our group, andwith the
imminent arrival of 64Cu and the current availability of 18F at the Cardiff PET centre it
was decided that we focus our efforts on the NO2A derived complexes.
4.2 NO2A derivatives
As discussed in previous chapters (3), it has been shown that sulphonamides act
as carbonic anhydrase (CA) inhibitors. The presence of tosylate groups in the synthe-
sis of TACN therefore lends itself to the formation of compounds that may act as CA
inhibitors.
Selective detosylation of the triprotected TACN has been known for a long time,
with methods of mono-, and tri-deprotections known - with diprotection best accessed
through addition of one tosylgroup to monotosyl TACN (fig. 4.3).[88] Following the
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Figure 4.3: TACN deprotection routes
(i) 1. 33 % HBr/AcOH, PhOH. 2. NaOH (ii) H2SO4 (iii) TsCl, NaOH
established procedure by Sessler, formation of the monotosyl TACN was achieved.[89]
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Addition of a slight excess of bromo tbutylacetate gave the desired NO2A derivative in
a high yield. Deprotection of the tbutyl group was accessed through addition of TFA
to a DCM solution of the compound in the standard manner, and easily seen by a loss
of tbutyl peak in the 1H NMR spectrum. The deprotected compound was found to be
slightly hygroscopic, and so was stored in a vacuum dessicator. Addition of copper
acetate to a methanolic solution of the ligand resulted in a characteristic colour change
from colourless to deep blue. mass spectrometry showed the presense of the desired
complex and the expected isotopic pattern for the sodium salt. The UV-Vis spectrum
showed a single peak at 645 nm (ε = 89 mol−1cm−1) concordant with the 2T2g ←−
2Eg transtion. Crystals suitable for x-ray diffraction were grown by vapour diffusion
of diethyl ether in to acetonitrile. The crystal structure shows two discreet molecules,
with methanol and acetonitrile in the crystal lattice (fig. 4.4). The copper atom sits
in the centre of a 5 coordinate distorted square based pyramid arrangement, with the
sulphonamide nitrogen filling the axial site. As expected in copper complexes, there is
an elongation of the axial bond when compared to the equatorial bonds, this is due to
the Jahn-Teller distortion effect (see page 5). The average Cu-O bond length over both
molecules is found to be 1.927 Å which is comparable to those found by Spiccia et al. in
their ethylene and butylene bridge NO2A complexes (1.937 Å, and 1.940 Å respectively,
see fig. 4.5).[90] The Cu-Nbase bond lengths average at 2.007 Å, which almost identi-
cal to the Spiccia complexes (2.007 Å and 2.018 Å), whilst the average Cu-Naxial bond
lengths of 2.4285 Å are significantly longer than those reported (2.203 Å and 2.227 Å).
The longer axial bonds are believed to be caused by electron withdrawal from the ni-
trogen by the tosyl group, causing a weaker (longer) bond between the sulphonamide
nitrogen and the metal centre. The angles at the base of the square pyramid are also
slightly distorted, with O-N-N angles of 91.0° and 91.4° found in one moiety, and 91.4°
and 92.4° in the other, this is caused by the rigidity imposed on the system by the TACN
ring. The tosyl moiety bends away from the copper centre in both molecules due to
steric reasons.
It has been previously reported byMcBride that NO2A compounds with aluminium
coordinated can be used to coordinate a PET active fluoride ion.[85] We decided to test
our compound with this theory and added AlCl3 to a solution of free TsTACNA2 in
sodium acetate buffer (1 M at pH 3.5). Gentle heating and stirring followed by addi-
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Selected Bond Lengths: Cu(1)-N(1) 2.009(3) Å, Cu(1)-N(2) 2.004(3) Å, Cu(1)-N(3) 2.429(3) Å, Cu(1)-O(2) 1.934(2) Å, Cu(1)-O(4) 1.920(2) Å,
Cu(2)-N(4) 2.017(3) Å, Cu(2)-N(5) 1.998(3) Å, Cu(2)-N(6) 2.428(3) Å, Cu(2)-O(8) 1.930(2) Å, Cu(2)-O(10) 1.924(2) Å
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Figure 4.5: Spiccia’s bridged NO2A complexes
tion of KF gave a colourless solution. Due to the scale of this test reaction, purification
and isolation were not attempted. However, mass spectrum analysis show the presence
of a series of related compounds, with the desired product, a bridge species, and an
extended double fluoride bridge system seen in the spectrum (fig. 4.6). Further investi-
gation and the reaction being repeated on a larger scale would allow a more thorough
understanding of the bonding in these complexes and offer insights as to its potential
use in PET imaging.
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Figure 4.6: Bridged species seen in AlTsTACNA2 mass spectrum
Due to successful synthesis of the acid derivative, the synthesis of the alcohol equiv-
alent was also undertaken. Monotosyl TACN was reacted with an excess of enantio
pure (R)-propylene oxide, yielding the desired product (fig. 4.7). Addition of copper(II)
acetate as before gave a deep blue solution indicative of copper coordination. UV spec-
troscopy shows a single peak at 682 nm (ε = 57mol−1cm−1) associatedwith the 2T2g←−
2Eg transtion. Growth of crystals suitable for x-ray diffractionwas successfully achieved
CHAPTER 4. ACETATE FUNCTIONALISED TACNS AS PET AGENTS 87
NH
N
HN
SO O
N
N
N
SO O
N
N
N
SO O
O
OtBu
O
OtBu
(R)
OH
(R)
OH
Br OtBu
O
O (R)
Figure 4.7: Monotosyl substituted TACNs
through slow evaporation of an ethanol/water solution. mass spectrometry showed the
desired m/z and isotopic pattern for the complex. The structure shows the monoclinic
P1 (1) space group, with 2 distinct complex units1. (fig. 4.8).
The unit cell comprises of 2 different units of 2 CuTsTACNE2 moieties bridged by a
hydroxyl group. In both moieties the copper atoms sit in a distorted octahedral geom-
etry, with an alcoholic oxygen, bridging hydroxyl, and two macrocyclic nitrogens oc-
cupying the equatorial positions, whilst the sulphonamide nitrogen and one alcoholic
oxygen occupying the elongated axial sites. Although the moieties exhibit the same ge-
ometries they have distinct copper - hetero-atom bond lengths. In both cases though,
the copper environments either side of the bridging water are identical. In one moiety,
the Cu-alcohol bond length is found to be 1.962 Å in the equatorial position (Cu-Oe),
and 2.547 Å in the axial position (Cu-Oa), showing an extreme lengthening of the axial
bond, as would be expected for d9 Jahn-Teller distorted complexes. The bond length of
the bridging oxygen to the copper centre (Cu-Ob) is found to be 1.989 Å, which is longer
than its equatorial equivalent, but is explained as the electron density is split between
two copper sites, and so bond strength would be expected to be weaker, thus produc-
ing a longer bond. The situation is made complicated for the Cu-N bond lengths as
there are 3 separate nitrogen environments; sulphonamide nitrogen, ring nitrogen with
alcohol moiety bound equatorially to the copper atom (Nring−e), and ring nitrogen with
1Data return by the Crystallography service was incomplete, with only cartisean coordinate returned. All
bond lengths are found using the Avogadro program[91].
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Figure 4.8: X-Ray structure of CuTsTACNE2 (A: Both units. B: Single unit. C: Single copper moiety)
Selected Bond Lengths: Cu(1)-N(1) 2.077(9) Å, Cu(1)-N(2) 2.116(9) Å, Cu(1)-O(3) 1.969(8) Å, Cu(1)-O(4) 1.995(6) Å, Cu(2)-N(4) 2.023(10) Å,
Cu(2)-N(5) 2.079(9) Å, Cu(2)-O(8) 1.997(8) Å, Cu(2)-O(9) 1.983(6) Å
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axial alcohol moiety (Nring−a). The sulphonamide nitrogen is bound in an axial position,
and so has a long bond length of 2.641 Å, in keeping with the weak donor nature of a
sulphonamide (although still within the combined van der Waals radii). The Cu-Nring
bond lengths are different by 0.012 Å, with the Cu-Nring−e bond shorter at 2.080 Å, and
the Cu-Nring−a bond length 2.092 Å. In the second moiety this is found to be reversed,
with the Cu-Nring−e bonds longer than Cu-Nring−a bonds by 0.004 Å at 2.056 Å and
2.052 Å respectively. It is also found that the bridging oxygen is bound more strongly
than the alcohol oxygen, shown by the bond lengths 1.982 Å and 1.997 Å respectively.
This also indicates that the copper is more strongly coordinated by the equatorial ni-
trogen atoms in the second moiety than in the first, as the bond lengths between Cu-N
are relatively shorter, and the Cu-O bond lengths relatively longer than their immediate
relatives. This is also seen by longer bonds to the axial atoms, with the Cu-Nsulphonamide
bond length 2.726 Å (vs 2.641 Å), and Cu-Oa bond length 2.565 Å (vs 2.547 Å).
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Figure 4.9: Synthesis of NPhTACNA2
The success of the tosyl compounds lead us to try and add a potential linker group
to triazine molecules as discussed in chapter 3, allowing facile access to a library of
’PETable’ target specific compounds. The triazinemoiety reactswell with amines, so ad-
dition of an amine group to the TACNmolecule was sort. Use of our fluoronitrobenzene-
TACN chemistry as described in chapter 2 would allow access to an amine through re-
duction of a nitro moiety. Addition of 4-fluoronitrobenzene to an acetonitrile solution
of TACN without the presence of base yielded (after recrystallisation) pure the desired
product. Addition of 2.2 equivalents of bromo tbutylacetate gave the desired NO2A
derivative in good yield (fig. 4.9). Deprotection by TFA and addition of copper acetate
in methanol as before gave a deep blue solution indicative of TACN coordinated cop-
per. mass spectrometry showed the correct m/z and isotopic pattern for the desired
complex. Slow evaporation of the methanolic solution gave crystals of suitable quality
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for x-ray analysis (fig. 4.10).
The complex is found to have a monoclinic, p 21/c space group with each unit cell
containing a single complex moelcule and the ligand forming anN3O2 donor set. Whilst
similar values are noted for the Cu-O bond distances (1.9245(15)Å and 1.9323(16) Å2), 3
different distances are seen for the Cu-N bond. The average Cu-O bond distance of 1.927
Å is identical to that of the CuTsTACNA2 complex (vide supra) The shorter Cu-N bond
distances of 1.9945(18) Å and 2.0195(17) Å occur for the acetate substituted nitrogen
centres that use the equatorial coorindation sites, whilst the longer value of 2.4464(17)
Å found along the nitrophenyl substituted nitrogen bond, occuring in an axial geom-
etry. This is a similar value to that found in the CuTsTACNA2 complex showing the
nitrophenyl moiety to have a similar electron withdrawing strength to the tosyl group
as well as the Jahn-Teller distortion associated with Cu(II) complexes. UV spectroscopy
showed a single peak at 603 nm (ε = 82mol−1cm−1) resulting from the 2T2g ←− 2Eg
transition.
4.3 PET Data
The compounds TsTACNA2, NPhTACNA2, and TsTACNE2 were deemed to be suc-
cessful enough for PET studies. The studies were undertaken at the University of Al-
berta, by Dr. James Knight, and currently only preliminery results for TsTACNA2 and
NPhTACNA2 is available. The maximum specific activity of the complexes was as-
sessed through addition of 64Cu(OAc)2 (1 MBq) to a dilution series of the ligand (2.5
→ 50 ng). The radiolabelling efficiency is determind through radio-TLC (MeOH/10%
NH4OAc on C18 plates) where any uncoordinated 64Cu(OAc)2 remains on the baseline.
The result show maximum efficiency occurs for both complexes above 20 ng, with a
strong drop off for concentration under 10 ng (fig. 4.11).
An HPLC purification method3 was also obtained for each 64Cu complex with reten-
tion times for the copper complexes being shorter than those of the ligand: CuTsTACNA2
= 16 mins, TsTACNA2 = 20 mins; CuNPhTACNA2 = 14.5 mins, NPhTACNA2 = 21
2 Full refinement data was not supplied, so no root mean squared values were availible.
3Phenomenex C18 Luna column, linear gradient from 100:0 (H2O : MeCN) to 0:100 (H2O : MeCN)
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Figure 4.10: Single crystal structure of CuNPhTACNA2
Selected Bond Lengths: Cu-N(1) 2.4464(17) Å, Cu-N(2) 2.0195(17) Å, Cu-N(3) 1.9945(18) Å, Cu-O(1) 1.9245(15) Å, Cu-O(3) 1.9323(16) Å
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Figure 4.11: Radiolabelling efficiency of CuTsTACNA2 and CuNPhTACNA2
mins. LogP values were also determined for the complexes showing the partitioning
of the complexes between water and octan-1-ol. Values of -1.69 (CuTsTACNA2) and
-1.63 (CuNPhTACNA2) show the hydrophilic nature of the complexes.
The stability of the CuTsTACNA2 complex in human serum was also studied. Hu-
man serum was added to a solution of the 64Cu complex, this was shaken (400 rpm)
at 37 ºC and the percentage of remaining 64Cu complex was analysed by reverse phase
radio-TLC (vide supra). Measurementwere taken after 7.5, 15, 30, and 60 minutes as well
as at 3 and 24 hours (fig. 4.12). The percentage of 64Cu complex remaining after 1 hour
fell quickly to around 50 %, with a similar fall to 25 % noted after 2 hours. The value
of intact complex stayed steady at around 25 % for the 24 hour period. This stability
compares badly with C-substituted full acetate macrocycles such as p-SCN-Bn-DOTA
and p-SCN-Bn-NOTA (fig. 4.13) that commonly have stabilities of > 50 % after t = 12
hrs.[92]
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Figure 4.12: Stability of CuTsTACNA2 complex in human serum
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Figure 4.13: p-SCN-Bn-DOTA (left) and p-SCN-Bn-NOTA (right)
Chapter 5
Other Work
This section of the thesis is about some of the side projects that developed through-
out the course of our investigation. The work contained herein is unfinished, but the
early results are interesting and further work could result in the formation of further
final year projects, or PhDs.
5.1 Glutamate Chemistry
5.1.1 Introduction
During the research into RGD non-peptidic mimics, we aimed to make a compound
where the arginine residue was replaced by a functional chelating moiety. The theory
behind the idea is that the rigidity of the chelate would increase the bond strength be-
tween the metal and the ligand, whilst at the same time forcing the position of the outer
groups into one more akin to that in the RGD-Integrin crystal structure (62). Initial
DFT calculations suggested that a homopiperazine ring with appropriately function-
alised benzene rings would be too long for the coordination site on the protein (~18 Å
as against coordination site length of ~12 Å, fig. 5.1).
Substitution of the functional groups directly onto the macrocycle would therefore
be needed. The use of a bis-acid arm was theorised as one acid could act as the acetate
arm common to good PET chelators (DO3A, NO2A), whilst the other would function as
the coordinating ligand to the protein site (fig. 5.2).
Alternatively, the ’outer’ acid could be converted into an aspartate mimic through
amide synthesis. As well as getting the ’spacer’ length correct for the molecule, we
94
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Figure 5.1: DFT calculated distance of model compound
N N(R) (S)
OHO
OHO
HO O
HO O
'inner' acid
'outer' acid
Figure 5.2: Inner/outer acid shown on direct substitution of macrocycle
believe that adding chirality to it will also increase the binding to the specific integrin.
The use of amino acids allows facile access to the introduction of chirality as amino
acids are inherantly chiral. Whilst formation of macrocycles from amino-acids directly
is known, we wanted to use a generic core, followed by addition of targeting pendant
arms that could be more easily changed in a modular way, than by total synthesis from
step one.[40] Functional group interconversion of the amine group of an amino-acid
to a bromine would allow an SN2 addition of the amino-acid to the nitrogen atoms
of the macrocycles. Such interconversion of an amino-acid amine to a halogen can be
easily accessed through diazotisation, and addition of the appropriate acid (e.g.. for Br,
HBr), as shown by Koppenhoefer.[93] The exact length of the chain needed could not
be usefully calculated by DFT, so we planned on forming a series of compounds with
varying chain length and determining the best by in vivo studies.
5.1.2 Amino acid type bis-acid interconversion
Formation of the desired halogenated bis-acidwas first attemptedwith aspartic acid.
Before diazotisation, the acid groups were protected as simple ethyl esters, using the
standard acid catalysed reaction. The aspartate ester was diazotised with sodium ni-
trite, and then added dropwise to HBr (fig. 5.3). Polarimetry (qualitative) of the com-
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pound showed there had been a racemisation. This can be rationalised through an E2
elimination of the diazonium in solution to give the racemic product. E2 elimination
is likely given the acidic nature of the β-proton and would result in the formation of
a fumarate. Addition of bromide to the fumarate could occur from either face, and
hence form a racemic mixture. If the nature of the substitution were SN2, as expected
then there would be no loss but rather an inversion of chirality, whilst SN1 substitution
would result in racemisation through the planar transition state.
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Figure 5.3: Attempted synthesis of ethyl bromosuccinate
To overcome this problem, glutamic acid was used. The extra carbon in the back-
bone means that the β-proton is less acidic due to resonance structures, and so E2 elim-
ination should be stopped. Glutamic acid was protected as the ethyl ester as before,
and diazotised with sodium nitrite, followed by dropwise addition to HBr. Polarimetry
(qualitative) indicated chirality in the molecule, and so the ethyl bromoglutamate could
be used in the next step confident of its chirality.
5.1.3 Synthesis of Glutaric Macrocycles
Addition of the glutamate pendant arms to homopiperazine, TACNand 1,8-dimethylcyclam
(DMC) was attempted. Addition of a slight excess of ethyl bromoglutamate to each
macrocycle in the presence of equal moles of base resulted in the fully substituted
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macrocycle (fig. 5.4).
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Figure 5.4: Synthesis of glutarate functionalised macrocycles
Acid hydrolysis of the ester function resulted in the formation of the salt of the free
acid. Before coordination this salt must be neutralised. Attempts to synthesise partially
substituted macrocycles always resulted in the presence of multiple species in the mix-
ture, and separation of these species was not attempted. Coordination of a metal to
the macrocyclic compounds was accessed through addition of NaOH until neutral (as
shown by pH paper) and addition of metal acetate to an ethanolic solution of the lig-
and (fig. 5.5). Slow evaporation of an ethanolic solution of the CuDMC-Glut complex
yielded crystals suitable for x-ray diffraction (fig. 5.6).
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Figure 5.5: Synthesis of metal complexes
The CuDMC-Glut crystals exhibit a triclinic unit cell in the P-1 space group. It is
C2 symmetrical and the copper sits in the middle of a distorted N4O2 octahedron. The
distance between ’outer’ acid groups is found to be 11.5 Å, which is very close to the
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Figure 5.6: CuDMC-Glut X-ray structure
Selected Bond Lengths: Cu-N(1) 2.12(3) Å, Cu-N(2) 2.08(3) Å, Cu-O(1) 2.33(3) Å
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distance found between RGD extremities. The Cu-NMe distance is found to be 2.125(3)
Å whilst the Cu-Nacid distance is found to be 2.084(3) Å. The Cu-O distance is longer at
2.329(3) Å. The N-Cu-N bond angles are found to be 93.37(13)° and 86.4(13)°, whilst the
NMe-Cu-O angles are 86.7(11)° and 93.3(11)°, and the Nacid-Cu-O angles are 78.3(11)°
and 101.7(11)°. Whilst these value may appear significantly different, once the errors
are taken into consideration these values can all be considered the same.
5.1.4 Potential application as an MRI contrast agent
Due to the inability to control the stepwise addition of the pendant arm, wewould be
unable to use these molecules in their intended purpose. However, the dimethylcyclam
compound shows potential as an MRI contrast agent, due to its ability to coordinate
strongly to metal centres (c.f. CuDMC-glut bond lengths) and so preliminary tests were
undertaken to assess its suitability.
As with PET, it is important in MRI to have a strongly bound metal centre as the
paramagnetic metals that are commonly used are highly toxic and cause cell death.
Manganese and gadolinium are commonly used in MRI contrast agents due to their
strong paramagnetism leading to reductions in both T1 and T2 relaxation times.
First, it was important to be sure of the ratio of metal to ligand binding. A use-
ful method for determination of lanthanide concentration is a xylenol orange titration.
Xylenol orange is a weak lanthanide chelator, and will therefore chelate with any free
gadolinium in solution, as well as manganese ions (fig. 5.7). Xylenol orange has 2 ab-
sorption peaks in the UV/Vis spectrum, at 434 nm and 576 nm. Addition of lanthanide
to the solution causes an increase in absorption at 434 nm, and a fall in absorption at 576
nm. Upon addition of xylenol orange to a solution of free ligand, one can then see by
the changing absorptions, when the free ligand is coordinationally saturated, and hence
work out the ratio of metal to ligand. This is an important consideration with our lig-
ands, as the four carboxylates along with the four nitrogen donors gives the possibility
of multi-metal coordination that may only be present in solution.
To a solution of the free ligand with 2 drops of xylenol orange present was titrated
the metal ion (fig. 5.9 and 5.10). Addition of Gd3+ resulted in a steady increase in the
peak at 576 nm, along with a slight decrease and blue shift in the peak at 434 nm (fig.
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Figure 5.7: Structure of xylenol orange
5.9). The steady increase at 576 nm shows that there is always free Gd3+ in the solution
and that the gadolinium is not coordinating to our ligand. This may be a kinetic problem
due to the size of themetal ion and the cavity in which it is trying to fit. Heating between
the sampleswould allow coordination of the metal to our ligand, but this was not tested.
The Mn2+ titration shows a curve more consistent with coordination of metal ion. The
peaks remain constant to addition of around 200 mM of metal, followed by a constant
increase in peak height at 576 nm and consistent fall at 434 nm (fig. 5.8).
Figure 5.8: [Mn2+] vs Absorbance at 576 nm
The data indicates that the complex is forming in a 1:1 ratio of metal to ligand, con-
sistent with the copper crystal structure. The slight variation in metal concentration to
that of the ligand can be explained by the competition between the xylenol orange and
our ligand. This may also hint at the relative stability of the complex, and it maybe that
competition in vivo could cause a transmetalation of the manganese ion. This competi-
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tion reaction would also make an interesting study.
Following the xylenol orange titrations, we started to undertake relaxivity studies,
beginning with gadolinium as that is the metal we were most familiar with. For the
relaxivity study, two stock solutions were created; one of 1 mM ligand, and the other of
1 mM ligand + 4 mM Gd3+. The relaxivity of each solution was then measured giving
the two extremes of the relaxivity scale. The stock solution of ligand plus metal was
then added in aliquots to the ligand solution, so as the molarity of metal increased by
0.0625 whilst the ligand concentration remains unaffected after each addition, and the
relaxivity was measured after each addition. After 16 additions the ratio of metal to
ligand is 1:1 and after 32 the ratio is 2:1. However, after 8 or so additions, it became
clear that the results were the same as those expected for free Gd3+ (results not shown
here), and so the experiment was stopped.
5.2 Functionalisation of fluorobenene substituted homopiper-
azines
Due to the success of our rigid arm homopiperazine complexes we decided to at-
tempt a similar modular synthesis based upon previously unpublished work from our
group. Tatchell and Fallis have shown that it is possible to add difluoro-nitrobenzenes
to nitrogenmacrocycles in a selective manner (see page 27).[55] If the remaining fluorine
was in the ortho or para position to the nitro group (ie. 2,6,- or 2,4-difluoronitrobenzene)
this core could then be used to further substitute the benzene ring in the same manner
as the initial addition to the macrocycle. This is because the fluorine atomwould still be
activated towards substitution by the strongly electron withdrawing affect of the nitro
group. If using 2,6-difluoronitrobenzene then the fluorine atom would also have a con-
venient geometry to access the required shape for targeting the αvβ3 intergrin as with
our triazine core chemistry. We hypothesised a synthesis in which the core homopiper-
azine moiety would not change, but reaction with the targeting amines of choice would
result in the desired ligand in a stepwise and modular fashion (fig. 5.11).
Formation of the homopiperazine core was easily accessed through addition of ex-
cess 2,4-, or 2-6-difluoronitrobenzene to homopiperazine in the presence of base. The
C
H
A
PTER
5.
O
TH
ER
W
O
R
K
102
Figure 5.9: Titration of Gd3+ into a 1 mM solution of DMCGlut ligand with 2 drops of xylenol orange
Signals at ~ 380 and 560 nm are machine artifacts
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103Figure 5.10: Titration of Mn2+ into a 1 mM solution of DMCGlut ligand with 2 drops of xylenol orange
Legend shows volume of Mn2+ solution added (100mM, μL)
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Figure 5.11: Hypothesised stepwise route to targetting ligands
mis-insertion product (in the case of 2,4-difluoronitrobenzene) was removed by recrys-
tallisation from hot ethanol and shown by a single spot TLC. Functionalisation of the
compound with a targeting moiety was attempted using the same conditions as for ad-
dition to the macrocycle (i.e. refluxing acetonitrile and potassium carbonate under an
inert atmosphere), however, no reaction took place and starting material was recov-
ered. Attempts using more forceful conditions (refluxing DMF and Cs2CO3) with ethyl
glycine resulted in the desired product as shown by 1H NMR (fig. 5.12).
N N
NO2
HN
O2N
NH
CO2EtEtO2C
Figure 5.12: Addition of ethyl glycine
With alanine tbutyl ester and 2-aminomethyl benzimidazole, synthesis was unsuc-
cessful. It was also found that addition of just one amine to the homopiperazine core
was complicated and would require column chromatography between each addition.
Given this synthesis was to be simple and modular, we decided against following this
route.
5.3 Synthesis of trispyrazylborate analogues for potential
PET imaging
It has been previously shown by Jones et al., that trispyridinepyrazylborate (TpPy)
ligands with a coordinated actinide metal can abstract a fluoride from hexafluorophos-
phate counter ions (fig. 5.13).[94] This fluoride has been shown to be present in the mass
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spectra of these complexes as well as the crystal structures and hence is implied to have
an extremely strong bond to the metal centre.
Figure 5.13: Fluoride coordinated EuTpPy complex by Jones et al. (author?) [94]
Blue - nitrogen, Green - fluorine, Red - europium
We wanted to synthesise novel TpPy style ligands, which would show the potential
to functionalise into targeting molecules, and test whether this functionalisation would
have any affect on the binding of the fluoride ion. We decided to make the simpliest
’functionalised’ TpPy first, with the addition of a methyl group at the 4 position on
the imidazole ring. Acetyl pyridine was dissolved in THF and a strong base added.
Addition of ethyl acetate to this solution gave the desired acetylacetate derivative via
an aldol reaction (fig. 5.14). Addition of hydrazine hydrate in the presence of an organic
soluble base (p-tosylsulphonic acid) to this compound closes the imidazole ring, and
forms the methyl substituted pyrazylpryidine ligand (MePzPy) as shown by 1H NMR.
This synthesis can be adapted to allow access to further functionalisation via the choice
of ester used.
The synthesis of Tp from pyrazole and potassium borate is well established, and it
was this methodology we used to synthesise the MeTpPy ligand. An excess of MePzPy
was melted with potassium borate at 230 °C until no gas was further evolved. It was be-
lieved that sterics would dictate that the molecule only substitute 3 times (as shown by
Jones), however, 11B{1H} NMR showed a four fold substitution and was corroborated
by mass spectra evidence – IR and 1H NMR are inconclusive when trying to determine
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Figure 5.14: Synthesis of MePzPy
the degree of substitution. The shift of the boron peak in the 11B{1H} NMR spectra is in-
dicative of its substitution.[95] A signal at around -7 ppm is assigned to disubstitution,
-1 - 0 ppm for tri-, and > 1 ppm for tetra- substituted compounds, however it should
be noted that the boron signals obtained were very broad due to interference from the
boro-silicate nmr tube used. We believe that the temperature was too hot, allowing the
reaction to overcome the activation barrier for the final substitution. Synthesis in the
presence of a high boiling solvent was subsequently attempted, whilst simultaneously
reducing the number of equivalents of MePzPy to the required 3. Addition of MePzPy
to a suspension of potassium borate in dimethylacetamide (DMAC), followed by heat-
ing to 160°C enabled a reaction that evolved only 2 equivalents of hydrogen. Upon
cooling a solid precipitated and was isolated by filtration. 11B{1H} NMR showed this
to be the disubstituted borate (MeDpPy), as did mass spectral evidence. Reactions at
various temperatures between 160°C and 230°C have so far failed to yield the desired
trisubstituted compound (fig. 5.15).
In a test reaction to see how the ligands coordinate to PET active metals, copper ac-
etate was added to a solution of MeDpPy and left to stand. Evaporation of this solution
resulted in deep blue crystals suitable for x-ray diffraction and gave a surprising result
(fig. 5.16).
As can be seen the crystal structure shows two MePzPy molecules coordinated to
two copper atoms with coordinating acetates. The copper atoms are in a distorted
square based pyramid geometry with 3 unique nitrogens coordination environments.
Despite being different imidazole nitrogens, the Cu-Nimid bond lengths are identical
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Figure 5.15: Synthesis of MeXpPy ligands
(within experimental error) at around 1.96 Å (1.947(9) Å and 1.960(9) Å). The Cu-Npy
bond lengths are also the same at 2.032(10) Å (Cu1) and 2.057(9) Å (Cu2). The acetate
bonds are the same, the equatorial oxygens are shorter with Cu-Oeq 1.965(7) Å (Cu2)
and Cu-Oeq 1.973(8) Å (Cu1), whilst the longer axial bonds average at Cu-Oax 2.5875 Å.
This is explained by the Jahn-Teller distortion associated with copper complexes. No
other data has been collected yet for this sample and so no further conclusions can be
drawn.
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Figure 5.16: Single crystal structure of [Cu2(MePzPy2)](OAc)2
Selected Bond Lengths: Cu(1)-N(1) 2.057(9) Å, Cu(1)-N(2) 1.947(9) Å, Cu(1)-N(6) 1.960 Å, Cu(1)-O(1) 1.973(8) Å, Cu(2)-N(3) 1.961(9) Å, Cu(2)-N(4)
2.032(10) Å, Cu(2)-N(5) 1.965(10) Å, Cu(2)-O(3) 1.965(7) Å
Chapter 6
Conclusions
The synthesis of rigid arm homopiperazine complexes has shown that it is possible to
add useful functionality to these chelate systems, whilst not appreciably changing their
coordination properties. Little work outside of the Fallis group has previously focused
on the ligand systems, and the work contained herein has greatly added to the field.
DFT calculations are in good order for Ni(II), and Cu(II) complexes when compared to
the data obtained from x-ray crystallography, whilst Zn(II) complexes must be studied
under the assumption of coordinating solvent or anions. Further EPR studies of the
Cu(II) complexes would elucidate greater information as to the structure and bonding
in these systems.
Unfortunately purity data is lacking for these complexes and in order for these lig-
and frameworks to be useful in medical imaging studies HPLC methods should be ex-
plored. Conjugation of the homopiperazine core to an applicable protein or protein
mimic is now accessible, as an appropriate methodology has been shown through the
synthesis of the HPAmide ligand. Competition data, either through metal - metal compe-
tition, or pH formation dependance of the complexes would give a simple insight in to
how the molecules might perform in vivo.
The synthesis of triazine derived structures offers the largest scope for further work.
The integrin αvβ3 focused compound TzEtGlyBocGuanCl is the most promising com-
pound in the work. It would be necessary to focus effort on the current synthesis to
allow for larger volumes of the BocGuan arm to be synthesised successfully. Reduction
in temperature, or greater control over the speed of addition of the two composition
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moieties, may allow for this to be possible. Further derivatisation to include a common
metal coordinatingmacrocycle (e.g.. DO3A) or chelate would afford the proposed struc-
ture of a αvβ3 imaging agent. Work would then need to be undertaken on the suitability
of such a structure for use as a imaging agent. This could be achieved using either the
desired metal complexes in cell cultures and imaging as would be the case for a proper
organism, or through the synthesis of similar structures that contain fluorophores in
place of the coordination site, and studied via their fluorescence (fig. 6.1). If the com-
pound was found to be suitable for in vitro and then in vivo studies, the methodology
could be used to synthesise a large library of simple and affordable imaging agents tar-
geted for specific anatomical functions, reducing the need for expensive cyclic amino
acids, and therefore making the imaging agents themselves more economically accessi-
ble. The dipyridamole analogues tentatively explored in this work should also be eval-
uated for use in vitro. Whilst it is unlikely that these molecules themselves will have
any biological function, similar derivatives more alike to the dipyridamole compound
could be easily synthesised and explored using the described methodologies.
N
N
N
N
H
N
H
NH
NHN
H
NH2N
NH
CO2H
Figure 6.1: Possible structure of proposed fluorescent αvβ3 probe
Addition of moieties to the triazine core through a click synthesis would allow facile
access to a vast range of complexes. Current attempts at these reactions have so far failed
due to difficulties in the purification step. HPLCmethodologies for the purification and
analysis of the products would allow access to these compounds on scales acceptable in
PET chemistry.
Whilst the dendrimer compounds and complexes are not designed with medical
imaging function in mind, their highly symmetrical nature, and synthetic beauty afford
these molecules a bright future. It would be interesting to produce multilayer den-
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drimers, with each layer affording specific coordination sites, making them ideal for
multi metal compounds, or even complexes that can accommodate varying oxidation
states of a metal; i.e. Cu(I) and Cu(II) for imaging, or Fe(II) and Fe(III) for electron
transfer studies (fig. 6.2).
N
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N N N N
N
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N
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N
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N
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Figure 6.2: Possible multilayer dendrimer
Green denotes new layer
Synthesis of acetate functionalised TACN compounds led to initial PET studies.
Whilst the results from the compounds were not ideal, they can be assessed as a solid
basis from which to work. The ligands TsTACNA2 and NPhTACNA2 both show good
initial uptake of radio-copper, allowing formation of the complexes in a short period of
time. The sulfonamide containing complex showed aweak bond between themetal cen-
tre and the sulfonamide nitrogen, this is significant, as it shows that a strongly electron
withdrawing group does not completely remove the donor power of the tertiary amine.
Further derivatisation of the NPhTACNA2 compounds through reduction of the nitro
group to an aniline and subsequent addition to it would allow access to a peptide conju-
gate, or a molecule that could be attached to the triazine cores vide supra. Effort should
be afforded in the purification of the AlF complexes. Due to the (relatively) abundant
nature of 18F cyclotrons, PET agents based upon Al-F compounds will become common
in the coming years. This work could also be expanded with the use on mono anionic
ligand frameworks and Ca2+ ions to afford similar Ca-F complexes (fig. 6.3).
The glutaric acid compounds DMCGlut, TACNGlut, and HPGlut should be anal-
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Figure 6.3: Potential Ca-F compound
ysed further for their suitability for use as MRI agents. The initial results for the Mn(II)
complex, MnDMCGlut, show a good binding affinity of the metal to the macrocyclic
cavity when compared to that of the Gd(III) complex. Mn(II) complexes have fallen out
of fashion in the recent MRI literature, with work focusing more commonly on Gd(III)
complexes and iron nanoparticle. This means that work on the Mn(II) complex would
be of reasonable importance in the development of new MRI contrast agents.
It is accepted that the work in this thesis does not contain a successful PET imaging
agent, and therefore meet the initial aim of the project. However, what this work has
achieved is the formation of a series of solid fundamental foundations in the quest for
future PET imaging agents. The triazine core work is tantalisingly close to a potential
imaging agent, and, more importantly, a general methodology in the synthesis of tar-
geted imaging agents. The homopiperazine chelates now have a focused purpose, with
facile access to a series of amino acid functionalised complexes now shown through the
generic amide complexes contained herein. It has also been shown that Al-18F coordi-
nation is possible based on a NO2A style framework.
Chapter 7
Experimental
7.1 Experimental conditions
Non-synthesised reagents were purchased from Sigma-Aldrich, Alfa Aesar, Apollo
Scientific, and Bachem, and used as found. Solvents were pre-dried according to stan-
dard protocols. Mass spectra were obtained by atmospheric pressure chemical ionisa-
tion (APCI), electronic ionisation (EI), or electrospray ionisation (ES), in either positive
(+) or negative (−) modes. IR spectra were obtained from KBr discs using a Jasco FTIR
110 series spectrometer. UV/Vis spectra were recorded on a Perkin-Elmer Lambda 20
spectromoeter. NMR spectra were obtained on either a Brüker 500 Ultrashield, Brüker
Avance AMX 400, Brüker Avance 250 or JEOL Eclipse 300 spectrometer and referenced
to external TMS.
7.2 DFT calculations
Density functional theory (DFT) calculations were undertaken on the ARCCA SRIF-
3 (Merlin) cluster, using the Gaussian ’03 software package[96] and the B3LYP[97, 98, 99,
100] hybrid function with a 6-31G[101, 102, 103, 104, 105, 106, 107, 108, 109, 110] basis
set unless otherwise stated.
DFT calculations are of ideal gas phase molecules with no solvent interactions. All
geometry calculations have been checked to beminima with the appearence of no imag-
inary frequencies.
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7.3 EPR Measurements
All X-band EPR spectra were recorded on a Brüker EMX spectrometer operating
at 100 kHz field modulation and equipped with a high sensitivity X-band cavity (ER
4119HS). The spectra were recorded at a microwave power of 10 mW at 140 K.
7.4 X-Ray data
X-Ray crystallographic data was collected using a Nonius KappaCCD area detector,
Bruker AXS machine, and the Collect software. Structural solution and refinement was
achieved using SHELXS97 and SHELXL97 software, and absorption correction analy-
sised using SADABS software.
7.5 Radiolabelling
All radiolabelling studies were carried out by Dr. J. Knight at the University of Alberta.
No details of the experimental machinery have been provided.
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7.6 Rigid Arm Polyazamacrocycles
7.6.1 Pendant arms
7.6.1.1 Benzyl-2-fluoro-5-nitrobenzoate (1-NO2)
F
O
O
NO2
2-Fluoro-5-nitrobenzoic acid (3.27 g, 17.7 mmol), benzyl bromide (2.3 ml, 19.4 mmol),
potassium carbonate (2.68 g, 19.4 mmol), tetrabutylammonium iodide (50 mg), and
DMF (50 ml) were stirred for 18 hours at 50°C in a stoppered flask. Ethyl acetate (150
ml) was added, and the solution washed successively with sodium bicarbonate (100
ml), water (4 x 100 ml), and brine (1 x 50 ml). The organic phase was collected and dried
over MgSO4, filtered, and solvent removed in vacuo. The resulting oil was dissolved in
the minimum amount of hot CHCl3, and added drop-wise to a stirred beaker of hexane
(100ml). The resulting precipitate was filtered and dried under suction for 30 minutes
yielding the title product as an orange/yellow powder (4.46 g, 16.2 mmol, 92 %); 1H
NMR (400 MHz, CDCl3, ppm) δH : 8.86 (dd, 1 H, Ar-H, JH−H,H−F = 2.9 + 6.1 Hz), 8.43
(dt, 1 H, Ar-H, JH−H,H−F = 2.9 + 6.1 Hz), 8.40 (dt, 1 H, Ar-H, JH−H,H−F = 2.9 + 6.1 Hz),
7.50-7.36 (m, 4 H, Ar’-H), 7.33 (t, 1 H, Ar’-H, 2JH−H = 9.2 Hz), 5.43 (s, 2 H, CH2 ); 13C
NMR (62.90MHz, CDCl3 , ppm) δC: 167.3, 162.5 (d, 1JC−F = 31.2 Hz), 162.5, 135.0, 129.6,
128.8, 128.7, 128.4, 128.3, 120.0, 118.5, 67.9; IR (KBr, νmax, cm−1) 3091 (w), 3072 (w) 3034
(w), 2964 (w), 2942 (w), 2875 (w), 1722 (s), 1632 (s), 1587 (s), 1532 (s), 1498 (s), 1483 (s),
1421 (s), 1378 (s), 1353 (s), 1325 (s), 1274 (br, s), 1140 (s), 1122 (w), 1079 (s), 982 (s), 926
(s), 864 (s), 843 (s), 816 (w), 780 (w), 746 (s), 735 (s); MS (HR EI+) calc. for C17H9NO3
(M+) 275.0582 found 275.0592
7.6.1.2 Benzyl-2-chloro-5-nitrobenzoate (1-NO2) (Cl)
Cl
NO2
O
O
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2-Chloro-5-nitrobenzoic acid (10.1 g, 50.1 mmol), benzyl bromide (6.55 ml, 55.2 mmol),
potassium carbonate (7.61 g, 55.1 mmol), tetrabutylammonium iodide (200 mg), and
DMF (50 ml) were stirred for 18 hours at 50°C in a stoppered flask. Ethyl acetate (200
ml) was added, and the solution washed successively with sodium bicarbonate (100ml),
water (2 x 100 ml), and brine (2 x 100 ml). The organic phase was collected, dried over
MgSO4, filtered, and solvent removed in vacuo. The resulting oil was dissolved in the
hot CHCl3, and added drop-wise to a stirred beaker of hexane (200ml). The precipitate
was filtered, and dried under vacuum, affording the title compound as a pale yellow
powder (9.85 g , 34 mmol, 67.5 %); 1H NMR (400 MHz, CDCl3, ppm) δH : 8.59 (d, 1 H,
Ar-H, 2JH−H = 2.7 Hz), 8.15 (d, 1 H, Ar-H, 2JH−H = 2.7 Hz), 8.13 (d, 1 H, Ar-H, 2JH−H =
2.7 Hz), 7.53 (d, 1 H, Ar-H, 2JH−H = 8.8 Hz), 7.38 - 7.35 (m, 1 H, Ar’-H), 7.33 - 7.26 (m,
1 H, Ar’-H), 5.31 (s, 1H, CH2); IR (KBr, νmax, cm−1) 3106 (w), 3080 (w), 2971 (w), 2922
(w), 2853 (w), 1735 (s), 1610 (s), 1573 (s), 1523 (s), 1496 (w), 1460 (s), 1398 (w), 1368 (w),
1353 (s), 1307 (s), 1252 (s), 1242 (s), 1216 (w), 1137 (w), 1126 (s), 1103 (w), 1045 (s), 943
(s), 921 (s), 890 (s), 841 (s), 832 (w), 814 (w), 780 (s), 756 (s), 741 (s); MS (HR EI+) calc. for
C14H10NO4Cl (M+) 291.0298 found 291.0294.
7.6.1.3 Benzyl-2-fluorobenzoate (1)
F
O
O
2-Fluorobenzoic acid (9.84 g, 70.3mmol), benzyl bromide (9.2ml, 77.5mmol), potassium
carbonate (10.0 g, 72.5 mmol), tetrabutylammonium iodide (150 mg), and DMF (150 ml)
were stirred for 18 hours at 50°C in a stoppered flask. Ethyl acetate (250 ml) was added,
and the solution washed successively with sodium bicarbonate (150 ml), water (4 x 200
ml), and brine (1 x 100 ml). The organic phase was collected and dried over MgSO4,
filtered, and solvents removed in vacuo. The resulting oil was dissolved in the minimum
amount of hot CHCl3, and added drop-wise to a stirred beaker of hexane (300ml). The
resulting precipitate was filtered and dried under suction for 30 minutes yielding the
title compound as an orange/yellow powder (15.04 g, 65 mmol, 98.0 %) 1H NMR (400
MHz, CDCl3, ppm) δH : 7.97 (dt, 1 H, Ar-H, JH−H,H−F = 1.8 + 7.6 Hz), 7.55 - 7.49 (m, 1
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H, Ar-H), 7.47 (d, 2 H, Ar’-H, 2JH−H = 7.3 Hz), 7.43 - 7.31 (m, 3 H, Ar’-H), 7.20 (dt, 1
H, Ar-H, 2JH−H = 1.0 + 7.6 Hz), 7.14 (ddd, 1H, Ar-H, JH−H,H−F = 1.0 + 8.4 + 10.9 Hz),
5.40 (s, 2H, Ar’CH2); 13C NMR (100 MHz, CDCl3, ppm) δC: 164.2, 160.3, 135.8, 134.7,
134.5, 132.2, 128.6, 128.3, 128.1, 124.0, 124.0, 117.2, 116.9, 67.0; MS (HR APCI+) calc. for
C14H12O2F (M + H+) 231.0821 found 231.0812.
7.6.1.4 Benzyl-2-iodobenzoate (1) (I)
I
O
O
2-Iodobenzoic acid (1.11 g, 4.48 mmol), benzyl bromide (0.58 ml, 4.88 mmol), potassium
carbonate (0.68 g, 4.93 mmol), tetrabutylammonium iodide (40 mg), and DMF (20 ml),
were stirred for 18 hours at 50°C in a stoppered flask. Ethyl acetate (50 ml) was added,
and the solution washed successively with sodium bicarbonate (50 ml), water (2 x 50
ml), and brine (2 x 50 ml). The organic phase was collected, dried over MgSO4, filtered,
and solvent removed in vacuo, affording the title compound as a brown liquid (1.06 g,
3.14 mmol, 70 %) 1H NMR (400 MHz, CDCl3, ppm) δH : 7.81 (d, 1 H, Ar-H, 2JH−H = 7.9
Hz), 7.66 (dd, 1 H, Ar-H, 2JH−H = 1.6 + 7.8 Hz), 7.33 (d, 2 H, Ar-H, 2JH−H = 8.0 Hz), 7.26
- 7.18 (m, 3 H, Ar-H), 6.95 (dt, 2 H, Ar-H, 2,3JH−H = 1.6 + 7.7 + 7.9 Hz), 5.23 (s, 2 H, CH2
); MS (HR APCI+) calc. for C14H12O2I (M + H+) 338.9882 found 338.9878 also seen (M
+ MeCN + H+): 380.0125
7.6.1.5 tButyl-2-fluoro-5-nitrobenzoate (2-NO2)
F
O
O
NO2
2-Fluoro-5-nitrobenzoic acid (0.665 g, 3.59 mmol), butyl-boc-anhydride (0.86 g, mmol),
butanol (10 ml), and dimethylaminopyridine (0.050 g) were heated under reflux for
72 hours. After cooling to room temperature, ethyl acetate (100 ml) was added, and
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washed with saturated sodium bicarbonate solution (50 ml), water (3 x 50 ml), and
brine (1 x 50 ml). The organic phase was collected and dried over MgSO4, filtered, and
the solvents removed in vacuo, yielding the title compound as a yellow oil (0.340 g, 1.41
mmol, 38.9 %) 1HNMR (400MHz, CDCl3, ppm) δH : 8.68 (dd, 1 H, Ar-H, JH−H,H−F = 2.9
+ 6.2 Hz), 8.31 (m, 1 H, Ar-H), 7.22 (t, 1 H, Ar-H, JH−H = 9.2 Hz), 1.55 (s, 9 H, CH3); 13C
NMR (62.3MHz, CDCl3, ppm) δC: 167.2, 162.0 (1JC−F = 56 Hz), 143.8, 128.9, 128.0, 121.9,
118.3, 83.6, 28.1; MS (HR EI+) calc. for C11H12NO4F (M+) 241.0750 found 241.0745
7.6.1.6 tButyl-2-fluorobenzoate (2)
F
O
O
2-Fluorobenzoic acid (0.93 g, 6.64mmol), butyl-boc-anhydride (1.59 g, mmol), butanol (8
ml), and dimethylaminopyridine (0.100 g), were heated under reflux for 72 hours. Ethyl
acetate was added (100 ml), and washed with saturated sodium bicarbonate solution
(50 ml), water (3 x 50 ml), and brine (50 ml). The organic phase was collected and dried
over MgSO4, filtered, and the solvents removed in vacuo, yielding the title compound
as a pale yellow oil (0.51 g, 2.60 mmol, 39 %) 1HNMR (400 MHz, CDCl3, ppm) δH : 7.76
(dt, 1 H, Ar-H, JH−H,H−F = 1.9 + 7.6 Hz), 7.39 - 7.33 (m, 1 H, Ar-H), 7.06 (dt, 1 H, Ar-H,
JH−H,H−F = 1.1 + 7.6 + 7.7 Hz), 6.99 (ddd, 1 H, Ar-H, JH−H,H−F = 0.9 + 8.3 + 10.8 Hz),
1.50 (s, 9 H, CH3); MS (HR EI+) calc. for C11H13O2F (M+) 196.0900 found 196.0900
7.6.1.7 Ethyl-2-fluoro-5-nitrobenzoate (3-NO2)
F
NO2
OEt
O
2-Fluoro-5-nitrobenzoic acid (1.0 g, 5.41 mmol), was dissolved in ethanol (20 ml), and
sulphuric acid (1 ml) added. The solution was refluxed for 3 hours, before the solvent
was removed in vacuo and water (10 ml) added. Neutralisation with NaHCO3 solution,
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was followed by extraction with DCM (3 x 20 ml). The organic phases were combined
and washed with brine (20 ml), then dried over MgSO4, filtered, and the solvent re-
moved in vacuo yielding the title product as a light orange solid (806 mg, 3.84 mmol, 71
%) 1H NMR (250 MHz, CDCl3, ppm) δH : 8.77-8.73 (m, 1 H, Ar-H), 8.35 - 8.28 (m, 1 H,
Ar-H), 7.27 - 7.19 (m, 1 H, Ar-H), 4.36 - 4.34 (m, 2 H, CH2CH3), 1.34 (t, 3 H, CH3CH2);
IR (KBr, νmax, cm−1) 3119 (w), 3101 (s), 3087 (w), 2986 (s), 2944 (w), 2909 (w), 2875 (w),
2739 (w), 2652 (w), 1944 (s), 1841 (s), 1740 (br, s), 1626 (s), 1584 (s), 1532 (s), 1482 (s), 1444
(w), 1413 (s), 1351 (s), 1324 (s), 1265 (br), 1169 (w), 1138 (w), 1120 (s), 1068 (s), 1015 (s),
974 (w), 925 (s), 867 (w), 848 (s), 808 (w), 780 (s), 748 (s)
7.6.1.8 tButyl 4-fluoro-3-nitrobenzoate (tButyl)
F
NO2
OtBuO
3-Nitro-4-fluorobenzoic acid (1 g, 5.41 mmol), tbutyl acetate (30 ml), and perchloric acid
(2 drops, cat.), were stirred over night at room temperature. The organic phase was
washed with water (2 x 50 ml), sodium bicarbonate (50 ml), and brine (50 ml), dried
over MgSO4, filtered, and the solvent removed in vacuo, yielding the title compound as
an orange solid (0.95 g, 3.94 mmol, 73 %) 1H NMR (400 MHz, CDCl3, ppm) δH : 8.59 -
8.53 (m, 1 H, C(NO2)CHC(CO2)), 8.20 - 8.15 (m, 1 H, CHCHC(CO2)), 7.32 - 7.23 (m, 1
H, CHCF), 1.54 (s, 9 H, CH3); IR (KBr, νmax, cm−1) 3103 (s), 3079 (w), 3068 (w), 3009 (s),
2994 (s), 2941 (w), 2878 (w), 1946 (w), 1847 (w), 1718 (s), 1616 (s), 1594 (w), 1539 (br, s),
1492 (w), 1472 (w), 1460 (w), 1410 (w), 1395 (w), 1368 (s), 1353 (s), 1300 (br, s), 1267 (s),
1238 (w), 1168 (w), 1148 (s), 1125 (s), 1078 (w), 974 (w), 926 (s), 848 (s), 838 (s), 811 (w),
767 (w), 760 (s), 749 (s)
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7.6.1.9 4-Fluoro-3-nitro-N-((+/-)-1-phenylethyl)-benzamide (AmideRac)
F
NO2
NH
O
Under a nitrogen atmosphere and at 0°C, oxalyl chloride (2 ml, 23.2 mmol) and DMF
(1 drop, cat.) were added to 4-fluoro-3-nitrobenzoic acid (790 mg, 4.27 mmol) in DCM
(50 ml), and stirred for 1 hr at 0°C. The solvents were then removed in vacuo resulting
in a brown solid. The solid was dissolved in fresh DCM (50 ml), and cooled again to
0°C, (+/-)phenylethylamine (0.55 ml, 4.32 mmol) was added and the solution allowed
to warm to room temperature whilst stirring overnight. The solvents were removed
in vacuo. The resulting oil was dissolved in DCM (30 ml) and washed with saturated
aqueous NaHCO3 (30 ml), water (2 x 30 ml), and brine (30 ml). The organic phase was
then dried over MgSO4, filtered and the solvents removed in vacuo. The yellow solid
was dissolved in minimum hot CHCl3 and added dropwise to stirred hexane (50 ml).
The title compound was isolated by filtration as a yellow solid (470 mg, 1.63 mmol, 38
%). 1H NMR (400 MHz, CDCl3, ppm) δH : 8.44 (dd, 1 H, ArF-H, JH−F = 2.3 + 6.9 Hz),
8.11 (ddd, 1 H, ArF-H, JH−F = 2.3 + 4.1 + 8.7 Hz), 7.40 - 7.29 (m, 6 H, 5HAr-H + 1HArF-H),
6.42 (d, 1 H, NH, 2JH−H = 7.0 Hz), 5.32 (p, 1 H, NHCH, 2JH−H = 7.0 Hz), 1.64 (d, 1 H,
CH3, 2JH−H = 7.0 Hz); 13C (125 MHz, CDCl3, ppm) δC: 162.2, 157.2, 155.1, 143.7, 134.5
(d, JC−F = 10 Hz), 131.4 (d, JC−F = 4 Hz), 127.8 (d, JC−F = 8 Hz), 126.4, 125.7, 124.7 (d,
JC−F = 1 Hz), 118.0 (d, JC−F = 21 Hz), 48.8, and 20.9; IR (KBr, νmax, cm−1) 3312 (br, s),
3090 (w), 3068 (w), 3030 (w), 2926 (w), 2855 (w), 1653 (w), 1635 (s), 1623 (s), 1560 (s),
1538 (br, s), 1494 (s), 1451 (s), 1407 (w), 1381 (w), 1350 (s), 1330 (w), 1321 (w), 1268 (s),
1234 (w), 1210 (w), 1130 (s), 1085 (w), 1076 (w), 1013 (w), 928 (s), 854 (w), 846 (s), 754 (s).
7.6.1.10 4-Fluoro-3-nitro-N-((R)-1-phenylethyl)-benzamide (AmideR)
F
NO2
NH
O
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Using the same method as for 4-fluoro-3-nitro-N-((+/-)-1-phenylethyl)-benzamidewith
4-fluoro-3-nitrobenzoic acid (714 mg, 3.86 mmol), oxalyl chloride (1.67 ml, 19.4 mmol),
DMF (1 drop), DCM (40 ml), and (R)-phenylethylamine (0.50 ml, 3.88 mmol) the title
compound was isolated as a white solid (782 mg, 2.72 mmol, 70%). 1HNMR (400 MHz,
CDCl3, ppm) δH : 8.44 (dd, 1 H, ArF-H, JH−F = 2.4 + 6.9 Hz), 8.11 (ddd, 1 H, ArF-H, JH−F
= 2.4 + 4.1 + 8.7 Hz), 7.39 - 7.27 (m, 6 H, 5HAr-H + 1HArF-H), 6.42 (d, 1 H, NH, 2JH−H
= 7.0 Hz), 5.34 (p, 1 H, NHCH, 2JH−H = 6.9 Hz), 1.62 (d, 1 H, CH3CH, 2JH−H = 6.9 Hz);
13C (125MHz, CDCl3, ppm) δC: 162.2, 157.1, 155.1, 141.4, 133.6 (d, 1JC−F = 10 Hz), 130.4,
127.9, 126.8, 125.3, 123.7, 118.0, 48.9, 48.9, and 20.5
7.6.2 Sythesis of Carboxy Ligands
7.6.2.1 Benzyl-6,6’-(1,4-diazepane-1,4-diyl)bis(3-nitrobenzoate) (HP1−NO2)
N N
NO2O2N
OBnO BnO O
1-NO2 (Cl) (2.63 g, 9.04 mmol), homopiperazine (0.43 g , 4.25 mmol), caesium carbonate
(2.91 g, 8.93mmol), and acetonitrile (20ml) were heated under reflux for 18 hours. Chlo-
roform (30ml) was added, the solution filtered, then solvent removed in vacuo, leading
to a brown solid. This was washed with hot ethanol (50 ml), followed by cold diethyl
ether (30 ml), affording the title compound as a brown-yellow solid (2.10 g, 3.44 mmol,
81 %) 1H NMR (400 MHz, CDCl3, ppm) δH : 8.57 - 8.52 (m, 1 H, Ar-H), 8.15 (dd, 1 H
Ar-H, 2JH−H = 2.8 + 9.3 Hz), 7.46 (dd, 2 H, Ar’-H, 2JH−H = 1.5 + 8.0 Hz), 7.42 - 7.35 (m, 3
H, Ar’-H), 6.81 (d, 1 H, Ar-H, 2JH−H = 9.4 Hz), 5.36 (s, 2 H), 3.41 (s, 2 H CH2), 3.36 (t, 2
H, CH2), 1.58 (s, 1 H, CH2); 13C NMR (126 MHz, CDCl3) 166.4, 154.6, 138.3, 135.4, 128.7,
128.7, 128.5, 127.4, 118.7, 116.3, 67.5, 56.6, 52.3, 27.8 ; IR (KBr, νmax, cm−1) 3454 (br), 2925
(w), 2857 (w), 1717 (s), 1602 (s), 1579 (s), 1498 (s), 1457 (w), 1328 (s), 1283 (w), 1224 (w),
1205 (w), 1176 (w), 1128 (s), 1083 (w), 959 (w), 929 (w), 748 (s); MS (HR ES−) calc. for
C33H30N4O8Cl (M + Cl−) 645.1752 found 645.1755
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7.6.2.2 6,6’-(1,4-Diazepane-1,4-diyl)bis(3-aminobenzoate) (HPR)
N N
NH2H2N
OHO HO O
Into a schlenk under an atmosphere of H2 were placed, HP1−NO2 (0.188 g, mmol), THF
(20 ml), acetic acid (0.1 ml), and palladium on carbon (10 %, 50 mg) in methanol (1 ml).
The hydrogenolysis was left stirring under an atmosphere of hydrogen for 18 hours.
The air sensitive liquid was removed via filter cannula, and the solvent removed in
vacuo resulting in a very air sensitive white solid. The solid was used without further
purification.
7.6.2.3 Diethyl 6,6’-(1,4-diazepane-1,4-diyl)bis(3-nitrobenzoate) (HP3−NO2)
N N
CO2Et EtO2C
NO2O2N
3-NO2 (440 mg, 2.10 mmol), homopiperazine (95 mg , 0.95 mmol), potassium carbonate
(290 mg, 2.10 mmol), and acetonitrile (20 ml) were heated under reflux for 18 hours.
Chloroform (30ml) was added, the solution filtered, then solvent removed in vacuo,
leading to a brown solid. The solid was dissolved in the minimum cold CHCl3 and
then added dropwise to a stirred beaker of hexane. The resulting precipitate was fil-
tered, washed with ether and dried in vacuo, affording the title compound as a yellow
solid (362 mg, 0.75 mmol, 79 %) IR (KBr, νmax, cm−1) 3446 (br), 3085 (w), 2965 (w), 2904
(w), 2865 (w), 1717 (s), 1700 (s), 1600 (s), 1568 (s), 1499 (s), 1475 (w), 1453 (w), 1429 (s),
1393 (s), 1373 (s), 1320 (br, s), 1284 (s), 1256 (s), 1224 (w), 1211 (w), 1177 (s), 1143 (w),
1127 (s), 1109 (w), 1068 (s), 1018 (s), 970 (s), 956 (w), 941 (s), 918 (s), 895 (w), 864 (s), 832
(w), 812 (s), 778 (s), 747 (s), 732 (s), 719 (s); MS (HR ES−) calc. for C23H26N4O8Cl (M +
Cl−) 521.1439 found 521.1422
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7.6.2.4 Diethyl 6,6’-(piperazine-1,4-diyl)bis(3-nitrobenzoate) (Pip3−NO2)
N N
EtO2C
CO2Et
NO2O2N
3-NO2 (230 mg, 1.10 mmol), piperazine (43 mg, 0.50 mmol), Et3N (100 mg, 1.00 mmol),
and acetonitrile (20 ml) were heated under reflux for 18 hours. The solvents were re-
moved in vacuo, leading to a yellow solid. The yellow solid was recrystallised from
DCM/ethanol yielding the title compound as a yellow solid (128 mg, 0.27 mmol, 54 %)
1H NMR (400 MHz, CDCl3, ppm) δH : 8.66 – 8.53 (m, 2 H, Ar-H), 8.25 – 8.12 (m, 2 H,
Ar-H), 7.01 – 6.87 (m, 2 H, Ar-H), 4.33 (q, 4 H, CH2CH3, 2JH−H = 7 + 14 Hz), 3.44 (s, 4 H,
CH2CH2), 3.32 – 3.26 (m, 2 H, CH(2)CH2), 3.19 - 3.08 (m, 2 H, CH(2)CH2), 1.45 – 1.27 (m,
6 H, CH3CH2); IR (KBr, νmax, cm−1) 3240 (br), 2976 (s), 2938 (s), 2806 (w), 2738 (w), 2677
(s), 2492 (s), 1699 (s), 1606 (s), 1567 (s), 1506 (s), 1476 (w), 1449 (s), 1434 (s), 1397 (s), 1382
(w), 1336 (br, s), 1265 (s), 1229 (br), 1186 (w), 1169 (w), 1129 (s), 1071 (s), 1034 (br, s), 972
(w), 944 (s), 932 (s0, 867 (s), 849 (w), 830 (s), 806 (w), 784 (s), 749 (s), 712 (s), 706 (w); MS
(HR ES−) calc. for C22H24N4O835Cl (M + Cl−) 507.1283 found 507.1299
7.6.2.5 Diethyl 6,6’-(piperazine-1,4-diyl)bis(3-aminobenzoate) (Pip3−NH2)
N N
EtO2C
CO2Et
NH2H2N
Into a schlenk under an atmosphere of H2 were placed Pip3−NO2 (305 mg, 0.65 mmol),
Pd-C (10%, 60 mg), and MeOH (20 ml), and stirred for 3 hours until the solution turned
colourless. This solution was used as found in the synthesis of PipR.2HCl .
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7.6.2.6 6,6’-(Piperazine-1,4-diyl)bis(3-aminobenzoate) (PipR.2HCl)
N N NH2H2N
O
OH
O
HO
.2HCl
Solution of Pip3−NH2 was cannulared directly into degassed HCl (2M) and stirred for 18
hours. The solvent was removed in vacuo yielding the title compound as a hygroscopic
white solid that was stored in a vacuum desicator (259 mg, 0.60 mmol, 95%) 1H NMR
(400 MHz, D2O, ppm) δH : 7.91 (s, 1 H), 7.61 (s, 2 H, Ar-H), 3.63 (s, 4 H, CH2); MS (HR
ES−) calc. for C18H21N4O4 (M + H+) 357.1563 found 357.1565
7.6.2.7 Benzyl-6,6’,6”-(1,4,7-triazonane-1,4,7-triyl)tris(3-nitrobenzoate) (TACN1−NO2)
N
N
N
O
O
Bn
O
O
Bn
O
O Bn
NO2
NO2
NO2
Triazacyclononane (0.430 g, 3.33 mmol), 1-NO2 (2.84 g, 10.3 mmol), potassium carbon-
ate (1.5 g, 10.9 mmol), and acetonitrile (50 ml) were heated under reflux for 18 hours
resulting in a yellow solution. Chloroform (50ml) was added, and the solution filtered.
The filtrate was collected and dried in vacuo resulting in a yellow solid. This was dis-
solved in DCM, and EtOH added. The DCM was allowed to evaporate over night.
The resulting crystals were filtered and dried under reduced pressure. Crystals of suf-
ficient quality for X-Ray crystallography were obtained by vapour diffusion of pentane
into toluene plus 2 drops of methanol (2.43 g, 2.72 mmol, 81.5 %) 1H NMR (400 MHz,
CDCl3, ppm) δH : 8.46 (1 H, d, Ar-H, 2JH−H = 2.8 Hz), 8.03 (1 H, dd, Ar-H, 2JH−H = 2.8
+ 9.3 Hz), 7.41 - 7.35 (5 H, m, Ar’-H), 6.58 (1 H, d, Ar-H, 2JH−H = 9.4 Hz), 5.30 (2 H, s,
Ar’CH2), 3.45 (4 H, s, NCH2); 13C NMR (100 MHz, CDCl3, ppm) δC: 167.1, 153.7, 139.0,
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135.7, 129.4, 129.3, 129.2, 128.7, 128.1, 119.8, 116.7, 68.0, 54.0; IR (KBr, νmax, cm−1) 3446
(br), 3033 (w), 2973 (w), 2919 (w), 2849 (w), 1714 (s), 1602 (s), 1575 (s), 1499 (s), 1456 (w),
1429 (w), 1320 (br, s), 1260 (w), 1220 (w), 1186 (w), 1122 (s), 1059 (s), 972 (w), 943 (w), 814
(s), 781 (w), 749 (s), 720 (w); MS (HR APCI+) calc. for C48H43N6O12 (M + H+): 895.2939,
found: 895.2935
7.6.2.8 6,6’,6”-(1,4,7-Triazonane-1,4,7-triyl)tris(3-aminobenzoate) (TACNR)
N
N
N
HO2C
NH2
CO2H
NH2
HO2C
NH2
Into a schlenk under an atmosphere of H2 were placed, TACN1−NO2 (115 mg, 0.13
mmol), THF:MeOH (7:1, 35 ml), and palladium on carbon (10 %, 88 mg) in methanol
(3 ml). The hydrogenolysis was left stirring under an atmosphere of hydrogen for 48
hours.Completion of the reaction was judged by a colour change from yellow to colour-
less. The air sensitive liquid was removed via filter cannula, and the solvent removed
in vacuo resulting in a very air sensitive white solid. The solid was used as found for
coordination.
7.6.2.9 Benzyl-6,6’-(4,11-dimethyl-1,4,8,11-tetraazacyclotetradecane-1,8-diyl)bis(3-nitrobenzoate)
(DMC1−NO2)
N N
N N
O2N
NO2
O
O Bn
O
O
Bn
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1,8-Dimethylcyclam (0.450 g, 1.97 mmol), 1-NO2 (1.19 g, 4.33 mmol), potassium car-
bonate (0.60 g, 4.34 mmol), and acetonitrile (30 ml) were heated under reflux for 18
hours. Chloroform (50 ml) was added, and the solution filtered. The solvent was re-
moved in vacuo resulting in a yellow solid, which was dissolved in minimum amount of
room temperature chloroform, and methanol added (5 ml). The title compound (0.91 g,
1.23 mmol, 78.9%) was afforded as yellow crystals that slowly formed at the methanol-
chloroform interface 1H NMR (400 MHz, CDCl3, ppm) δH : 8.50 (1 H, d, Ar-H, 2JH−H =
2.8 Hz), 8.13 (1 H, dd, Ar-H, 2JH−H = 2.8 + 9.4 Hz), 7.47 - 7.34 (5 H, m, Ar’-H), 6.90 (1 H,
d, Ar-H, 2JH−H = 9.4 Hz), 5.35 (2 H, s, Ar’-CH2), 3.54 (2 H, t, ring-CH2, 2JH−H = 8.6 Hz),
3.28 (2 H, t, ring-CH2, 2JH−H = 5.8 Hz), 2.49 (2 H, t, ring-CH2, 2JH−H = 5.9 Hz), 2.25 (2 H,
t, ring-CH2, 2JH−H = 5.7 Hz), 2.07 (3 H, s, CH3), 1.70 (2 H, m, ring-CH2); 13C NMR (126
MHz, CDCl3, ppm) δC: 166.6, 154.6, 137.4, 135.4, 128.7, 128.6, 128.5, 127.2, 116.5, 67.3,
55.4, 54.0, 52.1, 49.0, 43.2, 24.0; IR (KBr, νmax, cm−1) 3007 (w), 2979 (w), 2954 (w), 2845
(s), 2788 (s), 1704 (s), 1600 (s), 1573 (s), 1496 (s), 1480 (w), 1493 (w), 1456 (w), 1448 (s),
1425 (s), 1398 (w), 1321 (s), 1292 (s), 1260 (s), 1240 (w), 1218 (s), 1201 (s), 1165 (s), 1125
(br, s), 1084 (w), 1057 (w), 1039 (s), 959 (s), 953 (w), 940 (s), 919 (s), 883 (s), 859 (w), 820
(s), 810 (w), 786 (w), 780 (w), 763 (w), 757 (s), 749 (w), 721 (s); MS (HR ES+) calc. for
C40H47N6O8 (M + H+) 739.3455 found 739.3456
7.6.3 Metal Complexes of Carboxyl Ligands
7.6.3.1 Copper(II) (6,6’-(piperazine-1,4-diyl)bis(3-aminobenzoate)) (CuPipR)
N N NH2H2N
O
O
O
O
Cu
To PipR.2HCl(48.5 mg, 0.1 mmol) in degassed methanol (10 ml) under an atmosphere
of nitrogen was added Et3N (0.14 ml, 0.1 mmol). CuCl2.2H2O (17 mg, 0.1 mmol) in
degassed methanol (5 ml) was added resulting in a colour change from colourless to
dark blue, and the solution stirred at room temperature for 18 hours. The solvents were
removed in vacuo, leaving a dark blue solid. This was dissolved in the minimum cold
CHCl3, and added to hexane, yielding the title compound as a blue solid (19 mg, 0.046
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mmol, 46 %) IR (KBr, νmax, cm−1) 3446 (br), 3356 (br), 3221 (br), 2979 (s), 2821 (w), 1714
(s), 1597 (s), 1495 (s), 1447 (s), 1377 (w), 1230 (br, s), 1080 (br, w), 1026 (br, w), 806 (br, s)
7.6.3.2 Nickel(II) (6,6’-(1,4-diazepane-1,4-diyl)bis(3-aminobenzoate)) (NiHPR)
N N
H2N NH2
OO O O
Ni
HPR(67 mg, 0.11 mmol) was dissolved in fresh THF and kept under a nitrogen atmo-
sphere. To this, nickel acetate (28 mg, 0.11 mmol) in ethanol (10 ml) was added via
cannula. The solution changed colour from blue to grey after stirring for 5 minutes. The
solvent was removed in vacuo and the resulting solid was air stable (21 mg, 0.049 mmol,
45 %). ; IR (KBr, νmax, cm−1) 3429 (br), 2925 (w), 2852 (w), 1634 (br, s), 1506 (w), 1458 (w),
1384 (w), 1340 (w), 1313 (w), 1234 (w), 797 (w); MS (LR ES+) 426.81 (M + H+), 444.81 (M
+ H2O + H+)
7.6.3.3 Copper(II) (6,6’-(1,4-diazepane-1,4-diyl)bis(3-aminobenzoate)) (CuHPR)
N N
OO-O-O
Cu
NH2H2N
HPR(189 mg, 0.31 mmol) was dissolved in fresh THF and kept under a nitrogen atmo-
sphere. To this, copper acetate (60 mg, 0.30 mmol) in ethanol (10 ml) was added via
cannula. The solution changed colour from blue to green after stirring for 5 minutes.
The solvent was removed in vacuo and the resulting solid was air stable. IR (KBr, νmax,
cm−1) 3437 (br), 3217 (br), 2977 (s), 2939 (s), 2740 (s), 2678 (s), 2603 (s), 2494 (s), 1711
(s), 1596 (br, s), 1473 (s), 1444 (s), 1398 (s), 1206 (br, w), 1037 (s);MS (HR ES+) calc. for
C19H20N4O4Cu Na (M + Na+) 454.0678 found 454.0698
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7.6.3.4 Copper(II) 6,6’,6”-(1,4,7-triazonane-1,4,7-triyl)tris(3-aminobenzoate) (CuTACNR)
N
N
N
H2N NH2
NH2
O O
O
O
O
O
Cu
H+
TACNR (150 mg, 0.28 mmol) was dissolved in THF and kept under an atmosphere of
nitrogen. To this, copper nitrate (67 mg, 0.29 mmol) in ethanol (10 ml) was added via
filter canula. There was an instant colour change from colourless to dark purple. Gentle
heat was applied for 2 minutes, followed by stirring at room temperature for 18 hours.
Filtration by filter canula, followed by removal of solvent in vacuo yielded the title prod-
uct as a dark purple/black solid (79 mg, 0.13 mmol, 46 %) IR (KBr, νmax, cm−1) 3352 (br,
s), 3216 (br), 2962 (w), 2922 (w), 2865 (w), 1612 (w), 1588 (s), 1560 (br, s), 1495 (s), 1435
(s), 1374 (br, s), 1261 (s), 1163 (w), 1089 (s), 802 (s); MS (LR ES−) 594.18 (M−); MS (HR
ES−) calc. for C27H27N6O663Cu (M−) 594.1288 found 594.1289
7.6.4 Synthesis of Anilino Ligands
7.6.4.1 General Experimental Procedure (A) - 1,4-Bis(2-nitrophenyl)-1,4-diazepane
(L22−NO2)
N N
NO2 O2N
To a solution of homopiperazine (1 eq.) in acetonitrile, was added fluorobenzene (2.2
eq.) and potassium carbonate (2.2 eq.). Under a nitrogen atmosphere, the mixture was
refluxed for 18 hrs and the allowed to cool. The solution was filtered, and the solvent
removed in vacuo.
A typical procedure is that of 1,4-bis(2-nitrophenyl)-1,4-diapaneas reported by Perkins:
To a solution of homopiperazine (4.08 g, 40.8 mmol) in acetonitrile (100 ml), were
added fluoronitrobenzene (9.5 ml, 89.6 mmol), and potassium carbonate (12.4 g, 89.8
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mmol). Under a nitrogen atmosphere, the mixture was refluxed for 18 hrs and then
allowed to cool. The solution was filtered, and the solvents removed in vacuo, yielding
the title as an orange solid (12.6 g, 36.8 mmol, 90 %). 1H NMR (400 MHz, CDCl3, ppm)
δH : 7.71 (2 H, dd, Ar-H, 2JH−H = 1.5 + 8.4 Hz), 7.42 (2 H, ddd, Ar-H, 2,3JH−H = 1.5 + 6.6
+ 8.4 Hz), 7.13 (2 H, dd, Ar-H, 2JH−H = 1.5 + 8.4 Hz), 6.94 (2 H, ddd, Ar-H, 2,3JH−H = 1.5
+ 6.6 + 8.4 Hz), 3.48 (4 H, s, CH2N), 3.36 - 3.34 (4 H, m, CH2CH2N), 2.11 - 2.05 (2 H, m,
CH2CH2CH2)
7.6.4.2 1,4-Bis(2-nitro-4-tolyl)-1,4-diazepane (HPTol−NO2)
N N
NO2 O2N
Using general procedure A; homopiperazine (70 mg, 0.70 mmol) in acetonitrile (10 ml),
4-fluoro-3-nitrotoluene (238 mg, 1.54 mmol), and potassium carbonate (212 mg, 1.54
mmol) yielded the crude title compound. The crude productwas dissolved inminimum
hot CHCl3 and added dropwise to a stirred beaker of hexane (20 ml). The precipitate
was filtered, and gave the title compound as an orange solid (160 mg, 0.68 mmol, 97
%). 1H NMR (400 MHz, CDCl3, ppm) δH : 7.61 (2 H, d, Ar-H, 2JH−H = 8.3 Hz), 6.84 (2
H, s, Ar-H), 6.67 (2 H, d, Ar-H, 2JH−H = 8.3 Hz), 3.42 (4 H, s, CH2N), 3.29 - 3.25 (4 H,
m, CH2CH2N), 2.30 (6 H, s, Ar-CH3 ), 2.03 - 1.97 (2 H, m, CH2CH2CH2); 13C (125 MHz,
CDCl3, ppm) δC: 146.3, 144.4, 139.2, 126.4, 120.9, 120.9, 53.8, 53.5, 28.9, and 21.8; IR (KBr,
νmax, cm−1) 3446 (br), 2950 (w), 2922 (w), 2855 (w), 1604 (s), 1576 (s), 1506 (s), 1454 (w),
1424 (w), 1383 (w), 1340 (s), 1329 (s), 1308 (w), 1260 (s), 1188 (w), 1172 (w), 1149 (w),
1084 (w), 958 (s), 944 (s), 861 (w), 838 (s), 829 (w), 815 (w), 753 (w), 749 (s); MS (HR ES+)
calc. for C19H23N4O4 (M + H+) 371.1719 found 371.1731
7.6.4.3 1,4-Bis(2-amino-4-tolyl)-1,4-diazepane (HPTol)
N N
H2NNH2
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1,4-bis(2-nitro-4-tolyl)-1,4-diazepane (993 mg, 2.68 mmol), and Pd-C (10 %, 150 mg)
were placed in MeOH (50 ml) and degassed. The mixture was then stirred under an
atmosphere of hydrogen for 18 hrs. The solids were removed by filter cannula and the
mother liquer was concentrated in vacuo yielding the title compound as a pale yellow
air-sensitive solid (618 mg, 1.99 mmol, 74 %); IR (KBr, νmax, cm−1) 3392 (s), 3304 (m),
2919 (s), 2827 (s), 1617 (s), 1585 (s), 1510 (s), 1448 (s), 1380 (s), 1359 (s), 1295 (s), 1248 (s),
1205 (s), 1158 (s), 1092 (s)
7.6.4.4 1,4-Bis(2-nitro-4-trifluoromethylphenyl)-1,4-diazepane (HPCF3−NO2)
N N
NO2 O2N
F3C CF3
Using general procedure A; homopiperazine (76 mg, 0.76 mmol), in acetonitrile (10 ml),
4-fluoro-3-nitrobenzo-trifluoride (0.23 ml, 1.67 mmol), and potassium carbonate (230
mg, 1.67 mmol) yielded the title compound as an orange solid (170 mg, 0.36 mmol, 47
%). 1H NMR (400 MHz, CDCl3, ppm) δH : 7.95 (2 H, d, Ar-H, 2JH−H = 1.6 Hz), 7.56 (2
H, dd, Ar-H, 2JH−H = 1.6, 3JH−F = 8.8 Hz), 7.09 (2 H, d, Ar-H, 3JH−F = 8.8 Hz), 3.51 (4 H,
s, CH2N), 3.37 (4 H, m, CH2CH2N), 2.10 (2 H, m, CH2CH2CH2); 13C (125 MHz, CDCl3,
ppm) δC: 147.4, 139.3, 129.8, 124.4, 122.2, 121.4, 119.9, 52.7, 52.5, and 28.2; IR (KBr, νmax,
cm−1) 3411 (br), 2973 (w), 2922 (w), 2848 (w), 1630 (s), 1560 (s), 1538 (s), 1507 (w), 1462
(w), 1423 (), 1396 (w), 1328 (s), 1289 (s), 1261 (s), 1211 (w), 1188 (w), 1172 (w), 1147 (w),
1118 (s), 1040 (w), 1019 (w), 964 (w), 945 (w), 925 (w), 901 (s), 886 (w), 863 (w), 818 (s),
782 (s), 760 (w), 740 (w), 729 (w), 714 (s); MS (HR ES−) calc. for C19H16N4O4F635Cl (M
+ Cl−) 513.0764 found 513.0783
7.6.4.5 1,4-Bis(2-amino-4-trifluoromethylphenyl)-1,4-diazepane (HPCF3)
N N
NH2 H2N
F3C CF3
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1,4-bis(2-nitro-4-trifluoromethylphenyl )-1,4-diazepane (1.03 g, 2.15 mmol), and Pd-C
(10%, 200 mg) were placed in MeOH:THF (2:1, 30 ml) and degassed. The mixture was
then stirred under an atmosphere of hydrogen for 3 hrs. The solids are removed by filter
cannula and the mother liquer was concentrated in vacuo yielding the title compound as
a pale yellow air-sensitive solid (714 mg, 1.71 mmol, 80 %) 1H NMR (400 MHz, CDCl3,
ppm) δH : 7.04 - 7.02 (m , 1 H, Ar-H), 6.92 - 6.87 (m, 2 H, Ar-H), 4.05 (br s, 4 H, NH2), 3.20
- 3.17 (m, 8 H, CH2N), 1.98 (m, 2 H, CH2CH2CH2)
7.6.4.6 Di-tert-butyl 4,4’-(1,4-diazepane-1,4-diyl)bis(3-nitrobenzoate) (HP
tButyl−NO2)
N N
O2NNO2
O
OtBu
O
tBuO
Homopiperazine (120 mg, 1.20 mmol), tButyl 4-fluoro-3-nitrobenzoate (640 mg, 2.66
mmol), potassium carbonate (364mg, 2.64mmol), and acetonitrile (40ml) were refluxed
overnight under an atmosphere of nitrogen. Methanol (20 ml) was added, the solution
filtered, and the solvent removed in vacuo, yielding the title product as a yellow solid
(584 mg, 1.08 mmol, 90 %) 1H NMR (300 MHz, CDCl3, ppm) 8.32 (s, 2 H, Ar-H), 7.98
(dd, 2 H, Ar-H, JH−H = 2 + 12 Hz), 7.03 (d, 2 H, Ar-H, JH−H= 9 Hz), 3.56 (s, 4 H, CH2N),
3.42 (m, 4 H, CH2N), 2.14 (m, 2 H, CH2CH2CH2), 1.57 (s, 18 H, CH3); IR (KBr, νmax,
cm−1) 3446 (br), 2968 (w), 2922 (w), 2851 (w), 1700 (s), 1616 (s), 1559 (w), 1524 (s), 1456
(w), 1384 (s), 1368 (w), 1306 (br, s), 1167 (s), 1119 (s), 912 (w), 848 (w), 755 (w)
7.6.4.7 Di-tert-butyl 4,4’-(1,4-diazepane-1,4-diyl)bis(3-aminobenzoate) (HP
tButyl)
N N
H2NNH2
O
OtBu
O
tBuO
di-tert-butyl 4,4’-(1,4-diazepane-1,4-diyl)bis(3-nitrobenzoate)(816 mg, 1.51 mmol), and
Pd-C (10%, 160mg) were placed inMeOH:THF (15:2, 17 ml) and degassed. The mixture
was then stirred under an atmosphere of hydrogen for 24 hrs. The solids are removed
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by filter cannula and the mother liquer was concentrated in vacuo yielding the title com-
pound as a pale yellow air-sensitive solid (508mg, 1.05mmol, 68 %) 1HNMR (400MHz,
CDCl3, ppm) δH : 7.40 - 7.33 (m , 1 H, Ar-H), 7.09 - 7.01 (m, 2 H, Ar-H), 4.0 (br s, 4 H,
NH2), 3.28 - 3.25 (m, 8 H, CH2N), 2.10 - 2.02 (m, 2 H, CH2CH2CH2), 1.56 (s, 18 H, CH3)
7.6.4.8 1,4-Bis(2,4-dinitrophenyl)-1,4-diazepane (HPSang−NO2)
N N
NO2 O2N
O2N NO2
Homopiperazine (105 mg, 1.05 mmol), 2,4-dinitrofluorobenzene (0.29 ml, 2.30 mmol),
potassium fluoride (133 mg, 2.29 mmol), and acetonitrile (10 ml) were placed in a pres-
sure tube and heated to 95°C for 24 hrs. After cooling to 80°C the product was filtered
and the solution left to cool to room temperature. The solvent was reduced by half un-
der reduced pressure, and then filtered yielding the product as a yellow solid (220 mg,
0.51 mmol, 49 %). 1H NMR (400 MHz, MeOD, ppm) δH : 8.56 (2 H, d, Ar-H, 2JH−H =
2.8 Hz), 8.21 (2 H, dd, Ar-H, 2JH−H = 2.8 + 9.5 Hz), 7.26 (2 H, d, Ar-H, 2JH−H = 9.5 Hz),
3.62 (4 H, s, CH2N), 3.58 - 3.52 (4 H, m, CH2CH2N), 1.98 - 1.95 (2 H, m, CH2CH2CH2);
IR (KBr, νmax, cm−1) 3446 (br), 3105 (w), 3081 (w), 2919 (w), 2851 (w), 1602 (s), 1576 (s),
1526 (s), 1490 (s), 1433 (s0, 1402 (w), 1381 (w), 1330 (s), 1309 (s), 1290 (w), 1248 (w), 1233
(w), 1176 (s), 1145 (w), 1135 (s), 1068 (s), 977 (w), 946 (w), 933 (s), 912 (s), 842 (w), 827 (s),
804 (w), 751 (s), 743 (s), 717 (s).
7.6.4.9 1,4-Bis(2-nitro-4-anilinyl)-1,4-diazepane (HPNH2)
N N
NO2 O2N
H2N NH2
Using general procedure A; homopiperazine (148 mg, 1.48 mmol) in acetonitrile (20
ml), 4-fluoro-3-nitroaniline (480 mg, 3.08 mmol), and potassium carbonate (448 mg,
3.25 mmol) yielded the crude product as a red-brown solid. Recrytallisation from hot
EtOH:Hexane (100 ml, 9:1) gave the title compound as red-brown crystals (502 mg, 1.35
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mmol, 91 %). 1HNMR (400 MHz, CDCl3, ppm) δH : 7.01 (2 H, d, Ar-H, 2JH−H = 8.7 Hz),
6.89 (2 H, d, Ar-H, 2JH−H = 2.8 Hz), 6.73 (2 H, dd, Ar-H, 2JH−H = 2.8 + 8.7 Hz), 3.61 (4
H, s, Ar-NH2), 3.18 (4 H, s, CH2N), 3.16 - 3.12 (4 H, m, CH2CH2N), 1.90 - 1.84 (2 H, m,
CH2CH2CH2); 13C (125 MHz, CDCl3, ppm) δC: 145.2, 141.6, 139.2, 124.7, 120.0, 110.1,
56.4, 55.1, and 29.3; IR (KBr, νmax , cm−1) 3462 (br, s), 3374 (br, s), 2925 (w), 2851 (w),
2833 (w), 1635 (s), 1520 (s0, 1362 (s), 1307 (s), 1264 (w), 1211 (w), 1153 (w), 910 (s), 851
(w), 813 (s); MS (HR ES+) calc. for C17H21N6O4 (M + H+) 373.1624 found 373.1616
7.6.4.10 1,4-Bis(2-nitro-N-((+/-)-1-phenylethyl)-4-benzamide)-1,4-diazepane(HPAmideRac)
N
NO2
NH
O
N
O2N
HN
O
Using general procedure A; homopiperazine (34 mg, 0.34 mmol) in acetonitrile (20 ml),
((+/-)-1-phenylethyl)-4-fluoro-3-nitrobenzamide (197 mg, 0.68 mmol), and potassium
carbonate (94 mg, 0.68 mmol) yielded the crude product as a yellow oil. The yellow
oil was dissolved in minimum hot CHCl3 and added dropwise to a stirred beaker of
hexane. The purified product was isolated by filtration as a yellow solid (165 mg, 0.26
mmol, 76 %). 1HNMR (400 MHz, CDCl3, ppm) δH : 8.05 (2 H, d, Ar-H, 2JH−H = 2.2 Hz),
7.80 (2 H, dd, Ar-H, 2JH−H = 2.2 + 8.8 Hz), 7.29 (10 H, m, Ar’-H), 7.01 (2 H, d, Ar-H,
2JH−H = 8.8 Hz), 6.19 (2 H, d, NH, 2JH−H = 7.6 Hz), 5.24 (2 H, m, CH3CHNH), 3.47 (4 H,
s, CH2N), 3.35 (4 H, m, CH2CH2N), 2.07 (2 H, m CH2CH2CH2), 1.54 (6 H, d, CH3CH, J
= 6.9 Hz); IR (KBr, νmax, cm−1) 3441 (br, s), 2973 (w), 2923 (w), 2855 (w), 1616 (br, s), 1516
(s), 1456 (w), 1412 (w), 1336 (br), 1264 (br), 1205 (w), 1153 (w), 1013 (w), 823 (w), 760 (s);
MS (HR ES−) calc. for C35H35N6O6 (M - H+) 635.2618 found 635.2611
7.6.4.11 1,4-Bis(2-nitro-N-((R)-1-phenylethyl)-4-benzamide)-1,4-diazepane “doped”
N
NO2
NH
O
N
O2N
HN
O
+
N
NO2
NH
O
N
O2N
HN
O
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Using the samemethod as for 1,4-bis(2-nitro-N-((+/-)-1-phenylethyl)-4-benzamide)-1,4-
diazepanewith homopiperazine (35mg, 0.35mmol), 4-fluoro-3-nitro-N-((+/-)-1-phenylethyl)-
benzamide (180mg, 0.625mmol), 4-fluoro-3-nitro-N-((R)-1-phenylethyl)-benzamide (21.6
mg, 0.75 mmol) and potassium carbonate (96 mg, 0.70 mmol) yielded the title com-
pound as a yellow solid (165 mg, 0.26 mmol, 74 %). 1H NMR (400 MHz, CDCl3, ppm)
δH : 8.04 (2 H, d, Ar-H, 2JH−H = 2.2 Hz), 7.79 (2 H, dd, Ar-H, 2JH−H = 2.2 + 8.8 Hz), 7.33
- 7.21 (10 H, m, Ar’-H), 6.99 (2 H, d, Ar-H, 2JH−H = 8.8 Hz), 6.25 (2 H, d, NH, 2JH−H =
7.0 Hz), 5.23 (2 H, p, CH3CHN, 2JH−H = 7.0 Hz), 3.46 (4 H, s, CH2N), 3.38 - 3.30 (4 H, m,
CH2CH2N), 2.10 - 2.02 (2 H, m, CH2CH2CH2), 1.54 (6 H, d, CH3CH, 2JH−H = 7.0 Hz);
13C (125MHz, CDCl3, ppm) δC: 147.3, 142.9, 139.2, 132.1, 128.8, 127.6, 127.5, 126.3, 125.4,
119.3, 52.6, 52.5, 49.5, 28.2, and 21.7
7.6.4.12 1,3-Bis(2-nitro-4-tolyl)-1,3-diazacyclohexane (PipTol−NO2)
N N
O2N
NO2
To a solution of piperazine (146 mg, 1.70 mmol) in acetonitrile (30 ml), were added
4-fluoro-3-nitrotoluene (530 mg, 3.42 mmol), and potassium carbonate (470 mg, 3.41
mmol). Under a nitrogen atmosphere, the mixture was refluxed for 18 hrs and then
allowed to cool. The solution was filtered, and the solvents removed in vacuo. The solid
was dissolved in the minimum hot CHCl3 and added dropwise to stirred hexane (30
ml). The purified title compound was isolated by filtration of the orange precipitate
(527mg, 1.48 mmol, 87 %) 1HNMR (400MHz, CDCl3, ppm) δH : 7.61 (2 H, s, Ar-H), 7.34
(2 H, dd, Ar-H, 2JH−H = 1.8 + 8.4 Hz), 7.16 (2 H, d, Ar-H, 2JH−H = 8.4 Hz), 3.18 (8 H, s,
CH2N), 2.38 (6 H, s, Ar-CH3); IR (KBr, νmax, cm−1) 3430 (br), 2064 (w), 3001 (s), 2958 (s),
2926 (w), 2892 (w), 1619 (s), 1559 (s), 1521 (s), 1498 (s), 1453 (s), 1382 (w), 1377 (s), 1343
(br, s), 1288 (s), 1256 (s), 1223 (s), 1165 (s), 1135 (w), 1087 (w), 1041 (s), 969 (w), 943 (s),
909 (s), 835 (w), 824 (s), 799 (s), 764 (w), 724 (w).
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7.6.4.13 1,3-Bis(2-amino-4-tolyl)-1,3-diazacyclohexane (PipTol)
N N
H2N
NH2
1,3-Bis(2-nitro-4-tolyl)-1,3-diazacyclohexane (53mg, 0.15mmol), and Pd-C (10%, 15mg)
were placed in MeOH (15 ml) and degassed. The mixture was then stirred under an
atmosphere of hydrogen for 3 hr. The colourless liquid was transfered by filter cannula
and the volitiles removed in vacuo yielding the title compound as a pale yellow air-
sensitive solid. This was used immediately for coordination experiments.
7.6.4.14 1,4,7-Tris(2-nitro-4-trifluoromethylphenyl)-1,4,7-triazacyclononane(TACNCF3−NO2)
N
N
N
O2N
NO2
O2N
CF3
CF3
CF3
To a solution of triazacyclononane (208 mg, 1.61 mmol) in acetonitrile (30 ml), were
added 4-fluoro-3-nitrobenzo-trifluoride (1.01 g, 4.83 mmol), and potassium carbonate
(670 mg, 4.86 mmol). Under a nitrogen atmosphere, the mixture was refluxed for 18 hrs
and then allowed to cool. The solution was filtered, and the solvent removed in vacuo.
The solid was redissolved in the minimum hot CHCl3 and added dropwise to stirred
hexane (50 ml). The purified title compound was isolated as a yellow solid by filtration
(860 mg, 1.24 mmol, 77 %) 1H NMR (400 MHz, CDCl3, ppm) δH : 7.84 (3 H, d, Ar-H,
2JH−H = 1.7 Hz), 7.56 (3 H, dd, Ar-H, 2JH−H = 2.0 Hz, 3JH−F = 8.8 Hz), 7.10 (3 H, d, Ar-
H, 3JH−F = 8.8 Hz), 3.55 (12 H, s, CH2N); IR (KBr, νmax, cm−1) 3402 (br), 3093 (br), 2960
(w), 2930 (br), 1871 (w), 1624 (s), 1561 (s), 1532 (s), 1466 (w), 1439 (w), 1427 (w), 1402 (s),
1328 (br, s) 1290 (s), 1275 (s), 1248 (w), 1227 (s), 1194 (w), 1163 (s), 1118 (s), 1090 (s), 1024
(w), 991 (w), 970 (w), 909 (s), 882 (w), 875 (w), 854 (w), 811 (s), 787 (s), 7557 (w), 718 (s),
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712 (s); MS (HR ES−) calc. for C27H21N6O6F9Cl (M + Cl−) 731.1067 found 731.1074
7.6.4.15 1,4,7-Tris(2-amino-4-trifluoromethylphenyl)-1,4,7-triazacyclononane(TACNCF3)
N
N
N
H2N
NH2
H2N
CF3
CF3
CF3
1,4,7-tris(2-nitro-4-trifluoromethylphenyl)-1,4,7-triazacyclononane (85 mg, 0.12 mmol)
and Pd-C (10 %, 25 mg) were placed in MeOH (15 ml) and degassed, the mixture was
then stirred for 3 hrs in an atmosphere of hydrogen. The colourless liquid was removed
by filter cannula and the solvent was removed in vacuo yielding the title compound as a
white solid that was used immediately.
7.6.4.16 1,7-Bis(2-nitro-4-anilinyl)-1,4,7,10-tetraazacyclododecane (CyclenNH2)
N
NH
HN
N
NO2H2N
O2N NH2
To a solution of tetraazacyclododecane (117 mg, 0.68 mmol) in acetonitrile (25 ml), were
added 4-fluoro-3-nitroaniline (540 mg, 3.46 mmol), and potassium carbonate (470 mg,
3.41 mmol). Under a nitrogen atmosphere, the mixture was refluxed for 18 hrs and then
allowed to cool. The solution was filtered, and the solvent removed in vacuo. The solid
was dissolved in hot THF (20 ml) and allowed to cool. The resulting orange crystals
were isolated by filtration, yielding the title compound as an orange solid (263 mg, 0.59
mmol, 87 %). 1H NMR (400 MHz, MeOD, ppm) δH : 7.45 (2 H, m, Ar-H), 6.93 (2 H, d,
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Ar-H, 2JH−H = 1.8 Hz), 6.91 (2 H, d, Ar-H, 2JH−H = 2.7 Hz), 3.33 (4 H, m, Ar-NH2), 3.12
(8 H, s, CH2NAr), 2.63 (8 H, s, CH2NH); MS (LR, ES+) 444.84 (M+)
7.6.5 Metal Complexes of Anilino Ligands
7.6.5.1 Nickel(II) 1,4-bis(2-amino-4-tolyl)-1,4-diazepane (perchlorate salt) (NiHPTol)
N N
N
H2
N
H2
Ni
2 ClO4-
Under an inert atmosphere Ni(ClO4)2.6H2O (80 mg, 0.22 mmol) was dissolved in de-
gassed EtOH (10 ml), and added via cannula to 1,4-bis(2-amino-4-tolyl)-1,4-diazepane
(62 mg, 0.20 mmol), gently heated for 2 minutes, and then stirred for 1 hr at room tem-
perature. The solution was then reduced in volume by half under reduced pressure,
and Et2O (20 ml) added, which initiates precipitation of the product. The title product
was isolated by filtration as a cream solid (74 mg, 0.13mmol, 59 %). 1HNMR (400MHz,
Acetone-d6, ppm) δH : 7.49 (2 H, s, Ar-H), 7.29 - 7.25 (4 H, m, Ar-H), 5.02 - 4.94 (4 H, m,
Mac-H), 4.78 - 4.68 (2 H, m, Mac-H), 4.22 - 4.16 (2 H, m, Mac-H), 4.12 - 4.02 (2 H, m, Mac-
H), 3.77 - 3.59 (2 H, m, Mac-H), 2.97 - 2.87 (6 H, m, Mac-H), 2.70 - 2.51 (2 H, m, Mac-H),
2.37 (6H, s, Ar-CH3); UV (acetone, nm) 435 (ε = 76mol−1cm−1), 583 (ε = 18 mol−1cm−1),
764 (ε = 11 mol−1cm−1); IR (Diamond anvil, νmax, cm−1) 3226 (m), 3186 (m), 2970 (w),
1730 (s), 1706 (s), 1506 (s), 1411 (s), 1342 (s), 1234 (s), 1112 (s); MS (LR ES+) 367.13 (M2+
- H+), (HR ES+) calc. for C19H26N4O4Cl58Ni (M2+ + ClO4−) 467.0996, found 467.0979
7.6.5.2 Copper(II) 1,4-bis(2-amino-4-tolyl)-1,4-diazepane(perchlorate salt) (CuHPTol)
N N
N
H2
N
H2
Cu
2 ClO4-
Under an inert atmosphere Cu(ClO4)2.6H2O (60 mg, 0.16 mmol) was dissolved in de-
gassed EtOH (10 ml), and added via cannula to 1,4-bis(2-amino-4-tolyl)-1,4-diazepane
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(54 mg, 0.17 mmol), gently heated for 2 minutes and then stirred for 1 hr at room tem-
perature. The solution was then reduced in volume by half under reduced pressure,
and Et2O (20 ml) added, which initiates precipitation of the product. The title product
was isolated by filtration as a purple solid (40 mg, 0.11 mmol, 67 %). UV (acetone, nm)
577 (ε = 292mol−1cm−1); IR (KBr, νmax, cm−1) 3522 (b), 3243 (b), 2963 (w), 2941 (w), 2905
(w), 2360 (m), 2342 (m), 1621 (m), 1601 (m), 1568 (m), 1503 (s), 1464 (m), 1261 (s), 1209
(s), 1088 (b); MS (LR ES+) 311.23 (M2+ - 63Cu2+ + H+, 100 %), 372.14 (M2+ - H+, 10 %)
(HR ES+) calc. for C19H25N4Cu (M2+ - H+) 372.1375 found 372.1383
7.6.5.3 Zinc(II) 1,4-bis(2-amino-4-tolyl)-1,4-diazepane (perchlorate salt) (ZnHPTol)
N N
N
H2
N
H2
Zn
2 ClO4-
Under an inert atmosphere Zn(ClO4)2.6H2O (63 mg, 0.17 mmol) was dissolved in de-
gassed EtOH (10 ml), and added via cannula to 1,4-bis(2-amino-4-tolyl)-1,4-diazepane
(48 mg, 0.15 mmol), gently heated for 2 minutes and then stirred for 1 hr at room tem-
perature. The solution was then reduced in volume by half in vacuo, and Et2O (20 ml)
added, which initiates precipitation of the product. The title product was isolated by
filtration as an off white solid (53 mg, 0.093 mmol, 62 %) MS (LR ES+) 373.14 (M2+ -
H+, 100 %), (HR ES+) calc. for C19H25N464Zn (M2+ - H+) 373.1371 found 373.1381
7.6.5.4 Nickel(II) 1,4-bis(2-amino-4-trifluoromethylphenyl)-1,4-diazepane (perchlo-
rate salt) (NiHPCF3)
N N
N
H2
N
H2
CF3F3C
Ni
2 ClO4-
Under an inert atmosphere Ni(ClO4)2.6H2O (60 mg, 0.16 mmol) was dissolved in de-
gassed EtOH (10ml), and added via cannula to 1,4-bis(2-amino-4-trifluoromethylphenyl)-
1,4-diazepane (68 mg, 0.16 mmol), gently heated for 2 minutes, and then stirred for 1 hr
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at room temperature.The solution was then filtered, and the solvent removed in vacuo
yielding the title product as a cream solid (31 mg, 0.05 mmol, 29 %). UV (acetone, nm)
507 (ε = 20 mol−1cm−1), 562 (ε = 12 mol−1cm−1), 803 (ε = 11 mol−1cm−1); IR (KBr, νmax,
cm−1) 3419 (br, w), 3344 (br), 2967 (w), 2934 (w), 2854 (w), 1630 (s), 1554 (w), 1431 (w),
1332 (s), 1261 (w), 1119 (br, s), 802 (w); MS (LR ES+) 475.09 (M2+ - H+, 100 %), (HR ES+)
calc. for C19H19N4F6 58Ni (M2+ - H+) 475.0867 found 475.0880
7.6.5.5 Copper(II) 1,4-bis(2-amino-4-trifluoromethylphenyl)-1,4-diazepane(perchlo-
rate salt) (CuHPCF3)
N N
N
H2
N
H2
CF3F3C
Cu
2 ClO4-
Under an inert atmosphere Cu(ClO4)2.6H2O (47 mg, 0.13 mmol) was dissolved in de-
gassed EtOH (10 ml), and added via cannula to 1,4-bis(2-amino-4-tolyl)-1,4-diazepane
(53 mg, 0.13 mmol), gently heated for 2 minutes and then stirred for 1 hr at room tem-
perature.The solution was then filtered, and the solvent removed in vacuo yielding the
title product as a purple solid (52 mg, 0.08 mmol, 59 %). UV (acetone, nm) 572 (ε = 143
mol−1cm−1); IR (KBr, νmax, cm−1) 3519 (br, w), 3433 (br), 2965 (w), 2925 (w), 2854 (w),
1635 (s), 1532 (w), 1435 (w), 1332 (s), 1260 (w), 1121 (br), 1109 (br, s), 1087 (br, s), 808 (w);
MS (LR ES+) 480.08 (M2+ - H+, 100 %), (HR ES+) calc. for C19H19N4F6 63Cu (M2+ - H+)
480.0810 found 480.0813
7.6.5.6 Zinc(II) 1,4-bis(2-amino-4-trifluoromethylphenyl)-1,4-diazepane(perchlorate
salt) (ZnHPCF3)
N N
N
H2
N
H2
CF3F3C
Zn
2 ClO4-
Under an inert atmosphere Zn(ClO4)2.6H2O (58 mg, 0.16 mmol) was dissolved in de-
gassed EtOH (10ml), and added via cannula to 1,4-bis(2-amino-4-trifluoromethylphenyl)-
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1,4-diazepane (65 mg, 0.16 mmol), gently heated for 2 minutes, and then stirred for 1
hr at room temperature. The solution was then filtered, and the solvent removed in
vacuo yielding the title product as a cream solid (42 mg, 0.06 mmol, 38 %). IR (KBr, νmax,
cm−1) 3287 (br), 2963 (w), 2925 (w), 2894 (w), 2856 (w), 1627 (s), 1576 (w), 1512 (s), 1429
(s), 1334 (s), 1291 (w), 1262 (w), 1122 (br, s), 897 (w), 798 (w), 746 (s)
7.6.5.7 Nickel(II) di-tert-butyl 4,4’-(1,4-diazepane-1,4-diyl)bis(3-aminobenzoate) (NiHP
tButyl)
N N
N
H2
N
H2
Ni
2 ClO4-
O
O
O
O
Under an inert atmosphere Ni(ClO4)2.6H2O (52 mg, 0.14 mmol) was dissolved in de-
gassed EtOH (10 ml), and added via cannula to di-tert-butyl 4,4’-(1,4-diazepane-1,4-
diyl)bis(3-aminobenzoate) (68 mg, 0.14 mmol), gently heated for 2 minutes, and then
stirred for 1 hr at room temperature. The solution was then filtered, and the solvent
removed in vacuo yielding the title product as a cream solid (50 mg, 0.07 mmol, 48 %)
UV (MeOH, nm) 487 (ε = 131 mol−1cm−1), 623 (ε = 85mol−1cm−1); IR (KBr, νmax, cm−1)
3399 (br, s), 2968 (w), 2930 (w), 2879 (w), 1635 (s), 1540 (s), 1496 (s), 1456 (w), 1399 (w),
1331 (w), 1263 (s), 1147 (s), 1115 (s), 1088 (s), 802 (w), 764 (w); MS (LR ES+) 483.29 (M
- Ni2+ + 2H+, 50 %), 539.22 (M2+ - H+, 100 %), (HR ES+) calc. for C27H37N4O4 58Ni
(M2+ - H+) 539.2168 found 539.2165
7.6.5.8 Copper(II) di-tert-butyl 4,4’-(1,4-diazepane-1,4-diyl)bis(3-aminobenzoate) (CuHP
tButyl)
N N
N
H2
N
H2
Cu
2 ClO4-
O
O
O
O
Under an inert atmosphere Cu(ClO4)2.6H2O (52 mg, 0.14 mmol) was dissolved in de-
gassed EtOH (10 ml), and added via cannula to di-tert-butyl 4,4’-(1,4-diazepane-1,4-
diyl)bis(3-aminobenzoate) (68 mg, 0.14 mmol), gently heated for 2 minutes, and then
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stirred for 1 hr at room temperature. The solution was then filtered, and the solvent
removed in vacuo yielding the title product as a cream solid (50 mg, 0.07 mmol, 48
%) UV (MeOH, nm) 410 (ε = 654 mol−1cm−1), 612 (ε = 458 mol−1cm−1), 813 (ε = 371
mol−1cm−1); IR (KBr, νmax, cm−1) 3382 (br, w), 3245 (br, w), 2966 (w), 2931 (w), 2871
(w), 1635 (s), 1537 (s), 1495 (s), 1451 (w), 1380 (w), 1318 (w), 1262 (w), 1088 (br, s), 904
(w), 803 (w), 762 (w), 742 (w), 702 (w); MS (LR ES+) 483.29 (M - Cu2+ + 2H+, 80 %),
544.21 (M2+ - H+, 100 %), (HR ES+) calc. for C27H37N4O4 63Cu (M2+ - H+) 544.211
found 544.2096
7.6.5.9 Zinc(II) di-tert-butyl 4,4’-(1,4-diazepane-1,4-diyl)bis(3-aminobenzoate) (ZnHP
tButyl)
N N
N
H2
N
H2
Zn
2 ClO4-
O
O
O
O
Under an inert atmosphere Zn(ClO4)2.6H2O (40 mg, 0.11 mmol) was dissolved in de-
gassed EtOH (10 ml), and added via cannula to di-tert-butyl 4,4’-(1,4-diazepane-1,4-
diyl)bis(3-aminobenzoate) (51 mg, 0.11 mmol), gently heated for 2 minutes, and then
stirred for 1 hr at room temperature. The solution was then filtered, and the solvent
removed in vacuo yielding the title product as a cream solid (57 mg, 0.08 mmol, 69 %) IR
(KBr, νmax, cm−1) 3466 (br, w), 3260 (br, w) 2975 (w), 2925 (w), 2855 (w), 1714 (s), 1616
(s), 1501 (w), 1456 (w), 1419 (w), 1370 (w), 1312 (s), 1260 (w), 1122 (br, s), 844 (w), 814
(w), 770 (s), 732 (w); MS (LR ES+) 546.22 (M2+ - H+, 100 %)
7.6.5.10 Nickel(II) 1,3-bis(2-amino-4-tolyl)-1,3-diazacyclohexane(perchlorate salt) (NiPipTol)
N N
N
H2
N
H2
Ni
2 ClO4-
Ni(ClO4)2.6H2O (69 mg, 0.19 mmol) was dissolved in EtOH and degassed. Under a
nitrogen atmosphere the nickel solution was added by cannula to 1,3-bis(2-amino-4-
tolyl)-1,3-diazacyclohexane (56.5 mg, 0.19 mmol) and the mixture was gently heated for
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2 minutes stirred for an hour at room temperature. A fine yellow precipitate formed,
which was isolated by centrifugation, and then redissolved in MeOH. The insoluble
residue was discarded. The mother liquor concentrated in vacuo, yielding the title com-
pound as a yellow solid. IR (KBr, νmax, cm−1) 3421 (br, s), 3222 (br, w), 2927 (w), 2849
(w), 1616 (s), 1559 (w), 1506 (s), 1456 (w), 1145 (s), 1113 (br, s), 1089 (s), 797 (w); MS (LR
ES+): 353.13 (M + H+)
7.6.5.11 Copper(II) 1,4,7-tris(2-amino-4-trifluoromethylphenyl)-1,4,7-triazacyclononane
(perchlorate salt) (CuTACNCF3)
N
N
N
H2N
NH2
H2
N
CF3
CF3
CF3
Cu
Cu(ClO4)2.6H2O (52 mg, 0.14 mmol) was dissolved in EtOH (10 ml) and degassed. The
copper solution was then transferedvia canula onto 1,4,7-tris(2-amino-4-trifluoromethylphenyl)-
1,4,7-triazacyclononane (85 mg, 0.14 mmol), then gently heated for 2 minutes and then
stirred for an hour at room temperature. The solvent was then removed in vacuo, giving
a green oil, which was then redissolved in a minimum of EtOH. Single crystals for x-ray
diffraction were obtain by vapour diffusion of pentane into this solution. X-Ray data -
see appendix.
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7.7 Triazine Core Dervived Compounds
7.7.1 Dipyridamole type complexes
7.7.1.1 2,4-Dichloro-6-(piperidin-1-yl)-1,3,5-triazine (TzPipCl2)
N
N
N
N
ClCl
Cyanuric chloride (48.1 g, 261 mmol) was dissolved in a mixture of acetone (400 ml)
and THF (200 ml), added to ice water (400 ml) to form a slurry, and cooled to 0°C.
Piperidine (25.8 ml, 261 mmol) in acetone (100 ml), was added dropwise to the stirred
slurry. Na2CO3 (27.7 g, 261 mmol) was added portion-wise throughout so as to keep
the pH neutral. The mixture was stirred at room temperature for 48 hours, filtered, and
the solid was recrystallised from hot MeOH (2.5 g/50 ml), yielding the title product as
colourless crystals (40.1 g, 172 mmol, 66 %) 1HNMR (400 MHz, MeOD, ppm) δH : 3.90 –
3.77 (m, 4 H, NCH2), 1.77 – 1.71 (m, 2 H, CH2CH2CH2), 1.69 – 1.58 (m, 4 H, NHCH2CH2);
IR (KBr, νmax, cm−1) 2943 (s), 2927 (s), 2862 (w), 1615 (s), 1594 (s), 1552 (s), 1466 (s), 1441
(s), 1348 (s), 1329 (s), 1289 (s), 1258 (w), 1229 (s), 1170 (s), 1155 (s), 1116 (s), 1064 (s), 1022
(w), 987 (s), 951 (w), 903 (w), 843 (s), 790 (s).
7.7.1.2 4,6-dichloro-2-thiomorphyl-1,3,5-triazine (TzMorphCl2)
N
N
N
N
ClCl
S
Cyanuric chloride (1.8 g, 10 mmol) was dissolved in acetone (10 mL) and added to
ice-water to form a slurry. Thiomorpholine (1 ml, 11 mmol) in acetone (10 ml) was
added dropwise to the stirred slurry. Na2CO3 (0.9 g, 10 mmol) was added portionwise
throughout so as to keep the pH neutral. The mixture was stirred at room temperature
for 24 hours, filtered, and the solid was recrystallised from hot EtOH, yielding the title
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product as colourless crystals (1.46 g, 5 mmol, 61%) 1H NMR (500Mhz, CDCl3, ppm)
δH : 4.12 - 4.03 (m, 4 H, NCH2), 2.73 - 2.68 (m, 4 H, SCH2). 13C NMR (500MHz, CDCl3,
ppm) δC: 170.4, 164.0, 46.9, 27.4
7.7.1.3 4,4’-(6-chloro-1,3,5-triazine-2,4-diyl)dipiperidine (TzPip2Cl)
N
N
N
N
NCl
TzPipCl2 (3.25 g, 13.9 mmol) was dissolved in acetone (15 ml) and added to ice wa-
ter resulting in a slurry. Piperidene (1.4 ml, 14.2 mmol) was dissolved in acetone (15
ml) added dropwise to the TzPipCl2 slurry. NaHCO3 (1.17 g, 13.9 mmol) was added
portion-wise so as the pH remained neutral, and the mixture stirred over night at room
temperature. Themixture was filtered, and the solid recrystallised from hot EtOH yield-
ing the title compound as a white solid (2.5 g, 8.9 mmol, 64 %) 1H NMR (250 MHz,
CDCl3, ppm) δH : 3.86 – 3.76 (m, 8 H, NCH2), 1.74 – 1.71 (m, 4 H, CH2CH2CH2), 1.62
– 1.53 (m, 8 H, NHCH2CH2); MS (HR AP+) calc. for C13H21N5Cl (M + H+) 282.1485
found 282.1478
7.7.1.4 4-(4-chloro-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (TzPipMorphCl)
N
N
N
N
ClN
O
TzPipCl2 (3.18 g, 13.6 mmol) was dissolved in acetone (15 ml) and added to ice wa-
ter resulting in a slurry. Morpholine (1.19 ml, 13.6 mmol) was dissolved in acetone (15
ml) added dropwise to the TzPipCl2 slurry. NaHCO3 (1.15 g, 13.7 mmol) was added
portion-wise so as the pH remained neutral, and the mixture stirred over night at room
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temperature. Themixture was filtered, and the solid recrystallised from hot EtOH yield-
ing the title compound as a white solid (2.2 g, 7.8 mmol, 57 %) 1H NMR (250 MHz,
CDCl3, ppm) δH : 3.85 – 3.63 (m, 12 H), 1.76 – 1.47 (m, 6 H)
7.7.1.5 2,2’-((4,6-Dichloro-1,3,5-triazin-2-yl)azanediyl)diethanol (TzDEACl2)
N
N
N
N
ClCl
OHHO
Cyanuric chloride (9.2 g, 49.9 mmol) was dissolved in acetone (50 ml) and added to ice
water (100 ml) to form a slurry. Diethanolamine (5.2 g, 49.5 mmol) was dissolved in
acetone (50 ml) and added dropwise to the slurry at 0ºC over 1 hr. NaHCO3 (4.2 g, 50
mmol) was added periodically so as to keep pH neutral. The solution was allowed to
warm to room temperature and stirred for a further 12 hours. The resulting precipitate
was filtered, washed with water (50 ml) and Et2O (50 ml), and dried in vacuo, yielding
the title product as a white solid (9.7 g, 38.3 mmol, 77 %) 1HNMR (500MHz, DMSO-d6,
ppm) δH : 3.98 (s, CH2OH), 3.66 (t, 4 H, 2JH−H = 5.7 Hz, NCH2), 3.59 (t, 4 H, 2JH−H = 5.8
Hz, CH2OH); 13C NMR (126 MHz, DMSO-d6, ppm) δC: 168.7, 164.3, 57.7, 50.8; IR (KBr,
νmax, cm−1) 3237 (br), 3156 (br), 2997 (w), 2965 (w), 2889 (w), 2847 (w), 1596 (s), 1559 (s),
1478 (s), 1424 (s), 1363 (s), 1350 (s), 1328 (s), 1292 (s), 1225 (s), 1185 (s), 1153 (s), 1060 (s),
1023 (s), 985 (w), 954 (w), 922 (s), 859 (s), 842 (s), 793 (s), 751 (br, w) ; MS (LR ES−) 286.99
(M + Cl−), (HR ES−) calc. for C7H10N4O2Cl3 (M + Cl−) 286.9869 found 286.9864.
7.7.1.6 2,2’,2”,2”’-((6-Chloro-1,3,5-triazine-2,4-diyl)bis(azanetriyl))tetraethanol(TzDEA2Cl)
N
N
N
N
ClN
OHHO
OH
HO
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TzDEACl2 (2.71 g, 10.7 mmol) was dissolved in acetone (50 ml) and added to ice water
(50 ml) to form a slurry. Diethanolamine (1.12 g, 10.7 mmol) was dissolved in acetone
(50 ml) and added dropwise to the slurry at 0ºC over 1 hr. NaHCO3 (0.90 g, 10.7 mmol)
was added periodically so as to keep pH neutral. The solution was stirred at room
temperature overnight and the the solvent removed in vacuo. The resulting solid was
dissolved in hot methanol (100 ml), filtered, and the solvent removed in vacuo, yielding
the title product as an off white solid (3.08 g, 9.6 mmol, 90 %) 1H NMR (500 MHz,
DMSO-d6, ppm) δH : 4.83 (s, 4 H, CH2OH), 3.64 – 3.48 (m, 16 H, NCH2 and CH2OH);
13CNMR (126MHz, DMSO-d6, ppm) δC: 168.1, 164.1, 58.7, 58.5, 50.7, 50.3; IR (KBr, νmax,
cm−1) 3407 (br), 2951 (w), 2911 (w), 2886 (w), 1585 (s), 1511 (s), 1482 (s), 1463 (s), 1440
(s), 1412 (w), 1369 (s), 1333 (w), 1308 (s), 1235 (s), 1185 (w), 1163 (s), 1129 (s), 1080 (s),
1065 (s), 1054 (s), 1041 (s), 1009 (w), 979 (s), 925 (s), 870 (s), 807 (w), 794 (s), 732 (w) ; MS
(LR ES+) 322.13 (7 %, M + H+), 344.11 (100 %, M + Na+), 385.14 (20 %, M + MeCN +
Na+) (HR ES+) calc. for C11H21N5O4Cl (M + H+) 322.1282 found 322.1283.
7.7.1.7 2,2’-((4-Chloro-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)azanediyl)diethanol (TzPipDEACl)
N
N
N
N
ClN
OH
HO
TzPipCl2 (2.33 g, 10 mmol) was dissolved in acetone (50 ml) and added to ice water
(50 ml) to form a slurry, and cooled to 0°C. To this slurry was added dropwise di-
ethanolamine (1.05 g, 10 mmol) with NaHCO3 (0.84 g, 10 mmol) added portion-wise
so as to keep the pH neutral. The mixture was stirred at room temperature for 18 hours,
filtered, and chloroform (100 ml) added. KBr was added to the solution until the aque-
ous phase was saturated, and the organic phase separated, washed with brine (50 ml),
dried over MgSO4, filtered, and solvent removed in vacuo resulting in a colourless oil.
This was dissolved in EtOAc (20 ml) and placed in the freezer for 24 hours. The solution
was the filtered and the solvent removed in vacuo leaving an off white solid (1.86 g, 6.2
mmol, 62 %). 1H NMR (500 MHz, CDCl3, ppm) δH : 3.85 – 3.77 (m, 8 H), 3.76 – 3.70 (m,
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2 H), 3.70 – 3.59 (m, 4 H), 1.62 – 1.57 (m, 2 H), 1.53 – 1.46 (m, 2 H); 13C NMR (126 MHz,
CDCl3, ppm) δC: 169.0, 165.8, 163.5, 61.9, 61.5, 52.3, 52.0, 44.7, 25.7, 25.6, 24.5; MS (LR
ES+) 302.14 (100 %, M + H+), 324.12 (90 %, M + Na+), (HR ES+) calc for C12H21N5O2Cl
(M + H+) 302.1384 found 302.1377.
7.7.2 DO3A Ligands
7.7.2.1 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (TzMorphCl2)
N
N
N
N
ClCl
O
Cyanuric chloride (11.0 g, 59.6mmol) was dissolved in acetone (100ml) and added to ice
water (100 ml) to form a slurry, and cooled to 0°C. Morpholine (5.19 g, 59.6 mmol) was
dissolved in acetone (100 ml), and added dropwise to the stirred solution. NaHCO3
(5.00 g, 59.5 mmol) was added portion-wise so as to keep the pH neutral. The solu-
tion was warmed to room temperature and stirred for 18 hours. The white solid was
collected by filtration and recrystallised from hot EtOH yielding the title product as a
colourless solid (8.53 g, 36.3 mmol, 61 %) 1H NMR (500 MHz, CDCl3, ppm) δH : 3.85 –
3.82 (m, 4 H), 3.72 – 3.69 (m, 4 H); 13C NMR (126 MHz, CDCl3, ppm) δC: 170.4, 164.1,
66.4, 44.5; IR (KBr, νmax, cm−1) 2970 (s), 2924 (s), 2862 (s), 1587 (s), 1558 (s), 1478 (s), 1457
(w), 1442 (s), 1361 (s), 1343 (s), 1322 (w), 1300 (s), 1279 (s), 1261 (w), 1231 (s), 1194 (s),
1161 (s), 1126 (w), 1113 (s), 1075 (s), 1069 (w), 1019 (s), 993 (s), 922 (w), 847 (s), 837 (s),
804 (w), 790 (s).
7.7.2.2 4,4’-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (TzMorph2Cl)
N
N
N
N
ClN
O
O
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TzMorphCl2 (8.23 g, 35.0mmol) was dissolved in acetone (50ml) and added to ice water
(100 ml) to form a slurry. Morpholine (3.05 g, 35.1 mmol) was dissolved in acetone
(50 ml) and added dropwise to the solution. NaHCO3 (2.94 g, 35.0 mmol) was added
portion-wise so as to keep the pH neutral. The solution was stirred for 18 hours, the
solid collected by filtration and recrystallised from hot EtOH, yielding the title product
as colourless crystals (6.47 g, 22.7 mmol, 65 %) 1H NMR (500 MHz, CDCl3, ppm) δH :
3.81 – 3.69 (m, 4 H), 3.68 – 3.64 (m, 4 H); 13C NMR (126 MHz, CDCl3, ppm) δC: 169.7,
164.5, 66.6, 43.9; IR (KBr, νmax, cm−1) 2966 (s), 2920 (s), 2852 (s), 1575 (s), 1489 (s), 1451
(s), 1362 (s), 1299 (s), 1269 (s), 1245 (s), 1233 (s), 1183 (s), 1116 (s), 1063 (s), 1008 (s), 981
(s), 956 (s), 860 (s), 817 (s), 798 (s), 730 (s).
7.7.2.3 Tri-tert-butyl 2,2’,2”-(10-(4,6-dimorpholino-1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate (TzMorph2DO3A)
N
N
N
N
N
O
O
N
N
N
N
O
OtBu
O
OtBu
O
tBuO
TzMorph2Cl (87 mg, 0.30 mmol), DO3A.HBr (182 mg, 0.31 mmol), and NaHCO3 (51
mg, 0.61 mmol) were refluxed in CH3CN (30 ml) under an atmosphere of nitrogen for
5 days. The solvents were removed in vacuo, and the solid dissolved in CHCl3, washed
with water then brine, and dried over MgSO4. The solvents were removed in vacuo
yielding the title compound as a white hydroscopic solid (213 mg, 0.28 mmol, 84 %)
1H NMR (500 MHz, CDCl3, ppm) δH : 3.79 – 3.58 (m, 16 H, CH2O + CH2N), 3.39 – 3.21
(m, 6 H, CH2CO2), 3.11 – 2.99 (m, 8 H, Mac-H), 2.94 – 2.68 (m, 8 H, Mac-H), 1.44 (s, 9
H, CH3), 1.43 (s, 9 H, CH3), 1.41 (s, 9 H, CH3); 13C NMR (126 MHz, CDCl3, ppm) δC:
170.67, 169.83, 165.46, 81.87, 81.75, 80.97, 80.81, 67.05, 58.35, 57.38, 55.07, 52.87, 52.65,
52.05, 51.53, 49.42, 47.64, 47.02, 43.80, 28.36, 28.34, 28.31, 18.53; MS (HR EI+) calc. for
C37H65N9O8 (M+) 763.4956 found 763.4940
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7.7.2.4 2,2’,2”-(10-(4,6-dimorpholino-1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid (TzMorph2DO3a)
N
N
N
N
N
O
O
N
N
N
N
O
OH
O
OH
O
HO
TzMorph2DO3A (213 mg, 0.28 mmol), was dissolved in DCM (3 ml), and TFA (3 ml)
added. The solution was stirred at room temperature for 48 hours. The solvents were
removed in vacuo and MeOH (5 ml) added, this was repeated 3 times yielding an off
white oil, which was tritrated with Et2O yielding the title product as an off white solid
(157 mg, 0.26 mmol, 93 %) 1H NMR (500 MHz, MeOD, ppm) δH : 3.84 – 3.59 (m, 16 H,
CH2O + CH2N), 3.40 – 3.23 (m, 6 H, CH2CO2), 3.00 – 2.62 (br m, 16 H, Mac-H); IR (KBr,
νmax, cm−1) 3436 (br), 2925 (s), 2852 (s), 1739 (w), 1679 (w), 1558 (w), 1528 (w), 1483 (w),
1447 (w), 1376 (w), 1369 (w), 1313 (w), 1263 (w), 1198 (s), 1139 (s), 811 (w), 721 (w), 704
(w); MS (LR ES+) 596.32 (100 %, M + H+), 618.34 (20 %, M + Na+), (HR ES+) calc. for
C25H42N9O8 (M + H+) 596.3156 found 596.3151
7.7.2.5 Tri-tert-butyl 2,2’,2”-(10-(4,6-dichloro-1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate (TzDO3ACl2)
N
N
N
ClCl
N
N
N
N
OtBu
O
OtBu
O
tBuO
O
Cyanuric chloride (205 mg, 1.11 mmol) was dissolved in acetone (50 ml) and added
to stirred ice water (50 ml) resulting in a slurry. DO3A.HBr (660 mg, 1.11 mmol) was
CHAPTER 7. EXPERIMENTAL 150
dissolved in acetone (50 ml) and added dropwise to the slurry at 0°C. NaHCO3 (187
mg, 2.23 mmol) was added at such a rate as to keep the pH neutral. The mixture was
stirred for 18 hours at room temperature, the resulting solid was collected by filtration,
and recrystallised from hot EtOH, yielding the title product as a white solid (466 mg,
0.70 mmol, 63 %) 1H NMR (250 MHz, CDCl3, ppm) δH : 13C NMR (126 MHz, CDCl3,
ppm) δC: ; IR (KBr, νmax, cm−1) 3438 (br), 2976 (s), 2932 (s), 2846 (w), 1733 (s), 1571(s),
1510 (w), 1450 (w), 1433 (w), 1367 (s), 1307 (w), 1260 (w), 1159 (s), 848 (w), 805 (w),
752 (w) ; MS (LR EI+) 661.31 (10 %, M+), 560.25 (50 %, M - TzCl2) (HR EI+) calc. for
C29H49N7O665Cl2 (M+) 661.3121 found 661.3124
7.7.2.6 Tri-tert-butyl 2,2’,2”-(10-(2-chloro-1,3,5-triazin-4,6-yl)-di-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate (TzDO3A2Cl)
N
N
N
Cl
N
N
N
N
OtBu
O
OtBu
O
tBuO
O
N
N
N
N
OtBuO
OtBu
O
tBuO
O
Cyanuric chloride (115 mg, 0.62 mmol) was dissolved in acetone (30 ml) and added
to stirred ice water (30 ml) resulting in a slurry. DO3A.HBr (742 mg, 1.24 mmol) was
dissolved in acetone (30 ml) and added dropwise to the slurry at 0°C. NaHCO3 was
added portion-wise at a rate so as the pH was neutral. The mixture was stirred at room
temperature for 18 hours, the solid filtered and recrystallised from hot EtOH, yielding
the title product as a white solid (620 mg, 0.54 mmol, 88 %) 1HNMR (500 MHz, MeOD,
ppm) δH : 3.51 – 3.33 (br, m, 16 H), 3.25 – 3.10 (br, m, 8 H), 3.10 – 2.88 (br, m, 8 H), 2.84
– 2.55 (br, m, 12 H), 1.52 – 1.44 (m, 54 H); IR (KBr, νmax, cm−1) 3441 (br), 2977 (s), 2930
(s), 2849 (w), 1733 (s), 1664 (w), 1569 (s), 1505 (w), 1459 (w), 1428 (w), 1368 (s), 1305 (w),
1259 (w), 1226 (w), 1156 (s), 849 (w), 801 (w), 755 (w); MS (LR ES+) 1140.71 (65 %, M +
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H+) 1162.69 (65 %, M + Na+) (HR ES+) calc. for C55H99N11O12Cl (M + H+) 1140.7163
found 1140.7133
7.7.3 DO3A Complexes
7.7.3.1 Copper(II) 2,2’,2”-(10-(4,6-dimorpholino-1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate (CuTzM2D)
N
N
N
N
N
O
O
N
N
N
N
O
O
O
OH
O
O
Cu
TzMorph2DO3a (24 mg, 0.04 mmol) and Cu(OAc)2.6H2O (12 mg, 0.04 mmol) were
heated in MeOH (10 ml) for 10 minutes. MS (HR ES+) calc. for C25H40N9O863Cu (M +
H+) 657.2296 found 657.2296
7.7.3.2 Zinc(II) 2,2’,2”-(10-(4,6-dimorpholino-1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate (ZnTzM2D)
N
N
N
N
N
O
O
N
N
N
N
O
O
O
OH
O
O
Zn
TzMorph2DO3a (21 mg, 0.04 mmol) and ZnCl2.2H2O (8 mg, 0.04 mmol) were heated
in MeOH (5 ml) for 10 minutes. MS (HR ES+) calc. for C25H40N9O864Zn (M + H+)
658.2291 found 658.2310
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7.7.4 Dendrimers
7.7.4.1 1,4,7-tris(4,6-dichloro-1,3,5-triazin-2-yl)-1,4,7-triazonane (TCl6)
N
N
NN
N N N N
N
N
N
N
Cl Cl
Cl
ClCl
Cl
To stirred cyanuric chloride (2.58 g, 14.0 mmol) in acetone (50 ml) was added dropwise
TACN (200 mg, 1.55 mmol) in THF (20 ml). NaHCO3 (403 mg, 4.8 mmol) was added
portion-wise to keep the pH neutral. The mixture was stirred at room temperature for
18 hours then water (50 ml) was added, the solid collected by vacuum filtration, and
recrystallised from hot MeOH, yielding the title product as a white solid (883 mg, 1.54
mmol, 99 %) 1HNMR (400MHz, DMSO-d6, ppm) δH : 3.87 (s, 12 H, TACN-H). 13CNMR
(126MHz, CDCl3, ppm) δC: 169.0, 165.3, 48.7; IR (KBr, νmax, cm−1) 3211 (br, s), 3085 (br),
2922 (w), 2832 (w), 2780 (w), 2123 (w), 1717 (br, s), 1562 (s), 1483 (s), 1400 (s), 1365 (w),
1350 (w), 1330 (s), 1307 (s), 1234 (s), 1167 (s), 1071 (s), 1045 (s), 1022 (w), 977 (w), 965 (s),
907 (w), 849 (s), 75 (s), 762 (w), 742 (w)
7.7.4.2 1,4,7-tris(4-chloro-6-morpholino-1,3,5-triazin-2-yl)-1,4,7-triazonane (TM3Cl3)
N
N
NN
N N N N
N
N
N
N
N Cl
N
ClN
Cl
O
O
O
TACN (125mg, 0.97mmol), TzMorphCl2 (700mg, 2.98mmol), and K2CO3 (411mg, 2.98
mmol) in MeCN (50 ml) were stirred in an inert atmosphere under reflux for 18 hours.
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After cooling, the solvent was removed in vacuo. The solid was suspended in water (50
ml), extracted in CHCl3 (3 x 50 ml), the organic phases dried over MgSO4, filtered and
solvent removed in vacuo, yielding the title product as an off white solid (423 mg, 0.58
mmol, 60 %) 1H NMR (500 MHz, CDCl3, ppm) δH : 3.97 – 3.54 (m, 36 H), 13C NMR (125
MHz, CDCl3, ppm) δC: 171.5, 170.4, 169.4, 169.3, 169.2, 168.7, 165.7, 165.7, 165.6, 165.5,
164.3, 164.3, 66.6, 66.4, 66.4, 49.9, 49.7, 49.5, 49.4, 48.4, 48.2, 47.7, 44.5, 44.5, 44.4, 43.8; IR
(KBr, νmax, cm−1) 2964 (w), 2921 (w), 2855 (s), 1564 (s), 1495 (s), 1418 (s), 1362 (s), 1303
(w), 1254 (w), 1234 (s), 1176 (s), 1114 (s), 1069 (w), 1028 (w), 984 (s), 971 (s), 931 (w), 852
(w), 799 (s), 752 (w); MS (LR ES+) 724.22 (M + H+), 787.37 (M + MeCN + Na+), (HR
ES+) calc. for C27H37N15O3Cl3 (M + H+) 724.2269 found 724.2245
7.7.4.3 1,4,7-tris(4,6-dimorpholino-1,3,5-triazin-2-yl)-1,4,7-triazonane (TM6)
N
N
NN
N N N N
N
N
N
N
N N
N
NN
N
O
O
O
O
O
O
TACN (66 mg, 0.51 mmol), TzMorph2Cl (510 mg, 1.78 mmol), and K2CO3 (246 mg,
1.78 mmol) in MeCN (40 ml) were stirred under reflux for 18 hours. Acetone (30 ml)
was added, the solid was collected by filtration, washed with water, and dried under
vacuum yielding the title product as a white solid (427 mg, 0.49 mmol, 96 %) 1H NMR
(250 MHz, CDCl3, ppm) δH : 3.79 (s, 12 H, CH2N), 3.74 – 3.61 (m, 48 H, Morph-H),
13C NMR (125 MHz, CDCl3, ppm) δC: 166.06, 165.30, 67.06, 48.89, 43.72. ; IR (KBr, νmax,
cm−1) 2969 (w), 2923 (w), 2855 (s), 1541 (s), 1477 (s), 1447 (s), 1411 (w), 1362 (s), 1327 (w),
1302 (w), 1254 (s), 1215 (w), 1191 (w), 1113 (s), 1028 (w), 1008 (s), 957 (w), 860 (s), 808 (s);
MS (LR ES+) 628.38 (M - ), 877.50 (70 %, M + H+), (HR ES+) calc. for C39H61N18O6 (M
+ H+) 877.5021 found 877.5016
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7.7.4.4 1,4,7-tris(4-chloro-6-(tri-tert-butyl2,2’,2”-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetate)-1,3,5-triazin-2-yl)-1,4,7-triazonane (TD3Cl3)
N
N
NN
N N N N
N
N
N
N
Cl
Cl
Cl
N
N
N
N
N
N
N
N
N
N
N
NO
OtBu
O
OtBu
O
tBuO
O
OtBu
O
OtBu
O
tBuO
tBuO
O
OtBu
O
O
tBuO
TACN (15 mg, 0.12 mmol), TzDO3ACl2 (241 mg, 0.36 mmol), and K2CO3 (50 mg, 0.36
mmol) in MeCN (10 ml) were stirred in a pressure tube at 70°C for 48 hours. After
cooling, the solution was filtered, and the solvent removed in vacuo yielding the title
product as an off-white solid (100 mg, 0.05 mmol, 41 %) 1H NMR (500 MHz, CDCl3,
ppm) δH : 3.78 – 3.65 (br, m, 24 H, cyclen-H and TACN-H), 3.34 – 3.12 (br, m, 24 H,
cyclen-H), 3.01 – 2.87 (br, m, 12 H, cyclen-H), 2.83 – 2.57 (br, m, 18 H, CH2CO2), 1.38
(s, 81 H, CCH3). 13C NMR (125 MHz, CDCl3, ppm) δC: 170.96, 164.41, 122.92, 122.15,
110.09, 80.78, 65.86, 57.97, 55.19, 53.32, 52.08, 47.52, 46.94, 28.30, 28.27, 22.66, 15.31; IR
(KBr, νmax, cm−1) 3448 (br), 2978 (s), 2930 (s), 2849 (w), 1733 (s), 1675 (w), 1569 (s), 1543
(s), 1490 (s), 1418 (w), 1368 (s), 1297 (w), 1257 (w), 1221 (w), 1155 (s), 848 (w), 810 (w)
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7.7.4.5 1,4,7-tris(4-morpholino-6-(tri-tert-butyl2,2’,2”-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate)-1,3,5-triazin-2-yl)-1,4,7-triazonane (TD3M3)
N
N
NN
N N N N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
NO
OtBu
O
OtBu
O
tBuO
O
OtBu
O
OtBu
O
tBuO
tBuO
O
OtBu
O
O
tBuO
O
O
O
TM3Cl3 (200mg, 0.28 mmol), DO3A.HBr (542 mg, 0.91mmol), and K2CO3 (252 mg, 1.83
mmol) in MeCN (30 ml) were stirred in an inert atmosphere under reflux for 72 hours
after cooling the solvent was removed in vacuo. The resulting solid was taken up in
DCM (50 ml), washed with water (50 ml), and brine (50 ml), dried over MgSO4, filtered,
and the solvent was removed in vacuo yielding the title compound as a yellow solid (212
mg, 0.10 mmol, 36 %) 1H NMR (500 MHz, CDCl3, ppm) δH : 3.71 – 3.46 (br, m, 36 H),
3.33 – 3.16 (br, m, 24 H), 3.05 – 2.87 (br, m, 12 H), 2.80 – 2.61 (br, m, 30 H, CH2CO2 and
NCH2), 1.39-1.35 (m, 81 H, CCH3). 13C NMR (126 MHz, CDCl3, ppm) δC: 171.3, 165.3,
164.5, 80.9, 80.7, 67.2, 57.7, 54.9, 52.9, 52.1, 47.0, 43.9, 28.4; IR (KBr, νmax, cm−1) 3450 (br),
2976 (s), 2927 (s), 2852 (s), 1733 (s), 1683 (w), 1539 (s), 1489 (s), 1425 (w), 1392 (w), 1367
(s), 1301 (w), 1258 (s), 1216 (w), 1154 (s), 1118 (w), 1026 (w), 993 (w), 849 (s), 809 (s), 741
(w); MS (LR ES+) 2160.24 (20 %, M+), 1080.71 (100 %, M2+)
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7.7.5 RGD type ligands
7.7.5.1 Ethyl 2-((4,6-dichloro-1,3,5-triazin-2-yl)amino)acetate (Tz(EtGly)Cl2)
N
N
N
Cl
Cl N
H
CO2Et
1,3,5-triazine (9.11 g, 49.4 mmol) was dissolved in acetone and added to water (100 ml)
and the resulting slurry cooled to 0°C. Ethylglycine hydrochloride (6.80 g, 48.7 mmol) in
water (100ml) was added dropwise to the stirred slurry over 1 hour with the addition of
NaHCO3 (8.30 g, 98.8 mmol) periodically to keep the pH neutral. After complete addi-
tion of the amino acid, the solution was allowed to stir at room temperature for 1 hour,
then filtered, and the precipitate washed with water (2 x 25 ml). The solid was dried
under vacuum before being recrystallised from hot ethanol, yielding the title product as
a white solid (8.08 g, 32.2 mmol, 66 %) 1HNMR (500 MHz, CDCl3, ppm) δH : 4.23 – 4.14
(m, 4 H, NCH2 and CH2CH3), 1.23 (t, 3 H, 2JH−H = 7.1 Hz, CH2CH3); 13C NMR (126
MHz, CDCl3, ppm) δC: 171.0, 169.9, 168.7, 166.0, 62.0, 43.0, 14.1; IR (KBr, νmax, cm−1)
3478 (s), 3272 (br, s), 3178 (w), 3123 (w), 2998 (s), 2937 (w), 1749 (s), 1614 (s), 1548 (s),
1425 (w), 1397 (w), 1375 (w), 1327 (w), 1255 (s), 1213 (s), 1135 (s), 1034 (s), 1021 (s), 979
(s), 936 (s), 918 (s), 897 (w), 852 (s), 799 (s), 714 (br, s) ; MS (LR EI−) (100 %, M - H+)
248.99, (HR EI−) (M - H+) calc: 248.9946, found: 248.9939
7.7.5.2 tButyl (2-aminoethyl)carbamate (BocEDA)
N
H
NH2O
O
Under an atmosphere of Argon: Into a solution of ethylene diamine (32 ml, 470 mmol)
and triethylamine (2.8 ml, mmol) in ethanol (30 ml) was added dropwise di-tbutyl di-
carbonate (4.45 g, 20.4 mmol) in ethanol (20 ml) at 0°C. After complete addition the
solution was stirred at room temperature for a further hour, before being evaporated to
dryness. The resulting solid was dissolved in DCM (50 ml), extracted in acetic acid (1
M, 3 x 50 ml), then neutralised with NaOH (2 M) and extracted with DCM (3 x 50 ml).
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The organic layer was dried over MgSO4, filtered, and the solvent removed in vacuo
resulting in the title compound as a pale yellow oil (1.76 g, 11.0 mmol, 55 %) 1H NMR
(400 MHz, CDCl3, ppm) δH : 4.81 (s, 1 H, NH2CH2), 3.16 - 3.06 (m, 2 H, NHCH2), 2.77 –
2.70 (m, 2 H, NH2CH2), 1.38 (s, 9 H, CCH3)
7.7.5.3 tButyl (3-aminopropyl)carbamate (BocPDA)
N
H
NH2O
O
Under an atmosphere of Argon: Into a solution of diaminopropane (30 ml, 361 mmol)
and triethylamine (2.8 ml, mmol) in ethanol (30 ml) was added dropwise di-tbutyl di-
carbonate (4.45 g, 20.4 mmol) in ethanol (20 ml) at 0°C. After complete addition the
solution was stirred at room temperature for a further hour, before being evaporated to
dryness. The resulting solid was dissolved in DCM (50 ml), extracted in acetic acid (1
M, 3 x 50 ml), then neutralised with NaOH (2 M) and extracted with DCM (3 x 50 ml).
The organic layer was dried over MgSO4, filtered, and the solvent removed in vacuo re-
sulting in the title compound as a pale yellow oil (1.74 g, 10.0 mmol, 49 %) 1HNMR (400
MHz, CDCl3, ppm) δH : 4.89 (s, 2 H, NH2), 3.21 (q, 2 H, 2JH−H = 6.3 Hz, CH2NHCO2),
2.76 (t, 2 H, 2JH−H = 6.6 Hz, CH2NH2), 1.61 (p, 2 H, 2JH−H = 6.6 Hz, CH2CH2CH2), 1.44
(s, 9 H, CCH3)
7.7.5.4 1-(2-Aminoethyl)-2,3-di-Boc-guanidine (BocGuanEDA)
BocHN
NBoc
N
H
NH2
Under an inert atmosphere ethylene diamine (0.03 ml, 0.45 mmol) and triethylamine
(0.017 ml, 0.12 mmol) were dissolved in dry DCM (5 ml). To this was added dropwise
a solution of Boc2GuanTf (47 mg, 0.12 mmol) in dry DCM (5 ml). The mixture was
stirred at room temperature for 12 hours. The solvents were removed in vacuo, and the
resulting solid purified by flash column chromatography (EtOAc, MeOH, Et3N, 5 : 3 :
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2) yielding the title product as a tan oil (19 mg, 0.06 mmol, 50 %) 1H NMR (250 Mhz,
CDCl3, ppm) δH : 3.56 (m, 2 H, CH2NH), 2.96 (m, 2 H, CH2NH2), 1.43 (s, 18 H, CH3); MS
(HR ES+) calc. for C13H27N4O4 (M + H+) 303.2032 found 303.2039
7.7.5.5 Ethyl 2-((4-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-6-chloro-1,3,5-triazin-
2-yl)amino)acetate (Tz(EtGly)(BocEDA)Cl)
N
N
N
N
H
N
H
Cl
CO2Et
BocHN
TzEtGlyCl2 (762 mg, 3.04 mmol) was dissolved in acetone (50 ml) and added to wa-
ter (50 ml), the resulting slurry was cooled to 0°C. BocEDA (2) (485 mg, 3.03 mmol) in
acetone (20 ml) was added to the stirred slurry dropwise over 1 hour with addition of
NaHCO3 (255 mg, 3.03 mmol) at a rate so as to keep a neutral pH. After complete addi-
tion the mixture was allowed to warm to room temperature, and stirred for 3 hours. The
precipitate was then filtered, washed with water, and recrystallised from hot ethanol,
yielding the title product as a white solid (667 mg, 1.78 mmol, 59 %) 1H NMR (500
MHz, CDCl3, ppm) δH : 4.26 – 4.07 (m, 4 H, CH2CO2 and CH2CH3), 3.46 - 3.41 (m, 2 H,
NHCH2), 3.28 – 3.21 (m, 2 H, NH2CH2), 1.35 (s, 9 H, CCH3), 1.21 (t, 3 H, CH2CH3); 13C
NMR (126 MHz, CDCl3, ppm) δC: 169.8, 168.2, 165.9, 165.7, 156.3, 61.6, 43.1, 41.3, 40.2,
28.5, 14.3; IR (KBr, νmax, cm−1) 3354 (s), 3256 (s), 3105 (s), 2978 (s), 1749 (s), 1720 (w),
1689 (s), 1642 (s), 1558 (br, s), 1415 (w), 1274 (w), 1248 (w), 1202 (s), 1175 (w), 1122 (s),
1029 (w), 990 (s), 873 (s), 800 (s), 726 (w); MS (LR EI+) 257.05 (100 %, M – HNHCO2tBu),
301.08 (90 %, M+ - tBuO), 374.15 (10 %, M+); (HR EI+) calc. for C14H23N6O4Cl (M+)
374.1469 found 374.1458
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7.7.5.6 Ethyl 2-((4-((3-((tert-butoxycarbonyl)amino)propyl)amino)-6-chloro-1,3,5-triazin-
2-yl)amino)acetate (Tz(EtGly)(BocPDA)Cl)
N
N
N
N
H
N
H
Cl
CO2EtBocHN
TzEtGlyCl2 (575 mg, 2.29 mmol) was dissolved in acetone (50 ml) and added to wa-
ter (50 ml), the resulting slurry was cooled to 0°C. BocPDA (3) (394 mg, 2.29 mmol) in
acetone (20 ml) was added to the stirred slurry dropwise over 1 hour with addition of
NaHCO3 (193 mg, 2.29 mmol) at a rate so as to keep a neutral pH. After complete addi-
tion the mixture was allowed to warm to room temperature, and stirred for 3 hours. The
precipitate was then filtered, washed with water, and recrystallised from hot ethanol,
yielding the title product as a white solid (513 mg, 1.32 mmol, 58 %) 1H NMR (400
MHz, CDCl3, ppm) δH : 4.30 – 4.14 (m, 4 H, CH2CH3 and CH2CO2), 3.47 - 3.43 (m, 2 H,
NHBocCH2), 3.19 - 3.15 (m, 2 H, CH2NH), 1.70 (q, 2 H, 2JH−H = 6.2 Hz, CH2CH2CH2),
1.43 (s, 9 H, CCH3), 1.28 (t, 3 H, 2JH−H = 7.1 Hz, CH2CH3); 13C NMR (126 MHz, CDCl3,
ppm) δC: 169.8, 165.9, 165.8, 156.4, 79.6, 61.7, 43.2, 42.9, 38.1, 37.6, 30.4, 28.5, 14.3; IR (KBr,
νmax, cm−1) 3359 (s), 3257 (s), 3110 (s), 2978(s), 2871(w), 1748 (s), 1717 (w), 1688 (s), 1641
(s), 1558 (s), 1415 (w), 1365 (w), 1278 (w), 1247 (s), 1203 (w), 1175 (w), 1118 (s), 1029 (w),
995 (w), 887 (w), 865 (w), 800 (s), 740 (br); MS (LR EI+) 258.08 (M+ – tBuCO2 - Et), 270.08
(M+ – tBuO - EtO), 331.10 (M+ - tBu), 388.16 (M+), (HR EI+) calc. for C15H25N6O4Cl
(M+) 388.1626 found 388.1637
7.7.5.7 Ethyl 2-((4-azido-6-((3-((tert-butoxycarbonyl)amino)propyl)amino)-1,3,5-triazin-
2-yl)amino)acetate (TzEtGlyBocPDAN3)
N
N
N
N
H
N
H
N3
CO2EtBocHN
TzEtGlyBocPDACl (94 mg, 0.24 mmol) was dissolved in CH3CN (2 ml), and NaN3 (32
mg, 0.49 mmol) added. The solution was heated to 60ºC with stirring for 3 hours, after
which a solid precipitate appeared. The solvents were removed in vacuo and water (10
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ml) added. The product was extracted with CHCl3 (2 x 10 ml), washed with brine (10
ml), and dried over MgSO4. The solution was filtered and the solvents removed in
vacuo yielding the title compound as a white solid (84 mg, 0.23 mmol, 94 %) IR (KBr,
νmax, cm−1) 3356 (s), 3259 (s), 3111 (s), 2978 (s), 2937 (w), 2871 (w), 2137 (s), 1747 (s), 1690
(s), 1641 (s), 1558 (br, s), 1414 (w), 1365 (w), 1275 (s), 1201 (s), 1172 (s), 1118 (w), 1027 (s),
996 (s), 866 (s), 800 (s), 757 (w); MS (HR ES+) calc. for C15H26N9O4 (M + H+) 396.2108
found 396.2098
7.7.5.8 Ethyl 2-((4-((2-(2,3-bis(tert-butoxycarbonyl)guanidino)ethyl)amino)-6-chloro-
1,3,5-triazin-2-yl)amino)acetate (TzEtGlyBocGuanCl)
N
N
N
Cl
N
H
N
H
CO2Et
H
NBocHN
NBoc
TzEtGlyCl2 (32 mg, 0.13 mmol) was dissolved in acetone (5 ml) and added to water
(10 ml), the resulting slurry was cooled to 0°C. BocGuanEDA (40 mg, 0.13 mmol) in
acetone (5 ml) was added to the stirred slurry dropwise over 30 minutes with addition
of NaHCO3 (12 mg, 0.13 mmol) at a rate so as to keep a neutral pH. After complete
addition the mixture was allowed to warm to room temperature, and stirred for 3 hours.
The solvents were removed in vacuo and the solid washed with water (5 ml). The title
product was isolated as a white solid (15 mg, 0.03 mmol, 23 %) MS (HR ES+) calc. for
C20H34N8O6Cl (M + H+) 517.2290 found 517.2286
7.7.5.9 2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethanol (AlkyGly)
HO O O O
NaH (60 %, 1.03 g, 25.75 mmol) was dissolved in degassed THF (40 ml) under an inert
atmosphere, cooled to 0ºC, and triethylene glycol (6.9 ml, 51.5 mmol) added dropwise.
Propargyl bromide (80 % w/toluene, 2.87 ml, 32.2 mmol) was added slowly so as the
temperature didnt increase. After 2 hours at the reduced temperature the solution was
CHAPTER 7. EXPERIMENTAL 161
allowed towarm to room temperature and stirred for 20 hours. The solutionwas poured
onto water (100 ml) and the product extracted with DCM (3 x 50 ml). The organic phase
was dried over MgSO4, filtered, and the solvents removed in vacuo resulting in a dark
yellow oil. The product was purified by flash chromatography (EtOAc, Hexane, 3 : 2),
yielding the title product as a yellow oil (4.3 g, 22.9 mmol, 89 %) 1H NMR (400 MHz,
CDCl3, ppm) δH : 4.15 (s, 2 H, OCH2C), 3.68 - 3.54 (m, 13 H, CH2 and CH); MS (HR ES
+) calc. for C9H16O423Na (M + Na+) 211.0946 found 211.0945
7.7.5.10 Tri-tert-butyl 2,2’,2”-(10-(4-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-6-((2-
ethoxy-2-oxoethyl)amino)-1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate (Tz(EtGly)(BocEDA)(DO3A))
N
N
N
N
H
N
H
CO2Et
BocHN
N
N
N
N
O
tBuO
O
tBuO
O
OtBu
To a solution of Tz(EtGly)(BocEDA)Cl (55 mg, 0.15 mmol) in MeCN (50 ml) was added
NaHCO3 (50 mg, 60 mmol) and DO3A.HBr (112 mg, 0.19 mmol). The solution was re-
fluxed for 72 hours, and the solvent removed in vacuo. The resulting solid was dissolved
in DCM (50 ml) and washed with water (50 ml), brine (50 ml), dried over MgSO4 , and
the solvent removed in vacuo, yielding the title product as a white solid (104 mg, 0.12
mmol, 82 %) 1H NMR (500 MHz, CDCl3, ppm) δH : 4.19 – 4.06 (m, 2 H, CH2CH3), 4.02
(br, m, 2 H, NHCH2CO2Et), 3.73 – 3.57 (br, m, 2 H, NCH2CO2), 3.46 – 3.34 (br, m, 2 H,
NCH2CO2), 3.33 – 3.30 (br, m, 2 H, NHCH2CH2), 3.27 – 3.22 (br, m, 4 H, NHCH2CH2
and NCH2CO2), 3.06 – 2.90 (br, m, 4 H, Ring-H), 2.89 – 2.62 (br, m, 12 H, Ring-H), 1.41
– 1.32 (m, 36 H, CCH3), 1.20 (t, 3 H, 2JH−H = 7.1 Hz, CH2CH3); 13C NMR (126 MHz,
CDCl3, ppm) δC: 171.2, 171.1, 171.0, 170.6, 169.8, 165.6, 165.0, 156.3, 81.7, 80.7, 61.4, 61.0,
58.2, 57.7, 55.1, 55.0, 53.3, 52.8, 52.0, 51.4, 49.4, 49.1, 47.5, 46.9, 42.9, 40.7, 28.4, 28.4, 28.2,
28.2, 14.2; IR (KBr, νmax, cm−1) 3404 (br), 2978 (s), 2932 (s), 2870 (s), 2732 (w), 1732 (s),
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1558 (s), 1511 (s), 1456 (w), 1426 (w), 1393 (w), 1368 (s), 1259 (s), 1028 (w), 937 (w), 917
(w), 849 (s), 812 (s), 728 (s) ; MS (LR ES+) 515.37 (100 %, M – Tz(EtGly)(BocEDA) + H+),
537.37 (40 %, M - Tz(EtGly)(BocEDA) + Na+), 853.55 (35 %, M + H+), (HR ES+) calc. for
C40H72N10O10 (M + H+) 853.5511 found 853.5530
7.7.5.11 2,2’,2”-(10-(4-((2-Aminoethyl)amino)-6-((2-ethoxy-2-oxoethyl)amino)-1,3,5-triazin-
2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triaceticacid (Tz(EtGly)(EDA)(DO3a))
N
N
N
N
H
N
H
CO2Et
H2N
N
N
N
N
O
HO
O
HO
O
OH
To a solution of Tz(EtGly)(BocEDA)(DO3A) (80 mg, 0.09 mmol) in DCM (3 ml) was
added TFA (3 ml), and stirred for 48 hours at room temperature. The solvents were re-
moved in vacuo and the resulting oil redissolved in methanol. The solvent was removed
in vacuo and the sequence repeated twice more. This yielded the title product as a white
solid (54 mg, 0.09 mmol, 98 %) 1HNMR (400 MHz, MeOD, ppm) δH : 4.26 – 3.84 (br, m),
3.80 – 3.28 (br, m), 3.14 - 2.84 (br, m), 2.83 – 2.62 (br, m) [total integration = 34 H], 1.19 (br,
apparent t, 3 H, 2JH−H = 6.2 Hz, CH2CH3); 13CNMR (126 MHz, MeOD, ppm) δC: 175.1,
169.6, 163.4, 163.1, 162.9, 162.6, 122.1, 119.4, 116.9, 62.9, 56.5, 54.3, 53.9, 53.1, 50.7, 43.6,
39.6, 14.5; IR (KBr, νmax, cm−1) 3406 (br), 3105 (br), 2965 (br), 1738 (w), 1676 (s), 1530 (w),
1430 (br), 1202 (s), 1132 (s), 1025 (w), 834 (s), 799 (s), 722 (s) ; MS (LR ES+) 347.19 (100
%, M – Tz(EtGly)(EDA) + H+), 369.18 (25 %, M - Tz(EtGly)(EDA) + Na+), 585.31 (30 %,
M + H+), 607.29 (15 %, M + Na+), (HR ES+) calc. for C23H40N10O8 (M + H+) 585.3109
found 585.3108
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7.7.6 RGD type complexes
7.7.6.1 Nickel(II) 2,2’,2”-(10-(4-((2-aminoethyl)amino)-6-((2-ethoxy-2-oxoethyl)amino)-
1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate(NiTzEtG-
lyEDADO3a)
N
N
N
N
H
N
H
CO2Et
H2N
N
N
N
N
O
O
O
HO
O
O
Ni
TzEtGlyEDADO3a (20 mg, 0.03 mmol) and Ni(OAc)2.6H2O (10 mg, 0.03 mmol) were
heated in MeOH (10 ml) for 10 minutes. MS (HR ES+) calc. for C23H39N10O858Ni (M +
H+) 641.2306 found 641.2294
7.7.6.2 Copper(II) 2,2’,2”-(10-(4-((2-aminoethyl)amino)-6-((2-ethoxy-2-oxoethyl)amino)-
1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate(CuTzEtG-
lyEDADO3a)
N
N
N
N
H
N
H
CO2Et
H2N
N
N
N
N
O
O
O
HO
O
O
Cu
TzEtGlyEDADO3a (26 mg, 0.04 mmol) and Cu(OAc)2.6H2O (12 mg, 0.03 mmol) were
heated in MeOH (5 ml) for 10 minutes. MS (HR ES+) calc. for C23H39N10O863Cu (M +
H+) 646.2248 found 646.2266
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7.8 Acetate and Alcohol Functionalised TACNs and Ho-
mopiperazines
7.8.1 Functionalised TACNs
7.8.1.1 1-tosyl-1,4,7-triazonane (TsTACN)
NH
N
HN
SO O
Using the method of Sessler [89] Ts3TACN (4.87g, mmol), phenol (5.6 g, mmol), and
HBr.AcOH (45% w/w) (60 ml) were heated under an inert atmosphere to reflux for
18 hours, with the gas evolved bubbled through a NaOH bubbler. The solution was
filtered, and washed with Et2O, leaving a colourless solid. The solid was dissolved
in NaOH (1 M), and the product extracted in CHCl3 (3 x 70 ml). The organic fractions
were combined andwashed with brine, dried over MgSO4, and the solvents removed in
vacuo, yielding the title product as a white solid. 1H data correlated with that of Sessler
7.8.1.2 Di-tert-butyl 2,2’-(7-tosyl-1,4,7-triazonane-1,4-diyl)diacetate (TsTACNtBu2)
N
N
N
SO O
O
OtBu
O
OtBu
TsTACN (1.37 g, 4.84 mmol), tbuytl bromoacetate (1.43 ml, 9.68 mmol), and potassium
carbonate (1.34 g, 9.71 mmol) were dissolved in acetonitrile (50 ml) and stirred in a
stoppered flask for 18 hours. Filtration, followed by removal of solvents in vacuo gave
an off white oil. Tritration of the oil with diethyl ether followed by filtration yielded the
title product as a white solid (2.31 g, 4.52mmol, 93 %) 1HNMR (250MHz, CDCl3, ppm)
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δH : 7.66 (d, 2 H, Ar-H, 2JH−H = 8 Hz), 7.29 (d, 2 H, Ar-H, 2JH−H = 8 Hz), 3.39 – 3.18 (m,
8 H; 4 H, CH2CO2, 4 H, Mac-H), 3.11 (s, 4 H, Mac-H), 2.80 (s, 4 H, Mac-H), 2.41 (s, 3 H,
Ar-CH3), 1.44 (s, 18 H, CH3); MS (LR ES+) 512.28 (M + H+, 100 %), 534.26 (M + Na+, 50
%), (HR ES+) calc. for C25H42N3O6S (M + H+) 512.2794 found 512.2808
7.8.1.3 2,2’-(7-tosyl-1,4,7-triazonane-1,4-diyl)diacetic acid (TsTACNA2)
N
N
N
SO O
O
OH
O
OH
TsTACNtBu2 (725 mg, 1.42 mmol) was dissolved in DCM (20 ml). To this TFA (5 ml)
was added, and the mixture stirred for 48 hours in a stoppered flask. The solvents were
removed in vacuo, and thenMeOH (10ml) added and stirred for 5 minutes. The solvents
were removed in vacuo and the MeOH step repeated 5 times yielding the title product
as a colourless solid (558 mg, 1.40 mmol, 99 %) 1H NMR (400 MHz, MeOD, ppm) δH :
7.77 (d, 2 H, Ar-H, 2JH−H = 8.3 Hz), 7.44 (d, 2 H, Ar-H, 2JH−H = 8.0 Hz), 3.95 (s, 4 H,
CH2CO2), 3.45 – 3.28 (m, 12 H, obscured by MeOH signal), 2.45 (s, 3 H, CH3); MS (LR
ES+) 400.1532 (M + H+, 100 %), (HR ES+) calc. for C17H26N3O6S (M + H+) 400.1542
found 400.1532
7.8.1.4 (2R,2’R)-1,1’-(7-tosyl-1,4,7-triazonane-1,4-diyl)bis(propan-2-ol) (TsTACNE2)
N
N
N
SO O
OHOH
TsTACN (1.16 g, 4.10 mmol) and (R-)-propylene oxide (0.6 ml, 8.59 mmol) in EtOH (25
ml) were stirred in a stoppered flask for 48 hours. The solvents were removed in vacuo,
CHAPTER 7. EXPERIMENTAL 166
yielding the title product as a colourless oil that solidified overnight (1.57 g, 3.93 mmol,
96 %) 1H NMR (500 MHz, CDCl3, ppm) δH : 7.66 – 7.55 (m, 2 H, Ar-H), 7.27 - 7.25 (m, 2
H, Ar-H, obscured by CHCl3), 3.83 – 3.69 (m, 2 H, CHOH), 3.30 – 3.08 (m, 4 H, Mac-H),
2.99 – 2.80 (m, 6 H, Mac-H), 2.72 – 2.63 (m, 2 H, Mac-H), 2.55 (m, 2 H, CH2CH), 2.37
(s, 3 H, CH3), 2.29 – 2.18 (m, 2 H, CH2CH), 1.03 (d, 6 H, CH3CH, 2JH−H = 6.2 Hz).; 13C
NMR (126 MHz, CDCl3, ppm) 143.5, 135.6, 129.6, 127.2, 67.0, 64.2, 57.8, 55.7, 54.6, 21.5,
20.0; MS (LR ES+) 400.23 (M + H+, 100 %), (HR ES+) calc. for C19H34N3O4S (M + H+)
400.2270 found 400.2280
7.8.1.5 1-(4-nitrophenyl)-1,4,7-triazonane (NPhTACN)
NH
N
HN
NO2
TACN (482mg, 3.74mmol) and 4-fluoronitrobenzene (0.39ml, 3.67mmol) in acetonitrile
(150 ml) were stirred at room temperature. The solvent was reduced to half its volume,
and the solid precipitate collected by vacuumfiltration. Recrystallisation fromhot EtOH
yielded the title product as an orange solid (874 mg, 3.50 mmol, 95 %)
7.8.1.6 Di-tert-butyl 2,2’-(7-(4-nitrophenyl)-1,4,7-triazonane-1,4-diyl)diacetate (NPhTACNtBu2)
N
N
N
NO2
O
OtBu
O
OtBu
NPhTACN (360 mg, 1.44 mmol), tbutyl bromoacetate (0.45 ml, 3.05 mmol), and potas-
sium carbonate (420 mg, 3.04 mmol) were dissolved in acetonitrile/THF (2:1, 100 ml),
and heated with stirring to reflux under and inert atmophere for 18 hours. Filtration,
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followed by washing of the solid with methanol, gave an orange solution. Removal
of the solvents in vacuo followed by recrystallisation from hot MeOH yielded the title
product as a bright yellow solid (609 mg, 1.27 mmol, 88 %) 1H NMR (250 MHz, CDCl3,
ppm) δH : 8.02 (d, 2 H, Ar-H, JH−H = 9.5 Hz), 6.57 (d, 2 H, Ar-H, JH−H = 9.5 Hz), 3.73 –
3.48 (m, 4 H, Mac-H), 3.32 - 3.25 (m, 4 H, Mac-H), 3.18 – 2.95 (m, 4 H, Mac-H), 2.55 (s, 4
H, CH2CO2), 1.39 (s, 18 H, CH3); MS (LR ES+) 479.29 (M + H+, 100 %), (HR ES+) calc.
for C24H39N4O6 (M + H+) 479.2870 found 479.2879
7.8.1.7 2,2’-(7-(4-nitrophenyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NPhTACNA2)
N
N
N
NO2
O
OH
O
OH
NPhTACNtBu2 (150 mg, 0.314 mmol) was dissolved in DCM (10 ml). TFA (1 ml) was
added, and the solution stirred for 48 hours. The solvents were removed in vacuo, and
MeOH (10 ml) added and the solution stirred for 5 minutes. The MeOH was removed
in vacuo and the process repeated 5 times, yielding the title product as a yellow solid
(113 mg, 310 mmol, 99 %) 1H NMR (400 MHz, MeOD, ppm) δH : 8.05 (d, 2 H, Ar-H, J =
9.3 Hz), 6.76 (d, 2 H, Ar-H, J = 9.4 Hz), 3.89 (br s, 6 H, Mac-H), 3.53 (br s, 2 H, Mac-H),
3.44 – 3.28 (br m, 4 H, CH2CO2), 3.04 (br m, 4 H, Mac-H); MS (LR ES+) 367.16 (M + H+,
100 %), (HR ES+) calc. for C16H23N4O6 367.1618 found 367.1616
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7.8.2 TACN Complexes
7.8.2.1 Copper(II) 2,2’-(7-tosyl-1,4,7-triazonane-1,4-diyl)diaceticacid (CuTsTACNA2)
N
N
N
SO O
O
O
O
O Cu
TsTACNA2 (52 mg, 0.13 mmol) was dissolved in MeOH (10 ml) and Cu(OAc)2.H2O
(26 mg, 0.13 mmol) added. Gentle heat was applied for 5 minutes, and the solvents
removed in vacuo, yielding the title product as a deep blue solid (46 mg, 0.10 mmol,
78 %) Crystals suitable for x-ray diffraction were grown from slow vapour diffusion of
diethyl ether into acetonitrile. UV (MeOH, nm) 645 (ε = 89 mol−1cm−1); MS (HR ES+)
calc. for C17H23N3O623Na S 64Cu (M+Na+) 483.0501 found 483.0500
7.8.2.2 Aluminium(III) 2,2’-(7-tosyl-1,4,7-triazonane-1,4-diyl)diaceticacid fluoride (AlTsTACNA2F)
N
N
N
SO O
O
O
O
O Al
F
TsTACNA2 (15 mg, 0.038 mmol) was dissolved in sodium acetate buffer (1 M, pH 3.5)
and AlCl3.6H2O (10 mg, 0.041 mmol) added. After gentle heating for 10 minutes, KF (4
mg, 0.069 mmol) was added. The products were not isolated, but the solution was used
for mass spectrometry. MS (HR ES+) calc. for C17H24N3O6S 27Al F (M + H+) 444.1185
found 444.1186
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7.8.2.3 CuTsTACNE2
N
N
N
SO O
OO Cu
TsTACNE2 (220mg, 0.55mmol) and Cu(OAc)2.H2O (110mg, 0.55mmol) were dissolved
in EtOH (10 ml). Gentle heat for 5 minutes, followed by removal of the solvents in vacuo
yielded the title product as a deep blue solid ( 240 mg, 0.52 mmol, 95 %) Crystal suitable
for x-ray diffraction were grown by slow evaporation of an ethanol/water solution. UV
(MeOH, nm) 682 (ε = 57); MS (LR ES+) 461.14 (M + H+, 100 %), 400.23 (M - 63Cu + 3H+,
50 %), (HR ES+) calc. for C19H32N3O4S 63Cu (M + H+) 461.1410 found 461.1410
7.8.2.4 CuNPhTACNA2
N
N
N
NO2
O
O
O
O Cu
NPhTACNA2 (50mg, 0.14mmol) was dissolved inmethanol (10ml) and Cu(OAc)2.H2O
(28 mg, 0.14 mmol) added. Gentle heat was applied for 5 minutes, and the solvents
removed in vacuo, yielding the title product as a deep blue solid (56 mg, 0.13 mmol,
93 %) Crystals suitable for x-ray diffraction were grown from slow vapour diffusion of
diethyl ether into acetonitrile. UV (MeOH, nm) 603 (ε = 82); MS (HR ES+) calc. for
C16H21N4O6 63Cu (M + H+) 428.0757 found 428.0763
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7.9 Other Work
7.9.1 Glutamate Chemistry
7.9.1.1 (S)-Bromoglutamic acid
HO
O
OH
O
Br
Monosodium glutamate (MSG) (18.9 g, 11.2 mmol) was dissolved in HBr (9 M, 100 ml)
and cooled to 0°C. NaNO2 (14.0 g, 20.3 mmol) was dissolved in the minimum amount
of cold water, and added dropwise to the solution over a period of 3 hours. Upon
complete addition, the solution was stirred for a further 15 minutes, before H2SO4 (6
ml) was added. The solution was stirred for 15 minutes and then allowed to warm
slowly to room temperature. The product was extracted in diethyl ether (3 x 100 ml),
washed with brine (100 ml) and sodium sulfite (100 ml), dried over MgSO4, filtered and
the solvents removed in vacuo, yielding the title product as a yellow oil (21.6 g, 10.3
mmol, 92 %) 1HNMR (400 Mhz, CDCl3, ppm) δH : 4.35 - 4.33 (t, 1 H, CH, 2JH−H = 7 Hz),
2.66 - 2.48 (m, 2 H, CH2CO2), 2.43 - 2.26 (m, 2 H, CH2CH)
7.9.1.2 Ethyl (S)-bromoglutarate
EtO
O
OEt
O
Br
(S)-Bromoglutamic acid (7.4 g, 3.51mmol) and ethanol (50ml) were refluxed in the pres-
ence of H2SO4 (3 drops) for 3 hours. Diethyl ether (100 ml) was added, and the solution
was neutralised with NaHCO3 (aq). The organic layer was seperated and washed with
brine (100 ml) before being dried over MgSO4. Filtration followed by removal of the
solvents in vacuo yielded the title product as a colourless oil (8.33 g, 3.12 mmol, 89 %)
1H NMR (400 Mhz, CDCl3) δH : 4.29 (dd, 1 H, CH, 2JH−H = 5.8 + 8.5 Hz), 4.23 – 4.12 (m,
2 H, CH2CH3), 4.13 – 4.03 (m, 2 H, CH2CH3), 2.51 – 2.38 (m, 2 H, CH2CH2), 2.37 – 2.14
(m, 2 H, CH2CH2), 1.29 – 1.20 (m, 6 H, CH3CH2)
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7.9.1.3 (2S,2’S)-2,2’-(1,4-diazepane-1,4-diyl)dipentanedioic acid (HPGlut)
N N(S) (S)
HO2C
HO2C
CO2H
CO2H
Homopiperazine (96 mg, 0.96 mmol), potassium carbonate (300 mg, 2.17 mmol), and
ethyl (S)-bromoglutamate (590 mg, 2.21 mmol) were refluxed in acetonitrile (100 ml)
for 18 hours. MeOH (20 ml) was added, and the solution filtered. The solvents were
removed in vacuo resulting in a yellow oil. To this oil was added HCl (2 M, 20 ml),
and the solution refluxed for 6 hours. The solvents were removed in vacuo yielding the
dihydrochloride salt of the title compound as a white solid (274 mg, 0.76 mmol, 79 %)
MS (LR ES+ - intermediate step) 474.14 (M + H+); 1H NMR (400 Mhz, D2O, ppm) δH :
4.23 (br s, 2 H, CH), 3.60 (br m, 8 H, CH2N), 2.59 (br m, 4 H, CH2CO2), 2.18 (br m, 4 H,
CH2CH), 1.25 (br s, 2 H, CH2CH2CH2); IR (KBr, νmax, cm−1) 2963 (s), 2923 (s), 2853 (s),
1733 (s), 1628 (s), 1455 (w), 1416 (w), 1262 (s), 803 (w); MS (LR ES−) 359.19 (M - H+, 100
%)
7.9.1.4 Copper (2S,2’S)-2,2’-(1,4-diazepane-1,4-diyl)dipentanedioic acid (CuHPGlut)
N N
HO2C CO2H
OO O O
Cu
HPGlut (237 mg, 0.55 mmol), was dissolved in water, and NaOH (44 mg, 1.1 mmol)
added. To this was added BaCl2 (134 mg, 0.55 mmol) and gently heated for 5 minutes.
Cu(SO4)2.5H2O (171 mg, 0.55 mmol) was added to the solution and gently heated for
10 minutes. The solution was filtered, the residue washed with MeOH (5 ml), and the
solvent removed in vacuo. The blue solid was dissolved in the minimum volume of hot
MeOH, filtered, and the solvents removed in vacuo yielding the title product as a blue
solid (93 mg, 0.22 mmol, 40 %); UV (H2O, nm) 680 (ε = 4) IR (KBr, νmax, cm−1) 3429 (br,
s), 2960 (s), 2925 (s), 2853 (s), 1627 (s), 1581 (s), 1463 (s), 1408 (s), 1261 (s), 1106 (w), 1032
(s), 803 (s); MS (HR ES−) calc. for C15H21N2O863Cu (M- H+) 420.0594 found 420.0600
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7.9.1.5 Hexaethyl 2,2’,2”-(1,4,7-triazonane-1,4,7-triyl)tripentanedioate (TACNEtGlut)
N
N
N
CO2Et
O
OEt
OEtO
CO2Et
OEt
O
EtO2C
TACN (129 mg, 1.00 mmol) and potassium carbonate (455 mg, 3.30 mmol) were dis-
solved in acetonitrile (50 ml). To this was added ethyl bromoglutamate (881 mg, 3.3
mmol). The solution was refluxed for 4 hours, and then MeOH (10 ml) added. The
solution was filtered, and the solvent removed in vacuo resulting in a yellow oil. The oil
was dissolved in the minimum hot MeOH and diethyl ether added until precipitation
occurred. The precipitate was placed in a fridge for 3 hours, and isolated by filtration,
yielding the title compound as a white solid (519 mg, 0.755 mmol, 76 %) 1H NMR (400
MHz, CDCl3) δH : 4.26 – 4.01 (m, 12 H, CH2CH3), 3.30 – 3.15 (m, 3 H, CH), 2.99 – 2.53
(m, 12 H, Mac-H), 2.53 – 2.37 (m, 6 H, CH2CO2), 2.10 – 1.95 (m, 3 H, CH2CH), 1.93 – 1.79
(m, 3 H, CH2CH), 1.24 (t, 18 H, CH3, JH−H = 5.0 Hz); 13C NMR (126 MHz, CDCl3) δC:
173.1, 66.3, 60.4, 54.5, 31.2, 25.4, 14.6; MS (LR ES+) 716.70 (M + H+, 100 %)
7.9.1.6 2,2’,2”-(1,4,7-triazonane-1,4,7-triyl)tripentanedioic acid (TACNGlut)
N
N
N
CO2H
O
OH
OHO
CO2H
OH
O
HO2C
TACNEtGlut (234 mg, 0.34 mmol) was dissolved in HCl (2M, 20 ml) and refluxed for 4
hours. The solvents were removed in vacuo, and the resulting solid washed with MeOH
(5 ml), yielding the title product as a white solid (129 mg, 0.24 mmol, 72 %) 1H NMR
(400 MHz, D2O, ppm) δH : 3.65 (d, 3 H, CH, 2JH−H = 12 Hz), 3.28 - 3.27 (m, 6 H, Mac-H),
2.61 – 2.58 (m, 6 H, Mac-H), 2.48 – 2.40 (m, 6 H, CH2CO2), 2.15 – 1.90 (m, 6 H, CH2CH)
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7.9.1.7 2,2’-(4,11-dimethyl-1,4,8,11-tetraazacyclotetradecane-1,8-diyl)dipentanedioicacid
(DMCGlut)
N
N
N
N
HO2C
CO2H
O OH
OHO
To a solution of dimethylcyclam (657 mg, 2.88 mmol) in acetonitrile (50 ml), was added
ethyl bromoglutamate (1.69 g, 6.33mmol) and potassium carbonate (875mg, 6.34mmol)
and refluxed under an inert atmosphere for 18 hours. The solution was filtered and the
solvent removed in vacuo yielding the ethyl ester. HCl (6 M, 50 ml) was added, and
refluxed for 18 hours, the solvents were removed in vacuo. The solid was dissolved
in methanol and diethyl ether added until a precipitate formed and was then put in a
fridge for 5 hours. The solid was filtered and dried under vacuum yielding the title
product as a white solid (967 mg, 1.53 mmol, 53 %) 1H NMR (250 MHz, D2O, ppm) δH :
3.68 – 3.16 (m, 18 H), 3.05 – 2.76 (m, 10 H), 2.74 – 2.58 (m, 2 H), 2.59 – 2.37 (m, 2 H), 2.21
– 1.98 (m, 4 H, CH2CH), 1.98 – 1.75 (m, 4 H, CH2CH2CH2)
7.9.1.8 Nickel 2,2’-(4,11-dimethyl-1,4,8,11-tetraazacyclotetradecane-1,8-diyl)dipentanedioic
acid (NiDMCGlut)
N
N
N
N
HO2C
CO2H
O O
OO
Ni
DMCGlut (50 mg, 0.08 mmol) was dissolved in water, and NaOH (2M) added until
neutral. Ni(OAc)2.4H2O (20 mg, 0.08 mmol) was added and the solution gentle heated
for 5 minutes. The solvents were removed in vacuo yielding the title product as a grey
solid (31 mg, 0.057 mmol, 71 %) MS (LR ES−) 449.16 (M - pendant arm+ + 2 H2O, 60 %),
485.14 (M - CH2CO−2 - H
+, 80 %), 487.13 (M - 2 CO2H +MeOH - H+)
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7.9.1.9 Copper 2,2’-(4,11-dimethyl-1,4,8,11-tetraazacyclotetradecane-1,8-diyl)dipentanedioic
acid (CuDMCGlut)
N
N
N
N
HO2C
CO2H
O O
OO
Cu
DMCGlut (60 mg, 0.09 mmol) was dissolved in water, and NaOH (2 M) added until
neutral. Cu(OAc)2.H2O (20 mg, 0.10 mmol) was added, and the solution gently heated
for 5 minutes. The solution turned a deep blue colour. Slow evaporation of this solution
resulted in crystals of x-ray quality (31 mg, 0.056 mmol, 63 %); MS (HR ES−) calc. for
C22H37N4O863Cu (M - H+) 548.1907 found 548.1921
7.9.2 Trispyrazylborate analogues
7.9.2.1 1-(pyridin-2-yl)butane-1,3-dione (PyAcac)
N
O O
2-Acetyl pyridine (0.35 ml, mmol) was dissolved in degassed THF under an inert at-
mosphere. Potassium tbutoxide (1.04 g, 9.29 mmol) was added slowly, and the mixture
stirred for 20minutes. Dry EtOAc (3ml) was added and the mixture stirred for 18 hours.
Water (10 ml) was added slowly, followed by diethyl ether (10 ml). The aqueous layer
was seperated and acetic acid added until pH 7. The product was extracted in diethyl
ether (5 x 100 ml), the fractions combined, and dried over MgSO4. The solvents were
removed in vacuo yielding the title product as a brown oil (437 mg, mmol, %) 1H NMR
(250MHz, CDCl3, ppm) δH : 8.70 (d, 1 H, Ar-H, 2JH−H = 4 Hz), 8.13 - 8.10 (m, 1 H, Ar-H),
7.91-7.90 (m, 1 H, Ar-H), 7.47 - 7.45 (m, 1 H, Ar-H), 6.87 (s, 1 H, COCH(2)CO), 2.30 (s, 3
H, CH3)
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7.9.2.2 2-(5-methyl-1H-pyrazol-3-yl)pyridine (MePzPy)
N
N NH
PyAcac (437 mg, mmol), hydrazine hydrate (0.45 ml), p-TSA (10 mg) and ethanol (25
ml) were refluxed for 18 hours under an inert atmosphere. The solvents were removed
in vacuo, and the resulting solid dissolved in water (20 ml). The product was extracted
in DCM (4 x 50 ml), the fractions combined, dried over MgSO4, filtered, and the solvent
removed in vacuo yielding the title product as a yellow oil (493 mg, mmol, %) 1H NMR
(250 MHz, CDCl3, ppm) δH : 8.54 - 8.52 (m, 1 H, Ar-H), 7.66 - 7.61 (m, 2 H, Ar-H), 7.15
- 7.11 (m, 1 H, Ar-H), 6.50 (s, 1 H, Pz-H), 2.30 (s, 3 H, CH3); MS (HR APCI+) calc. for
C9H10N3 (M + H+) 160.0875 found 160.0877
7.9.2.3 Bis(5-methyl-3-(pyridin-2-yl)-1H-pyrazol-1-yl)borane (MeDpPy)
N
N N
N
N N
BH
MePzPy (300 mg, 1.89 mmol) and KBH4 (34 mg, 0.63 mmol) were dissolved in DMAC
(10 ml), and heated to 160°C under a inert atmosphere for 18 hours. After cooling, the
solid precipitate was isolated by filtration, yielding the title product as a white solid
(183 mg, 0.56 mmol, 89 %); 11B NMR (96 MHz, DMSO-d6, ppm) δB: -12.7 (br s); IR (KBr,
νmax, cm−1) 3413 (br, w), 3301 (br, w), 3179 (br, w), 3053 (br, w), 2846 (br, w), 2361 (s),
2342 (w), 1669 (br, s), 1612 (br, s), 1498 (s), 1368 (s), 1137 (br, w), 1085 (s), 812 (w), 741
(w); MS (HR ES−) calc for C18H1811B N6 (M + H−) 329.1686 found 329.1688
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7.9.2.4 Hydrogen tetra(5-methyl-3-(pyridin-2-yl)-1H-pyrazol-1-yl)borate (MeQpPy)
N
N N
N
N
N B
N
N
N
N
NN H+
MePzPy (2.03 g, 12.8 mmol) and KBH4 (200 mg, 3.70 mmol) were melted together at
230°C until no further gas was evolved (2 hours), yielding the title product as a white
solid (1.94 g, 3.02 mmol, 82 %) 11B NMR (96 MHz, DMSO-d6) δB: 2.0 - 0.8 (br s); IR (KBr,
νmax, cm−1) 3219 (br, w), 3137 (br, w). 3056 (br, w), 2927 (s), 2860 (s), 2362 (w) 2341 (w),
1594 (s), 1500 (s), 1449 (s), 1342 (s), 1182 (br, s), 1096 (w), 968 (s), 840 (s), 814 (s), 783 (s),
743 (w); MS (HR ES−) calc. for C36H3211B N12 (M−) 643.2966 found 643.2987
7.10 PET experiments
These experiments were performed by Dr. J. Knight, University of Alberta
7.10.1 64Cu radiolabelling
For both TsTACNA2 andNPhTACNA2, a dilution series was prepared in 0.1MNH4OAc
buffer (pH 5.5) to give final chelating agent masses in the range 2.5 to 50 ng. To each of
these eppendorf tubes was added 64Cu(OAc)2 (1 MBq) and the volume was adjusted to
100 μL with 0.1 M NH4OAc buffer (pH 5.5). Each eppendorf tube was vortexed briefly
and then placed in a thermoshaker (750 rpm) at 37 °C for 1 h. The radiolabeling effi-
ciency of each reaction was then monitored by radio-TLC (C18) using MeOH / 10 %
NH4OAc (1/1) as the solvent system. All reactions were performed in triplicate.
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7.10.2 Determination of logP values
64CuTsTACNA2 or 64CuNPhTACNA2 (5 µL)was added to a biphasicmixture consisting
of deionised water (1 mL) and octan-1-ol (1 mL). Eachmixture was vortexed thoroughly
for 5 minutes followed by centrifugation at 1,000 rpm for a further 5 minutes. A single
portion of 100 µLwas taken from each layer using amicropipette and transferred to sep-
arate eppendorf tubes. The radioactivity in each eppendorf tube was measured using a
gamma scintillation counter. This experiment was performed in triplicate.
7.10.3 Stability in human serum
To a solution of TsTACNA2 (35 ng, 0.088 nmol) in 0.1 M NH4OAc (95 μL, pH 5.5) in
an eppendorf tube was added 64Cu(OAc)2 (5 μL, 2.2 MBq). The eppendorf tube was
vortexed briefly and then placed in a thermoshaker (750 rpm) at 37 °C for 30 minutes.
The progress of the reaction was monitored by reverse phase (C18) radio-TLC using
MeOH / 10 % NH4OAc (1/1). Upon completion of the complexation reaction (> 96
%), human serum (900 μL) was added to the reaction mixture. The eppendorf tube
was vortexed briefly and then placed in a thermoshaker (400 rpm) at 37 °C and the
percentage of intact 64Cu-complex was determined by reverse phase radio-TLC (vide
supra) at 0.08, 0.25, 0.5, 1, 3, and 24 h.
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Appendix A
Crystal structures of ligands and
ligand precursors
A.1 Crystal structure of HP1−NO2
Crystallisation method:
Hydrogen atoms removed for clarity
Figure A.1: Benzyl-6,6’-(1,4-diazepane-1,4-diyl)bis(3-nitrobenzoate) (HP1−NO2)
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A.2 Crystal structure of TACN1−NO2
Crystallisation method: Slow evaporation of DCM/Ethanol solution
hydrogen atoms removed for clarity
Figure A.2: Benzyl-6,6’,6”-(1,4,7-triazonane-1,4,7-triyl)tris(3-nitrobenzoate)
(TACN1−NO2)
A.3 Crystal structure of DMC1−NO2
Crystallisation method: Vapour diffusion of pentane into a toluene/methanol solution
Hydrogen atoms removed for clarity
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Figure A.3: Benzyl-6,6’-(4,11-dimethyl-1,4,8,11-tetraazacyclotetradecane-1,8-diyl)bis(3-
nitrobenzoate) (DMC1−NO2)
A.4 Crystal structure of HP3−NO2
Crystallisation method:
Hydrogen atoms removed for clarity
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Figure A.4: Diethyl 6,6’-(1,4-diazepane-1,4-diyl)bis(3-nitrobenzoate) (HP3−NO2)
A.5 Crystal structure of HPSang−NO2
Crystallisation method:
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Figure A.5: 1,4-bis(2,4-dinitrophenyl)-1,4-diazepane (HPSang−NO2)
A.6 Crystal structure of HPCF3
Crystallisation method: Isolated from attempts to crystallise metal complex - Diffusion
of ether into acetonitrile.
Hydrogen atoms removed for clarity
Figure A.6: 1,4-bis(2-amino-4-trifluoromethylphenyl)-1,4-diazepane (HPCF3)
A.7 Crystal structure of Pip3−NH2
Crystallisation method:
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Hydrogen atoms removed for clarity
Figure A.7: Diethyl 6,6’-(piperazine-1,4-diyl)bis(3-aminobenzoate) (Pip3−NH2)
A.8 Crystal structure of PipTol
Crystallisation method: Isolated from attempts to crystallise metal complex - Diffusion
of ether into acetonitrile.
Hydrogen atoms removed for clarity
Figure A.8: 1,3-bis(2-amino-4-tolyl)-1,3-diazacyclohexane (PipTol)
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Appendix B
Amino Acids
Appendix C
X-Ray crystal structure data
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Ortep plot of NiHPtButyl - Ellipsoids at 50% probability 
 
Identification code  NiHPtBu 
Empirical formula  C27H38Cl4N4Ni2O4 
Formula weight  741.83 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca  
Unit cell dimensions a = 16.445(2) Å  = 90° 
 b = 11.9620(17) Å  = 90° 
 c = 34.343(6) Å   = 90° 
Volume 6756.0(17) Å3 
Z 8 
Density (calculated) 1.459 Mg / m3 
Absorption coefficient 1.468 mm1 
F(000) 3072 
Crystal Needle; Colourless 
Crystal size 0.04  0.03  0.01 mm3 
 range for data collection 3.01  27.48° 
Index ranges 21  h  12, 15  k  15, 44  l  31 
Reflections collected 23751 
Independent reflections 7733 [Rint = 0.1206] 
Completeness to  = 27.48° 99.7 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 0.9855 and 0.9436 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7733 / 0 / 376 
Goodness-of-fit on F2 1.065 
Final R indices [F2 > 2(F2)] R1 = 0.0846, wR2 = 0.1087 
R indices (all data) R1 = 0.1619, wR2 = 0.1339 
Largest diff. peak and hole 0.833 and 0.674 e Å3 
 
Bond Lengths (Å) 
 
C1N2 1.508(7) 
C1C2 1.542(8) 
C1H1A 0.9900 
C1H1B 0.9900 
C2N3 1.505(7) 
C2H2A 0.9900 
C2H2B 0.9900 
C3N3 1.516(6) 
C3C4 1.517(8) 
C3H3A 0.9900 
C3H3B 0.9900 
C4C5 1.521(7) 
C4H4A 0.9900 
C4H4B 0.9900 
C5N2 1.508(6) 
C5H5A 0.9900 
C5H5B 0.9900 
C6C7 1.389(8) 
C6C11 1.389(8) 
C6N2 1.472(7) 
C7C8 1.379(8) 
C7H7 0.9500 
C8C9 1.393(8) 
C8H8 0.9500 
C9C10 1.381(8) 
C9C12 1.502(8) 
C10C11 1.383(7) 
C10H10 0.9500 
C11N1 1.451(7) 
C12O1 1.210(7) 
C12O2 1.337(8) 
C13O2 1.491(7) 
C13C14 1.507(9) 
C13C15 1.513(9) 
C13C16 1.515(10) 
C14H14A 0.9800 
C14H14B 0.9800 
C14H14C 0.9800 
C15H15A 0.9800 
C15H15B 0.9800 
C15H15C 0.9800 
C16H16A 0.9800 
 
Bond Angles (°) 
 
N2C1C2 108.9(5) 
N2C1H1A 109.9 
 
 
C16H16B 0.9800 
C16H16C 0.9800 
C17C22 1.369(8) 
C17C18 1.383(8) 
C17N3 1.481(7) 
C18C19 1.388(8) 
C18H18 0.9500 
C19C20 1.388(8) 
C19H19 0.9500 
C20C21 1.390(8) 
C20C23 1.496(8) 
C21C22 1.397(8) 
C21H21 0.9500 
C22N4 1.458(6) 
C23O3 1.204(7) 
C23O4 1.336(7) 
C24O4 1.504(7) 
C24C27 1.509(8) 
C24C25 1.531(9) 
C24C26 1.532(8) 
C25H25A 0.9800 
C25H25B 0.9800 
C25H25C 0.9800 
C26H26A 0.9800 
C26H26B 0.9800 
C26H26C 0.9800 
C27H27A 0.9800 
C27H27B 0.9800 
C27H27C 0.9800 
N1Ni1 1.916(4) 
N1H1C 0.9200 
N1H1D 0.9200 
N2Ni1 1.905(5) 
N3Ni1 1.905(5) 
N4Ni1 1.905(4) 
N4H4C 0.9200 
N4H4D 0.9200 
Cl1Ni2 2.2591(15) 
Cl2Ni2 2.2492(17) 
Cl3Ni2 2.3013(18) 
Cl4Ni2 2.3026(17) 
 
 
 
 
C17C18H18 121.0 
C19C18H18 121.0 
C2C1H1A 109.9 
N2C1H1B 109.9 
C2C1H1B 109.9 
H1AC1H1B 108.3 
N3C2C1 109.3(5) 
N3C2H2A 109.8 
C1C2H2A 109.8 
N3C2H2B 109.8 
C1C2H2B 109.8 
H2AC2H2B 108.3 
N3C3C4 111.3(5) 
N3C3H3A 109.4 
C4C3H3A 109.4 
N3C3H3B 109.4 
C4C3H3B 109.4 
H3AC3H3B 108.0 
C3C4C5 115.0(5) 
C3C4H4A 108.5 
C5C4H4A 108.5 
C3C4H4B 108.5 
C5C4H4B 108.5 
H4AC4H4B 107.5 
N2C5C4 110.9(4) 
N2C5H5A 109.5 
C4C5H5A 109.5 
N2C5H5B 109.5 
C4C5H5B 109.5 
H5AC5H5B 108.0 
C7C6C11 121.2(6) 
C7C6N2 122.4(5) 
C11C6N2 116.4(5) 
C8C7C6 118.5(6) 
C8C7H7 120.8 
C6C7H7 120.8 
C7C8C9 120.7(6) 
C7C8H8 119.7 
C9C8H8 119.7 
C10C9C8 120.3(6) 
C10C9C12 119.1(6) 
C8C9C12 120.6(6) 
C9C10C11 119.7(6) 
C9C10H10 120.2 
C11C10H10 120.2 
C10C11C6 119.6(6) 
C10C11N1 124.5(5) 
C6C11N1 116.0(5) 
O1C12O2 125.9(6) 
O1C12C9 123.1(7) 
O2C12C9 111.0(6) 
C20C19C18 121.5(6) 
C20C19H19 119.3 
C18C19H19 119.3 
C19C20C21 119.5(6) 
C19C20C23 123.8(6) 
C21C20C23 116.7(6) 
C20C21C22 119.2(6) 
C20C21H21 120.4 
C22C21H21 120.4 
C17C22C21 120.1(6) 
C17C22N4 117.2(5) 
C21C22N4 122.7(5) 
O3C23O4 125.8(7) 
O3C23C20 122.6(7) 
O4C23C20 111.6(6) 
O4C24C27 111.5(5) 
O4C24C25 102.0(5) 
C27C24C25 111.0(6) 
O4C24C26 109.0(5) 
C27C24C26 112.5(6) 
C25C24C26 110.3(6) 
C24C25H25A 109.5 
C24C25H25B 109.5 
H25AC25H25B 109.5 
C24C25H25C 109.5 
H25AC25H25C 109.5 
H25BC25H25C 109.5 
C24C26H26A 109.5 
C24C26H26B 109.5 
H26AC26H26B 109.5 
C24C26H26C 109.5 
H26AC26H26C 109.5 
H26BC26H26C 109.5 
C24C27H27A 109.5 
C24C27H27B 109.5 
H27AC27H27B 109.5 
C24C27H27C 109.5 
H27AC27H27C 109.5 
H27BC27H27C 109.5 
C11N1Ni1 108.3(4) 
C11N1H1C 110.0 
Ni1N1H1C 110.0 
C11N1H1D 110.0 
Ni1N1H1D 110.0 
H1CN1H1D 108.4 
C6N2C5 110.2(4) 
C6N2C1 113.0(4) 
C5N2C1 110.8(4) 
C6N2Ni1 107.7(4) 
O2C13C14 101.1(5) 
O2C13C15 108.2(6) 
C14C13C15 111.2(7) 
O2C13C16 108.7(6) 
C14C13C16 110.8(7) 
C15C13C16 115.8(7) 
C13C14H14A 109.5 
C13C14H14B 109.5 
H14AC14H14B 109.5 
C13C14H14C 109.5 
H14AC14H14C 109.5 
H14BC14H14C 109.5 
C13C15H15A 109.5 
C13C15H15B 109.5 
H15AC15H15B 109.5 
C13C15H15C 109.5 
H15AC15H15C 109.5 
H15BC15H15C 109.5 
C13C16H16A 109.5 
C13C16H16B 109.5 
H16AC16H16B 109.5 
C13C16H16C 109.5 
H16AC16H16C 109.5 
H16BC16H16C 109.5 
C22C17C18 121.7(6) 
C22C17N3 115.4(5) 
C18C17N3 123.0(6) 
C17C18C19 118.0(6) 
 
C5N2Ni1 110.2(4) 
C1N2Ni1 104.7(3) 
C17N3C2 113.5(4) 
C17N3C3 108.7(4) 
C2N3C3 113.2(5) 
C17N3Ni1 108.6(4) 
C2N3Ni1 103.1(4) 
C3N3Ni1 109.3(4) 
C22N4Ni1 108.8(4) 
C22N4H4C 109.9 
Ni1N4H4C 109.9 
C22N4H4D 109.9 
Ni1N4H4D 109.9 
H4CN4H4D 108.3 
C12O2C13 122.5(5) 
C23O4C24 120.0(5) 
N3Ni1N2 83.2(2) 
N3Ni1N4 89.1(2) 
N2Ni1N4 172.1(2) 
N3Ni1N1 172.3(2) 
N2Ni1N1 89.1(2) 
N4Ni1N1 98.6(2) 
Cl2Ni2Cl1 118.19(7) 
Cl2Ni2Cl3 109.20(6) 
Cl1Ni2Cl3 108.09(6) 
Cl2Ni2Cl4 108.00(6) 
Cl1Ni2Cl4 103.06(6) 
Cl3Ni2Cl4 110.01(7) 
 
 
 
Ortep plot of CuTsTACNA2 - ellipsoids at 50% probability 
 
Identification code  CuTsTACNA2 
Empirical formula  C37H53Cu2N7O13S2 
Formula weight  995.06 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  P21/c  
Unit cell dimensions a = 10.4488(3) Å  = 90° 
 b = 15.0109(4) Å  = 92.900(7)° 
 c = 26.8299(18) Å   = 90° 
Volume 4202.8(3) Å3 
Z 4 
Density (calculated) 1.573 Mg / m3 
Absorption coefficient 1.184 mm1 
F(000) 2072 
Crystal Prism; dark blue 
Crystal size 0.08  0.06  0.03 mm3 
 range for data collection 3.04  27.48° 
Index ranges 13  h  13, 18  k  17, 16  l  34 
Reflections collected 18879 
Independent reflections 9506 [Rint = 0.0430] 
Completeness to  = 27.48° 98.6 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 0.9653 and 0.9112 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9506 / 0 / 555 
Goodness-of-fit on F2 1.090 
Final R indices [F2 > 2(F2)] R1 = 0.0485, wR2 = 0.1103 
R indices (all data) R1 = 0.0702, wR2 = 0.1184 
Largest diff. peak and hole 0.669 and 0.678 e Å3 
 
Bond Lengths (Å) 
 
C1N1 1.498(4) 
C1C2 1.531(5) 
C1H1A 0.9900 
C1H1B 0.9900 
C2N2 1.497(4) 
C2H2A 0.9900 
C2H2B 0.9900 
C3N2 1.486(4) 
C3C4 1.521(4) 
C3H3A 0.9900 
C3H3B 0.9900 
C4N3 1.494(4) 
C4H4A 0.9900 
C4H4B 0.9900 
C5N3 1.489(4) 
C5C6 1.513(4) 
C5H5A 0.9900 
C5H5B 0.9900 
C6N1 1.496(4) 
C6H6A 0.9900 
C6H6B 0.9900 
C7N2 1.496(4) 
C7C8 1.531(4) 
C7H7A 0.9900 
C7H7B 0.9900 
C8O1 1.227(4) 
C8O2 1.292(4) 
C9N1 1.487(4) 
C9C10 1.531(5) 
C9H9A 0.9900 
C9H9B 0.9900 
C10O3 1.227(4) 
C10O4 1.288(4) 
C11C12 1.388(4) 
C11C16 1.393(4) 
C11S1 1.760(3) 
C12C13 1.391(5) 
C12H12 0.9500 
C13C14 1.394(5) 
C13H13 0.9500 
C14C15 1.383(5) 
C14C17 1.503(5) 
C15C16 1.379(5) 
C15H15 0.9500 
C16H16 0.9500 
C17H17A 0.9800 
C17H17B 0.9800 
 
 
C21H21B 0.9900 
C22N6 1.488(4) 
C22C23 1.522(5) 
C22H22A 0.9900 
C22H22B 0.9900 
C23N4 1.497(4) 
C23H23A 0.9900 
C23H23B 0.9900 
C24N5 1.488(4) 
C24C25 1.528(4) 
C24H24A 0.9900 
C24H24B 0.9900 
C25O7 1.229(4) 
C25O8 1.295(4) 
C26N4 1.491(4) 
C26C27 1.529(5) 
C26H26A 0.9900 
C26H26B 0.9900 
C27O9 1.234(4) 
C27O10 1.288(4) 
C28C29 1.394(4) 
C28C33 1.399(4) 
C28S2 1.756(3) 
C29C30 1.380(5) 
C29H29 0.9500 
C30C31 1.392(5) 
C30H30 0.9500 
C31C32 1.396(5) 
C31C34 1.504(5) 
C32C33 1.386(5) 
C32H32 0.9500 
C33H33 0.9500 
C34H34A 0.9800 
C34H34B 0.9800 
C34H34C 0.9800 
C35C36 1.510(9) 
C35H35A 0.9800 
C35H35B 0.9800 
C35H35C 0.9800 
C36N7 1.205(8) 
Cu1O4 1.920(2) 
Cu1O2 1.934(2) 
Cu1N2 2.004(3) 
Cu1N1 2.009(3) 
Cu1N3 2.429(3) 
Cu2O10 1.924(2) 
Cu2O8 1.930(2) 
C17H17C 0.9800 
C18N4 1.506(4) 
C18C19 1.526(5) 
C18H18A 0.9900 
C18H18B 0.9900 
C19N5 1.503(4) 
C19H19A 0.9900 
C19H19B 0.9900 
C20N5 1.491(4) 
C20C21 1.524(4) 
C20H20A 0.9900 
C20H20B 0.9900 
C21N6 1.492(4) 
C21H21A 0.9900 
Bond Angles (°) 
 
N1C1C2 110.1(3) 
N1C1H1A 109.6 
C2C1H1A 109.6 
N1C1H1B 109.6 
C2C1H1B 109.6 
H1AC1H1B 108.2 
N2C2C1 110.5(3) 
N2C2H2A 109.5 
C1C2H2A 109.5 
N2C2H2B 109.5 
C1C2H2B 109.5 
H2AC2H2B 108.1 
N2C3C4 113.7(3) 
N2C3H3A 108.8 
C4C3H3A 108.8 
N2C3H3B 108.8 
C4C3H3B 108.8 
H3AC3H3B 107.7 
N3C4C3 111.3(3) 
N3C4H4A 109.4 
C3C4H4A 109.4 
N3C4H4B 109.4 
C3C4H4B 109.4 
H4AC4H4B 108.0 
N3C5C6 111.7(3) 
N3C5H5A 109.3 
C6C5H5A 109.3 
N3C5H5B 109.3 
C6C5H5B 109.3 
H5AC5H5B 107.9 
N1C6C5 112.2(3) 
N1C6H6A 109.2 
C5C6H6A 109.2 
Cu2N5 1.998(3) 
Cu2N4 2.017(3) 
Cu2N6 2.428(3) 
N3S1 1.665(3) 
N6S2 1.674(3) 
O5S1 1.436(2) 
O6S1 1.433(2) 
O11S2 1.432(2) 
O12S2 1.433(2) 
O13C37 1.384(5) 
O13H13A 0.8400 
C37H37A 0.9800 
C37H37B 0.9800 
C37H37C 0.9800 
 
 
O7C25C24 119.2(3) 
O8C25C24 115.9(3) 
N4C26C27 111.8(3) 
N4C26H26A 109.3 
C27C26H26A 109.3 
N4C26H26B 109.3 
C27C26H26B 109.3 
H26AC26H26B 107.9 
O9C27O10 124.5(3) 
O9C27C26 118.9(3) 
O10C27C26 116.5(3) 
C29C28C33 120.4(3) 
C29C28S2 120.6(3) 
C33C28S2 118.9(2) 
C30C29C28 119.1(3) 
C30C29H29 120.5 
C28C29H29 120.5 
C29C30C31 121.6(3) 
C29C30H30 119.2 
C31C30H30 119.2 
C30C31C32 118.6(3) 
C30C31C34 121.1(3) 
C32C31C34 120.3(3) 
C33C32C31 120.9(3) 
C33C32H32 119.5 
C31C32H32 119.5 
C32C33C28 119.3(3) 
C32C33H33 120.3 
C28C33H33 120.3 
C31C34H34A 109.5 
C31C34H34B 109.5 
H34AC34H34B 109.5 
C31C34H34C 109.5 
N1C6H6B 109.2 
C5C6H6B 109.2 
H6AC6H6B 107.9 
N2C7C8 110.6(3) 
N2C7H7A 109.5 
C8C7H7A 109.5 
N2C7H7B 109.5 
C8C7H7B 109.5 
H7AC7H7B 108.1 
O1C8O2 124.5(3) 
O1C8C7 119.3(3) 
O2C8C7 116.3(3) 
N1C9C10 112.5(3) 
N1C9H9A 109.1 
C10C9H9A 109.1 
N1C9H9B 109.1 
C10C9H9B 109.1 
H9AC9H9B 107.8 
O3C10O4 124.6(3) 
O3C10C9 117.9(3) 
O4C10C9 117.4(3) 
C12C11C16 120.3(3) 
C12C11S1 119.6(2) 
C16C11S1 120.0(2) 
C11C12C13 119.2(3) 
C11C12H12 120.4 
C13C12H12 120.4 
C12C13C14 121.1(3) 
C12C13H13 119.4 
C14C13H13 119.4 
C15C14C13 118.2(3) 
C15C14C17 121.3(3) 
C13C14C17 120.5(3) 
C16C15C14 121.8(3) 
C16C15H15 119.1 
C14C15H15 119.1 
C15C16C11 119.3(3) 
C15C16H16 120.4 
C11C16H16 120.4 
C14C17H17A 109.5 
C14C17H17B 109.5 
H17AC17H17B 109.5 
C14C17H17C 109.5 
H17AC17H17C 109.5 
H17BC17H17C 109.5 
N4C18C19 109.8(3) 
N4C18H18A 109.7 
C19C18H18A 109.7 
N4C18H18B 109.7 
H34AC34H34C 109.5 
H34BC34H34C 109.5 
C36C35H35A 109.5 
C36C35H35B 109.5 
H35AC35H35B 109.5 
C36C35H35C 109.5 
H35AC35H35C 109.5 
H35BC35H35C 109.5 
N7C36C35 177.9(6) 
O4Cu1O2 99.41(9) 
O4Cu1N2 170.89(10) 
O2Cu1N2 85.24(10) 
O4Cu1N1 87.10(10) 
O2Cu1N1 166.60(10) 
N2Cu1N1 86.81(11) 
O4Cu1N3 104.64(9) 
O2Cu1N3 106.85(9) 
N2Cu1N3 81.25(10) 
N1Cu1N3 82.51(10) 
O10Cu2O8 98.43(9) 
O10Cu2N5 171.61(10) 
O8Cu2N5 85.79(10) 
O10Cu2N4 86.35(10) 
O8Cu2N4 159.16(11) 
N5Cu2N4 87.20(11) 
O10Cu2N6 102.87(10) 
O8Cu2N6 116.00(10) 
N5Cu2N6 81.54(10) 
N4Cu2N6 82.22(11) 
C9N1C6 111.5(3) 
C9N1C1 114.1(3) 
C6N1C1 111.7(2) 
C9N1Cu1 105.22(19) 
C6N1Cu1 112.37(19) 
C1N1Cu1 101.39(19) 
C3N2C7 109.3(3) 
C3N2C2 113.0(3) 
C7N2C2 114.2(3) 
C3N2Cu1 109.25(19) 
C7N2Cu1 101.66(18) 
C2N2Cu1 108.7(2) 
C5N3C4 115.3(2) 
C5N3S1 113.3(2) 
C4N3S1 115.9(2) 
C5N3Cu1 95.06(17) 
C4N3Cu1 103.04(17) 
S1N3Cu1 111.54(13) 
C26N4C23 112.2(3) 
C26N4C18 113.5(3) 
C19C18H18B 109.7 
H18AC18H18B 108.2 
N5C19C18 110.6(3) 
N5C19H19A 109.5 
C18C19H19A 109.5 
N5C19H19B 109.5 
C18C19H19B 109.5 
H19AC19H19B 108.1 
N5C20C21 112.7(3) 
N5C20H20A 109.1 
C21C20H20A 109.1 
N5C20H20B 109.1 
C21C20H20B 109.1 
H20AC20H20B 107.8 
N6C21C20 111.3(2) 
N6C21H21A 109.4 
C20C21H21A 109.4 
N6C21H21B 109.4 
C20C21H21B 109.4 
H21AC21H21B 108.0 
N6C22C23 112.2(3) 
N6C22H22A 109.2 
C23C22H22A 109.2 
N6C22H22B 109.2 
C23C22H22B 109.2 
H22AC22H22B 107.9 
N4C23C22 112.9(3) 
N4C23H23A 109.0 
C22C23H23A 109.0 
N4C23H23B 109.0 
C22C23H23B 109.0 
H23AC23H23B 107.8 
N5C24C25 110.4(3) 
N5C24H24A 109.6 
C25C24H24A 109.6 
N5C24H24B 109.6 
C25C24H24B 109.6 
H24AC24H24B 108.1 
O7C25O8 124.9(3) 
 
C23N4C18 111.9(3) 
C26N4Cu2 104.3(2) 
C23N4Cu2 113.0(2) 
C18N4Cu2 101.26(19) 
C24N5C20 109.1(2) 
C24N5C19 113.6(2) 
C20N5C19 112.4(2) 
C24N5Cu2 104.21(19) 
C20N5Cu2 108.59(19) 
C19N5Cu2 108.6(2) 
C22N6C21 115.3(3) 
C22N6S2 115.2(2) 
C21N6S2 113.9(2) 
C22N6Cu2 96.26(19) 
C21N6Cu2 102.43(18) 
S2N6Cu2 111.42(13) 
C8O2Cu1 111.5(2) 
C10O4Cu1 113.4(2) 
C25O8Cu2 113.8(2) 
C27O10Cu2 114.3(2) 
C37O13H13A 109.5 
O6S1O5 119.57(14) 
O6S1N3 106.83(13) 
O5S1N3 106.44(13) 
O6S1C11 108.21(14) 
O5S1C11 109.28(14) 
N3S1C11 105.65(14) 
O11S2O12 119.96(14) 
O11S2N6 105.51(14) 
O12S2N6 106.36(14) 
O11S2C28 109.16(15) 
O12S2C28 107.83(14) 
N6S2C28 107.38(15) 
O13C37H37A 109.5 
O13C37H37B 109.5 
H37AC37H37B 109.5 
O13C37H37C 109.5 
H37AC37H37C 109.5 
H37BC37H37C 109.5 
Identification code  CuTACNCF3 
Empirical formula  C22H29Cl2CuF6N5O9 
Formula weight  755.94 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
 
Space group  P1  
Unit cell dimensions a = 10.7028(2) Å  = 83.081(2)° 
 b = 10.9956(4) Å  = 82.641(2)° 
 c = 12.5512(4) Å   = 81.629(2)° 
Volume 1441.47(7) Å3 
Z 2 
Density (calculated) 1.742 Mg / m3 
Absorption coefficient 1.042 mm1 
F(000) 770 
Crystal Fragment; blue 
Crystal size 0.20  0.14  0.10 mm3 
 range for data collection 3.22  27.48° 
Index ranges 13  h  13, 14  k  14, 16  l  16 
Reflections collected 30364 
Independent reflections 6592 [Rint = 0.0689] 
Completeness to  = 27.48° 99.7 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 0.9030 and 0.8188 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6592 / 3 / 436 
Goodness-of-fit on F2 1.045 
Final R indices [F2 > 2(F2)] R1 = 0.0531, wR2 = 0.1083 
R indices (all data) R1 = 0.0788, wR2 = 0.1197 
Largest diff. peak and hole 0.854 and 0.548 e Å3 
 
Bond Lengths (Å) 
 
Cu1N22 1.995(3) 
Cu1N12 2.008(3) 
Cu1N11 2.039(3) 
Cu1N21 2.060(3) 
Cu1N31 2.188(3) 
F11C17 1.337(4) 
F12C17 1.346(4) 
F13C17 1.335(4) 
F21AC27 1.281(6) 
F22AC27 1.254(6) 
F23AC27 1.403(7) 
F21BC27 1.488(12) 
F22BC27 1.251(12) 
F23BC27 1.220(19) 
N11C11 1.461(4) 
N11C1 1.497(4) 
 
 
C5H5A 0.9900 
C5H5B 0.9900 
C6H6A 0.9900 
C6H6B 0.9900 
C11C12 1.386(4) 
C11C16 1.386(4) 
C12C13 1.382(4) 
C13C14 1.391(5) 
C13H13 0.9500 
C14C15 1.381(5) 
C14C17 1.497(5) 
C15C16 1.382(4) 
C15H15 0.9500 
C16H16 0.9500 
C21C22 1.383(4) 
C21C26 1.388(5) 
N11C6 1.506(4) 
N12C12 1.455(4) 
N12H12A 0.9200 
N12H12B 0.9200 
N21C21 1.455(4) 
N21C2 1.499(4) 
N21C3 1.499(4) 
N22C22 1.450(4) 
N22H22A 0.9200 
N22H22B 0.9200 
N31C4 1.476(4) 
N31C5 1.485(4) 
N31H31 0.9300 
C1C2 1.521(5) 
C1H1A 0.9900 
C1H1B 0.9900 
C2H2A 0.9900 
C2H2B 0.9900 
C3C4 1.514(5) 
C3H3A 0.9900 
C3H3B 0.9900 
C4H4A 0.9900 
C4H4B 0.9900 
C5C6 1.520(4) 
 
Bond Angles (°) 
 
N22Cu1N12 100.23(11) 
N22Cu1N11 167.66(10) 
N12Cu1N11 84.61(10) 
N22Cu1N21 84.48(10) 
N12Cu1N21 153.52(11) 
N11Cu1N21 86.24(10) 
N22Cu1N31 102.87(10) 
N12Cu1N31 119.91(11) 
N11Cu1N31 84.14(10) 
N21Cu1N31 83.67(10) 
C11N11C1 114.9(2) 
C11N11C6 108.1(2) 
C1N11C6 112.3(2) 
C11N11Cu1 107.14(18) 
C1N11Cu1 108.29(19) 
C6N11Cu1 105.46(19) 
C12N12Cu1 107.57(18) 
C12N12H12A 110.2 
Cu1N12H12A 110.2 
C12N12H12B 110.2 
Cu1N12H12B 110.2 
H12AN12H12B 108.5 
C22C23 1.381(4) 
C23C24 1.385(5) 
C23H23 0.9500 
C24C25 1.383(5) 
C24C27 1.493(5) 
C25C26 1.388(5) 
C25H25 0.9500 
C26H26 0.9500 
Cl1O1 1.396(3) 
Cl1O2 1.410(3) 
Cl1O4 1.423(3) 
Cl1O3 1.442(3) 
Cl2O5 1.426(3) 
Cl2O7 1.430(3) 
Cl2O8 1.430(3) 
Cl2O6 1.448(3) 
O9C51 1.412(5) 
O9H9 0.8400 
C52C51 1.442(7) 
C52H52A 0.9800 
C52H52B 0.9800 
C52H52C 0.9800 
C51H51A 0.9900 
C51H51B 0.9900 
 
 
 
C12C13C14 119.6(3) 
C12C13H13 120.2 
C14C13H13 120.2 
C15C14C13 120.4(3) 
C15C14C17 121.4(3) 
C13C14C17 118.2(3) 
C14C15C16 120.0(3) 
C14C15H15 120.0 
C16C15H15 120.0 
C15C16C11 119.6(3) 
C15C16H16 120.2 
C11C16H16 120.2 
F13C17F11 107.1(3) 
F13C17F12 106.6(3) 
F11C17F12 106.5(3) 
F13C17C14 112.7(3) 
F11C17C14 112.0(3) 
F12C17C14 111.5(3) 
C22C21C26 120.9(3) 
C22C21N21 116.8(3) 
C26C21N21 122.3(3) 
C23C22C21 119.7(3) 
C21N21C2 113.2(2) 
C21N21C3 111.5(2) 
C2N21C3 113.4(2) 
C21N21Cu1 106.43(18) 
C2N21Cu1 101.55(18) 
C3N21Cu1 110.13(19) 
C22N22Cu1 108.22(19) 
C22N22H22A 110.1 
Cu1N22H22A 110.1 
C22N22H22B 110.1 
Cu1N22H22B 110.1 
H22AN22H22B 108.4 
C4N31C5 113.1(3) 
C4N31Cu1 102.35(19) 
C5N31Cu1 107.79(18) 
C4N31H31 111.1 
C5N31H31 111.1 
Cu1N31H31 111.1 
N11C1C2 111.3(2) 
N11C1H1A 109.4 
C2C1H1A 109.4 
N11C1H1B 109.4 
C2C1H1B 109.4 
H1AC1H1B 108.0 
N21C2C1 109.9(3) 
N21C2H2A 109.7 
C1C2H2A 109.7 
N21C2H2B 109.7 
C1C2H2B 109.7 
H2AC2H2B 108.2 
N21C3C4 111.8(3) 
N21C3H3A 109.3 
C4C3H3A 109.3 
N21C3H3B 109.3 
C4C3H3B 109.3 
H3AC3H3B 107.9 
N31C4C3 110.7(3) 
N31C4H4A 109.5 
C3C4H4A 109.5 
N31C4H4B 109.5 
C3C4H4B 109.5 
H4AC4H4B 108.1 
N31C5C6 111.1(2) 
N31C5H5A 109.4 
C6C5H5A 109.4 
N31C5H5B 109.4 
C6C5H5B 109.4 
H5AC5H5B 108.0 
N11C6C5 112.4(3) 
C23C22N22 122.1(3) 
C21C22N22 118.3(3) 
C22C23C24 119.7(3) 
C22C23H23 120.2 
C24C23H23 120.2 
C25C24C23 120.8(3) 
C25C24C27 120.2(3) 
C23C24C27 119.0(3) 
C24C25C26 119.6(3) 
C24C25H25 120.2 
C26C25H25 120.2 
C25C26C21 119.3(3) 
C25C26H26 120.4 
C21C26H26 120.4 
F23BC27F22B 116.2(14) 
F23BC27F22A 123.9(11) 
F22BC27F22A 46.4(10) 
F23BC27F21A 25.2(18) 
F22BC27F21A 128.5(8) 
F22AC27F21A 113.4(7) 
F23BC27F23A 76.5(16) 
F22BC27F23A 59.0(12) 
F22AC27F23A 104.3(6) 
F21AC27F23A 101.3(5) 
F23BC27F21B 94.6(15) 
F22BC27F21B 96.6(12) 
F22AC27F21B 51.9(7) 
F21AC27F21B 72.0(10) 
F23AC27F21B 143.9(6) 
F23BC27C24 119.0(11) 
F22BC27C24 117.3(7) 
F22AC27C24 113.6(4) 
F21AC27C24 114.1(5) 
F23AC27C24 108.7(4) 
F21BC27C24 106.2(6) 
O1Cl1O2 108.7(3) 
O1Cl1O4 109.1(2) 
O2Cl1O4 111.9(3) 
O1Cl1O3 111.2(2) 
O2Cl1O3 108.76(19) 
O4Cl1O3 107.19(17) 
O5Cl2O7 109.85(18) 
O5Cl2O8 110.26(19) 
O7Cl2O8 110.13(19) 
O5Cl2O6 108.46(17) 
O7Cl2O6 107.87(19) 
O8Cl2O6 110.2(2) 
C51O9H9 109.5 
C51C52H52A 109.5 
N11C6H6A 109.1 
C5C6H6A 109.1 
N11C6H6B 109.1 
C5C6H6B 109.1 
H6AC6H6B 107.9 
C12C11C16 120.4(3) 
C12C11N11 116.3(3) 
C16C11N11 123.2(3) 
C13C12C11 119.9(3) 
C13C12N12 121.8(3) 
C11C12N12 118.3(3) 
C51C52H52B 109.5 
H52AC52H52B 109.5 
C51C52H52C 109.5 
H52AC52H52C 109.5 
H52BC52H52C 109.5 
O9C51C52 110.6(4) 
O9C51H51A 109.5 
C52C51H51A 109.5 
O9C51H51B 109.5 
C52C51H51B 109.5 
H51AC51H51B 108.1 
 
 
  
Ortep plot of CuNPhTACNA2 – Ellipsoids at 50% probability 
 
Identification code  CuNPhTACNA2 
Empirical formula  C16H20CuN4O6 
Formula weight  427.90 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  P21/c  
Unit cell dimensions a = 16.054(4) Å  = 90° 
 b = 13.373(3) Å  = 99.402(3)° 
 c = 7.8011(17) Å   = 90° 
Volume 1652.3(7) Å3 
Z 4 
Density (calculated) 1.720 Mg / m3 
Absorption coefficient 1.368 mm1 
F(000) 884 
Crystal Lath; blue 
Crystal size 0.18  0.03  0.01 mm3 
 range for data collection 2.99  27.49° 
Index ranges 20  h  20, 15  k  17, 10  l  10 
Reflections collected 28242 
Independent reflections 3784 [Rint = 0.0401] 
Completeness to  = 27.49° 99.9 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 0.9865 and 0.7909 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3784 / 0 / 244 
Goodness-of-fit on F2 1.145 
Final R indices [F2 > 2(F2)] R1 = 0.0350, wR2 = 0.0709 
R indices (all data) R1 = 0.0386, wR2 = 0.0721 
Largest diff. peak and hole 0.414 and 0.452 e Å3 
 
 
Bond Lengths (Å) 
 
C1N1 1.489(3) 
C1C2 1.514(3) 
C1H1A 0.9900 
C1H1B 0.9900 
C2N2 1.498(2) 
C2H2A 0.9900 
C2H2B 0.9900 
C3N2 1.488(3) 
C3C4 1.524(3) 
C3H3A 0.9900 
C3H3B 0.9900 
C4N3 1.498(3) 
C4H4A 0.9900 
C4H4B 0.9900 
C5N3 1.488(2) 
C5C6 1.528(3) 
C5H5A 0.9900 
C5H5B 0.9900 
C6N1 1.489(3) 
C6H6A 0.9900 
C6H6B 0.9900 
C7N2 1.485(3) 
C7C8 1.525(3) 
C7H7A 0.9900 
C7H7B 0.9900 
C8O2 1.232(3) 
 
Bond Angles (°) 
 
N1C1C2 113.51(17) 
N1C1H1A 108.9 
C2C1H1A 108.9 
N1C1H1B 108.9 
C2C1H1B 108.9 
H1AC1H1B 107.7 
N2C2C1 112.10(17) 
N2C2H2A 109.2 
C1C2H2A 109.2 
N2C2H2B 109.2 
C1C2H2B 109.2 
H2AC2H2B 107.9 
N2C3C4 109.97(16) 
N2C3H3A 109.7 
C4C3H3A 109.7 
N2C3H3B 109.7 
C4C3H3B 109.7 
H3AC3H3B 108.2 
 
 
C8O1 1.289(3) 
C9N3 1.485(2) 
C9C10 1.532(3) 
C9H9A 0.9900 
C9H9B 0.9900 
C10O4 1.228(3) 
C10O3 1.291(3) 
C11C16 1.407(3) 
C11C12 1.408(3) 
C11N1 1.417(3) 
C12C13 1.387(3) 
C12H12 0.9500 
C13C14 1.385(3) 
C13H13 0.9500 
C14C15 1.388(3) 
C14N4 1.460(3) 
C15C16 1.380(3) 
C15H15 0.9500 
C16H16 0.9500 
N1Cu1 2.4464(17) 
N2Cu1 2.0195(17) 
N3Cu1 1.9945(18) 
N4O6 1.230(3) 
N4O5 1.232(3) 
O1Cu1 1.9245(15) 
O3Cu1 1.9323(16) 
 
 
 
O3C10C9 116.50(18) 
C16C11C12 118.2(2) 
C16C11N1 119.50(19) 
C12C11N1 122.28(19) 
C13C12C11 120.8(2) 
C13C12H12 119.6 
C11C12H12 119.6 
C14C13C12 119.4(2) 
C14C13H13 120.3 
C12C13H13 120.3 
C13C14C15 121.2(2) 
C13C14N4 120.1(2) 
C15C14N4 118.6(2) 
C16C15C14 119.4(2) 
C16C15H15 120.3 
C14C15H15 120.3 
C15C16C11 121.0(2) 
C15C16H16 119.5 
N3C4C3 110.25(16) 
N3C4H4A 109.6 
C3C4H4A 109.6 
N3C4H4B 109.6 
C3C4H4B 109.6 
H4AC4H4B 108.1 
N3C5C6 112.65(16) 
N3C5H5A 109.1 
C6C5H5A 109.1 
N3C5H5B 109.1 
C6C5H5B 109.1 
H5AC5H5B 107.8 
N1C6C5 113.22(16) 
N1C6H6A 108.9 
C5C6H6A 108.9 
N1C6H6B 108.9 
C5C6H6B 108.9 
H6AC6H6B 107.7 
N2C7C8 112.40(17) 
N2C7H7A 109.1 
C8C7H7A 109.1 
N2C7H7B 109.1 
C8C7H7B 109.1 
H7AC7H7B 107.9 
O2C8O1 125.0(2) 
O2C8C7 117.54(19) 
O1C8C7 117.43(18) 
N3C9C10 111.71(17) 
N3C9H9A 109.3 
C10C9H9A 109.3 
N3C9H9B 109.3 
C10C9H9B 109.3 
H9AC9H9B 107.9 
O4C10O3 125.0(2) 
O4C10C9 118.3(2) 
 
C11C16H16 119.5 
C11N1C6 115.06(16) 
C11N1C1 115.65(17) 
C6N1C1 115.35(16) 
C11N1Cu1 114.69(12) 
C6N1Cu1 100.44(11) 
C1N1Cu1 92.36(11) 
C7N2C3 113.42(16) 
C7N2C2 112.43(16) 
C3N2C2 111.81(16) 
C7N2Cu1 105.66(12) 
C3N2Cu1 102.12(12) 
C2N2Cu1 110.72(12) 
C9N3C5 110.56(16) 
C9N3C4 112.91(16) 
C5N3C4 112.23(15) 
C9N3Cu1 102.87(12) 
C5N3Cu1 108.44(13) 
C4N3Cu1 109.33(12) 
O6N4O5 123.5(2) 
O6N4C14 117.8(2) 
O5N4C14 118.7(2) 
C8O1Cu1 113.93(13) 
C10O3Cu1 111.56(13) 
O1Cu1O3 97.69(6) 
O1Cu1N3 168.46(7) 
O3Cu1N3 86.19(7) 
O1Cu1N2 86.37(7) 
O3Cu1N2 160.42(7) 
N3Cu1N2 86.46(7) 
O1Cu1N1 105.66(6) 
O3Cu1N1 113.08(6) 
N3Cu1N1 82.53(6) 
N2Cu1N1 83.88(6) 
 Ortep plot of CuMePyPz – Ellipsoids at 50% probability 
Identification code  CuMePyPz 
Empirical formula  C44 H44 Cu4 N12 O8 
Formula weight  1123.07 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 12.12(3) Å = 90°. 
 b = 13.34(3) Å = 107.72(3)°. 
 c = 14.74(3) Å  = 90°. 
Volume 2270(9) Å3 
Z 2 
Density (calculated) 1.643 Mg/m3 
Absorption coefficient 1.916 mm-1 
F(000) 1144 
Crystal size 0.05 x 0.05 x 0.02 mm3 
Theta range for data collection 2.90 to 25.00°. 
Index ranges -14<=h<=12, -15<=k<=15, -16<=l<=17 
Reflections collected 20500 
Independent reflections 3943 [R(int) = 0.1135] 
Completeness to theta = 25.00° 98.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9627 and 0.9103 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3943 / 7 / 311 
Goodness-of-fit on F2 1.221 
Final R indices [I>2sigma(I)] R1 = 0.1454, wR2 = 0.3448 
R indices (all data) R1 = 0.1753, wR2 = 0.3786 
Largest diff. peak and hole 5.089 and -1.182 e.Å-3 
Bond lengths [Å] 
 
C(18)-C(17)  1.514(14) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(19)-O(1)  1.234(13) 
C(19)-O(2)  1.260(12) 
C(19)-C(20)  1.486(15) 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
O(1)-Cu(1)  1.973(8) 
C(1)-N(1)  1.355(13) 
C(1)-C(2)  1.386(15) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.410(16) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.399(16) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.378(15) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.367(14) 
C(5)-C(6)  1.493(15) 
C(6)-N(2)  1.364(13) 
C(6)-C(7)  1.389(15) 
C(7)-C(8)  1.392(13) 
C(7)-H(7)  0.9500 
C(8)-N(3)  1.373(12) 
C(8)-C(9)  1.535(14) 
C(9)-H(9A)  0.9800 
C(9)-H(9B)  0.9800 
C(9)-H(9C)  0.9800 
C(10)-N(4)  1.360(15) 
C(10)-C(11)  1.403(15) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.372(16) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.349(15) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.383(14) 
C(13)-H(13)  0.9500 
C(14)-N(4)  1.377(14) 
C(14)-C(15)  1.448(14) 
C(15)-N(5)  1.347(12) 
C(15)-C(16)  1.382(15) 
C(16)-C(17)  1.409(15) 
C(16)-H(16)  0.9500 
C(17)-N(6)  1.375(13) 
C(21)-O(4)  1.255(12) 
C(21)-O(3)  1.289(13) 
C(21)-C(22)  1.528(15) 
C(22)-H(22A)  0.9800 
C(22)-H(22B)  0.9800 
C(22)-H(22C)  0.9800 
Cu(1)-N(2)  1.947(9) 
Cu(1)-N(6)  1.960(9) 
Cu(1)-N(1)  2.057(9) 
Cu(2)-N(3)  1.961(9) 
Cu(2)-O(3)  1.965(7) 
Cu(2)-N(5)  1.965(10) 
Cu(2)-N(4)  2.032(10) 
N(2)-N(3)  1.393(12) 
N(5)-N(6)  1.377(12) 
 
Bond Angles [°] 
 
C(17)-C(18)-H(18A) 109.5 
C(17)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(17)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
O(1)-C(19)-O(2) 122.5(10) 
O(1)-C(19)-C(20) 118.0(10) 
O(2)-C(19)-C(20) 119.4(11) 
C(19)-C(20)-H(20A) 109.5 
C(19)-C(20)-H(20B) 109.5 
H(20A)-C(20)-H(20B) 109.5 
C(19)-C(20)-H(20C) 109.5 
H(20A)-C(20)-H(20C) 109.5 
H(20B)-C(20)-H(20C) 109.5 
C(19)-O(1)-Cu(1) 106.0(7) 
N(1)-C(1)-C(2) 122.5(11) 
N(1)-C(1)-H(1) 118.7 
C(2)-C(1)-H(1) 118.7 
C(1)-C(2)-C(3) 118.1(10) 
C(1)-C(2)-H(2) 121.0 
C(3)-C(2)-H(2) 121.0 
C(4)-C(3)-C(2) 120.2(10) 
C(4)-C(3)-H(3) 119.9 
C(2)-C(3)-H(3) 119.9 
C(5)-C(4)-C(3) 117.4(11) 
C(5)-C(4)-H(4) 121.3 
C(3)-C(4)-H(4) 121.3 
N(1)-C(5)-C(4) 123.5(10) 
N(1)-C(5)-C(6) 113.4(9) 
C(4)-C(5)-C(6) 123.0(11) 
N(2)-C(6)-C(7) 111.6(9) 
N(2)-C(6)-C(5) 114.6(10) 
C(7)-C(6)-C(5) 133.8(9) 
C(6)-C(7)-C(8) 103.9(9) 
C(6)-C(7)-H(7) 128.0 
C(8)-C(7)-H(7) 128.0 
N(3)-C(8)-C(7) 110.6(9) 
N(3)-C(8)-C(9) 121.8(8) 
C(7)-C(8)-C(9) 127.6(9) 
C(8)-C(9)-H(9A) 109.5 
C(8)-C(9)-H(9B) 109.5 
H(9A)-C(9)-H(9B) 109.5 
C(8)-C(9)-H(9C) 109.5 
H(9A)-C(9)-H(9C) 109.5 
H(9B)-C(9)-H(9C) 109.5 
N(4)-C(10)-C(11) 122.1(10) 
N(4)-C(10)-H(10) 118.9 
C(11)-C(10)-H(10) 118.9 
C(12)-C(11)-C(10) 118.1(10) 
C(12)-C(11)-H(11) 121.0 
C(10)-C(11)-H(11) 121.0 
C(13)-C(12)-C(11) 120.6(10) 
C(13)-C(12)-H(12) 119.7 
C(11)-C(12)-H(12) 119.7 
C(12)-C(13)-C(14) 120.5(11) 
C(12)-C(13)-H(13) 119.7 
C(14)-C(13)-H(13) 119.7 
N(4)-C(14)-C(13) 120.7(9) 
N(4)-C(14)-C(15) 111.7(9) 
C(13)-C(14)-C(15) 127.5(10) 
N(5)-C(15)-C(16) 109.3(9) 
N(5)-C(15)-C(14) 118.2(9) 
C(16)-C(15)-C(14) 132.6(9) 
C(15)-C(16)-C(17) 105.5(9) 
C(15)-C(16)-H(16) 127.3 
C(17)-C(16)-H(16) 127.3 
N(6)-C(17)-C(16) 109.1(9) 
N(6)-C(17)-C(18) 121.4(9) 
C(16)-C(17)-C(18) 129.5(9) 
O(4)-C(21)-O(3) 124.3(10) 
O(4)-C(21)-C(22) 118.9(11) 
O(3)-C(21)-C(22) 116.8(10) 
C(21)-C(22)-H(22A) 109.5 
C(21)-C(22)-H(22B) 109.5 
H(22A)-C(22)-H(22B) 109.5 
C(21)-C(22)-H(22C) 109.5 
H(22A)-C(22)-H(22C) 109.5 
H(22B)-C(22)-H(22C) 109.5 
N(2)-Cu(1)-N(6) 96.6(4) 
N(2)-Cu(1)-O(1) 164.0(3) 
N(6)-Cu(1)-O(1) 95.8(4) 
N(2)-Cu(1)-N(1) 81.1(4) 
N(6)-Cu(1)-N(1) 156.3(4) 
O(1)-Cu(1)-N(1) 91.6(3) 
N(3)-Cu(2)-O(3) 96.0(4) 
N(3)-Cu(2)-N(5) 96.5(4) 
O(3)-Cu(2)-N(5) 163.5(3) 
N(3)-Cu(2)-N(4) 153.0(4) 
O(3)-Cu(2)-N(4) 92.6(3) 
N(5)-Cu(2)-N(4) 81.0(4) 
C(1)-N(1)-C(5) 118.1(9) 
C(1)-N(1)-Cu(1) 128.0(8) 
C(5)-N(1)-Cu(1) 113.9(6) 
C(6)-N(2)-N(3) 106.6(8) 
C(6)-N(2)-Cu(1) 117.0(7) 
N(3)-N(2)-Cu(1) 136.4(7) 
C(8)-N(3)-N(2) 107.3(8) 
C(8)-N(3)-Cu(2) 131.7(7) 
N(2)-N(3)-Cu(2) 120.8(6) 
C(10)-N(4)-C(14) 117.9(9) 
C(10)-N(4)-Cu(2) 127.4(8) 
C(14)-N(4)-Cu(2) 114.6(7) 
C(15)-N(5)-N(6) 109.7(8) 
C(15)-N(5)-Cu(2) 114.5(7) 
N(6)-N(5)-Cu(2) 135.8(6) 
C(17)-N(6)-N(5) 106.4(8) 
C(17)-N(6)-Cu(1) 132.0(7) 
N(5)-N(6)-Cu(1) 121.6(6) 
C(21)-O(3)-Cu(2) 102.7(6)
 
 
 
Ortep plot of CuDMCGlut - Ellipsoids at 50% probability 
 
Identification code    CuDMCGlut  
Emperical formula    C22H44CuN4O12  
Formula Weight    620.15  
Temperature     150(2) K 
Wavelength      
Crystal system               Triclinic  
Space group     P-1  
Unit cell dimensions    a = 8.2527(3) Å   α = 70.802(2)° 
      b = 9.4377(4)  Å  β = 77.401(2)° 
      c = 9.4139(3)  Å  γ = 89.393(2) ° 
Volume     674.28(4)  Å3 
Z      1  
Density (calculated) 
Absorption coefficient   0.879 
F(000)      329 
Crystal     Deep blue 
Crystal size     0.20 x 0.20 x 0.06 mm3 
θ range for data collection   3.04 – 28.29° 
Index ranges     -9 ≤ h ≤ 10, -12 ≤ k ≤12, -12 ≤ l ≤ 12 
Reflections collected    3289 
Independent reflections   2773 [Rint = 0.0473] 
Completeness to θ = 28.29°   0.978  
Absorption correction   Semi-emperical from equivalents 
Max. and min. transmission    
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   3289 / 196 / 4 
Goodness-of-fit on F2    1.111 
Final R indices [F2 > 2σ(F2)]   R1 = 0.0686, wR2 = 0.0541 
R indices (all data)    R1 = 0.1456, wR2 = 0.1302 
Largest diff. Peak and hole  
 
Bond Lengths (Å) 
 
C1-N1   1.50(5)   
C1-C2   1.53(6)   
C1-H1A  0.9900  
C1-H1B  0.9900  
C2-C3   1.52(6)  
C2-H2A  0.9900 
C2-H2B  0.9900 
C3-N2   1.50(5) 
C3-C2   1.52(6)  
C3-H3A  0.9900  
C3-H3B  0.9900  
C4-N2   1.49(5)   
C4-C5   1.51(6)    
C4-H4A   0.9900  
C4-H4B   0.9900  
C5-N1   1.49(5)   
C5-H5A   0.9900  
C5-H5B   0.9900  
C6-O2   1.24(5)  
C6-O1   1.26(5)  
C6-C8   1.55(5)  
C7-N1   1.48(5)   
C7-H7A   0.9800 
C7-H7B   0.9800  
 
Bond Angles (°) 
 
N1-C1-C2   114(3) 
N1-C1-H1A   108.7  
C2-C1-H1A   108.7  
N1-C1-H1B   108.7  
C2-C1-H1B   108.7  
H1A-C1-H1B  107.6  
C3-C2-C1   116(4)  
C3-C2-H2A  108.3  
C1-C2-H2A   108.3  
C3-C2-H2B   108.3  
C1-C2-H2B   108.3  
H2A-C2-H2B  107.4  
N2-C3-C2   116(3)  
N2-C3-H3A  108.4  
C2-C3-H3A   108.4  
N2-C3-H3B   108.4  
C2-C3-H3B   108.4  
H3A-C3-H3B  107.4  
N2-C4-C5   110(3)  
N2-C4-H4A   109.6  
C5-C4-H4A   109.6  
N2-C4-H4B   109.6  
 
 
C7-H7C   0.9800  
C8-N2   1.50(5)  
C8-C9   1.53(6)  
C8-C6   1.55(5)  
C8-H8   1.0000   
C9-C10   1.54(6)  
C9-H9A  0.9900  
C9-H9B   0.9900  
C10-C11   1.51(6)  
C10-H10A  0.9900 
C10-H10B   0.9900 
C11-O3   1.20(5) 
C11-O4   1.31(5) 
N1-Cu1   2.12(3)  
N2-Cu1   2.08(3)  
O1-Cu1   2.33(3)  
O5-H6O  0.87(14)  
O5-H5O   0.87(15) 
O6-H8O   0.86(15) 
O6-H7O   0.9(8)  
Cu1-N2   2.08(3)  
Cu1-N1   2.12(3) 
Cu1-O1   2.33(3) 
 
 
 
 
C8-C9-C10   111(3)  
C8-C9-H9A   109.3  
C10-C9-H9A   109.3  
C8-C9-H9B   109.3  
C10-C9-H9B   109.3  
H9A-C9-H9B  108.0  
C11-C10-C9   111(3)  
C11-C10-H10A  109.5  
C9-C10-H10A  109.5  
C11-C10-H10B  109.5  
C9-C10-H10B  109.5  
H10A-C10-H10B  108.0  
O3-C11-O4   123(4)  
O3-C11-C10  123(4)  
O4-C11-C10   113(4)  
C7-N1-C5   107(3)  
C7-N1-C1   110(3)  
C5-N1-C1   109(3)  
C7-N1-Cu1   116(2)  
C5-N1-Cu1   104(2)  
C1-N1-Cu1   111(2)  
C4-N2-C3   109(3)  
C5-C4-H4B   109.6  
H4A-C4-H4B  108.2  
N1-C5-C4   109(3) 
N1-C5-H5A   109.8  
C4-C5-H5A   109.8  
N1-C5-H5B   109.8  
C4-C5-H5B   109.8  
H5A-C5-H5B  108.2  
O2-C6-O1   126(4)  
O2-C6-C8   118(4)  
O1-C6-C8   116(3)  
N1-C7-H7A   109.5  
N1-C7-H7B   109.5  
H7A-C7-H7B  109.5  
N1-C7-H7C   109.5  
H7A-C7-H7C  109.5  
H7B-C7-H7C  109.5  
N2-C8-C9   115(3)  
N2-C8-C6   112(3)  
C9-C8-C6   114(3)  
N2-C8-H8   105.0  
C9-C8-H8   105.0  
C6-C8-H8   105.0  
C4-N2-C8   111(3)  
C3-N2-C8   111(3)  
C4-N2-Cu1   104(2)  
C3-N2-Cu1   111(2)  
C8-N2-Cu1   111(2)  
C6-O1-Cu1   112(2)  
H6O-O5-H5O  119(10)  
H8O-O6-H7O  110(10)  
N2-Cu1-N2   180(3)  
N2-Cu1-N1   86.4(13)  
N2-Cu1-N1   93.6(13)  
N2-Cu1-N1   93.6(13)  
N2-Cu1-N1   86.4(13)  
N1-Cu1-N1   180(2)  
N2-Cu1-O1   78.3(11)  
N2-Cu1-O1   101.7(11)  
N1-Cu1-O1   86.7(11)  
N1-Cu1-O1   93.3(11)  
N2-Cu1-O1   101.7(11)  
N2-Cu1-O1   78.3(11)  
N1-Cu1-O1   93.3(11)  
N1-Cu1-O1   86.7(11)  
O1-Cu1-O1   180.0(13)  
 
 
Ortep plot of EuDO3A - Ellipsiods at 50% probability 
Identification code  EuDO3A 
Empirical formula  C42H62Cl4Eu5N12O37 
Formula weight  2228.64 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 36.519(16) Å = 90°. 
 b = 15.158(7) Å = 91.843(9)°. 
 c = 28.531(12) Å  = 90°. 
Volume 15785(12) Å3 
Z 8 
Density (calculated) 1.876 Mg/m3 
Absorption coefficient 4.139 mm-1 
F(000) 8616 
Crystal size 0.04 x 0.04 x 0.01 mm3 
Theta range for data collection 2.91 to 25.03°. 
Index ranges -42<=h<=43, -18<=k<=18, -32<=l<=33 
Reflections collected 84375 
Independent reflections 13898 [R(int) = 0.1669] 
Completeness to theta = 25.03° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9598 and 0.8519 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 13898 / 0 / 878 
Goodness-of-fit on F2 1.199 
Final R indices [I>2sigma(I)] R1 = 0.1136, wR2 = 0.2953 
R indices (all data) R1 = 0.1448, wR2 = 0.3182 
Largest diff. peak and hole 2.499 and -1.799 e.Å-3 
Bond lengths [Å] 
  
C(1)-N(12)  1.46(3) 
C(1)-C(2)  1.48(3) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-N(10)  1.48(2) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-N(10)  1.47(3) 
C(3)-C(4)  1.52(3) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-O(29)#1  1.26(3) 
C(4)-O(6)  1.30(2) 
C(4)-Eu(5)#1  2.87(2) 
C(5)-N(10)  1.40(3) 
C(5)-C(6)  1.50(3) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-N(9)  1.52(3) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-C(8)  1.42(4) 
C(7)-N(9)  1.47(3) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-N(11)  1.59(3) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-C(10)  1.41(3) 
C(9)-N(11)  1.45(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-N(12)  1.46(3) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(11)-N(12)  1.48(3) 
C(11)-C(12)  1.51(4) 
C(12)-O(28)#2  1.25(3) 
C(12)-O(5)  1.28(3) 
C(12)-Eu(3)  3.24(2) 
C(13)-O(1)  1.18(2) 
C(13)-O(2)  1.28(2) 
C(13)-C(14)  1.55(3) 
C(14)-N(9)  1.45(2) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-O(7)  1.23(2) 
C(15)-O(4)  1.24(2) 
C(15)-C(16)  1.55(3) 
C(15)-Eu(2)  3.27(2) 
C(16)-N(7)  1.44(3) 
C(16)-H(16A)  0.9900 
C(16)-H(16B)  0.9900 
C(17)-C(18)  1.49(3) 
C(17)-N(7)  1.50(2) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(18)-N(6)  1.49(3) 
C(18)-H(18A)  0.9900 
C(18)-H(18B)  0.9900 
C(19)-N(6)  1.49(3) 
C(19)-C(20)  1.50(3) 
C(19)-H(19A)  0.9900 
C(19)-H(19B)  0.9900 
C(20)-N(8)  1.52(3) 
C(20)-H(20A)  0.9900 
C(20)-H(20B)  0.9900 
C(21)-N(8)  1.44(3) 
C(21)-C(22)  1.51(4) 
C(21)-H(21A)  0.9900 
C(21)-H(21B)  0.9900 
C(22)-N(5)  1.45(3) 
C(22)-H(22A)  0.9900 
C(22)-H(22B)  0.9900 
C(23)-N(5)  1.45(3) 
C(23)-C(24)  1.49(3) 
C(23)-H(23A)  0.9900 
C(23)-H(23B)  0.9900 
C(24)-N(7)  1.49(3) 
C(24)-H(24A)  0.9900 
C(24)-H(24B)  0.9900 
C(25)-N(5)  1.45(3) 
C(25)-C(26)  1.51(4) 
C(25)-H(25A)  0.9900 
C(25)-H(25B)  0.9900 
C(26)-O(10)  1.23(3) 
C(26)-O(11)  1.27(3) 
C(26)-Eu(2)  3.17(3) 
C(27)-O(12)  1.26(2) 
C(27)-O(9)  1.28(2) 
C(27)-C(28)  1.46(3) 
C(27)-Eu(2)  3.243(19) 
C(28)-N(8)  1.51(3) 
C(28)-H(28A)  0.9900 
C(28)-H(28B)  0.9900 
C(29)-O(19)  1.24(2) 
C(29)-O(18)  1.28(2) 
C(29)-C(30)  1.44(3) 
C(29)-Eu(1)  3.226(18) 
C(30)-N(1)  1.52(3) 
C(30)-H(30A)  0.9900 
C(30)-H(30B)  0.9900 
C(31)-C(32)  1.43(3) 
C(31)-N(1)  1.52(3) 
C(31)-H(31A)  0.9900 
C(31)-H(31B)  0.9900 
C(32)-N(4)  1.43(3) 
C(32)-H(32A)  0.9900 
C(32)-H(32B)  0.9900 
C(33)-N(4)  1.49(3) 
C(33)-C(34)  1.52(3) 
C(33)-H(33A)  0.9900 
C(33)-H(33B)  0.9900 
C(34)-N(3)  1.48(3) 
C(34)-H(34A)  0.9900 
C(34)-H(34B)  0.9900 
C(35)-N(3)  1.44(3) 
C(35)-C(36)  1.54(3) 
C(35)-H(35A)  0.9900 
C(35)-H(35B)  0.9900 
C(36)-N(2)  1.44(3) 
C(36)-H(36A)  0.9900 
C(36)-H(36B)  0.9900 
C(37)-N(2)  1.47(3) 
C(37)-C(38)  1.49(3) 
C(37)-H(37A)  0.9900 
C(37)-H(37B)  0.9900 
C(38)-N(1)  1.54(2) 
C(38)-H(38A)  0.9900 
C(38)-H(38B)  0.9900 
C(39)-N(4)  1.48(3) 
C(39)-C(40)  1.53(3) 
C(40)-O(8)#1  1.25(2) 
C(40)-O(20)  1.28(2) 
C(40)-Eu(2)#1  2.93(2) 
C(41)-C(42)  1.49(3) 
C(41)-N(3)  1.56(3) 
C(41)-H(41A)  0.9900 
C(41)-H(41B)  0.9900 
C(42)-O(23)  1.26(2) 
C(42)-O(24)  1.28(2) 
C(42)-Eu(1)  3.258(19) 
Eu(1)-O(19)  2.355(13) 
Eu(1)-O(23)  2.398(12) 
Eu(1)-O(22)  2.406(13) 
Eu(1)-O(21)  2.472(12) 
Eu(1)-O(20)  2.481(9) 
Eu(1)-N(1)  2.597(17) 
Eu(1)-N(2)  2.598(14) 
Eu(1)-N(4)  2.637(19) 
Eu(1)-N(3)  2.656(16) 
Eu(2)-O(10)  2.327(13) 
Eu(2)-O(9)  2.344(12) 
Eu(2)-O(7)  2.387(14) 
Eu(2)-O(8)  2.438(14) 
Eu(2)-N(7)  2.592(16) 
Eu(2)-N(6)  2.600(16) 
Eu(2)-N(8)  2.611(15) 
Eu(2)-N(5)  2.613(16) 
Eu(2)-O(20)#1  2.660(10) 
Eu(2)-C(40)#1  2.93(2) 
Eu(3)-O(4)  2.364(12) 
Eu(3)-O(2)  2.367(12) 
Eu(3)-O(5)  2.376(14) 
Eu(3)-O(6)  2.407(14) 
Eu(3)-O(3)  2.530(15) 
Eu(3)-N(11)  2.554(16) 
Eu(3)-N(9)  2.619(16) 
Eu(3)-N(12)  2.652(17) 
Eu(3)-N(10)  2.676(19) 
Eu(4)-O(12)  2.290(13) 
Eu(4)-O(11)#1  2.303(16) 
Eu(4)-O(16)  2.414(19) 
Eu(4)-O(17)  2.432(15) 
Eu(4)-O(15)  2.471(17) 
Eu(4)-O(14)  2.48(2) 
Eu(4)-O(18)  2.484(14) 
Eu(4)-O(13)  2.52(2) 
Eu(5)-O(24)  2.324(16) 
Eu(5)-O(28)  2.359(19) 
Eu(5)-O(27)  2.418(17) 
Eu(5)-O(29)  2.438(16) 
Eu(5)-O(26)  2.44(2) 
Eu(5)-O(25)  2.53(2) 
Eu(5)-O(6)#1  2.561(14) 
Eu(5)-O(30)  2.748(16) 
Eu(5)-C(4)#1  2.87(2) 
O(6)-Eu(5)#1  2.561(14) 
O(8)-C(40)#1  1.25(2) 
O(11)-Eu(4)#1  2.303(16) 
O(20)-Eu(2)#1  2.660(10) 
O(28)-C(12)#3  1.25(3) 
O(29)-C(4)#1  1.26(3) 
Cl(4)-Cl(4)#4  1.87(4) 
 
Bond angles [°] 
 
N(12)-C(1)-C(2) 114(2) 
N(12)-C(1)-H(1A) 108.8 
C(2)-C(1)-H(1A) 108.9 
N(12)-C(1)-H(1B) 108.9 
C(2)-C(1)-H(1B) 108.9 
H(1A)-C(1)-H(1B) 107.7 
C(1)-C(2)-N(10) 112.3(17) 
C(1)-C(2)-H(2A) 109.1 
N(10)-C(2)-H(2A) 109.1 
C(1)-C(2)-H(2B) 109.1 
N(10)-C(2)-H(2B) 109.1 
H(2A)-C(2)-H(2B) 107.9 
N(10)-C(3)-C(4) 113.0(18) 
N(10)-C(3)-H(3A) 109.0 
C(4)-C(3)-H(3A) 109.0 
N(10)-C(3)-H(3B) 109.0 
C(4)-C(3)-H(3B) 109.0 
H(3A)-C(3)-H(3B) 107.8 
O(29)#1-C(4)-O(6) 120.1(19) 
O(29)#1-C(4)-C(3) 119(2) 
O(6)-C(4)-C(3) 120.5(19) 
O(29)#1-C(4)-Eu(5)#1 57.5(11) 
O(6)-C(4)-Eu(5)#1 63.0(11) 
C(3)-C(4)-Eu(5)#1 172(2) 
N(10)-C(5)-C(6) 119(2) 
N(10)-C(5)-H(5A) 107.7 
C(6)-C(5)-H(5A) 107.7 
N(10)-C(5)-H(5B) 107.7 
C(6)-C(5)-H(5B) 107.7 
H(5A)-C(5)-H(5B) 107.1 
C(5)-C(6)-N(9) 110(2) 
C(5)-C(6)-H(6A) 109.8 
N(9)-C(6)-H(6A) 109.8 
C(5)-C(6)-H(6B) 109.8 
N(9)-C(6)-H(6B) 109.8 
H(6A)-C(6)-H(6B) 108.2 
C(8)-C(7)-N(9) 113.9(19) 
C(8)-C(7)-H(7A) 108.8 
N(9)-C(7)-H(7A) 108.8 
C(8)-C(7)-H(7B) 108.8 
N(9)-C(7)-H(7B) 108.8 
H(7A)-C(7)-H(7B) 107.7 
C(7)-C(8)-N(11) 107.7(16) 
C(7)-C(8)-H(8A) 110.2 
N(11)-C(8)-H(8A) 110.2 
C(7)-C(8)-H(8B) 110.2 
N(11)-C(8)-H(8B) 110.2 
H(8A)-C(8)-H(8B) 108.5 
C(10)-C(9)-N(11) 110(2) 
C(10)-C(9)-H(9A) 109.7 
N(11)-C(9)-H(9A) 109.7 
C(10)-C(9)-H(9B) 109.7 
N(11)-C(9)-H(9B) 109.7 
H(9A)-C(9)-H(9B) 108.2 
C(9)-C(10)-N(12) 116(2) 
C(9)-C(10)-H(10A) 108.3 
N(12)-C(10)-H(10A) 108.3 
C(9)-C(10)-H(10B) 108.3 
N(12)-C(10)-H(10B) 108.3 
H(10A)-C(10)-H(10B) 107.4 
N(12)-C(11)-C(12) 110(2) 
O(28)#2-C(12)-O(5) 122(3) 
O(28)#2-C(12)-C(11) 114(2) 
O(5)-C(12)-C(11) 123.5(19) 
O(28)#2-C(12)-Eu(3) 160(2) 
O(5)-C(12)-Eu(3) 38.7(10) 
C(11)-C(12)-Eu(3) 85.0(12) 
O(1)-C(13)-O(2) 126.2(19) 
O(1)-C(13)-C(14) 120.6(17) 
O(2)-C(13)-C(14) 112.4(16) 
N(9)-C(14)-C(13) 113.5(16) 
N(9)-C(14)-H(14A) 108.9 
C(13)-C(14)-H(14A) 108.9 
N(9)-C(14)-H(14B) 108.9 
C(13)-C(14)-H(14B) 108.9 
H(14A)-C(14)-H(14B) 107.7 
O(7)-C(15)-O(4) 126.8(18) 
O(7)-C(15)-C(16) 115.0(18) 
O(4)-C(15)-C(16) 118(2) 
O(7)-C(15)-Eu(2) 36.3(10) 
O(4)-C(15)-Eu(2) 162.3(14) 
C(16)-C(15)-Eu(2) 78.7(11) 
N(7)-C(16)-C(15) 113.4(17) 
N(7)-C(16)-H(16A) 108.9 
C(15)-C(16)-H(16A) 108.9 
N(7)-C(16)-H(16B) 108.9 
C(15)-C(16)-H(16B) 108.9 
H(16A)-C(16)-H(16B) 107.7 
C(18)-C(17)-N(7) 115.2(16) 
C(18)-C(17)-H(17A) 108.5 
N(7)-C(17)-H(17A) 108.5 
C(18)-C(17)-H(17B) 108.5 
N(7)-C(17)-H(17B) 108.5 
H(17A)-C(17)-H(17B) 107.5 
N(6)-C(18)-C(17) 111.9(17) 
N(6)-C(18)-H(18A) 109.2 
C(17)-C(18)-H(18A) 109.2 
N(6)-C(18)-H(18B) 109.2 
C(17)-C(18)-H(18B) 109.2 
H(18A)-C(18)-H(18B) 107.9 
N(6)-C(19)-C(20) 109.7(17) 
N(6)-C(19)-H(19A) 109.7 
C(20)-C(19)-H(19A) 109.7 
N(6)-C(19)-H(19B) 109.7 
C(20)-C(19)-H(19B) 109.7 
H(19A)-C(19)-H(19B) 108.2 
C(19)-C(20)-N(8) 111.5(19) 
C(19)-C(20)-H(20A) 109.3 
N(8)-C(20)-H(20A) 109.3 
C(19)-C(20)-H(20B) 109.3 
N(8)-C(20)-H(20B) 109.3 
H(20A)-C(20)-H(20B) 108.0 
N(8)-C(21)-C(22) 110.4(16) 
N(8)-C(21)-H(21A) 109.6 
C(22)-C(21)-H(21A) 109.6 
N(8)-C(21)-H(21B) 109.6 
C(22)-C(21)-H(21B) 109.6 
H(21A)-C(21)-H(21B) 108.1 
N(5)-C(22)-C(21) 113.2(19) 
N(5)-C(22)-H(22A) 108.9 
C(21)-C(22)-H(22A) 108.9 
N(5)-C(22)-H(22B) 108.9 
C(21)-C(22)-H(22B) 108.9 
H(22A)-C(22)-H(22B) 107.7 
N(5)-C(23)-C(24) 111.4(18) 
N(5)-C(23)-H(23A) 109.3 
C(24)-C(23)-H(23A) 109.3 
N(5)-C(23)-H(23B) 109.3 
C(24)-C(23)-H(23B) 109.3 
H(23A)-C(23)-H(23B) 108.0 
N(7)-C(24)-C(23) 112.5(18) 
N(7)-C(24)-H(24A) 109.1 
C(23)-C(24)-H(24A) 109.1 
N(7)-C(24)-H(24B) 109.1 
C(23)-C(24)-H(24B) 109.1 
H(24A)-C(24)-H(24B) 107.8 
N(5)-C(25)-C(26) 117(2) 
N(5)-C(25)-H(25A) 108.2 
C(26)-C(25)-H(25A) 108.2 
N(5)-C(25)-H(25B) 108.2 
C(26)-C(25)-H(25B) 108.2 
H(25A)-C(25)-H(25B) 107.3 
O(10)-C(26)-O(11) 125(3) 
O(10)-C(26)-C(25) 118(2) 
O(11)-C(26)-C(25) 117(2) 
O(10)-C(26)-Eu(2) 37.7(11) 
O(11)-C(26)-Eu(2) 162.6(19) 
C(25)-C(26)-Eu(2) 80.2(15) 
O(12)-C(27)-O(9) 121.2(17) 
O(12)-C(27)-C(28) 120.6(19) 
O(9)-C(27)-C(28) 118.1(16) 
O(12)-C(27)-Eu(2) 157.9(14) 
O(9)-C(27)-Eu(2) 36.8(8) 
C(28)-C(27)-Eu(2) 81.4(11) 
C(27)-C(28)-N(8) 112(2) 
C(27)-C(28)-H(28A) 109.1 
N(8)-C(28)-H(28A) 109.1 
C(27)-C(28)-H(28B) 109.1 
N(8)-C(28)-H(28B) 109.1 
H(28A)-C(28)-H(28B) 107.8 
O(19)-C(29)-O(18) 124(2) 
O(19)-C(29)-C(30) 119.8(18) 
O(18)-C(29)-C(30) 116.6(16) 
O(19)-C(29)-Eu(1) 37.0(9) 
O(18)-C(29)-Eu(1) 159.1(14) 
C(30)-C(29)-Eu(1) 83.1(12) 
C(29)-C(30)-N(1) 113.0(16) 
C(29)-C(30)-H(30A) 109.0 
N(1)-C(30)-H(30A) 109.0 
C(29)-C(30)-H(30B) 109.0 
N(1)-C(30)-H(30B) 109.0 
H(30A)-C(30)-H(30B) 107.8 
C(32)-C(31)-N(1) 110.8(18) 
C(32)-C(31)-H(31A) 109.5 
N(1)-C(31)-H(31A) 109.5 
C(32)-C(31)-H(31B) 109.5 
N(1)-C(31)-H(31B) 109.5 
H(31A)-C(31)-H(31B) 108.1 
C(31)-C(32)-N(4) 119(2) 
C(31)-C(32)-H(32A) 107.5 
N(4)-C(32)-H(32A) 107.5 
C(31)-C(32)-H(32B) 107.5 
N(4)-C(32)-H(32B) 107.5 
H(32A)-C(32)-H(32B) 107.0 
N(4)-C(33)-C(34) 112.7(19) 
N(4)-C(33)-H(33A) 109.0 
C(34)-C(33)-H(33A) 109.0 
N(4)-C(33)-H(33B) 109.0 
C(34)-C(33)-H(33B) 109.0 
H(33A)-C(33)-H(33B) 107.8 
N(3)-C(34)-C(33) 111.4(18) 
N(3)-C(34)-H(34A) 109.3 
C(33)-C(34)-H(34A) 109.3 
N(3)-C(34)-H(34B) 109.3 
C(33)-C(34)-H(34B) 109.3 
H(34A)-C(34)-H(34B) 108.0 
N(3)-C(35)-C(36) 110.6(19) 
N(3)-C(35)-H(35A) 109.5 
C(36)-C(35)-H(35A) 109.5 
N(3)-C(35)-H(35B) 109.5 
C(36)-C(35)-H(35B) 109.5 
H(35A)-C(35)-H(35B) 108.1 
N(2)-C(36)-C(35) 112.7(19) 
N(2)-C(36)-H(36A) 109.0 
C(35)-C(36)-H(36A) 109.0 
N(2)-C(36)-H(36B) 109.0 
C(35)-C(36)-H(36B) 109.0 
H(36A)-C(36)-H(36B) 107.8 
N(2)-C(37)-C(38) 113(2) 
N(2)-C(37)-H(37A) 108.9 
C(38)-C(37)-H(37A) 108.9 
N(2)-C(37)-H(37B) 108.9 
C(38)-C(37)-H(37B) 108.9 
H(37A)-C(37)-H(37B) 107.7 
C(37)-C(38)-N(1) 110.8(19) 
C(37)-C(38)-H(38A) 109.5 
N(1)-C(38)-H(38A) 109.5 
C(37)-C(38)-H(38B) 109.5 
N(1)-C(38)-H(38B) 109.5 
H(38A)-C(38)-H(38B) 108.1 
N(4)-C(39)-C(40) 112.3(17) 
O(8)#1-C(40)-O(20) 120.2(18) 
O(8)#1-C(40)-C(39) 117.8(17) 
O(20)-C(40)-C(39) 121.8(16) 
O(8)#1-C(40)-Eu(2)#1 55.0(10) 
O(20)-C(40)-Eu(2)#1 65.2(9) 
C(39)-C(40)-Eu(2)#1 172.4(13) 
C(42)-C(41)-N(3) 114.4(16) 
C(42)-C(41)-H(41A) 108.7 
N(3)-C(41)-H(41A) 108.7 
C(42)-C(41)-H(41B) 108.7 
N(3)-C(41)-H(41B) 108.7 
H(41A)-C(41)-H(41B) 107.6 
O(23)-C(42)-O(24) 125.8(16) 
O(23)-C(42)-C(41) 120.3(16) 
O(24)-C(42)-C(41) 113.9(18) 
O(23)-C(42)-Eu(1) 38.1(8) 
O(24)-C(42)-Eu(1) 160.8(14) 
C(41)-C(42)-Eu(1) 83.6(11) 
O(19)-Eu(1)-O(23) 144.6(4) 
O(19)-Eu(1)-O(22) 82.8(4) 
O(23)-Eu(1)-O(22) 84.1(4) 
O(19)-Eu(1)-O(21) 73.5(4) 
O(23)-Eu(1)-O(21) 71.1(4) 
O(22)-Eu(1)-O(21) 70.3(4) 
O(19)-Eu(1)-O(20) 87.4(4) 
O(23)-Eu(1)-O(20) 82.0(4) 
O(22)-Eu(1)-O(20) 140.2(4) 
O(21)-Eu(1)-O(20) 69.9(4) 
O(19)-Eu(1)-N(1) 65.8(5) 
O(23)-Eu(1)-N(1) 140.6(5) 
O(22)-Eu(1)-N(1) 133.6(5) 
O(21)-Eu(1)-N(1) 125.9(5) 
O(20)-Eu(1)-N(1) 74.0(4) 
O(19)-Eu(1)-N(2) 74.1(5) 
O(23)-Eu(1)-N(2) 130.2(5) 
O(22)-Eu(1)-N(2) 69.1(5) 
O(21)-Eu(1)-N(2) 130.3(5) 
O(20)-Eu(1)-N(2) 143.7(4) 
N(1)-Eu(1)-N(2) 69.9(5) 
O(19)-Eu(1)-N(4) 132.7(5) 
O(23)-Eu(1)-N(4) 72.9(5) 
O(22)-Eu(1)-N(4) 141.7(5) 
O(21)-Eu(1)-N(4) 126.5(4) 
O(20)-Eu(1)-N(4) 67.0(5) 
N(1)-Eu(1)-N(4) 69.1(6) 
N(2)-Eu(1)-N(4) 103.2(6) 
O(19)-Eu(1)-N(3) 139.1(5) 
O(23)-Eu(1)-N(3) 67.0(4) 
O(22)-Eu(1)-N(3) 75.3(5) 
O(21)-Eu(1)-N(3) 127.6(5) 
O(20)-Eu(1)-N(3) 130.8(5) 
N(1)-Eu(1)-N(3) 106.5(5) 
N(2)-Eu(1)-N(3) 66.0(5) 
N(4)-Eu(1)-N(3) 67.8(6) 
O(19)-Eu(1)-C(29) 18.5(5) 
O(23)-Eu(1)-C(29) 151.9(4) 
O(22)-Eu(1)-C(29) 100.6(5) 
O(21)-Eu(1)-C(29) 84.3(4) 
O(20)-Eu(1)-C(29) 76.8(4) 
N(1)-Eu(1)-C(29) 48.6(6) 
N(2)-Eu(1)-C(29) 76.3(5) 
N(4)-Eu(1)-C(29) 114.2(6) 
N(3)-Eu(1)-C(29) 141.1(5) 
O(19)-Eu(1)-C(42) 150.2(5) 
O(23)-Eu(1)-C(42) 18.9(4) 
O(22)-Eu(1)-C(42) 72.9(5) 
O(21)-Eu(1)-C(42) 82.1(5) 
O(20)-Eu(1)-C(42) 100.2(4) 
N(1)-Eu(1)-C(42) 144.0(6) 
N(2)-Eu(1)-C(42) 111.4(5) 
N(4)-Eu(1)-C(42) 76.0(5) 
N(3)-Eu(1)-C(42) 50.1(5) 
C(29)-Eu(1)-C(42) 166.2(5) 
O(10)-Eu(2)-O(9) 80.5(5) 
O(10)-Eu(2)-O(7) 84.9(5) 
O(9)-Eu(2)-O(7) 143.4(5) 
O(10)-Eu(2)-O(8) 131.2(5) 
O(9)-Eu(2)-O(8) 82.3(5) 
O(7)-Eu(2)-O(8) 82.5(5) 
O(10)-Eu(2)-N(7) 75.9(5) 
O(9)-Eu(2)-N(7) 139.8(5) 
O(7)-Eu(2)-N(7) 66.0(5) 
O(8)-Eu(2)-N(7) 137.3(5) 
O(10)-Eu(2)-N(6) 144.1(5) 
O(9)-Eu(2)-N(6) 132.4(5) 
O(7)-Eu(2)-N(6) 74.5(6) 
O(8)-Eu(2)-N(6) 75.4(6) 
N(7)-Eu(2)-N(6) 69.0(6) 
O(10)-Eu(2)-N(8) 130.7(6) 
O(9)-Eu(2)-N(8) 66.9(4) 
O(7)-Eu(2)-N(8) 142.1(5) 
O(8)-Eu(2)-N(8) 81.2(6) 
N(7)-Eu(2)-N(8) 106.0(5) 
N(6)-Eu(2)-N(8) 68.5(5) 
O(10)-Eu(2)-N(5) 68.2(5) 
O(9)-Eu(2)-N(5) 73.4(5) 
O(7)-Eu(2)-N(5) 130.8(5) 
O(8)-Eu(2)-N(5) 145.9(5) 
N(7)-Eu(2)-N(5) 67.9(5) 
N(6)-Eu(2)-N(5) 103.9(6) 
N(8)-Eu(2)-N(5) 67.6(6) 
O(10)-Eu(2)-O(20)#1 80.5(4) 
O(9)-Eu(2)-O(20)#1 73.1(4) 
O(7)-Eu(2)-O(20)#1 71.4(4) 
O(8)-Eu(2)-O(20)#1 50.8(4) 
N(7)-Eu(2)-O(20)#1 132.6(4) 
N(6)-Eu(2)-O(20)#1 118.4(5) 
N(8)-Eu(2)-O(20)#1 120.5(5) 
N(5)-Eu(2)-O(20)#1 137.1(4) 
O(10)-Eu(2)-C(40)#1 106.4(4) 
O(9)-Eu(2)-C(40)#1 76.3(5) 
O(7)-Eu(2)-C(40)#1 76.0(5) 
O(8)-Eu(2)-C(40)#1 24.8(4) 
N(7)-Eu(2)-C(40)#1 141.7(5) 
N(6)-Eu(2)-C(40)#1 96.7(6) 
N(8)-Eu(2)-C(40)#1 100.7(6) 
N(5)-Eu(2)-C(40)#1 149.6(5) 
O(20)#1-Eu(2)-C(40)#1 26.0(4) 
O(10)-Eu(2)-C(26) 18.8(6) 
O(9)-Eu(2)-C(26) 71.1(5) 
O(7)-Eu(2)-C(26) 102.0(6) 
O(8)-Eu(2)-C(26) 140.9(5) 
N(7)-Eu(2)-C(26) 76.4(5) 
N(6)-Eu(2)-C(26) 143.5(6) 
N(8)-Eu(2)-C(26) 112.1(7) 
N(5)-Eu(2)-C(26) 50.4(6) 
O(20)#1-Eu(2)-C(26) 93.4(5) 
C(40)#1-Eu(2)-C(26) 118.0(5) 
O(10)-Eu(2)-C(27) 98.1(5) 
O(9)-Eu(2)-C(27) 19.1(4) 
O(7)-Eu(2)-C(27) 153.9(4) 
O(8)-Eu(2)-C(27) 76.1(5) 
N(7)-Eu(2)-C(27) 139.9(5) 
N(6)-Eu(2)-C(27) 113.4(5) 
N(8)-Eu(2)-C(27) 48.5(4) 
N(5)-Eu(2)-C(27) 73.2(5) 
O(20)#1-Eu(2)-C(27) 83.5(4) 
C(40)#1-Eu(2)-C(27) 78.3(5) 
C(26)-Eu(2)-C(27) 86.0(6) 
O(4)-Eu(3)-O(2) 86.7(4) 
O(4)-Eu(3)-O(5) 80.1(5) 
O(2)-Eu(3)-O(5) 146.7(5) 
O(4)-Eu(3)-O(6) 139.9(5) 
O(2)-Eu(3)-O(6) 88.8(4) 
O(5)-Eu(3)-O(6) 82.2(5) 
O(4)-Eu(3)-O(3) 71.2(5) 
O(2)-Eu(3)-O(3) 70.6(4) 
O(5)-Eu(3)-O(3) 76.3(5) 
O(6)-Eu(3)-O(3) 69.7(5) 
O(4)-Eu(3)-N(11) 72.8(5) 
O(2)-Eu(3)-N(11) 72.6(5) 
O(5)-Eu(3)-N(11) 130.3(5) 
O(6)-Eu(3)-N(11) 142.4(5) 
O(3)-Eu(3)-N(11) 129.1(5) 
O(4)-Eu(3)-N(9) 137.9(6) 
O(2)-Eu(3)-N(9) 66.1(5) 
O(5)-Eu(3)-N(9) 139.4(6) 
O(6)-Eu(3)-N(9) 74.0(6) 
O(3)-Eu(3)-N(9) 122.9(5) 
N(11)-Eu(3)-N(9) 68.7(6) 
O(4)-Eu(3)-N(12) 74.0(5) 
O(2)-Eu(3)-N(12) 138.0(5) 
O(5)-Eu(3)-N(12) 66.6(5) 
O(6)-Eu(3)-N(12) 129.6(5) 
O(3)-Eu(3)-N(12) 132.5(5) 
N(11)-Eu(3)-N(12) 66.2(5) 
N(9)-Eu(3)-N(12) 104.6(6) 
O(4)-Eu(3)-N(10) 139.0(5) 
O(2)-Eu(3)-N(10) 132.0(5) 
O(5)-Eu(3)-N(10) 72.4(6) 
O(6)-Eu(3)-N(10) 65.8(5) 
O(3)-Eu(3)-N(10) 128.0(6) 
N(11)-Eu(3)-N(10) 102.7(6) 
N(9)-Eu(3)-N(10) 67.9(6) 
N(12)-Eu(3)-N(10) 67.4(5) 
O(4)-Eu(3)-C(12) 70.9(6) 
O(2)-Eu(3)-C(12) 154.4(5) 
O(5)-Eu(3)-C(12) 19.6(7) 
O(6)-Eu(3)-C(12) 100.2(7) 
O(3)-Eu(3)-C(12) 90.0(6) 
N(11)-Eu(3)-C(12) 110.7(7) 
N(9)-Eu(3)-C(12) 139.4(6) 
N(12)-Eu(3)-C(12) 48.0(7) 
N(10)-Eu(3)-C(12) 73.1(6) 
O(12)-Eu(4)-O(11)#1 105.2(7) 
O(12)-Eu(4)-O(16) 84.3(7) 
O(11)#1-Eu(4)-O(16) 148.4(7) 
O(12)-Eu(4)-O(17) 149.0(6) 
O(11)#1-Eu(4)-O(17) 86.1(7) 
O(16)-Eu(4)-O(17) 72.4(7) 
O(12)-Eu(4)-O(15) 139.4(6) 
O(11)#1-Eu(4)-O(15) 83.9(7) 
O(16)-Eu(4)-O(15) 108.6(8) 
O(17)-Eu(4)-O(15) 69.5(6) 
O(12)-Eu(4)-O(14) 77.1(6) 
O(11)#1-Eu(4)-O(14) 143.2(9) 
O(16)-Eu(4)-O(14) 67.9(10) 
O(17)-Eu(4)-O(14) 111.0(8) 
O(15)-Eu(4)-O(14) 73.1(8) 
O(12)-Eu(4)-O(18) 78.5(5) 
O(11)#1-Eu(4)-O(18) 72.8(5) 
O(16)-Eu(4)-O(18) 80.1(7) 
O(17)-Eu(4)-O(18) 77.6(5) 
O(15)-Eu(4)-O(18) 140.7(6) 
O(14)-Eu(4)-O(18) 141.1(8) 
O(12)-Eu(4)-O(13) 74.1(6) 
O(11)#1-Eu(4)-O(13) 70.9(7) 
O(16)-Eu(4)-O(13) 140.1(8) 
O(17)-Eu(4)-O(13) 136.6(6) 
O(15)-Eu(4)-O(13) 71.9(6) 
O(14)-Eu(4)-O(13) 74.8(10) 
O(18)-Eu(4)-O(13) 125.9(6) 
O(24)-Eu(5)-O(28) 84.4(7) 
O(24)-Eu(5)-O(27) 152.5(6) 
O(28)-Eu(5)-O(27) 73.4(7) 
O(24)-Eu(5)-O(29) 129.2(6) 
O(28)-Eu(5)-O(29) 125.4(6) 
O(27)-Eu(5)-O(29) 77.9(6) 
O(24)-Eu(5)-O(26) 111.1(8) 
O(28)-Eu(5)-O(26) 140.4(8) 
O(27)-Eu(5)-O(26) 78.6(8) 
O(29)-Eu(5)-O(26) 73.5(9) 
O(24)-Eu(5)-O(25) 78.4(6) 
O(28)-Eu(5)-O(25) 74.0(8) 
O(27)-Eu(5)-O(25) 79.9(6) 
O(29)-Eu(5)-O(25) 143.5(7) 
O(26)-Eu(5)-O(25) 74.0(10) 
O(24)-Eu(5)-O(6)#1 80.5(5) 
O(28)-Eu(5)-O(6)#1 149.4(6) 
O(27)-Eu(5)-O(6)#1 126.6(5) 
O(29)-Eu(5)-O(6)#1 52.6(5) 
O(26)-Eu(5)-O(6)#1 70.2(7) 
O(25)-Eu(5)-O(6)#1 127.8(6) 
O(24)-Eu(5)-O(30) 84.0(5) 
O(28)-Eu(5)-O(30) 76.1(6) 
O(27)-Eu(5)-O(30) 105.6(5) 
O(29)-Eu(5)-O(30) 68.3(5) 
O(26)-Eu(5)-O(30) 139.4(8) 
O(25)-Eu(5)-O(30) 146.5(7) 
O(6)#1-Eu(5)-O(30) 76.0(4) 
O(24)-Eu(5)-C(4)#1 106.2(6) 
O(28)-Eu(5)-C(4)#1 144.7(7) 
O(27)-Eu(5)-C(4)#1 101.3(7) 
O(29)-Eu(5)-C(4)#1 25.9(5) 
O(26)-Eu(5)-C(4)#1 67.8(9) 
O(25)-Eu(5)-C(4)#1 140.6(8) 
O(6)#1-Eu(5)-C(4)#1 26.8(5) 
O(30)-Eu(5)-C(4)#1 71.9(6) 
C(30)-N(1)-C(31) 113.9(17) 
C(30)-N(1)-C(38) 106.7(17) 
C(31)-N(1)-C(38) 108.7(19) 
C(30)-N(1)-Eu(1) 107.2(12) 
C(31)-N(1)-Eu(1) 109.9(12) 
C(38)-N(1)-Eu(1) 110.4(12) 
C(36)-N(2)-C(37) 112.7(18) 
C(36)-N(2)-Eu(1) 116.0(14) 
C(37)-N(2)-Eu(1) 109.0(11) 
C(35)-N(3)-C(34) 107.6(18) 
C(35)-N(3)-C(41) 109.7(19) 
C(34)-N(3)-C(41) 107(2) 
C(35)-N(3)-Eu(1) 113.3(14) 
C(34)-N(3)-Eu(1) 112.7(14) 
C(41)-N(3)-Eu(1) 106.1(11) 
C(32)-N(4)-C(39) 109.5(18) 
C(32)-N(4)-C(33) 113.0(17) 
C(39)-N(4)-C(33) 106.2(17) 
C(32)-N(4)-Eu(1) 108.3(14) 
C(39)-N(4)-Eu(1) 108.0(11) 
C(33)-N(4)-Eu(1) 111.7(13) 
C(22)-N(5)-C(23) 110.4(16) 
C(22)-N(5)-C(25) 109.7(18) 
C(23)-N(5)-C(25) 108.6(17) 
C(22)-N(5)-Eu(2) 110.6(13) 
C(23)-N(5)-Eu(2) 113.6(12) 
C(25)-N(5)-Eu(2) 103.7(13) 
C(18)-N(6)-C(19) 110.1(17) 
C(18)-N(6)-Eu(2) 112.8(13) 
C(19)-N(6)-Eu(2) 114.2(13) 
C(16)-N(7)-C(24) 107.7(16) 
C(16)-N(7)-C(17) 107.5(15) 
C(24)-N(7)-C(17) 111.3(15) 
C(16)-N(7)-Eu(2) 108.0(11) 
C(24)-N(7)-Eu(2) 110.1(11) 
C(17)-N(7)-Eu(2) 112.0(12) 
C(21)-N(8)-C(28) 111.3(19) 
C(21)-N(8)-C(20) 112.1(17) 
C(28)-N(8)-C(20) 107(2) 
C(21)-N(8)-Eu(2) 112.7(15) 
C(28)-N(8)-Eu(2) 105.8(11) 
C(20)-N(8)-Eu(2) 107.9(13) 
C(14)-N(9)-C(7) 113.1(17) 
C(14)-N(9)-C(6) 108.0(18) 
C(7)-N(9)-C(6) 109.6(19) 
C(14)-N(9)-Eu(3) 104.4(11) 
C(7)-N(9)-Eu(3) 110.0(14) 
C(6)-N(9)-Eu(3) 111.6(14) 
C(5)-N(10)-C(3) 107(2) 
C(5)-N(10)-C(2) 111.4(19) 
C(3)-N(10)-C(2) 108.4(18) 
C(5)-N(10)-Eu(3) 110.6(14) 
C(3)-N(10)-Eu(3) 108.6(14) 
C(2)-N(10)-Eu(3) 110.4(13) 
C(9)-N(11)-C(8) 112.4(18) 
C(9)-N(11)-Eu(3) 116.7(14) 
C(8)-N(11)-Eu(3) 109.8(12) 
C(10)-N(12)-C(1) 110.9(18) 
C(10)-N(12)-C(11) 110.8(19) 
C(1)-N(12)-C(11) 106.7(17) 
C(10)-N(12)-Eu(3) 107.5(12) 
C(1)-N(12)-Eu(3) 111.2(13) 
C(11)-N(12)-Eu(3) 109.8(14) 
C(13)-O(2)-Eu(3) 126.0(12) 
C(15)-O(4)-Eu(3) 150.7(15) 
C(12)-O(5)-Eu(3) 121.7(15) 
C(4)-O(6)-Eu(3) 121.3(12) 
C(4)-O(6)-Eu(5)#1 90.1(12) 
Eu(3)-O(6)-Eu(5)#1 140.0(6) 
C(15)-O(7)-Eu(2) 125.9(13) 
C(40)#1-O(8)-Eu(2) 100.2(12) 
C(27)-O(9)-Eu(2) 124.1(10) 
C(26)-O(10)-Eu(2) 123.4(15) 
C(26)-O(11)-Eu(4)#1 150.4(16) 
C(27)-O(12)-Eu(4) 162.8(14) 
C(29)-O(18)-Eu(4) 133.9(12) 
C(29)-O(19)-Eu(1) 124.5(13) 
C(40)-O(20)-Eu(1) 118.9(11) 
C(40)-O(20)-Eu(2)#1 88.8(10) 
Eu(1)-O(20)-Eu(2)#1 151.3(5) 
C(42)-O(23)-Eu(1) 123.0(11) 
C(42)-O(24)-Eu(5) 144.5(15) 
C(12)#3-O(28)-Eu(5) 157(2) 
C(4)#1-O(29)-Eu(5) 96.6(13) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+2,-z+1    #2 x-1/2,-y+3/2,z-1/2    #3 x+1/2,-y+3/2,z+1/2  
#4 -x+1,y,-z+3/2  
 
Ortep plot of CuTsTACNE2 - Ellipsiods at 50 % probability 
Identification code  CuTsTACNE2 
Empirical formula  C76H124Cu4N12O43S4 
Formula weight  2276.27 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  C2 
Unit cell dimensions a = 22.21(5) Å = 90°. 
 b = 27.09(10) Å = 133.011(5)°. 
 c = 15.19(4) Å  = 90°. 
Volume 6683(34) Å3 
Z 2 
Density (calculated) 1.131 Mg/m3 
Absorption coefficient 0.761 mm-1 
F(000) 2376 
Crystal size 0.10 x 0.04 x 0.01 mm3 
Theta range for data collection 2.92 to 24.64°. 
Index ranges -25<=h<=25, -31<=k<=31, -14<=l<=17 
Reflections collected 29154 
Independent reflections 11006 [R(int) = 0.0837] 
Completeness to theta = 24.64° 97.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9924 and 0.9278 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 11006 / 190 / 611 
Goodness-of-fit on F2 0.963 
Final R indices [I>2sigma(I)] R1 = 0.0964, wR2 = 0.2471 
R indices (all data) R1 = 0.1213, wR2 = 0.2772 
Absolute structure parameter 0.03(3) 
Extinction coefficient 0.0008(4) 
Largest diff. peak and hole 0.899 and -0.771 e.Å-3 
Bond lengths [Å] 
 
C(1)-N(1)  1.520(14) 
C(1)-C(2)  1.620(14) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-N(2)  1.462(13) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-C(4)  1.538(15) 
C(3)-N(2)  1.556(14) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-N(3)  1.468(16) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(6)  1.463(18) 
C(5)-N(3)  1.530(16) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-N(1)  1.597(15) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-N(2)  1.506(13) 
C(7)-C(8)  1.575(15) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-O(5)  1.516(12) 
C(8)-C(9)  1.522(15) 
C(8)-H(8)  1.0000 
C(9)-H(9A)  0.9800 
C(9)-H(9B)  0.9800 
C(9)-H(9C)  0.9800 
C(10)-C(11)  1.533(16) 
C(10)-N(1)  1.535(12) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(11)-O(3)  1.505(13) 
C(11)-C(12)  1.543(18) 
C(11)-H(11)  1.0000 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
C(13)-C(14)  1.3900 
C(13)-C(18)  1.3900 
C(13)-S(1)  1.821(7) 
C(14)-C(15)  1.3900 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.3900 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.3900 
C(16)-C(19)  1.683(15) 
C(17)-C(18)  1.3900 
C(17)-H(17)  0.9500 
C(18)-H(18)  0.9500 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(20)-N(4)  1.561(15) 
C(20)-C(21)  1.584(17) 
C(20)-H(20A)  0.9900 
C(20)-H(20B)  0.9900 
C(21)-N(5)  1.547(13) 
C(21)-H(21A)  0.9900 
C(21)-H(21B)  0.9900 
C(22)-C(23)  1.513(17) 
C(22)-N(5)  1.562(13) 
C(22)-H(22A)  0.9900 
C(22)-H(22B)  0.9900 
C(23)-N(6)  1.452(14) 
C(23)-H(23A)  0.9900 
C(23)-H(23B)  0.9900 
C(24)-C(25)  1.419(19) 
C(24)-N(6)  1.538(16) 
C(24)-H(24A)  0.9900 
C(24)-H(24B)  0.9900 
C(25)-N(4)  1.583(16) 
C(25)-H(25A)  0.9900 
C(25)-H(25B)  0.9900 
C(26)-N(5)  1.586(14) 
C(26)-C(27)  1.595(14) 
C(26)-H(26A)  0.9900 
C(26)-H(26B)  0.9900 
C(27)-C(28)  1.426(18) 
C(27)-O(10)  1.550(14) 
C(27)-H(27)  1.0000 
C(28)-H(28A)  0.9800 
C(28)-H(28B)  0.9800 
C(28)-H(28C)  0.9800 
C(29)-C(30)  1.528(16) 
C(29)-N(4)  1.539(13) 
C(29)-H(29A)  0.9900 
C(29)-H(29B)  0.9900 
C(30)-O(8)  1.513(13) 
C(30)-C(31)  1.59(2) 
C(30)-H(30)  1.0000 
C(31)-H(31A)  0.9800 
C(31)-H(31B)  0.9800 
C(31)-H(31C)  0.9800 
C(32)-C(33)  1.3900 
C(32)-C(37)  1.3900 
C(32)-S(2)  1.855(8) 
C(33)-C(34)  1.3900 
C(33)-H(33)  0.9500 
C(34)-C(35)  1.3900 
C(34)-H(34)  0.9500 
C(35)-C(36)  1.3900 
C(35)-C(38)  1.699(18) 
C(36)-C(37)  1.3900 
C(36)-H(36)  0.9500 
C(37)-H(37)  0.9500 
C(38)-H(38A)  0.9800 
C(38)-H(38B)  0.9800 
C(38)-H(38C)  0.9800 
N(1)-Cu(01)  2.077(9) 
N(2)-Cu(01)  2.116(9) 
N(3)-S(1)  1.710(11) 
N(4)-Cu(02)  2.023(10) 
N(5)-Cu(02)  2.079(9) 
N(6)-S(2)  1.682(8) 
O(1)-S(1)  1.505(11) 
O(2)-S(1)  1.444(12) 
O(3)-Cu(01)  1.969(8) 
O(4)-Cu(01)#1  1.995(6) 
O(4)-Cu(01)  1.995(6) 
O(6)-S(2)  1.488(12) 
O(7)-S(2)  1.442(12) 
O(8)-Cu(02)  1.997(8) 
O(9)-Cu(02)#2  1.983(6) 
O(9)-Cu(02)  1.983(6) 
 
 
Bond angles [°] 
 
N(1)-C(1)-C(2) 105.4(8) 
N(1)-C(1)-H(1A) 110.7 
C(2)-C(1)-H(1A) 110.7 
N(1)-C(1)-H(1B) 110.7 
C(2)-C(1)-H(1B) 110.7 
H(1A)-C(1)-H(1B) 108.8 
N(2)-C(2)-C(1) 114.3(8) 
N(2)-C(2)-H(2A) 108.7 
C(1)-C(2)-H(2A) 108.7 
N(2)-C(2)-H(2B) 108.7 
C(1)-C(2)-H(2B) 108.7 
H(2A)-C(2)-H(2B) 107.6 
C(4)-C(3)-N(2) 112.1(8) 
C(4)-C(3)-H(3A) 109.2 
N(2)-C(3)-H(3A) 109.2 
C(4)-C(3)-H(3B) 109.2 
N(2)-C(3)-H(3B) 109.2 
H(3A)-C(3)-H(3B) 107.9 
N(3)-C(4)-C(3) 114.5(9) 
N(3)-C(4)-H(4A) 108.6 
C(3)-C(4)-H(4A) 108.6 
N(3)-C(4)-H(4B) 108.6 
C(3)-C(4)-H(4B) 108.6 
H(4A)-C(4)-H(4B) 107.6 
C(6)-C(5)-N(3) 113.8(11) 
C(6)-C(5)-H(5A) 108.8 
N(3)-C(5)-H(5A) 108.8 
C(6)-C(5)-H(5B) 108.8 
N(3)-C(5)-H(5B) 108.8 
H(5A)-C(5)-H(5B) 107.7 
C(5)-C(6)-N(1) 119.2(10) 
C(5)-C(6)-H(6A) 107.5 
N(1)-C(6)-H(6A) 107.5 
C(5)-C(6)-H(6B) 107.5 
N(1)-C(6)-H(6B) 107.5 
H(6A)-C(6)-H(6B) 107.0 
N(2)-C(7)-C(8) 113.7(7) 
N(2)-C(7)-H(7A) 108.8 
C(8)-C(7)-H(7A) 108.8 
N(2)-C(7)-H(7B) 108.8 
C(8)-C(7)-H(7B) 108.8 
H(7A)-C(7)-H(7B) 107.7 
O(5)-C(8)-C(9) 111.1(9) 
O(5)-C(8)-C(7) 107.0(8) 
C(9)-C(8)-C(7) 111.7(8) 
O(5)-C(8)-H(8) 109.0 
C(9)-C(8)-H(8) 109.0 
C(7)-C(8)-H(8) 109.0 
C(8)-C(9)-H(9A) 109.5 
C(8)-C(9)-H(9B) 109.5 
H(9A)-C(9)-H(9B) 109.5 
C(8)-C(9)-H(9C) 109.5 
H(9A)-C(9)-H(9C) 109.5 
H(9B)-C(9)-H(9C) 109.5 
C(11)-C(10)-N(1) 110.8(8) 
C(11)-C(10)-H(10A) 109.5 
N(1)-C(10)-H(10A) 109.5 
C(11)-C(10)-H(10B) 109.5 
N(1)-C(10)-H(10B) 109.5 
H(10A)-C(10)-H(10B) 108.1 
O(3)-C(11)-C(10) 106.1(8) 
O(3)-C(11)-C(12) 110.2(10) 
C(10)-C(11)-C(12) 112.4(10) 
O(3)-C(11)-H(11) 109.4 
C(10)-C(11)-H(11) 109.4 
C(12)-C(11)-H(11) 109.4 
C(11)-C(12)-H(12A) 109.5 
C(11)-C(12)-H(12B) 109.5 
H(12A)-C(12)-H(12B) 109.5 
C(11)-C(12)-H(12C) 109.5 
H(12A)-C(12)-H(12C) 109.5 
H(12B)-C(12)-H(12C) 109.5 
C(14)-C(13)-C(18) 120.0 
C(14)-C(13)-S(1) 117.4(5) 
C(18)-C(13)-S(1) 122.6(5) 
C(13)-C(14)-C(15) 120.0 
C(13)-C(14)-H(14) 120.0 
C(15)-C(14)-H(14) 120.0 
C(16)-C(15)-C(14) 120.0 
C(16)-C(15)-H(15) 120.0 
C(14)-C(15)-H(15) 120.0 
C(15)-C(16)-C(17) 120.0 
C(15)-C(16)-C(19) 123.8(12) 
C(17)-C(16)-C(19) 116.0(12) 
C(18)-C(17)-C(16) 120.0 
C(18)-C(17)-H(17) 120.0 
C(16)-C(17)-H(17) 120.0 
C(17)-C(18)-C(13) 120.0 
C(17)-C(18)-H(18) 120.0 
C(13)-C(18)-H(18) 120.0 
C(16)-C(19)-H(19A) 109.5 
C(16)-C(19)-H(19B) 109.5 
H(19A)-C(19)-H(19B) 109.5 
C(16)-C(19)-H(19C) 109.5 
H(19A)-C(19)-H(19C) 109.5 
H(19B)-C(19)-H(19C) 109.5 
N(4)-C(20)-C(21) 111.1(8) 
N(4)-C(20)-H(20A) 109.4 
C(21)-C(20)-H(20A) 109.4 
N(4)-C(20)-H(20B) 109.4 
C(21)-C(20)-H(20B) 109.4 
H(20A)-C(20)-H(20B) 108.0 
N(5)-C(21)-C(20) 109.9(8) 
N(5)-C(21)-H(21A) 109.7 
C(20)-C(21)-H(21A) 109.7 
N(5)-C(21)-H(21B) 109.7 
C(20)-C(21)-H(21B) 109.7 
H(21A)-C(21)-H(21B) 108.2 
C(23)-C(22)-N(5) 113.5(9) 
C(23)-C(22)-H(22A) 108.9 
N(5)-C(22)-H(22A) 108.9 
C(23)-C(22)-H(22B) 108.9 
N(5)-C(22)-H(22B) 108.9 
H(22A)-C(22)-H(22B) 107.7 
N(6)-C(23)-C(22) 116.1(9) 
N(6)-C(23)-H(23A) 108.3 
C(22)-C(23)-H(23A) 108.3 
N(6)-C(23)-H(23B) 108.3 
C(22)-C(23)-H(23B) 108.3 
H(23A)-C(23)-H(23B) 107.4 
C(25)-C(24)-N(6) 117.0(12) 
C(25)-C(24)-H(24A) 108.1 
N(6)-C(24)-H(24A) 108.1 
C(25)-C(24)-H(24B) 108.1 
N(6)-C(24)-H(24B) 108.1 
H(24A)-C(24)-H(24B) 107.3 
C(24)-C(25)-N(4) 125.5(11) 
C(24)-C(25)-H(25A) 105.9 
N(4)-C(25)-H(25A) 105.9 
C(24)-C(25)-H(25B) 105.9 
N(4)-C(25)-H(25B) 105.9 
H(25A)-C(25)-H(25B) 106.3 
N(5)-C(26)-C(27) 111.8(7) 
N(5)-C(26)-H(26A) 109.3 
C(27)-C(26)-H(26A) 109.3 
N(5)-C(26)-H(26B) 109.3 
C(27)-C(26)-H(26B) 109.3 
H(26A)-C(26)-H(26B) 107.9 
C(28)-C(27)-O(10) 111.3(10) 
C(28)-C(27)-C(26) 111.2(10) 
O(10)-C(27)-C(26) 107.9(7) 
C(28)-C(27)-H(27) 108.8 
O(10)-C(27)-H(27) 108.8 
C(26)-C(27)-H(27) 108.8 
C(27)-C(28)-H(28A) 109.5 
C(27)-C(28)-H(28B) 109.5 
H(28A)-C(28)-H(28B) 109.5 
C(27)-C(28)-H(28C) 109.5 
H(28A)-C(28)-H(28C) 109.5 
H(28B)-C(28)-H(28C) 109.5 
C(30)-C(29)-N(4) 110.2(8) 
C(30)-C(29)-H(29A) 109.6 
N(4)-C(29)-H(29A) 109.6 
C(30)-C(29)-H(29B) 109.6 
N(4)-C(29)-H(29B) 109.6 
H(29A)-C(29)-H(29B) 108.1 
O(8)-C(30)-C(29) 105.7(9) 
O(8)-C(30)-C(31) 107.8(10) 
C(29)-C(30)-C(31) 113.3(11) 
O(8)-C(30)-H(30) 110.0 
C(29)-C(30)-H(30) 110.0 
C(31)-C(30)-H(30) 110.0 
C(30)-C(31)-H(31A) 109.5 
C(30)-C(31)-H(31B) 109.5 
H(31A)-C(31)-H(31B) 109.5 
C(30)-C(31)-H(31C) 109.5 
H(31A)-C(31)-H(31C) 109.5 
H(31B)-C(31)-H(31C) 109.5 
C(33)-C(32)-C(37) 120.0 
C(33)-C(32)-S(2) 117.7(6) 
C(37)-C(32)-S(2) 122.3(5) 
C(34)-C(33)-C(32) 120.0 
C(34)-C(33)-H(33) 120.0 
C(32)-C(33)-H(33) 120.0 
C(35)-C(34)-C(33) 120.0 
C(35)-C(34)-H(34) 120.0 
C(33)-C(34)-H(34) 120.0 
C(34)-C(35)-C(36) 120.0 
C(34)-C(35)-C(38) 114.6(12) 
C(36)-C(35)-C(38) 125.0(12) 
C(37)-C(36)-C(35) 120.0 
C(37)-C(36)-H(36) 120.0 
C(35)-C(36)-H(36) 120.0 
C(36)-C(37)-C(32) 120.0 
C(36)-C(37)-H(37) 120.0 
C(32)-C(37)-H(37) 120.0 
C(35)-C(38)-H(38A) 109.5 
C(35)-C(38)-H(38B) 109.5 
H(38A)-C(38)-H(38B) 109.5 
C(35)-C(38)-H(38C) 109.5 
H(38A)-C(38)-H(38C) 109.5 
H(38B)-C(38)-H(38C) 109.5 
C(1)-N(1)-C(10) 110.7(8) 
C(1)-N(1)-C(6) 110.4(9) 
C(10)-N(1)-C(6) 114.6(8) 
C(1)-N(1)-Cu(01) 106.4(6) 
C(10)-N(1)-Cu(01) 105.1(6) 
C(6)-N(1)-Cu(01) 109.2(6) 
C(2)-N(2)-C(7) 113.8(8) 
C(2)-N(2)-C(3) 109.0(8) 
C(7)-N(2)-C(3) 110.1(7) 
C(2)-N(2)-Cu(01) 108.2(6) 
C(7)-N(2)-Cu(01) 107.6(6) 
C(3)-N(2)-Cu(01) 108.1(7) 
C(4)-N(3)-C(5) 120.6(11) 
C(4)-N(3)-S(1) 117.1(7) 
C(5)-N(3)-S(1) 109.1(9) 
C(29)-N(4)-C(20) 110.3(8) 
C(29)-N(4)-C(25) 107.3(9) 
C(20)-N(4)-C(25) 113.4(10) 
C(29)-N(4)-Cu(02) 106.8(6) 
C(20)-N(4)-Cu(02) 107.0(7) 
C(25)-N(4)-Cu(02) 111.9(7) 
C(21)-N(5)-C(22) 108.5(8) 
C(21)-N(5)-C(26) 111.6(7) 
C(22)-N(5)-C(26) 106.7(7) 
C(21)-N(5)-Cu(02) 110.9(6) 
C(22)-N(5)-Cu(02) 110.0(6) 
C(26)-N(5)-Cu(02) 109.1(6) 
C(23)-N(6)-C(24) 117.9(11) 
C(23)-N(6)-S(2) 117.1(7) 
C(24)-N(6)-S(2) 113.4(9) 
C(11)-O(3)-Cu(01) 117.3(7) 
Cu(01)#1-O(4)-Cu(01) 129.9(5) 
C(30)-O(8)-Cu(02) 116.1(7) 
Cu(02)#2-O(9)-Cu(02) 131.0(5) 
O(2)-S(1)-O(1) 115.8(7) 
O(2)-S(1)-N(3) 113.0(7) 
O(1)-S(1)-N(3) 103.6(6) 
O(2)-S(1)-C(13) 106.5(6) 
O(1)-S(1)-C(13) 111.0(5) 
N(3)-S(1)-C(13) 106.6(5) 
O(7)-S(2)-O(6) 118.3(9) 
O(7)-S(2)-N(6) 107.6(8) 
O(6)-S(2)-N(6) 105.7(6) 
O(7)-S(2)-C(32) 108.8(6) 
O(6)-S(2)-C(32) 108.3(5) 
N(6)-S(2)-C(32) 107.8(5) 
O(3)-Cu(01)-O(4) 90.8(3) 
O(3)-Cu(01)-N(1) 83.2(4) 
O(4)-Cu(01)-N(1) 172.0(3) 
O(3)-Cu(01)-N(2) 167.5(3) 
O(4)-Cu(01)-N(2) 101.2(3) 
N(1)-Cu(01)-N(2) 85.2(4) 
O(9)-Cu(02)-O(8) 89.3(3) 
O(9)-Cu(02)-N(4) 170.2(3) 
O(8)-Cu(02)-N(4) 83.3(4) 
O(9)-Cu(02)-N(5) 101.4(3) 
O(8)-Cu(02)-N(5) 166.4(3) 
N(4)-Cu(02)-N(5) 86.9(4) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y,-z+2    #2 -x+1,y,-z+3  
 
Ortep plot of CuNPhTACNA2 - Ellipsoids at 50% probability 
Identification code  CuNPhTACNA2 
Empirical formula  C16H20CuN4O6 
Formula weight  427.90 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 16.054(4) Å = 90°. 
 b = 13.373(3) Å = 99.402(3)°. 
 c = 7.8011(17) Å  = 90°. 
Volume 1652.3(7) Å3 
Z 4 
Density (calculated) 1.720 Mg/m3 
Absorption coefficient 1.368 mm-1 
F(000) 884 
Crystal size 0.18 x 0.03 x 0.01 mm3 
Theta range for data collection 2.99 to 27.49°. 
Index ranges -20<=h<=20, -15<=k<=17, -10<=l<=10 
Reflections collected 28242 
Independent reflections 3784 [R(int) = 0.0401] 
Completeness to theta = 27.49° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9865 and 0.7909 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3784 / 0 / 244 
Goodness-of-fit on F2 1.145 
Final R indices [I>2sigma(I)] R1 = 0.0350, wR2 = 0.0709 
R indices (all data) R1 = 0.0386, wR2 = 0.0721 
Largest diff. peak and hole 0.414 and -0.452 e.Å-3 
Bond lengths [Å] 
 
C(1)-N(1)  1.489(3) 
C(1)-C(2)  1.514(3) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-N(2)  1.498(2) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-N(2)  1.488(3) 
C(3)-C(4)  1.524(3) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-N(3)  1.498(3) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-N(3)  1.488(2) 
C(5)-C(6)  1.528(3) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-N(1)  1.489(3) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-N(2)  1.485(3) 
C(7)-C(8)  1.525(3) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-O(2)  1.232(3) 
C(8)-O(1)  1.289(3) 
C(9)-N(3)  1.485(2) 
C(9)-C(10)  1.532(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-O(4)  1.228(3) 
C(10)-O(3)  1.291(3) 
C(11)-C(16)  1.407(3) 
C(11)-C(12)  1.408(3) 
C(11)-N(1)  1.417(3) 
C(12)-C(13)  1.387(3) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.385(3) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.388(3) 
C(14)-N(4)  1.460(3) 
C(15)-C(16)  1.380(3) 
C(15)-H(15)  0.9500 
C(16)-H(16)  0.9500 
N(1)-Cu(1)  2.4464(17) 
N(2)-Cu(1)  2.0195(17) 
N(3)-Cu(1)  1.9945(18) 
N(4)-O(6)  1.230(3) 
N(4)-O(5)  1.232(3) 
O(1)-Cu(1)  1.9245(15) 
O(3)-Cu(1)  1.9323(16) 
 
Bond angles [°] 
 
N(1)-C(1)-C(2) 113.51(17) 
N(1)-C(1)-H(1A) 108.9 
C(2)-C(1)-H(1A) 108.9 
N(1)-C(1)-H(1B) 108.9 
C(2)-C(1)-H(1B) 108.9 
H(1A)-C(1)-H(1B) 107.7 
N(2)-C(2)-C(1) 112.10(17) 
N(2)-C(2)-H(2A) 109.2 
C(1)-C(2)-H(2A) 109.2 
N(2)-C(2)-H(2B) 109.2 
C(1)-C(2)-H(2B) 109.2 
H(2A)-C(2)-H(2B) 107.9 
N(2)-C(3)-C(4) 109.97(16) 
N(2)-C(3)-H(3A) 109.7 
C(4)-C(3)-H(3A) 109.7 
N(2)-C(3)-H(3B) 109.7 
C(4)-C(3)-H(3B) 109.7 
H(3A)-C(3)-H(3B) 108.2 
N(3)-C(4)-C(3) 110.25(16) 
N(3)-C(4)-H(4A) 109.6 
C(3)-C(4)-H(4A) 109.6 
N(3)-C(4)-H(4B) 109.6 
C(3)-C(4)-H(4B) 109.6 
H(4A)-C(4)-H(4B) 108.1 
N(3)-C(5)-C(6) 112.65(16) 
N(3)-C(5)-H(5A) 109.1 
C(6)-C(5)-H(5A) 109.1 
N(3)-C(5)-H(5B) 109.1 
C(6)-C(5)-H(5B) 109.1 
H(5A)-C(5)-H(5B) 107.8 
N(1)-C(6)-C(5) 113.22(16) 
N(1)-C(6)-H(6A) 108.9 
C(5)-C(6)-H(6A) 108.9 
N(1)-C(6)-H(6B) 108.9 
C(5)-C(6)-H(6B) 108.9 
H(6A)-C(6)-H(6B) 107.7 
N(2)-C(7)-C(8) 112.40(17) 
N(2)-C(7)-H(7A) 109.1 
C(8)-C(7)-H(7A) 109.1 
N(2)-C(7)-H(7B) 109.1 
C(8)-C(7)-H(7B) 109.1 
H(7A)-C(7)-H(7B) 107.9 
O(2)-C(8)-O(1) 125.0(2) 
O(2)-C(8)-C(7) 117.54(19) 
O(1)-C(8)-C(7) 117.43(18) 
N(3)-C(9)-C(10) 111.71(17) 
N(3)-C(9)-H(9A) 109.3 
C(10)-C(9)-H(9A) 109.3 
N(3)-C(9)-H(9B) 109.3 
C(10)-C(9)-H(9B) 109.3 
H(9A)-C(9)-H(9B) 107.9 
O(4)-C(10)-O(3) 125.0(2) 
O(4)-C(10)-C(9) 118.3(2) 
O(3)-C(10)-C(9) 116.50(18) 
C(16)-C(11)-C(12) 118.2(2) 
C(16)-C(11)-N(1) 119.50(19) 
C(12)-C(11)-N(1) 122.28(19) 
C(13)-C(12)-C(11) 120.8(2) 
C(13)-C(12)-H(12) 119.6 
C(11)-C(12)-H(12) 119.6 
C(14)-C(13)-C(12) 119.4(2) 
C(14)-C(13)-H(13) 120.3 
C(12)-C(13)-H(13) 120.3 
C(13)-C(14)-C(15) 121.2(2) 
C(13)-C(14)-N(4) 120.1(2) 
C(15)-C(14)-N(4) 118.6(2) 
C(16)-C(15)-C(14) 119.4(2) 
C(16)-C(15)-H(15) 120.3 
C(14)-C(15)-H(15) 120.3 
C(15)-C(16)-C(11) 121.0(2) 
C(15)-C(16)-H(16) 119.5 
C(11)-C(16)-H(16) 119.5 
C(11)-N(1)-C(6) 115.06(16) 
C(11)-N(1)-C(1) 115.65(17) 
C(6)-N(1)-C(1) 115.35(16) 
C(11)-N(1)-Cu(1) 114.69(12) 
C(6)-N(1)-Cu(1) 100.44(11) 
C(1)-N(1)-Cu(1) 92.36(11) 
C(7)-N(2)-C(3) 113.42(16) 
C(7)-N(2)-C(2) 112.43(16) 
C(3)-N(2)-C(2) 111.81(16) 
C(7)-N(2)-Cu(1) 105.66(12) 
C(3)-N(2)-Cu(1) 102.12(12) 
C(2)-N(2)-Cu(1) 110.72(12) 
C(9)-N(3)-C(5) 110.56(16) 
C(9)-N(3)-C(4) 112.91(16) 
C(5)-N(3)-C(4) 112.23(15) 
C(9)-N(3)-Cu(1) 102.87(12) 
C(5)-N(3)-Cu(1) 108.44(13) 
C(4)-N(3)-Cu(1) 109.33(12) 
O(6)-N(4)-O(5) 123.5(2) 
O(6)-N(4)-C(14) 117.8(2) 
O(5)-N(4)-C(14) 118.7(2) 
C(8)-O(1)-Cu(1) 113.93(13) 
C(10)-O(3)-Cu(1) 111.56(13) 
O(1)-Cu(1)-O(3) 97.69(6) 
O(1)-Cu(1)-N(3) 168.46(7) 
O(3)-Cu(1)-N(3) 86.19(7) 
O(1)-Cu(1)-N(2) 86.37(7) 
O(3)-Cu(1)-N(2) 160.42(7) 
N(3)-Cu(1)-N(2) 86.46(7) 
O(1)-Cu(1)-N(1) 105.66(6) 
O(3)-Cu(1)-N(1) 113.08(6) 
N(3)-Cu(1)-N(1) 82.53(6) 
N(2)-Cu(1)-N(1) 83.88(6) 
 
